5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 34_CD 34_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 1_CD Accounting_NN policies_NNS The_DT financial_JJ statements_NNS have_VBP been_VBN prepared_VBN in_IN accordance_NN with_IN applicable_JJ accounting_NN standards_NNS and_CC under_IN United_NNP Kingdom_NNP Generally_RB Accepted_JJ Accounting_NN Principles_NNPS UK_NNP GAAP_NNP ._.
The_DT particular_JJ accounting_NN policies_NNS adopted_VBN by_IN the_DT Directors_NNS ,_, all_DT of_IN which_WDT have_VBP been_VBN applied_VBN consistently_RB throughout_IN the_DT year_NN and_CC the_DT preceding_JJ year_NN ,_, are_VBP described_VBN below_IN ._.
a_DT Accounting_NN convention_NN The_DT financial_JJ statements_NNS have_VBP been_VBN prepared_VBN under_IN the_DT historical_JJ cost_NN convention_NN ._.
b_NN Basis_NN of_IN consolidation_NN The_DT consolidated_JJ financial_JJ statements_NNS incorporate_VBP the_DT financial_JJ statements_NNS of_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN and_CC all_DT its_PRP$ subsidiary_NN undertakings_NNS drawn_VBN up_RP to_TO 31_CD December_NNP each_DT year_NN ._.
c_NN Acquisitions_NNS and_CC disposals_NNS On_IN the_DT acquisition_NN of_IN a_DT business_NN ,_, including_VBG an_DT interest_NN in_IN an_DT associated_VBN undertaking_NN ,_, fair_JJ values_NNS are_VBP attributed_VBN to_TO the_DT Groups_NNS share_NN of_IN net_JJ separable_JJ assets_NNS ._.
Where_WRB the_DT cost_NN of_IN the_DT acquisition_NN exceeds_VBZ the_DT fair_JJ values_NNS attributable_JJ to_TO such_JJ net_JJ assets_NNS ,_, the_DT difference_NN is_VBZ treated_VBN as_IN purchased_VBN goodwill_NN and_CC capitalized_VBN in_IN the_DT balance_NN sheet_NN in_IN the_DT year_NN of_IN acquisition_NN ._.
Prior_RB to_TO the_DT implementation_NN of_IN FRS_NNP 10_CD in_IN the_DT year_NN ended_VBD 31_CD December_NNP 1998_CD ,_, purchased_VBD goodwill_NN was_VBD written-off_JJ directly_RB to_TO reserves_NNS and_CC has_VBZ not_RB been_VBN reinstated_VBN ._.
The_DT profit_NN or_CC loss_NN on_IN the_DT disposal_NN of_IN a_DT previously_RB acquired_VBN business_NN includes_VBZ the_DT attributable_JJ amount_NN of_IN any_DT purchased_VBN goodwill_NN relating_VBG to_TO that_DT business_NN not_RB previously_RB charged_VBN through_IN the_DT profit_NN and_CC loss_NN account_NN ._.
The_DT results_NNS and_CC cash_NN ows_NNS relating_VBG to_TO a_DT business_NN are_VBP included_VBN in_IN the_DT consolidated_JJ profit_NN and_CC loss_NN account_NN and_CC the_DT consolidated_JJ cash_NN ow_NN statement_NN from_IN the_DT date_NN of_IN acquisition_NN up_IN to_TO the_DT date_NN of_IN disposal_NN ._.
d_LS Intangible_JJ assets_NNS goodwill_NN For_IN the_DT acquisition_NN of_IN a_DT business_NN ,_, including_VBG an_DT interest_NN in_IN an_DT associated_VBN undertaking_NN ,_, purchased_VBD goodwill_NN is_VBZ capitalized_VBN in_IN the_DT year_NN in_IN which_WDT it_PRP arises_VBZ and_CC amortised_VBN over_IN its_PRP$ estimated_VBN useful_JJ economic_JJ life_NN up_IN to_TO a_DT maximum_NN of_IN 20_CD years_NNS ._.
The_DT Directors_NNS regard_VBP 20_CD years_NNS as_IN a_DT reasonable_JJ maximum_NN for_IN the_DT estimated_VBN useful_JJ economic_JJ life_NN of_IN goodwill_NN since_IN it_PRP is_VBZ difficult_JJ to_TO make_VB projections_NNS exceeding_VBG this_DT period_NN ._.
Provision_NNP is_VBZ made_VBN for_IN any_DT impairment_NN ._.
The_DT asset_NN is_VBZ deemed_VBN to_TO be_VB impaired_VBN to_TO the_DT extent_NN that_IN the_DT carrying_VBG amount_NN exceeds_VBZ the_DT recoverable_JJ amount_NN ._.
The_DT impairment_NN is_VBZ recognized_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
Capitalised_VBN purchased_VBN goodwill_NN in_IN respect_NN of_IN subsidiaries_NNS is_VBZ included_VBN within_IN intangible_JJ assets_NNS ._.
Capitalised_NNP purchased_VBD goodwill_NN relating_VBG to_TO associates_NNS is_VBZ included_VBN within_IN the_DT carrying_VBG value_NN of_IN the_DT associate_NN ._.
Goodwill_NN which_WDT arose_VBD on_IN the_DT acquisition_NN of_IN a_DT business_NN ,_, prior_RB to_TO the_DT implementation_NN of_IN FRS_NNP 10_CD which_WDT was_VBD written-off_JJ to_TO the_DT profit_NN and_CC loss_NN reserve_NN as_IN a_DT matter_NN of_IN accounting_NN policy_NN ,_, remains_VBZ eliminated_VBN in_IN that_DT reserve_NN and_CC will_MD be_VB charged_VBN or_CC credited_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN as_IN appropriate_JJ on_IN the_DT subsequent_JJ disposal_NN of_IN the_DT business_NN to_TO which_WDT it_PRP relates_VBZ ._.
e_LS Intangible_JJ assets_NNS intellectual_JJ property_NN Intellectual_NNP property_NN ,_, including_VBG trademarks_NNS ,_, for_IN products_NNS with_IN an_DT immediate_JJ dened_JJ revenue_NN stream_NN and_CC acquired_VBN for_IN valuable_JJ consideration_NN ,_, is_VBZ capitalized_VBN and_CC amortised_VBN in_IN equal_JJ annual_JJ instalments_NNS over_IN the_DT estimated_VBN useful_JJ life_NN of_IN the_DT product_NN generally_RB not_RB exceeding_VBG 20_CD years_NNS ._.
Intellectual_NNP property_NN with_IN no_DT dened_JJ revenue_NN stream_NN is_VBZ written-off_JJ on_IN acquisition_NN ._.
f_LS Tangible_JJ assets_NNS Depreciation_NN is_VBZ not_RB provided_VBN on_IN freehold_JJ land_NN ._.
All_DT other_JJ tangible_JJ xed_JJ assets_NNS are_VBP shown_VBN at_IN cost_NN less_JJR accumulated_VBN depreciation_NN and_CC any_DT provision_NN for_IN impairment_NN ._.
Depreciation_NN is_VBZ provided_VBN on_IN a_DT straight_JJ line_NN basis_NN at_IN rates_NNS calculated_VBN to_TO write-off_NN the_DT cost_NN less_JJR estimated_VBN residual_JJ value_NN of_IN each_DT asset_NN over_IN its_PRP$ estimated_VBN useful_JJ life_NN at_IN the_DT following_JJ annual_JJ rates_NNS :_: Freehold_NNP buildings_NNS 25_CD %_NN per_IN annum_NN Ofce_NNP furniture_NN and_CC ttings_NNS 1025_CD %_NN per_IN annum_NN Equipment_NNP and_CC other_JJ 1025_CD %_NN per_IN annum_NN g_NN Investments_NNP Except_IN as_IN stated_VBN below_IN ,_, investments_NNS held_VBD as_IN xed_JJ assets_NNS are_VBP stated_VBN at_IN cost_NN less_JJR provision_NN for_IN any_DT impairment_NN ._.
In_IN the_DT consolidated_JJ accounts_NNS ,_, shares_NNS in_IN joint_JJ ventures_NNS are_VBP accounted_VBN for_IN using_VBG the_DT equity_NN method_NN ._.
The_DT consolidated_JJ profit_NN and_CC loss_NN account_NN includes_VBZ the_DT Groups_NNS share_NN of_IN pre-tax_JJ profits_NNS and_CC attributable_JJ taxation_NN of_IN the_DT joint_JJ ventures_NNS based_VBN on_IN audited_JJ financial_JJ statements_NNS for_IN the_DT financial_JJ year_NN ._.
In_IN the_DT consolidated_JJ balance_NN sheet_NN ,_, the_DT investment_NN in_IN joint_JJ ventures_NNS is_VBZ shown_VBN as_IN the_DT Groups_NNS share_NN of_IN the_DT net_JJ assets_NNS of_IN the_DT joint_JJ ventures_NNS ._.
In_IN the_DT Company_NN balance_NN sheet_NN ,_, for_IN investments_NNS in_IN subsidiaries_NNS acquired_VBN for_IN consideration_NN including_VBG the_DT issue_NN of_IN shares_NNS qualifying_VBG for_IN merger_NN relief_NN ,_, advantage_NN has_VBZ not_RB been_VBN taken_VBN of_IN this_DT relief_NN and_CC the_DT share_NN premium_NN of_IN the_DT shares_NNS issued_VBN has_VBZ been_VBN included_VBN in_IN the_DT cost_NN ._.
Current_JJ asset_NN investments_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 35_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS 35_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD h_NN Stocks_NNS Stocks_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN ._.
Cost_NN incurred_VBN in_IN bringing_VBG each_DT product_NN to_TO its_PRP$ present_JJ location_NN and_CC condition_NN is_VBZ based_VBN on_IN purchase_NN costs_NNS calculated_VBN on_IN a_DT first-in_NN ,_, first-out_JJ basis_NN ,_, including_VBG transport_NN ._.
Net_JJ realisable_JJ value_NN is_VBZ based_VBN on_IN estimated_VBN normal_JJ selling_NN price_NN less_RBR further_JJ costs_NNS expected_VBN to_TO be_VB incurred_VBN to_TO completion_NN and_CC disposal_NN ._.
Provision_NNP is_VBZ made_VBN for_IN obsolete_JJ ,_, slow_JJ moving_VBG or_CC defective_JJ items_NNS where_WRB appropriate_JJ ._.
i_FW Deferred_JJ taxation_NN Deferred_VBN tax_NN is_VBZ provided_VBN in_IN full_JJ on_IN timing_NN differences_NNS which_WDT result_VBP in_IN an_DT obligation_NN at_IN the_DT balance_NN sheet_NN date_NN to_TO pay_VB more_JJR tax_NN ,_, or_CC a_DT right_NN to_TO pay_VB less_JJR tax_NN ,_, at_IN a_DT future_JJ date_NN ,_, at_IN rates_NNS expected_VBN to_TO apply_VB when_WRB they_PRP crystallise_VBP based_VBN on_IN current_JJ tax_NN rates_NNS and_CC law_NN ._.
Timing_NN differences_NNS arise_VBP from_IN the_DT inclusion_NN of_IN items_NNS of_IN income_NN and_CC expenditure_NN in_IN taxation_NN computations_NNS in_IN periods_NNS different_JJ from_IN those_DT in_IN which_WDT they_PRP are_VBP included_VBN in_IN the_DT financial_JJ statements_NNS ._.
Deferred_JJ tax_NN is_VBZ not_RB provided_VBN on_IN timing_NN differences_NNS arising_VBG on_IN unremitted_JJ earnings_NNS of_IN subsidiaries_NNS and_CC associates_NNS where_WRB there_EX is_VBZ no_DT commitment_NN to_TO remit_VB these_DT earnings_NNS ._.
Deferred_JJ tax_NN assets_NNS are_VBP recognized_VBN to_TO the_DT extent_NN that_IN it_PRP is_VBZ regarded_VBN as_IN more_RBR likely_JJ than_IN not_RB that_IN they_PRP will_MD be_VB recovered_VBN ._.
Deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS are_VBP not_RB discounted_VBN ._.
j_NN Turnover_NN The_DT Group_NNP recognizes_VBZ turnover_NN when_WRB :_: there_EX is_VBZ persuasive_JJ evidence_NN of_IN an_DT arrangement_NN ,_, delivery_NN of_IN products_NNS has_VBZ occurred_VBN or_CC services_NNS have_VBP been_VBN rendered_VBN ,_, the_DT sellers_NNS price_NN to_TO the_DT buyer_NN is_VBZ xed_VBN or_CC determinable_JJ ,_, and_CC collectibility_NN is_VBZ reasonably_RB assured_VBN ._.
Revenues_NNS are_VBP stated_VBN net_NN of_IN VAT_NNP and_CC similar_JJ taxes_NNS ,_, trade_NN discounts_NNS and_CC intra-Group_JJ transactions_NNS ._.
The_DT principal_JJ components_NNS of_IN the_DT Groups_NNS turnover_NN and_CC their_PRP$ respective_JJ accounting_NN treatments_NNS are_VBP set_VBN out_RP below_IN ._.
Revenue_NN from_IN the_DT sales_NNS of_IN products_NNS is_VBZ recognized_VBN upon_IN shipment_NN to_TO customers_NNS or_CC at_IN the_DT time_NN of_IN delivery_NN depending_VBG on_IN the_DT terms_NNS of_IN sale_NN ._.
Provisions_NNS for_IN certain_JJ rebates_NNS ,_, product_NN returns_NNS and_CC discounts_NNS to_TO customers_NNS are_VBP provided_VBN for_IN as_IN reductions_NNS to_TO net_JJ turnover_NN in_IN the_DT same_JJ period_NN as_IN the_DT related_JJ sales_NNS are_VBP recorded_VBN ._.
Licensing_NN and_CC development_NN fees_NNS represent_VBP revenues_NNS derived_VBN from_IN licence_NN agreements_NNS and_CC from_IN collaborative_JJ research_NN and_CC development_NN arrangements_NNS ._.
Initial_JJ licence_NN fees_NNS are_VBP not_RB considered_VBN to_TO be_VB separable_JJ from_IN the_DT associated_VBN research_NN and_CC development_NN activities_NNS ,_, even_RB where_WRB such_JJ fees_NNS are_VBP non-refundable_JJ and_CC not_RB creditable_JJ against_IN research_NN and_CC development_NN services_NNS to_TO be_VB rendered_VBN ._.
Initial_JJ licence_NN fees_NNS are_VBP deferred_VBN and_CC recognized_VBN over_IN the_DT period_NN of_IN the_DT licence_NN term_NN or_CC the_DT period_NN of_IN the_DT associated_VBN research_NN and_CC development_NN agreement_NN ._.
In_IN circumstances_NNS where_WRB initial_JJ licence_NN fees_NNS are_VBP not_RB for_IN a_DT dened_JJ period_NN ,_, revenues_NNS are_VBP deferred_VBN and_CC recognized_VBN over_IN the_DT period_NN to_TO the_DT expiration_NN of_IN the_DT relevant_JJ patent_NN to_TO which_WDT the_DT licence_NN relates_VBZ ._.
During_IN the_DT term_NN of_IN certain_JJ research_NN and_CC development_NN agreements_NNS ,_, the_DT Group_NNP receives_VBZ non-refundable_JJ milestones_NNS as_IN certain_JJ technical_JJ targets_NNS are_VBP achieved_VBN ._.
Revenue_NN is_VBZ recognized_VBN on_IN achievement_NN of_IN milestones_NNS ._.
The_DT Group_NNP also_RB receives_VBZ non-refundable_JJ clinical_JJ milestones_NNS when_WRB certain_JJ targets_NNS are_VBP achieved_VBN during_IN the_DT clinical_JJ phases_NNS of_IN development_NN ,_, such_JJ as_IN the_DT submission_NN of_IN clinical_JJ data_NNS to_TO a_DT regulatory_JJ authority_NN ._.
These_DT clinical_JJ milestones_NNS are_VBP recognized_VBN when_WRB receivable_NN ._.
If_IN milestone_NN payments_NNS are_VBP creditable_JJ against_IN future_JJ royalty_NN payments_NNS ,_, the_DT milestones_NNS are_VBP deferred_VBN and_CC released_VBN over_IN the_DT period_NN in_IN which_WDT the_DT royalties_NNS are_VBP anticipated_VBN to_TO be_VB paid_VBN ._.
Royalty_NN income_NN relating_VBG to_TO licensed_JJ technology_NN is_VBZ recognized_VBN when_WRB earned_VBN ._.
No_DT revenue_NN is_VBZ recognized_VBN for_IN consideration_NN ,_, the_DT value_NN or_CC receipt_NN of_IN which_WDT is_VBZ dependent_JJ on_IN future_JJ events_NNS ,_, future_JJ performance_NN ,_, or_CC refund_NN obligations_NNS ._.
k_NN Research_NN and_CC development_NN Research_NN and_CC development_NN expenditure_NN includes_VBZ funded_VBN and_CC unfunded_JJ expenditure_NN and_CC is_VBZ written_VBN off_RP in_IN the_DT period_NN in_IN which_WDT it_PRP is_VBZ incurred_VBN ._.
l_NN Pensions_NNS The_DT Group_NNP contributes_VBZ to_TO personal_JJ dened_VBN contribution_NN pension_NN plans_NNS of_IN employees_NNS ._.
Contributions_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN as_IN they_PRP become_VBP payable_JJ ._.
Differences_NNS between_IN contributions_NNS payable_JJ and_CC contributions_NNS actually_RB paid_VBN are_VBP shown_VBN as_IN either_DT accruals_NNS or_CC prepayments_NNS in_IN the_DT balance_NN sheet_NN ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 36_CD 36_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD m_NNP Foreign_NNP currency_NN Transactions_NNS in_IN foreign_JJ currencies_NNS are_VBP recorded_VBN at_IN the_DT rate_NN of_IN exchange_NN at_IN the_DT date_NN of_IN the_DT transaction_NN ._.
Monetary_NNP assets_NNS and_CC liabilities_NNS denominated_VBN in_IN foreign_JJ currencies_NNS at_IN the_DT balance_NN sheet_NN date_NN are_VBP reported_VBN at_IN the_DT rates_NNS of_IN exchange_NN prevailing_VBG at_IN that_DT date_NN ._.
The_DT results_NNS of_IN overseas_JJ operations_NNS are_VBP translated_VBN at_IN the_DT average_JJ rates_NNS of_IN exchange_NN during_IN the_DT period_NN and_CC their_PRP$ balance_NN sheets_NNS at_IN the_DT rates_NNS ruling_VBG at_IN the_DT balance_NN sheet_NN date_NN ._.
Exchange_NNP differences_NNS arising_VBG on_IN translation_NN of_IN the_DT opening_NN net_JJ assets_NNS and_CC on_IN foreign_JJ currency_NN borrowings_NNS ,_, to_TO the_DT extent_NN that_IN they_PRP hedge_VBP the_DT Groups_NNS investments_NNS in_IN such_JJ operations_NNS ,_, are_VBP reported_VBN in_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS ._.
All_DT other_JJ exchange_NN differences_NNS are_VBP included_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
n_JJ Leases_NNP Assets_NNPS acquired_VBD under_IN finance_NN leases_NNS are_VBP capitalized_VBN at_IN their_PRP$ fair_JJ value_NN on_IN the_DT inception_NN of_IN the_DT lease_NN and_CC depreciated_VBN over_IN the_DT shorter_JJR of_IN the_DT period_NN of_IN the_DT lease_NN and_CC the_DT useful_JJ economic_JJ lives_NNS of_IN the_DT assets_NNS ._.
The_DT finance_NN charges_NNS are_VBP allocated_VBN over_IN the_DT period_NN of_IN the_DT lease_NN in_IN proportion_NN to_TO the_DT capital_NN amount_NN outstanding_JJ and_CC are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN ._.
Operating_VBG lease_NN rentals_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN equal_JJ amounts_NNS over_IN the_DT lease_NN term_NN ._.
o_NN Finance_NNP costs_VBZ Finance_NNP costs_NNS of_IN debt_NN are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT term_NN of_IN the_DT debt_NN at_IN a_DT constant_JJ rate_NN on_IN the_DT carrying_VBG amount_NN ._.
p_NN Debt_NNP Debt_NNP is_VBZ initially_RB stated_VBN at_IN the_DT amount_NN of_IN the_DT net_JJ proceeds_NNS after_IN deduction_NN of_IN issue_NN costs_NNS ._.
The_DT carrying_VBG amount_NN is_VBZ increased_VBN by_IN the_DT finance_NN cost_NN in_IN respect_NN of_IN the_DT accounting_NN period_NN and_CC reduced_VBN by_IN payments_NNS made_VBN in_IN the_DT period_NN ._.
Convertible_JJ debt_NN is_VBZ treated_VBN as_IN a_DT liability_NN as_RB long_RB as_IN there_EX is_VBZ no_DT genuine_JJ commercial_JJ possibility_NN that_IN the_DT option_NN to_TO issue_VB ordinary_JJ shares_NNS or_CC American_JJ Depositary_NNP Shares_NNP will_MD be_VB exercised_VBN ._.
No_DT gain_NN or_CC loss_NN is_VBZ recognized_VBN on_IN conversion_NN ._.
q_NNP Government_NNP grants_NNS Government_NNP grants_NNS in_IN respect_NN of_IN funded_JJ research_NN and_CC development_NN expenditure_NN are_VBP credited_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN as_IN the_DT related_JJ expenditure_NN is_VBZ incurred_VBN ._.
r_NN Derivative_JJ financial_JJ instruments_NNS The_DT Group_NNP uses_VBZ derivative_JJ financial_JJ instruments_NNS to_TO reduce_VB exposure_NN to_TO foreign_JJ exchange_NN risk_NN and_CC interest_NN rate_NN movements_NNS ._.
The_DT Group_NNP does_VBZ not_RB hold_VB or_CC issue_VB derivative_JJ financial_JJ instruments_NNS for_IN speculative_JJ purposes_NNS ._.
For_IN a_DT forward_RB foreign_JJ exchange_NN contract_NN to_TO be_VB treated_VBN as_IN a_DT hedge_NN the_DT instrument_NN must_MD be_VB related_VBN to_TO actual_JJ foreign_JJ currency_NN assets_NNS or_CC liabilities_NNS or_CC to_TO a_DT probable_JJ commitment_NN ._.
It_PRP must_MD involve_VB the_DT same_JJ currency_NN or_CC similar_JJ currencies_NNS as_IN the_DT hedged_VBN item_NN and_CC must_MD also_RB reduce_VB the_DT risk_NN of_IN foreign_JJ currency_NN exchange_NN movements_NNS on_IN the_DT Group_NNP 's_POS operations_NNS ._.
Gains_NNS and_CC losses_NNS arising_VBG on_IN these_DT contracts_NNS are_VBP deferred_VBN and_CC recognized_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN ,_, or_CC as_IN adjustments_NNS to_TO the_DT carrying_VBG amount_NN of_IN xed_JJ assets_NNS ,_, only_RB when_WRB the_DT hedged_VBN transaction_NN has_VBZ itself_PRP been_VBN reected_VBN in_IN the_DT Group_NNP 's_POS accounts_NNS ._.
For_IN an_DT interest_NN rate_NN swap_NN to_TO be_VB treated_VBN as_IN a_DT hedge_NN the_DT instrument_NN must_MD be_VB related_VBN to_TO actual_JJ assets_NNS or_CC liabilities_NNS or_CC a_DT probable_JJ commitment_NN and_CC must_MD change_VB the_DT nature_NN of_IN the_DT interest_NN rate_NN by_IN converting_VBG a_DT xed_JJ rate_NN to_TO a_DT variable_JJ rate_NN or_CC vice_NN versa_RB ._.
Interest_NN differentials_NNS under_IN these_DT swaps_NNS are_VBP recognized_VBN by_IN adjusting_VBG net_JJ interest_NN payable_JJ over_IN the_DT periods_NNS of_IN the_DT contracts_NNS ._.
If_IN an_DT instrument_NN ceases_VBZ to_TO be_VB accounted_VBN for_IN as_IN a_DT hedge_NN ,_, for_IN example_NN because_IN the_DT underlying_VBG hedged_JJ position_NN is_VBZ eliminated_VBN ,_, the_DT instrument_NN is_VBZ marked_VBN to_TO market_NN and_CC any_DT resulting_JJ profit_NN or_CC loss_NN recognized_VBN at_IN that_DT time_NN ._.
s_PRP Employee_NNP share_NN schemes_NNS In_IN accordance_NN with_IN UITF_NNP Abstract_NNP 17_CD Employee_NN share_NN schemes_NNS ,_, the_DT cost_NN of_IN awards_NNS to_TO employees_NNS that_WDT take_VBP the_DT form_NN of_IN shares_NNS or_CC rights_NNS to_TO shares_NNS is_VBZ recognized_VBN as_IN a_DT charge_NN in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
The_DT amount_NN recognized_VBN ,_, which_WDT is_VBZ the_DT difference_NN between_IN the_DT market_NN value_NN at_IN date_NN of_IN grant_NN and_CC the_DT underlying_JJ share_NN and_CC any_DT exercise_NN price_NN ,_, is_VBZ charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT period_NN the_DT shares_NNS are_VBP vested_VBN ,_, with_IN a_DT corresponding_JJ credit_NN to_TO reserves_NNS ._.
t_NN Related_VBN party_NN transactions_NNS In_IN accordance_NN with_IN the_DT exemptions_NNS in_IN FRS_NNP 8_CD related_JJ party_NN disclosures_NNS ,_, transactions_NNS between_IN Group_NNP companies_NNS have_VBP not_RB been_VBN disclosed_VBN since_IN Group_NNP accounts_NNS are_VBP prepared_JJ and_CC include_VBP the_DT results_NNS of_IN all_DT subsidiary_NN undertakings_NNS ._.
u_JJ significant_JJ accounting_NN estimates_NNS Sales_NNS deductions_NNS primarily_RB consist_VBP of_IN statutory_JJ rebates_NNS to_TO state_NN Medicaid_NNP and_CC other_JJ Government_NN agencies_NNS ,_, contractual_JJ rebates_NNS with_IN healthmaintenance_NN organizations_NNS HMOs_NNS ,_, product_NN returns_NNS ,_, trade_NN discounts_NNS and_CC allowances_NNS for_IN the_DT coupon_NN sampling_VBG program_NN ._.
Statutory_JJ rebates_NNS to_TO state_NN Medicaid_NNP agencies_NNS and_CC contractual_JJ rebates_NNS with_IN HMOs_NNS are_VBP based_VBN on_IN price_NN differentials_NNS between_IN a_DT base_NN price_NN and_CC the_DT selling_NN price_NN ._.
As_IN a_DT result_NN ,_, the_DT rebates_NNS increase_NN as_IN a_DT percentage_NN of_IN the_DT selling_NN price_NN over_IN the_DT life_NN of_IN the_DT product_NN ._.
Provision_NNP for_IN rebates_NNS are_VBP recorded_VBN as_IN reductions_NNS to_TO turnover_NN in_IN the_DT same_JJ period_NN as_IN the_DT related_JJ sales_NNS with_IN estimates_NNS of_IN future_JJ utilization_NN derived_VBN from_IN historical_JJ trends_NNS ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 37_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS 37_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 2_CD Turnover_NN and_CC segment_NN information_NN a_DT Turnover_NN and_CC loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN The_DT Directors_NNS believe_VBP that_IN there_EX is_VBZ one_CD business_NN segment_NN ._.
Licensing_NN and_CC Other_JJ Product_NNP sales_NNS development_NN Royalties_NNS revenues_NNS Total_JJ Year_NN to_TO 31_CD December_NNP 2003 000 000 000_CD 000_CD 000_CD Turnover_NN 635,545_CD 2,232_CD 122,110_CD 1,181_CD 761,068_CD Cost_NN of_IN product_NN sales_NNS 102,384_CD 102,384_CD Distribution_NN costs_NNS 156,070_CD 156,070_CD Funded_VBN research_NN and_CC development_NN costs_NNS 3,273_CD 3,273_CD 377,091_CD 1,041_CD 122,110_CD 1,181_CD 499,341_CD Unfunded_JJ research_NN and_CC development_NN costs_NNS 128,381_CD Depreciation_NN and_CC amortisation_NN 582,889_CD Expenses_NNS not_RB allocated_VBN general_JJ overheads_NNS 88,006_CD Other_JJ operating_NN income_NN 698_CD Operating_NN loss_NN 229,237_CD Share_NN of_IN joint_JJ ventures_NNS operating_VBG loss_NN 2,806_CD Finance_NNP charges_NNS ,_, net_JJ 3,702_CD Loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 298,341_CD General_NNP overheads_NNS have_VBP not_RB been_VBN allocated_VBN by_IN business_NN activity_NN as_IN management_NN do_VBP not_RB run_VB the_DT business_NN in_IN this_DT way_NN ._.
Licensing_NN and_CC Other_JJ Product_NNP sales_NNS development_NN Royalties_NNS revenues_NNS Total_JJ Year_NN to_TO 31_CD December_NNP 2002 000 000 000_CD 000_CD 000_CD Turnover_NN 596,313_CD 2,041_CD 114,146_CD 27_CD 712,527_CD Cost_NN of_IN product_NN sales_NNS 95,042_CD 95,042_CD Distribution_NN costs_NNS 167,095_CD 167,095_CD Funded_VBN research_NN and_CC development_NN costs_NNS 5,041_CD 5,041_CD 334,176_CD 3,000_CD 114,146_CD 27_CD 445,349_CD Unfunded_JJ research_NN and_CC development_NN costs_NNS 121,105_CD Depreciation_NN and_CC amortisation_NN 794,499_CD Expenses_NNS not_RB allocated_VBN general_JJ overheads_NNS 62,890_CD Operating_NN loss_NN 533,145_CD Share_NN of_IN joint_JJ ventures_NNS operating_VBG loss_NN 559_CD Finance_NNP charges_NNS ,_, net_JJ 6,931_CD Loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 526,773_CD General_NNP overheads_NNS have_VBP not_RB been_VBN allocated_VBN by_IN business_NN activity_NN as_IN management_NN do_VBP not_RB run_VB the_DT business_NN in_IN this_DT way_NN ._.
c_NN Analysis_NN of_IN net_JJ operating_NN expenses_NNS 2003 2002 000 000_CD Distribution_NN costs_NNS 156,070_CD 167,095_CD Research_NNP and_CC development_NN 131,654_CD 126,146_CD Administrative_JJ expenses_NNS 670,895_CD 857,389_CD 958,619_CD 1,150,630_CD 3_CD Operating_NN loss_NN Operating_NN loss_NN is_VBZ stated_VBN after_IN charging_VBG crediting_VBG :_: 2003 2002 000 000_CD Government_NN grant_NN 2,169_CD 1,855_CD Research_NNP and_CC development_NN 131,654_CD 126,146_CD Auditors_NNS remuneration_JJ audit_NN fees_NNS Group_NNP 630_CD 600_CD Company_NN 20_CD 20_CD non-audit_JJ fees_NNS Group_NNP audit-related_JJ 1,015_CD 390_CD Group_NNP tax_NN 1,145_CD 511_CD Group_NNP other_JJ 177_CD 32_CD Company_NN 75_CD 48_CD Operating_NN lease_NN rentals_NNS plant_NN and_CC machinery_NN 3,591_CD 2,332_CD other_JJ 3,868_CD 2,264_CD Impairment_NN of_IN goodwill_NN 426,362_CD 613,983_CD Impairment_NN of_IN intangible_JJ xed_JJ assets_NNS 16,453_CD 17,464_CD Impairment_NN of_IN tangible_JJ xed_JJ assets_NNS 5,965_CD Depreciation_NN of_IN tangible_JJ xed_JJ assets_NNS owned_VBN 12,807_CD 8,995_CD held_VBN under_IN finance_NN leases_NNS and_CC hire_VB purchase_NN contracts_NNS 597_CD 78_CD Amortisation_NNP of_IN goodwill_NN 106,753_CD 138,513_CD Amortisation_NNP of_IN intangible_JJ xed_JJ assets_NNS 13,952_CD 15,466_CD profit_NN on_IN sale_NN of_IN discontinued_VBN operations_NNS 698_CD 2,006_CD profit_NN loss_NN on_IN sales_NNS of_IN tangible_JJ xed_JJ assets_NNS 100 854 5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 39_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS 39_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 4_CD Directors_NNS remuneration_NN ,_, interests_NNS and_CC transactions_NNS Aggregate_JJ remuneration_NN The_DT total_JJ amounts_NNS for_IN Directors_NNS remuneration_NN and_CC other_JJ benets_NNS were_VBD as_IN follows_VBZ :_: 2003 2002 000 000_CD Emoluments_NNP 2,256_CD 2,300_CD Money_NN purchase_NN pension_NN contributions_NNS 4,676_CD 383_CD Gains_NNS on_IN exercise_NN of_IN share_NN options_NNS 114_CD 2,962_CD Amounts_NNS receivable_JJ under_IN long-term_JJ incentive_NN schemes_NNS 276_CD Compensation_NNP for_IN loss_NN of_IN ofce_NN 1,335_CD 8,657_CD 5,645_CD No_DT fees_NNS were_VBD payable_JJ to_TO third_JJ parties_NNS in_IN respect_NN of_IN Directors_NNS services_NNS for_IN either_DT year_NN ._.
The_DT number_NN of_IN Directors_NNS who_WP were_VBD members_NNS of_IN a_DT Company_NN pension_NN scheme_NN was_VBD as_IN follows_VBZ :_: 2003_CD 2002_CD No._NN ._.
Money_NNP purchase_NN schemes_NNS 4_CD 4_CD Contributions_NNS paid_VBN by_IN the_DT Group_NNP in_IN respect_NN of_IN these_DT Directors_NNS can_MD be_VB found_VBN in_IN the_DT Directors_NNS remuneration_NN report_NN on_IN page_NN 24_CD ._.
The_DT above_JJ amounts_NNS for_IN remuneration_NN include_VBP the_DT following_VBG in_IN respect_NN of_IN the_DT highest_JJS paid_VBN Director_NNP :_: 2003 2002 000 000_CD Aggregate_NNP emoluments_NNS 311_CD 1,144_CD Gains_NNS on_IN exercise_NN of_IN share_NN options_NNS 21_CD 2,836_CD Amounts_NNS receivable_JJ under_IN long-term_JJ incentive_NN schemes_NNS 183_CD Compensation_NNP for_IN loss_NN of_IN ofce_NN 1,335_CD 1,850_CD 3,980_CD Further_JJ disclosures_NNS relating_VBG to_TO Directors_NNS remuneration_NN and_CC interests_NNS in_IN transactions_NNS can_MD be_VB found_VBN in_IN the_DT Directors_NNS remuneration_NN report_NN ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 40_CD 40_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 5_CD Staff_NN costs_NNS Particulars_NNPS of_IN employee_NN costs_NNS including_VBG executive_JJ Directors_NNS remuneration_NN are_VBP shown_VBN below_IN :_: 2003 2002 000 000_CD Wages_NNS and_CC salaries_NNS 85,026_CD 79,383_CD Social_NNP security_NN costs_NNS 8,527_CD 7,761_CD Pension_NN contributions_NNS 9,824_CD 4,702_CD 103,377_CD 91,846_CD The_DT Group_NNP operates_VBZ an_DT Inland_NNP Revenue_NN approved_VBD employee_NN share_NN option_NN scheme_NN and_CC has_VBZ taken_VBN advantage_NN of_IN the_DT exemption_NN given_VBN in_IN UITF_NNP Abstract_NNP 17_CD Employee_NN share_NN schemes_NNS from_IN recognizing_VBG a_DT charge_NN in_IN the_DT profit_NN and_CC loss_NN account_NN for_IN the_DT discount_NN on_IN the_DT options_NNS ._.
The_DT average_JJ monthly_JJ number_NN of_IN people_NNS employed_VBN by_IN the_DT Group_NNP during_IN the_DT year_NN was_VBD as_IN follows_VBZ :_: 2003_CD 2002_CD No._NN ._.
Manufacturing_NNP and_CC distribution_NN 374_CD 292_CD Sales_NNS and_CC marketing_NN 797_CD 791_CD General_NNP and_CC administrative_JJ 327_CD 298_CD Research_NNP and_CC development_NN 407_CD 424_CD 1,905_CD 1,805_CD 6_CD Finance_NNP charges_NNS ,_, net_JJ 2003 2002 000 000_CD Investment_NN income_NN 13,165_CD 15,434_CD Interest_NN payable_JJ and_CC similar_JJ charges_NNS 9,404_CD 8,458_CD Finance_NNP leases_NNS and_CC hire_VB purchase_NN contracts_NNS 59_CD 45_CD 9,463_CD 8,503_CD Finance_NNP charges_NNS ,_, net_JJ Investment_NN income_NN 13,165_CD 15,434_CD Interest_NN payable_JJ and_CC similar_JJ charges_NNS 9,463_CD 8,503_CD 3,702_CD 6,931_CD 5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 41_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS 41_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 7_CD Tax_NNP on_IN loss_NN on_IN ordinary_JJ activities_NNS The_DT tax_NN charge_NN comprises_VBZ :_: 2003 2002 000 000_CD Current_JJ tax_NN Overseas_JJ corporation_NN tax_NN 76,830_CD 66,461_CD Adjustment_NNP to_TO prior_JJ year_NN tax_NN charge_NN UK_NNP corporation_NN tax_NN 1,190_CD Overseas_NNP corporation_NN tax_NN 512_CD 196_CD 77,342_CD 67,455_CD Deferred_JJ tax_NN Origination_NNP and_CC reversal_NN of_IN timing_NN differences_NNS 12,328_CD 5,829_CD Total_JJ deferred_JJ tax_NN 12,328_CD 5,829_CD Total_JJ tax_NN on_IN loss_NN on_IN ordinary_JJ activities_NNS 65,014_CD 61,626_CD The_DT differences_NNS between_IN the_DT total_JJ current_JJ tax_NN shown_VBN above_IN and_CC the_DT amount_NN calculated_VBN by_IN applying_VBG the_DT standard_JJ rate_NN of_IN UK_NNP corporation_NN tax_NN to_TO the_DT profit_NN before_IN tax_NN is_VBZ as_IN follows_VBZ :_: 2003 2002 000 000_CD Group_NNP loss_NN on_IN ordinary_JJ activities_NNS before_IN tax_NN 298,341_CD 526,773_CD Tax_NNP on_IN loss_NN on_IN ordinary_JJ activities_NNS at_IN standard_JJ UK_NNP corporation_NN tax_NN rate_NN of_IN 30_CD %_NN 2002_CD :_: 30_CD %_NN 89,502_CD 158,032_CD Effects_NNPS of_IN :_: Expenses_NNS not_RB deductible_JJ for_IN tax_NN purposes_NNS 12,063_CD 9,247_CD Non_NNP deductible_JJ goodwill_NN 161,195_CD 225,749_CD Additional_JJ tax_NN benets_NNS non_VBP taxable_JJ income_NN 891_CD 1,796_CD Utilisation_NNP of_IN tax_NN losses_NNS 1,385_CD 9,255_CD Capital_NN taxes_NNS and_CC withholding_NN taxes_NNS 1,548_CD 550_CD Different_JJ tax_NN rates_NNS on_IN overseas_JJ earnings_NNS 26,008_CD 24,341_CD Deferred_JJ tax_NN liability_NN 12,328_CD 5,829_CD Adjustments_NNS to_TO tax_NN charge_NN in_IN respect_NN of_IN previous_JJ periods_NNS 5,224_CD 994_CD Group_NNP current_JJ tax_NN charge_NN for_IN period_NN 77,342_CD 67,455_CD The_DT Group_NNP earns_VBZ a_DT significant_JJ proportion_NN of_IN its_PRP$ profits_NNS in_IN the_DT US_NNP ._.
The_DT US_NNP statutory_JJ federal_JJ tax_NN rate_NN is_VBZ higher_JJR than_IN that_DT of_IN the_DT UK_NNP :_: profits_NNS being_VBG taxed_VBN at_IN 35_CD %_NN ._.
In_IN the_DT future_NN ,_, changes_NNS in_IN US_NNP tax_NN law_NN may_MD affect_VB the_DT Group_NNP tax_NN charge_NN ._.
No_DT tax_NN deduction_NN is_VBZ available_JJ on_IN the_DT impairment_NN of_IN goodwill_NN that_WDT was_VBD created_VBN on_IN the_DT acquisition_NN of_IN BioChem_NNP Pharma_NNP Inc._NNP 5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 42_CD 42_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 8_CD profit_NN attributable_JJ to_TO Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN The_DT profit_NN for_IN the_DT financial_JJ year_NN dealt_VBD with_IN in_IN the_DT accounts_NNS of_IN the_DT Company_NN was_VBD 194,246,000_CD 2002_CD :_: loss_NN of_IN 7,038,000_CD ._.
As_IN provided_VBN by_IN section_NN 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, no_DT profit_NN and_CC loss_NN account_NN is_VBZ presented_VBN in_IN respect_NN of_IN the_DT Company_NN ._.
9_CD Loss_NN per_IN share_NN Loss_NN per_IN share_NN has_VBZ been_VBN calculated_VBN by_IN dividing_VBG the_DT loss_NN on_IN ordinary_JJ activities_NNS after_IN taxation_NN for_IN each_DT period_NN by_IN the_DT weighted_JJ average_JJ number_NN of_IN shares_NNS in_IN issue_NN during_IN those_DT periods_NNS ._.
The_DT weighted_JJ average_JJ number_NN of_IN shares_NNS used_VBN in_IN calculating_VBG diluted_JJ earnings_NNS per_IN share_NN has_VBZ been_VBN adjusted_VBN for_IN the_DT effects_NNS of_IN all_DT dilutive_JJ potential_JJ ordinary_JJ shares_NNS ._.
No_DT such_JJ amounts_NNS were_VBD included_VBN as_IN their_PRP$ inclusion_NN would_MD be_VB anti-dilutive_JJ in_IN loss_NN making_VBG periods_NNS ._.
Similarly_RB the_DT $_$ 370_CD million_CD convertible_JJ loan_NN note_NN 2002_CD :_: $_$ 400_CD million_CD is_VBZ excluded_VBN as_IN it_PRP was_VBD not_RB dilutive_JJ ._.
Basic_JJ and_CC diluted_JJ 2003 2002 000 000_CD Loss_NN for_IN the_DT financial_JJ year_NN 363,355_CD 588,399_CD The_DT weighted_JJ average_JJ number_NN of_IN shares_NNS used_VBN in_IN each_DT year_NN are_VBP as_IN follows_VBZ :_: 2003_CD 2002_CD No._NN ._.
Total_JJ for_IN basic_JJ and_CC diluted_JJ loss_NN per_IN share_NN 498,212,826_CD 500,687,594_CD 10_CD Intangible_JJ assets_NNS intellectual_JJ property_NN Group_NNP Company_NNP 000_CD 000_CD Cost_NN As_IN at_IN 1_CD January_NNP 2003_CD 260,948_CD 23,668_CD Additions_NNPS 30,238_CD Foreign_JJ exchange_NN 15,976_CD As_IN at_IN 31_CD December_NNP 2003_CD 275,210_CD 23,668_CD Amortisation_NNP As_IN at_IN 1_CD January_NNP 2003_CD 77,544_CD 2,278_CD Charge_NNP for_IN the_DT year_NN 13,952_CD 2,060_CD Impairment_NN 16,453_CD Foreign_NNP exchange_NN 4,287_CD As_IN at_IN 31_CD December_NNP 2003_CD 103,662_CD 4,338_CD Net_JJ book_NN value_NN As_IN at_IN 31_CD December_NNP 2002_CD 183,404_CD 21,390_CD As_IN at_IN 31_CD December_NNP 2003_CD 171,548_CD 19,330_CD During_IN the_DT year_NN and_CC included_VBD within_IN additions_NNS for_IN the_DT year_NN ,_, the_DT Group_NNP purchased_VBD METHYPATCH_NNP ,_, a_DT transdermal_JJ methylphenidate_NN drug_NN delivery_NN system_NN ,_, from_IN Noven_NNP Pharmaceuticals_NNP Inc._NNP for_IN US$_$ 25.0_CD million_CD ,_, a_DT series_NN of_IN therapeutic_JJ products_NNS from_IN DRAXIS_NNP Health_NNP Inc_NNP for_IN CAN$_NNP 15.0_CD million_CD ,_, and_CC VANIQA_NNP from_IN Women_NNP First_NNP Healthcare_NNP Inc._NNP for_IN US$_$ 10.0_CD million_CD ._.
The_DT impairment_NN was_VBD in_IN respect_NN of_IN non-strategic_JJ products_NNS that_WDT are_VBP no_RB longer_RB marketed_VBN by_IN the_DT Group_NNP ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 43_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS 43_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 11_CD Intangible_JJ assets_NNS goodwill_NN Group_NNP Company_NNP 000_CD 000_CD Cost_NN As_IN at_IN 1_CD January_NNP 2003_CD 2,774,292_CD Prior_RB year_NN adjustment_NN 611_CD Foreign_NNP exchange_NN 412_CD As_IN at_IN 31_CD December_NNP 2003_CD 2,773,269_CD Amortisation_NNP As_IN at_IN 1_CD January_NNP 2003_CD 873,396_CD Charge_NNP for_IN the_DT year_NN 106,753_CD Impairment_NNP 426,362_CD Foreign_JJ exchange_NN 1,175_CD As_IN at_IN 31_CD December_NNP 2003_CD 1,407,686_CD Net_JJ book_NN value_NN As_IN at_IN 31_CD December_NNP 2002_CD 1,900,896_CD As_IN at_IN 31_CD December_NNP 2003_CD 1,365,583_CD At_IN 31_CD December_NNP 2003_CD ,_, an_DT impairment_NN charge_NN was_VBD booked_VBN in_IN relation_NN to_TO goodwill_NN which_WDT was_VBD created_VBN on_IN the_DT acquisition_NN of_IN BioChem_NNP Pharma_NNP Inc._NNP ._.
A_DT discounted_JJ cash_NN ow_NN model_NN was_VBD used_VBN to_TO estimate_VB the_DT recoverable_JJ value_NN of_IN the_DT business_NN and_CC the_DT impairment_NN is_VBZ included_VBN within_IN net_JJ operating_NN expenses_NNS in_IN the_DT consolidated_JJ profit_NN and_CC loss_NN account_NN ._.
A_DT range_NN of_IN discount_NN rates_NNS between_IN 7.5-10_CD %_NN was_VBD applied_VBN to_TO probability-adjusted_JJ forecasts_NNS ._.
The_DT prior_JJ year_NN cost_NN adjustment_NN relates_VBZ to_TO the_DT contingent_JJ cost_NN element_NN of_IN a_DT 2002_CD acquisition_NN which_WDT was_VBD ultimately_RB not_RB payable_JJ ._.
The_DT write-down_NN to_TO fair_JJ value_NN is_VBZ for_IN properties_NNS available_JJ for_IN sale_NN ._.
The_DT net_JJ book_NN value_NN of_IN the_DT Groups_NNS assets_NNS held_VBN under_IN finance_NN leases_NNS and_CC hire_VB purchase_NN agreements_NNS is_VBZ shown_VBN below_IN :_: 2003 2002 000 000_CD Buildings_NNS 3,277_CD 3,848_CD Equipment_NNP and_CC other_JJ 35_CD 61_CD 3,312_CD 3,909_CD All_DT finance_NN leases_NNS and_CC hire_VB purchase_NN arrangements_NNS are_VBP short_JJ leases_NNS with_IN a_DT life_NN of_IN less_JJR than_IN 50_CD years_NNS ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 45_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS 45_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 12_CD Tangible_JJ assets_NNS continued_VBD b_NN Company_NN Ofce_NNP furniture_NN and_CC Equipment_NNP ttings_NNS and_CC other_JJ Total_JJ 000 000 000_CD Cost_NN As_IN at_IN 1_CD January_NNP 2003_CD 1,608_CD 5,980_CD 7,588_CD Additions_NNS 281_CD 5,818_CD 6,099_CD Disposals_NNS 301 277 578_CD Transfers_NNPS 1,491_CD 1,491_CD As_IN at_IN 31_CD December_NNP 2003_CD 97_CD 13,012_CD 13,109_CD Depreciation_NN As_IN at_IN 1_CD January_NNP 2003_CD 949_CD 2,998_CD 3,947_CD Charge_NNP 307_CD 1,280_CD 1,587_CD Disposals_NNS 238 111 349_CD Transfers_NNPS 921_CD 921_CD As_IN at_IN 31_CD December_NNP 2003_CD 97_CD 5,088_CD 5,185_CD Net_JJ book_NN value_NN As_IN at_IN 31_CD December_NNP 2002_CD 659_CD 2,982_CD 3,641_CD As_IN at_IN 31_CD December_NNP 2003_CD 7,924_CD 7,924_CD The_DT net_JJ book_NN value_NN of_IN the_DT Companys_NNP equipment_NN includes_VBZ 35,480_CD 2002_CD :_: 61,000_CD in_IN respect_NN of_IN assets_NNS held_VBN under_IN finance_NN leases_NNS and_CC hire_VB purchase_NN agreements_NNS ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 46_CD 46_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 13_CD Fixed_VBN asset_NN investments_NNS Group_NNP Company_NNP 2003 2002 2003 2002_CD 000 000 000 000_CD Subsidiary_NNP undertakings_NNS 3,419,192_CD 3,435,332_CD Other_JJ investments_NNS 33,269_CD 37,345_CD 559_CD 559_CD 33,269_CD 37,345_CD 3,419,751_CD 3,435,891_CD Principal_NN Group_NNP investments_NNS The_DT parent_NN Company_NN and_CC the_DT Group_NNP have_VBP investments_NNS in_IN the_DT following_JJ subsidiary_NN undertakings_NNS and_CC other_JJ investments_NNS which_WDT principally_RB affected_VBD the_DT results_NNS or_CC net_JJ assets_NNS of_IN the_DT Group_NNP ._.
To_TO avoid_VB a_DT statement_NN of_IN excessive_JJ length_NN ,_, details_NNS of_IN investments_NNS which_WDT are_VBP not_RB significant_JJ have_VBP been_VBN omitted_VBN ._.
Country_NN of_IN incorporation_NN or_CC principal_NN business_NN Principal_NN address_NN activity_NN Holding_VBG %_NN Subsidiary_NNP undertakings_NNS Roberts_NNP Pharmaceutical_NNP Corporation_NNP US_NNP Intermediate_NNP holding_VBG company_NN 100_CD %_NN Shire_NNP Pharmaceuticals_NNP Limited_NNP UK_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Pharmaceutical_NNP Development_NNP Limited_NNP UK_NNP Development_NNP of_IN pharmaceuticals_NNS ,_, including_VBG on_IN behalf_NN of_IN other_JJ Group_NNP companies_NNS 100_CD %_NN Shire_NNP International_NNP Licensing_NNP BV_NNP Netherlands_NNP Licensing_NNP and_CC development_NN of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Laboratories_NNP ,_, Inc._NNP ._.
US_NNP Development_NNP and_CC licensing_NN of_IN pharmaceuticals_NNS ,_, including_VBG on_IN behalf_NN of_IN other_JJ Group_NNP companies_NNS 100_CD %_NN Shire_NNP Supplies_NNPS US_NNP ,_, LLC_NNP US_NNP Holder_NNP of_IN intellectual_JJ property_NN 100_CD %_NN Shire_NNP France_NNP SA_NNP France_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Deutschland_NNP GmbH_NNP &_CC Co_NNP K_NNP G_NNP Germany_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP US_NNP Inc._NNP ._.
US_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Pharmaceuticals_NNP Ireland_NNP Limited_NNP Ireland_NNP Marketing_NNP and_CC distribution_NN of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Italia_NNP SpA_NNP Italy_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Pharmaceuticals_NNP Iberica_NNP SL_NNP Spain_NNP Marketing_NNP and_CC distribution_NN of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Pharmaceuticals_NNP Development_NNP US_NNP Inc._NNP ._.
US_NNP Development_NNP of_IN pharmaceuticals_NNS ,_, including_VBG on_IN behalf_NN of_IN other_JJ Group_NNP companies_NNS 100_CD %_NN Shire_NNP BioChem_NNP Inc._NNP ._.
Canada_NNP Marketing_NNP ,_, research_NN and_CC development_NN of_IN pharmaceuticals_NNS ,_, including_VBG on_IN behalf_NN of_IN other_JJ Group_NNP companies_NNS 100_CD %_NN Shire_NNP Finance_NNP Limited_NNP Cayman_NNP Islands_NNP Issuer_NNP of_IN convertible_JJ notes_NNS 100_CD %_NN Shire_NNP Biologics_NNP Inc._NNP ._.
US_NNP Research_NNP and_CC development_NN of_IN pharmaceuticals_NNS ,_, including_VBG on_IN behalf_NN of_IN other_JJ Group_NNP companies_NNS 100_CD %_NN Shire_NNP Pharmaceutical_NNP Contracts_NNPS Limited_NNP UK_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP US_NNP Manufacturing_NNP Inc._NNP ._.
US_NNP Manufacturer_NNP of_IN pharmaceuticals_NNS 100_CD %_NN Held_VBN directly_RB by_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc._NN ._.
All_DT subsidiary_NN undertakings_NNS have_VBP been_VBN included_VBN in_IN the_DT consolidated_JJ financial_JJ statements_NNS ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 47_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS 47_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 13_CD Fixed_VBN asset_NN investments_NNS continued_VBD Subsidiary_NNP undertakings_NNS Company_NN Amounts_NNP Shares_NNP in_IN due_JJ from_IN subsidiary_NN subsidiary_NN undertakings_NNS undertakings_NNS Total_JJ 000 000 000_CD Cost_NN At_IN 1_CD January_NNP 2003_CD 3,206,336_CD 228,996_CD 3,435,332_CD Additions_NNS 2,433_CD 2,433_CD Disposal_NNP 727_CD 727_CD Net_JJ payback_NN of_IN loans_NNS 5,028_CD 5,028_CD Foreign_JJ exchange_NN 12,818_CD 12,818_CD At_IN 31_CD December_NNP 2003_CD 3,208,042_CD 211,150_CD 3,419,192_CD Other_JJ investments_NNS Group_NNP Company_NNP Other_JJ Other_JJ investments_NNS Total_JJ investments_NNS Total_JJ 000 000 000 000_CD Cost_NN At_IN 1_CD January_NNP 2003_CD 43,154_CD 43,154_CD 559_CD 559_CD Additions_NNS 3,447_CD 3,447_CD Foreign_JJ exchange_NN 1,968_CD 1,968_CD At_IN 31_CD December_NNP 2003_CD 48,569_CD 48,569_CD 559_CD 559_CD Provisions_NNS for_IN impairment_NN At_IN 1_CD January_NNP 2003_CD 5,809_CD 5,809_CD Written-off_JJ 9,491_CD 9,491_CD At_IN 31_CD December_NNP 2003_CD 15,300_CD 15,300_CD Net_JJ book_NN value_NN At_IN 31_CD December_NNP 2002_CD 37,345_CD 37,345_CD 559_CD 559_CD At_IN 31_CD December_NNP 2003_CD 33,269_CD 33,269_CD 559_CD 559_CD a_DT Investments_NNP in_IN private_JJ companies_NNS i_FW GeneChem_NNP funds_NNS The_DT Group_NNP has_VBZ made_VBN investments_NNS in_IN two_CD venture_NN capital_NN funds_NNS ._.
The_DT fund_NN managers_NNS distribute_VBP income_NN to_TO the_DT partners_NNS of_IN the_DT funds_NNS for_IN dividends_NNS or_CC realized_VBN gains_NNS made_VBN on_IN sale_NN of_IN investments_NNS ._.
As_IN part_NN of_IN its_PRP$ initial_JJ investment_NN the_DT Group_NNP were_VBD required_VBN to_TO make_VB additional_JJ future_JJ investments_NNS ._.
As_IN of_IN 31_CD December_NNP 2003_CD ,_, Shire_NNP is_VBZ committed_VBN to_TO making_VBG an_DT additional_JJ investment_NN of_IN 2.3_CD million_CD CAN$_NNP 5.3_CD million_CD ._.
ii_FW EGS_NNP Healthcare_NNP fund_NN In_IN November_NNP 2000_CD ,_, the_DT Group_NNP entered_VBD into_IN an_DT agreement_NN to_TO invest_VB up_RP to_TO 5.6_CD million_CD $_$ 10.0_CD million_CD in_IN various_JJ EGS_NNP healthcare_NN funds_NNS ._.
EGS_NNP is_VBZ a_DT private_JJ equity_NN company_NN that_WDT makes_VBZ investments_NNS in_IN healthcare_NN companies_NNS that_WDT focus_VBP mainly_RB on_IN biotechnology_NN and_CC pharmaceuticals_NNS ._.
As_IN of_IN 31_CD December_NNP 2003_CD ,_, the_DT Group_NNP has_VBZ invested_VBN 3.4_CD million_CD $_$ 6.1_CD million_CD in_IN EGS_NNP healthcare_NN funds_NNS and_CC the_DT Group_NNP is_VBZ ,_, therefore_RB ,_, committed_VBN to_TO invest_VB a_DT further_JJ 2.2_CD million_CD $_$ 3.9_CD million_CD into_IN these_DT funds_NNS ._.
b_NN Investments_NNP in_IN public_JJ companies_NNS As_IN at_IN 31_CD December_NNP 2003_CD ,_, the_DT Group_NNP held_VBD 7.5_CD million_CD of_IN investments_NNS in_IN public_JJ companies_NNS 2002_CD :_: 8.8_CD million_CD ._.
During_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD ,_, there_EX were_VBD no_DT new_JJ investments_NNS made_VBN in_IN public_JJ companies_NNS ._.
The_DT Group_NNP impaired_VBD the_DT cost_NN of_IN investments_NNS in_IN public_JJ companies_NNS by_IN 1.0_CD million_CD ._.
Fixed_JJ asset_NN investments_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN and_CC as_IN a_DT result_NN ,_, any_DT market_NN gains_NNS have_VBP not_RB been_VBN recognized_VBN ._.
As_IN at_IN 31_CD December_NNP 2003_CD ,_, the_DT market_NN value_NN of_IN listed_VBN investments_NNS was_VBD 4.8_CD million_CD above_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN 2002_CD :_: 0.8_CD million_CD ._.
There_EX are_VBP no_DT other_JJ differences_NNS between_IN cost_NN and_CC market_NN value_NN ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 48_CD 48_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 14_CD Acquisitions_NNS and_CC disposals_NNS Acquisitions_NNP The_NNP Group_NNP made_VBD no_DT acquisitions_NNS during_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD ._.
Disposals_NNS On_IN 31_CD December_NNP 2003_CD ,_, the_DT Group_NNP completed_VBD its_PRP$ divestment_NN of_IN its_PRP$ investment_NN in_IN the_DT joint_JJ venture_NN ,_, Qualia_NNP Computing_NNP Inc._NNP ._.
This_DT was_VBD sold_VBN to_TO iCAD_NNP Inc._NNP for_IN a_DT total_JJ consideration_NN of_IN 3.1_CD million_CD $_$ 5.5_CD million_CD ._.
The_DT following_JJ table_NN summarises_VBZ the_DT major_JJ categories_NNS of_IN assets_NNS and_CC liabilities_NNS attributed_VBD to_TO the_DT joint_JJ venture_NN at_IN the_DT date_NN of_IN disposal_NN ._.
000_CD Investments_NNPS 2,375_CD profit_NN on_IN sale_NN 698_CD 3,073_CD satisfied_VBN by_IN :_: Cash_NN consideration_NN 559_CD Deferred_JJ consideration_NN 2,514_CD 3,073_CD 15_CD Investments_NNP in_IN joint_JJ ventures_NNS In_IN accordance_NN with_IN FRS_NNP No._NN ._.
9_CD associates_NNS and_CC joint_JJ ventures_NNS the_DT following_JJ information_NN regarding_VBG the_DT Groups_NNS share_NN in_IN Qualia_NNP is_VBZ disclosed_VBN ,_, prior_RB to_TO its_PRP$ disposal_NN in_IN December_NNP 2003_CD :_: 2003_CD 2002_CD Qualia_NNP 000_CD 000_CD Turnover_NN 3,594_CD 762_CD Loss_NN before_IN tax_NN 2,806_CD 559_CD Taxation_NNP Loss_NN after_IN tax_NN 2,806_CD 559_CD Fixed_VBN assets_NNS 2,648_CD Current_JJ assets_NNS 2,434_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN 342_CD 16_CD Stocks_NNS Group_NNP Company_NNP 2003 2002 2003 2002_CD 000 000 000 000_CD Raw_NNP materials_NNS and_CC consumables_NNS 3,797_CD 4,862_CD Work_NN in_IN progress_NN 5,644_CD 8,520_CD Finished_VBN goods_NNS and_CC goods_NNS for_IN resale_NN 15,841_CD 17,189_CD 25,282_CD 30,571_CD There_EX is_VBZ no_DT material_NN difference_NN between_IN the_DT balance_NN sheet_NN value_NN of_IN stocks_NNS and_CC their_PRP$ replacement_NN cost_NN ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 49_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS 49_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 17_CD Deferred_JJ tax_NN Deferred_VBN tax_NN 000_CD Group_NNP At_IN 1_CD January_NNP 2002_CD 22,196_CD Credited_VBN to_TO profit_VB and_CC loss_NN account_NN 5,829_CD Foreign_NNP Exchange_NNP 2,518_CD At_IN 31_CD December_NNP 2002_CD 25,507_CD Credited_VBN to_TO profit_VB and_CC loss_NN account_NN 12,328_CD Foreign_NNP Exchange_NNP 2,568_CD At_IN 31_CD December_NNP 2003_CD 35,267_CD Included_VBN in_IN the_DT above_JJ balance_NN at_IN 31_CD December_NNP 2003_CD is_VBZ a_DT liability_NN of_IN 782,000_CD 2002_CD :_: asset_NN of_IN 3,861,000_CD which_WDT is_VBZ due_JJ after_IN more_JJR than_IN one_CD year_NN ._.
Deferred_JJ tax_NN is_VBZ provided_VBN and_CC unprovided_JJ as_IN follows_VBZ :_: Unprovided_JJ Provided_VBN Unprovided_NNP Provided_VBD 2003 2003 2002 2002_CD 000 000 000 000_CD Group_NNP Accelerated_VBD capital_NN allowances_NNS 18,684_CD 18,676_CD Other_JJ timing_NN differences_NNS 9,226_CD 11,300_CD Tax_NNP losses_NNS available_JJ 93,948_CD 44,725_CD 92,283_CD 32,883_CD Deferred_JJ tax_NN asset_NN 93,948_CD 35,267_CD 92,283_CD 25,507_CD Amounts_NNS unprovided_JJ principally_RB represent_VBP the_DT deferred_JJ tax_NN assets_NNS arising_VBG from_IN overseas_JJ tax_NN ,_, operating_VBG loss_NN carryforwards_NNS and_CC capital_NN loss_NN carryforwards_NNS ._.
The_DT utilisation_NN of_IN operating_VBG loss_NN carryforwards_NNS is_VBZ restricted_VBN to_TO the_DT taxable_JJ income_NN of_IN the_DT subsidiary_NN generating_VBG the_DT losses_NNS ._.
As_IN at_IN 31_CD December_NNP 2003_CD ,_, based_VBN upon_IN the_DT level_NN of_IN historical_JJ taxable_JJ income_NN and_CC projections_NNS for_IN future_JJ taxable_JJ income_NN ,_, management_NN believes_VBZ it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB that_IN the_DT Group_NNP will_MD realize_VB the_DT benets_NNS of_IN the_DT provided_VBN deferred_VBN tax_NN assets_NNS ._.
However_RB ,_, the_DT amount_NN of_IN the_DT deferred_JJ tax_NN asset_NN considered_VBN realisable_JJ could_MD be_VB adjusted_VBN in_IN the_DT future_NN if_IN estimates_NNS of_IN taxable_JJ income_NN are_VBP revised_VBN ._.
Company_NN The_DT Company_NN has_VBZ an_DT unprovided_JJ deferred_JJ tax_NN asset_NN of_IN 10.3_CD million_CD 2002_CD :_: nil_NN carried_VBD forward_RB ._.
The_DT amount_NN shown_VBN above_IN is_VBZ the_DT gross_JJ asset_NN represented_VBN by_IN non-current_JJ marketable_JJ securities_NNS ._.
A_DT related_JJ liability_NN of_IN approximately_RB 5.0_CD million_CD is_VBZ included_VBN within_IN notes_NNS 20_CD and_CC 21_CD ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 50_CD 50_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 19_CD Current_JJ asset_NN investments_NNS Group_NNP Company_NNP 2003 2002 2003 2002_CD 000 000 000 000_CD Institutional_JJ and_CC managed_VBD cash_NN funds_NNS 102,373_CD 141,800_CD Commercial_JJ paper_NN 67,522_CD 54,564_CD 169,895_CD 196,364_CD There_EX were_VBD no_DT material_NN differences_NNS between_IN book_NN value_NN and_CC fair_JJ value_NN of_IN the_DT managed_VBN cash_NN funds_NNS as_IN at_IN 31_CD December_NNP 2003_CD or_CC as_RB at_IN 31_CD December_NNP 2002_CD ._.
Investments_NNP are_VBP held_VBN at_IN amortised_JJ cost_NN because_IN of_IN their_PRP$ short-term_JJ nature_NN and_CC they_PRP are_VBP generally_RB held_VBN to_TO maturity_NN ._.
20_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN Group_NNP Company_NNP 2003 2002 2003 2002_CD 000 000 000 000_CD Other_JJ creditors_NNS Bank_NNP loans_NNS note_VBP 21_CD ii_FW 431_CD 389_CD Obligations_NNS under_IN finance_NN leases_NNS 158_CD 162_CD 35_CD 32_CD Trade_NNP creditors_NNS 11,895_CD 29,153_CD 308_CD 862_CD Amounts_NNS due_JJ to_TO other_JJ Group_NNP undertakings_NNS 241,661_CD 218,219_CD Overseas_JJ corporation_NN tax_NN 10,395_CD 8,835_CD Other_JJ taxation_NN and_CC social_JJ security_NN 2,683_CD 2,416_CD 1,162_CD 367_CD Other_JJ creditors_NNS 7,662_CD 2,033_CD 168_CD 197_CD Accruals_NNPS and_CC deferred_VBN income_NN 108,498_CD 88,897_CD 7,706_CD 5,630_CD 141,722_CD 131,885_CD 251,040_CD 225,307_CD Obligations_NNS under_IN finance_NN leases_NNS are_VBP secured_VBN on_IN the_DT assets_NNS to_TO which_WDT they_PRP relate_VBP ._.
Included_VBN within_IN other_JJ creditors_NNS is_VBZ 1,553,000_CD relating_VBG to_TO the_DT SERP_NNP 2002_CD :_: 766,000_CD ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 51_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS 51_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 21_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ after_IN more_JJR than_IN one_CD year_NN Group_NNP Company_NNP 2003 2002 2003 2002_CD Notes_NNP 000 000 000 000_CD Convertible_JJ debt_NN 2_CD %_NN guaranteed_VBN convertible_JJ loan_NN notes_NNS 2011_CD i_FW 202,659_CD 243,547_CD Deferred_JJ tax_NN liability_NN 782_CD Other_JJ creditors_NNS Bank_NNP loans_NNS ii_VBP 424_CD 778_CD Obligations_NNS under_IN finance_NN leases_NNS and_CC hire_VB purchase_NN contracts_NNS 3,238_CD 3,757_CD 36_CD Amounts_NNS due_JJ to_TO other_JJ Group_NNP undertakings_NNS 206,459_CD 252,258_CD Other_JJ creditors_NNS 5,792_CD 9,247_CD Deferred_JJ income_NN 7,503_CD 16,957_CD 13,782_CD 206,459_CD 252,294_CD 220,398_CD 257,329_CD 206,459_CD 252,294_CD Included_VBN within_IN other_JJ creditors_NNS is_VBZ 3,409,000_CD relating_VBG to_TO the_DT SERP_NNP 2002_CD :_: 4,430,000_CD ._.
Subject_JJ to_TO the_DT conditions_NNS below_IN ,_, borrowings_NNS are_VBP repayable_JJ as_IN follows_VBZ :_: Group_NNP Company_NNP 2003 2002 2003 2002_CD Notes_NNP 000 000 000 000_CD Convertible_JJ loan_NN notes_NNS :_: i_FW After_IN five_CD years_NNS 202,659_CD 243,547_CD 202,659_CD 243,547_CD Bank_NNP loans_NNS :_: ii_FW Between_IN one_CD and_CC two_CD years_NNS 424_CD 389_CD Between_IN two_CD and_CC five_CD years_NNS 389 424 778_CD Obligations_NNS under_IN finance_NN leases_NNS and_CC hire_VB purchase_NN contracts_NNS :_: Between_IN one_CD and_CC two_CD years_NNS 142_CD 158_CD 36_CD After_IN five_CD years_NNS 3,096_CD 3,599_CD 3,238_CD 3,757_CD 36_CD 206,321_CD 248,082_CD 36_CD 5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 52_CD 52_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 21_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ after_IN more_JJR than_IN one_CD year_NN continued_VBD i_FW $_$ 400_CD million_CD 2_CD %_NN guaranteed_VBN convertible_JJ loan_NN notes_NNS 2011_CD The_DT $_$ 400_CD million_CD of_IN guaranteed_VBN convertible_JJ loan_NN notes_NNS due_JJ 2011_CD were_VBD issued_VBN on_IN 15_CD August_NNP 2001_CD by_IN Shire_NNP Finance_NNP Limited_NNP the_DT Issuer_NNP ,_, a_DT wholly_RB owned_VBN subsidiary_NN ._.
The_DT notes_NNS bear_VBP interest_NN of_IN 2_CD %_NN per_IN annum_NN ,_, paid_VBD semi-annually_RB in_IN arrears_NNS ._.
The_DT convertible_JJ notes_NNS are_VBP guaranteed_VBN by_IN Shire_NNP and_CC are_VBP convertible_JJ into_IN redeemable_JJ preference_NN shares_NNS of_IN the_DT Issuer_NN which_WDT upon_IN issuance_NN will_MD be_VB immediately_RB exchanged_VBN for_IN either_DT i_FW Shire_FW ordinary_JJ shares_NNS or_CC ii_FW Shire_FW ADSs_FW ,_, or_CC iii_NN at_IN the_DT Issuers_NNPS option_NN ,_, a_DT cash_NN amount_NN based_VBN upon_IN the_DT London_NNP Stock_NNP Exchange_NNP volume-weighted_JJ average_NN prices_NNS of_IN ordinary_JJ shares_NNS from_IN the_DT fourth_JJ to_TO the_DT eighth_JJ business_NN days_NNS following_VBG conversion_NN ._.
At_IN the_DT choice_NN of_IN investors_NNS ,_, each_DT $_$ 1000_CD of_IN nominal_JJ value_NN notes_NNS can_MD be_VB converted_VBN into_IN 49.62_CD Shire_NNP ordinary_JJ shares_NNS subject_JJ to_TO adjustment_NN or_CC 16.54_CD Shire_NNP ADSs_NNP subject_NN to_TO adjustment_NN at_IN any_DT time_NN up_RP to_TO 21_CD August_NNP 2011_CD ._.
Alternatively_RB ,_, investors_NNS can_MD choose_VB to_TO receive_VB repayment_NN of_IN the_DT nominal_JJ principal_NN in_IN cash_NN either_CC at_IN the_DT maturity_NN date_NN of_IN 21_CD August_NNP 2011_CD or_CC by_IN exercising_VBG a_DT put_NN option_NN on_IN any_DT of_IN the_DT three_CD put_VBD dates_NNS being_VBG 21_CD August_NNP 2004_CD ,_, 21_CD August_NNP 2006_CD and_CC 21_CD August_NNP 2008_CD ._.
At_IN the_DT option_NN of_IN the_DT Company_NN ,_, repayment_NN can_MD be_VB made_VBN in_IN the_DT form_NN of_IN Shire_NNP ordinary_JJ shares_NNS or_CC ADSs_NNS ._.
The_DT number_NN of_IN ordinary_JJ shares_NNS that_IN a_DT note_NN holder_NN would_MD receive_VB would_MD be_VB based_VBN on_IN the_DT notional_JJ principal_NN of_IN the_DT notes_NNS divided_VBN by_IN 95_CD %_NN of_IN the_DT London_NNP Stock_NNP Exchange_NNP volume-weighted_JJ average_JJ price_NN of_IN ordinary_JJ shares_NNS on_IN the_DT five_CD trading_NN days_NNS after_IN the_DT Company_NN gives_VBZ notice_NN of_IN the_DT exercise_NN of_IN its_PRP$ option_NN ._.
Such_JJ notice_NN will_MD be_VB on_IN or_CC before_IN the_DT tenth_NN business_NN day_NN preceding_VBG the_DT repayment_NN put_VBD date_NN ._.
On_IN or_CC after_IN 21_CD August_NNP 2004_CD ,_, the_DT Company_NN may_MD redeem_VB ,_, for_IN cash_NN ,_, all_DT or_CC part_NN of_IN the_DT notes_NNS provided_VBD the_DT ordinary_JJ share_NN price_NN has_VBZ exceeded_VBN $_$ 26.20_CD Sterling_NN equivalent_NN at_IN the_DT time_NN for_IN 20_CD of_IN the_DT 30_CD consecutive_JJ dealing_VBG days_NNS in_IN the_DT period_NN prior_RB to_TO redemption_NN ._.
During_IN the_DT second_JJ quarter_NN of_IN 2003_CD ,_, the_DT Company_NN repurchased_VBD 17.6_CD million_CD $_$ 29.8_CD million_CD of_IN the_DT $_$ 400_CD million_CD 2_CD %_NN guaranteed_VBN convertible_JJ notes_NNS due_JJ 2011_CD ._.
The_DT decision_NN as_IN to_TO whether_IN a_DT note_NN holder_NN would_MD exercise_VB a_DT put_NN option_NN will_MD depend_VB on_IN a_DT number_NN of_IN factors_NNS particularly_RB the_DT price_NN of_IN Shire_NNP shares_NNS at_IN the_DT put_JJ date_NN and_CC the_DT likelihood_NN of_IN Shires_NNP share_NN price_NN exceeding_VBG the_DT conversion_NN threshold_NN price_NN ._.
The_DT conversion_NN threshold_NN price_NN is_VBZ 12.52_CD for_IN ordinary_JJ shares_NNS ._.
If_IN the_DT price_NN of_IN Shire_NNP ordinary_JJ shares_NNS at_IN the_DT first_JJ put_JJ date_NN of_IN 21_CD August_NNP 2004_CD remains_VBZ at_IN a_DT level_NN similar_JJ to_TO the_DT year_NN end_NN price_NN of_IN 5.425_CD ,_, it_PRP is_VBZ quite_RB possible_JJ that_IN note_NN holders_NNS will_MD choose_VB to_TO exercise_VB their_PRP$ put_JJ options_NNS ._.
The_DT Group_NNP currently_RB has_VBZ adequate_JJ resources_NNS from_IN which_WDT it_PRP could_MD satisfy_VB repayment_NN of_IN the_DT entire_JJ convertible_JJ debt_NN principal_NN of_IN $_$ 370.2_CD million_CD ._.
ii_FW Canadian_JJ federal_JJ and_CC provincial_JJ government_NN loan_NN The_DT Group_NNP has_VBZ a_DT Canadian_JJ federal_JJ and_CC provincial_JJ government_NN loan_NN outstanding_JJ of_IN 0.8_CD million_CD CAN$_NNP 2.0_CD million_CD ._.
This_DT facility_NN is_VBZ non-interest_JJ bearing_NN and_CC is_VBZ repayable_JJ in_IN annual_JJ instalments_NNS of_IN 0.4_CD million_CD CAN$_NNP 1.0_CD million_CD in_IN October_NNP of_IN 2004_CD and_CC 2005_CD ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 53_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS 53_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 22_CD Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS The_DT Financial_NNP review_NN on_IN pages_NNS 6_CD to_TO 9_CD provides_VBZ an_DT explanation_NN of_IN the_DT role_NN that_WDT financial_JJ instruments_NNS have_VBP had_VBN during_IN the_DT year_NN ._.
The_DT explanation_NN summarises_VBZ the_DT objectives_NNS and_CC policies_NNS for_IN holding_VBG or_CC issuing_VBG financial_JJ instruments_NNS and_CC similar_JJ contracts_NNS ,_, and_CC the_DT strategies_NNS for_IN achieving_VBG those_DT objectives_NNS that_WDT have_VBP been_VBN followed_VBN during_IN the_DT year_NN ._.
No_DT foreign_JJ exchange_NN ,_, interest_NN rate_NN or_CC other_JJ derivative_JJ contracts_NNS were_VBD entered_VBN into_IN or_CC transacted_VBN during_IN 2003_CD or_CC 2002_CD ._.
The_DT numerical_JJ disclosures_NNS in_IN this_DT note_NN deal_NN with_IN financial_JJ assets_NNS and_CC financial_JJ liabilities_NNS as_IN dened_VBN in_IN FRS_NNP 13_CD derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS :_: disclosures_NNS ._.
Certain_JJ financial_JJ assets_NNS such_JJ as_IN investments_NNS in_IN subsidiary_NN companies_NNS are_VBP excluded_VBN from_IN the_DT scope_NN of_IN these_DT disclosures_NNS ._.
As_IN permitted_VBN by_IN FRS_NNP 13_CD ,_, short-term_JJ debtors_NNS and_CC creditors_NNS have_VBP been_VBN excluded_VBN from_IN the_DT disclosures_NNS ,_, other_JJ than_IN the_DT currency_NN disclosures_NNS ._.
Interest_NN rate_NN prole_VB The_DT currency_NN and_CC interest_NN rate_NN prole_NN of_IN the_DT Groups_NNS financial_JJ assets_NNS ,_, excluding_VBG short-term_JJ debtors_NNS at_IN 31_CD December_NNP 2003_CD ,_, are_VBP as_RB below_RB ._.
In_IN addition_NN to_TO cash_NN and_CC cash_NN equivalents_NNS ,_, there_EX are_VBP current_JJ asset_NN investments_NNS as_IN detailed_VBN in_IN note_NN 19_CD ._.
Weighted_JJ Weighted_NNP Weighted_NNP average_JJ average_JJ average_JJ interest_NN interest_NN interest_NN Financial_NNP Financial_NNP period_NN rate_NN rate_NN instruments_NNS instruments_NNS Fixed_VBN rate_NN Floating_VBG rate_NN Fixed_VBN rate_NN Floating_VBG rate_NN Fixed_VBN rate_NN Total_JJ Days_NNS %_NN %_NN '_'' 000_CD '_'' 000_CD '_'' 000_CD Pounds_NNS sterling_JJ 7_CD 3.07_CD 3.50_CD 14,729_CD 3,875_CD 18,604_CD US_NNP dollars_NNS 204_CD 1.00_CD 1.32_CD 604,822_CD 113,889_CD 718,711_CD Euro_NNP 76_CD 0.89_CD 2.00_CD 9,027_CD 6,634_CD 15,661_CD Canadian_JJ dollars_NNS 70_CD 0.25_CD 2.99_CD 3,093_CD 35,392_CD 38,485_CD Other_JJ 0.25_CD 104 104 631_CD ,775_CD 159,790_CD 791,565_CD The_DT benchmark_NN rates_NNS for_IN oating_NN rate_NN assets_NNS are_VBP primarily_RB :_: US_NNP dollar_NN 7_CD day_NN ,_, 1_CD month_NN and_CC 3_CD month_NN LIBID_NNP ,_, and_CC pounds_NNS sterling_NN 7_CD day_NN LIBID_NNP ._.
The_DT currency_NN and_CC interest_NN rate_NN prole_NN of_IN the_DT Groups_NNS financial_JJ assets_NNS excluding_VBG short-term_JJ debtors_NNS at_IN 31_CD December_NNP 2002_CD are_VBP as_RB below_RB ._.
Weighted_JJ Weighted_NNP Weighted_NNP average_JJ average_JJ average_JJ interest_NN interest_NN interest_NN Financial_NNP Financial_NNP period_NN rate_NN rate_NN instruments_NNS instruments_NNS Fixed_VBN rate_NN Floating_VBG rate_NN Fixed_VBN rate_NN Floating_VBG rate_NN Fixed_VBN rate_NN Total_JJ Days_NNS %_NN %_NN '_'' 000_CD '_'' 000_CD '_'' 000_CD Pounds_NNS sterling_JJ 2_CD 3.4_CD 3.9_CD 14,298_CD 3,296_CD 17,594_CD US_NNP dollars_NNS 60_CD 1.5_CD 1.9_CD 426,017_CD 237,011_CD 663,028_CD Euro_NNP 6_CD 3.1_CD 6,437_CD 3,891_CD 10,328_CD Canadian_JJ dollars_NNS 131_CD 2.9_CD 2,128_CD 61,718_CD 63,846_CD 448,880_CD 305,916_CD 754,796_CD The_DT interest_NN rate_NN prole_NN of_IN the_DT Groups_NNS financial_JJ liabilities_NNS at_IN 31_CD December_NNP 2003_CD was_VBD as_IN follows_VBZ :_: Floating_VBG Fixed_NNP Interest_NNP free_JJ Total_JJ Currency_NNP '_POS 000_CD '_'' 000_CD '_'' 000_CD '_'' 000_CD Canadian_JJ dollars_NNS Federal_NNP and_CC provincial_JJ government_NN loan_NN 855_CD 855_CD US_NNP dollars_NNS Convertible_JJ debt_NN 202,659_CD 202,659_CD Total_JJ 202,659_CD 855_CD 203,514_CD The_DT $_$ 370.2_CD million_CD of_IN guaranteed_VBN convertible_JJ loan_NN notes_NNS due_JJ 2011_CD ,_, were_VBD issued_VBN on_IN 15_CD August_NNP 2001_CD by_IN Shire_NNP Finance_NNP Limited_NNP ,_, a_DT wholly_RB owned_VBN subsidiary_NN ._.
The_DT weighted_JJ average_JJ period_NN to_TO maturity_NN of_IN the_DT guaranteed_VBN convertible_JJ loan_NN notes_NNS is_VBZ 7_CD years_NNS ._.
For_IN further_JJ information_NN on_IN the_DT guaranteed_VBN convertible_JJ loan_NN notes_NNS ,_, see_VBP note_NN 21_CD i._NN Weighted_VBN average_JJ period_NN to_TO maturity_NN of_IN interest_NN free_JJ government_NN loans_NNS is_VBZ 16_CD months_NNS ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 54_CD 54_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 22_CD Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS continued_VBD The_DT interest_NN rate_NN prole_NN of_IN the_DT Groups_NNS financial_JJ liabilities_NNS at_IN 31_CD December_NNP 2002_CD was_VBD as_IN follows_VBZ :_: Floating_VBG Fixed_NNP Interest_NNP free_JJ Total_JJ Currency_NNP '_POS 000_CD '_'' 000_CD '_'' 000_CD '_'' 000_CD Canadian_JJ dollars_NNS Federal_NNP and_CC provincial_JJ government_NN loan_NN 1,167_CD 1,167_CD US_NNP dollars_NNS Convertible_JJ debt_NN 243,547_CD 243,547_CD Total_JJ 243,547_CD 1,167_CD 244,714_CD Currency_NNP exposures_NNS The_DT Groups_NNS objectives_NNS in_IN managing_VBG the_DT currency_NN exposures_NNS arising_VBG from_IN its_PRP$ net_JJ investment_NN overseas_RB in_IN other_JJ words_NNS ,_, its_PRP$ structural_JJ currency_NN exposures_NNS are_VBP to_TO maintain_VB a_DT low_JJ cost_NN of_IN borrowings_NNS and_CC minimize_VB currency_NN related_VBN exposures_NNS ._.
Gains_NNS and_CC losses_NNS arising_VBG from_IN structural_JJ currency_NN exposures_NNS are_VBP recognized_VBN in_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS ._.
The_DT table_NN below_IN shows_NNS the_DT Groups_NNS currency_NN exposures_NNS :_: in_IN other_JJ words_NNS ,_, those_DT transactional_JJ or_CC non-structural_JJ exposures_NNS that_WDT give_VBP rise_VB to_TO the_DT net_JJ currency_NN gains_NNS and_CC losses_NNS recognized_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
Such_JJ exposures_NNS comprise_VBP the_DT monetary_JJ assets_NNS and_CC monetary_JJ liabilities_NNS of_IN the_DT Group_NNP that_WDT are_VBP not_RB denominated_VBN in_IN the_DT operating_NN or_CC functional_JJ currency_NN of_IN the_DT operating_VBG unit_NN involved_VBN ,_, other_JJ than_IN certain_JJ non-sterling_JJ borrowings_NNS treated_VBN as_IN hedges_NNS of_IN net_JJ investments_NNS in_IN overseas_JJ operations_NNS ._.
As_IN at_IN 31_CD December_NNP 2003_CD these_DT exposures_NNS were_VBD as_IN follows_VBZ :_: Net_JJ foreign_JJ currency_NN monetary_JJ assets_NNS Pounds_NNP US_NNP Canadian_NNP Functional_NNP currency_NN sterling_NN dollars_NNS Euro_NNP dollars_NNS Other_JJ Total_NNP of_IN Group_NNP operation_NN '_'' 000_CD '_'' 000_CD '_'' 000_CD '_'' 000_CD '_'' 000_CD '_'' 000_CD Pounds_NNS sterling_JJ 333,969_CD 681_CD 436_CD 80_CD 333,287_CD US_NNP dollars_NNS 12,447_CD 8,171_CD 20_CD 25_CD 21,178_CD Euro_NNP 2,201_CD 5,455_CD 7,656_CD Canadian_JJ dollars_NNS 49,183_CD 108,267_CD 26_CD 157,476_CD 63,831_CD 220,247_CD 8,878_CD 456 105 146_CD ,978_CD The_DT exposures_NNS at_IN 31_CD December_NNP 2002_CD for_IN comparison_NN purposes_NNS were_VBD as_IN follows_VBZ :_: Net_JJ foreign_JJ currency_NN monetary_JJ assets_NNS Pounds_NNP US_NNP Functional_NNP currency_NN sterling_NN dollars_NNS Euro_NNP Other_JJ Total_NNP of_IN Group_NNP operation_NN '_'' 000_CD '_'' 000_CD '_'' 000_CD '_'' 000_CD '_'' 000_CD Pounds_NNS sterling_JJ 330,714_CD 242_CD 49_CD 331,005_CD Euro_NNP 1,268_CD 1,830_CD 3,098_CD Canadian_JJ dollars_NNS 1,702_CD 662_CD 301_CD 40_CD 2,705_CD 2,970_CD 333,206_CD 543_CD 89_CD 336,808_CD 5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 55_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS 55_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 22_CD Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS continued_VBD Maturity_NN of_IN financial_JJ liabilities_NNS The_DT maturity_NN prole_NN of_IN the_DT Groups_NNS financial_JJ liabilities_NNS at_IN 31_CD December_NNP 2003_CD is_VBZ shown_VBN below_IN :_: Convertible_JJ loan_NN notes_NNS Bank_NNP loans_NNS Total_NNP Group_NNP '_POS 000_CD '_'' 000_CD '_'' 000_CD Less_RBR than_IN one_CD year_NN 431_CD 431_CD Between_IN one_CD and_CC two_CD years_NNS 424_CD 424_CD Between_IN two_CD and_CC five_CD years_NNS Over_IN five_CD years_NNS 202,659_CD 202,659_CD 202,659_CD 855_CD 203,514_CD See_VB note_NN 21_CD i_FW and_CC 21_CD ii_NN for_IN further_JJ information_NN on_IN convertible_JJ loan_NN notes_NNS and_CC bank_NN loans_NNS respectively_RB ._.
Borrowing_NN facilities_NNS The_DT Group_NNP had_VBD no_DT undrawn_JJ committed_JJ borrowing_NN facilities_NNS at_IN 31_CD December_NNP 2003_CD or_CC 2002_CD ._.
Fair_NNP values_VBZ The_DT market_NN price_NN of_IN the_DT convertible_JJ loan_NN stock_NN 2011_CD as_RB at_IN 31_CD December_NNP 2003_CD was_VBD $_$ 100.537_CD compared_VBN with_IN an_DT issue_NN price_NN of_IN $_$ 100_CD ._.
If_IN the_DT loan_NN is_VBZ not_RB converted_VBN into_IN equity_NN ,_, it_PRP would_MD be_VB repayable_JJ at_IN $_$ 100_CD per_IN note_NN ._.
The_DT total_JJ fair_JJ value_NN of_IN the_DT debt_NN as_IN at_IN 31_CD December_NNP 2003_CD ,_, based_VBN on_IN the_DT above_JJ market_NN price_NN ,_, was_VBD 207.9_CD million_CD $_$ 372.2_CD million_CD compared_VBN to_TO a_DT face_NN value_NN of_IN 206.8_CD million_CD ._.
In_IN addition_NN at_IN 31_CD December_NNP 2003_CD the_DT fair_JJ value_NN ,_, being_VBG market_NN value_NN ,_, of_IN listed_VBN investments_NNS was_VBD 4.8_CD million_CD above_IN book_NN value_NN 2002_CD :_: 0.8_CD million_CD above_IN ._.
There_EX were_VBD no_DT other_JJ material_NN differences_NNS between_IN the_DT book_NN values_NNS and_CC fair_JJ values_NNS of_IN all_DT other_JJ Group_NNP financial_JJ assets_NNS and_CC liabilities_NNS at_IN 31_CD December_NNP 2003_CD 2002_CD :_: nil_NN ._.
Gains_NNS and_CC losses_NNS on_IN hedges_NNS The_DT Group_NNP had_VBD no_DT foreign_JJ exchange_NN ,_, interest_NN rate_NN or_CC other_JJ derivative_JJ contracts_NNS outstanding_JJ at_IN 31_CD December_NNP 2003_CD or_CC 31_CD December_NNP 2002_CD ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 56_CD 56_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 23_CD Called-up_JJ share_NN capital_NN Ordinary_NNP shares_NNS Number_NNP '_POS 000_CD 000_CD Authorised_VBN At_IN 31_CD December_NNP 2002_CD ordinary_JJ shares_NNS of_IN 5p_JJ each_DT 800,000_CD 40,000_CD At_IN 31_CD December_NNP 2003_CD ordinary_JJ shares_NNS of_IN 5p_JJ each_DT 800,000_CD 40,000_CD Allotted_NNP ,_, issued_VBN and_CC fully_RB paid_VBN At_IN 1_CD January_NNP 2003_CD ordinary_JJ shares_NNS of_IN 5p_JJ each_DT 484,344_CD 24,217_CD Issued_VBN on_IN exercise_NN of_IN options_NNS for_IN cash_NN consideration_NN 1,040_CD 53_CD Issued_VBN on_IN exchange_NN of_IN exchangeable_JJ shares_NNS 104_CD 5_CD Cancelled_VBN on_IN repurchase_NN of_IN ordinary_JJ shares_NNS 7,593_CD 380_CD At_IN 31_CD December_NNP 2003_CD ordinary_JJ shares_NNS of_IN 5p_JJ each_DT 477,895_CD 23,895_CD Special_JJ ordinary_JJ voting_NN shares_NNS exchangeable_JJ shares_NNS Number_NNP '_POS 000_CD 000_CD Authorised_VBN At_IN 31_CD December_NNP 2002_CD special_JJ ordinary_JJ voting_NN shares_NNS of_IN 0.00001_CD p_NN 17,500_CD At_IN 31_CD December_NNP 2003_CD special_JJ ordinary_JJ voting_NN shares_NNS of_IN 0.00001_CD p_NN 17,500_CD Allotted_NNP ,_, issued_VBN and_CC fully_RB paid_VBN At_IN 1_CD January_NNP 2003_CD 5,874_CD Exchanged_VBN for_IN ordinary_JJ shares_NNS 34_CD At_IN 31_CD December_NNP 2003_CD 5,840_CD Authorised_JJ share_NN capital_NN As_IN at_IN 31_CD December_NNP 2003_CD the_DT authorised_JJ share_NN capital_NN of_IN the_DT Company_NN was_VBD 40,000,000_CD divided_VBN into_IN 799,999,965_CD ordinary_JJ shares_NNS of_IN 5p_JJ each_DT and_CC 17,500,000_CD Special_JJ Ordinary_NNP Voting_NNP Shares_NNP exchangeable_JJ shares_NNS of_IN 0.00001_CD p_NN each_DT ._.
Issue_NN of_IN ordinary_JJ shares_NNS During_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD the_DT Company_NN allotted_VBD 103,653_CD ordinary_JJ shares_NNS with_IN a_DT nominal_JJ value_NN of_IN 5,182_CD on_IN the_DT exchange_NN of_IN special_JJ ordinary_JJ voting_NN shares_NNS exchangeable_JJ shares_NNS ,_, which_WDT were_VBD issued_VBN following_VBG the_DT acquisition_NN of_IN BioChem_NNP in_IN 2001_CD ._.
These_DT shares_NNS were_VBD issued_VBN at_IN a_DT premium_NN of_IN 1,121,525_CD ._.
Repurchase_NN of_IN ordinary_JJ shares_NNS During_IN the_DT year_NN the_DT Company_NN repurchased_VBD a_DT total_NN of_IN 7,592,778_CD ordinary_JJ shares_NNS for_IN a_DT total_JJ consideration_NN of_IN 31,627,815_CD representing_VBG an_DT average_JJ price_NN per_IN share_NN of_IN 416.55_CD p._NN All_DT of_IN these_DT shares_NNS were_VBD canceled_VBN ._.
Any_DT decision_NN by_IN the_DT Company_NN to_TO acquire_VB further_JJ ordinary_JJ shares_NNS in_IN future_NN will_MD be_VB dependent_JJ upon_IN the_DT level_NN of_IN its_PRP$ distributable_JJ profits_NNS ,_, its_PRP$ financial_JJ condition_NN ,_, the_DT terms_NNS of_IN any_DT then_RB existing_VBG debt_NN facilities_NNS ,_, the_DT renewal_NN after_IN 16_CD June_NNP 2004_CD of_IN the_DT authority_NN given_VBN by_IN shareholders_NNS and_CC other_JJ relevant_JJ factors_NNS existing_VBG at_IN that_DT time_NN ._.
Issue_NN of_IN special_JJ ordinary_JJ voting_NN shares_NNS The_DT Company_NN exchanged_VBD 34,551_CD special_JJ ordinary_JJ voting_NN shares_NNS during_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD ._.
Each_DT of_IN these_DT shares_NNS is_VBZ equivalent_JJ to_TO 3_CD ordinary_JJ shares_NNS and_CC is_VBZ exchangeable_JJ into_IN ordinary_JJ shares_NNS or_CC ADSs_NNS ,_, at_IN a_DT rate_NN of_IN one_CD exchangeable_JJ share_NN for_IN three_CD ordinary_JJ shares_NNS or_CC one_CD exchangeable_JJ share_NN for_IN one_CD ADS_NNPS ,_, at_IN any_DT time_NN at_IN the_DT request_NN of_IN the_DT holder_NN ._.
Only_RB BioChem_NNP shareholders_NNS with_IN Canadian_JJ residency_NN had_VBD the_DT option_NN to_TO receive_VB exchangeable_JJ shares_NNS for_IN their_PRP$ shares_NNS of_IN BioChem_NNP at_IN the_DT time_NN of_IN acquisition_NN ._.
The_DT exchangeable_JJ shares_NNS were_VBD issued_VBN by_IN Shire_NNP Acquisition_NNP Inc._NNP a_DT company_NN incorporated_VBN under_IN the_DT Canada_NNP Business_NNP Corporations_NNS Act_NNP ,_, which_WDT is_VBZ a_DT wholly_RB owned_VBN subsidiary_NN of_IN the_DT Company_NN ,_, and_CC is_VBZ listed_VBN on_IN the_DT Toronto_NNP Stock_NNP Exchange_NNP ._.
Holders_NNS of_IN the_DT exchangeable_JJ shares_NNS are_VBP entitled_VBN to_TO dividend_NN and_CC other_JJ rights_NNS that_WDT are_VBP economically_RB equivalent_JJ to_TO those_DT of_IN ordinary_JJ shares_NNS ._.
Through_IN a_DT voting_NN trust_NN and_CC by_IN means_NNS of_IN special_JJ voting_NN shares_NNS in_IN Shire_NNP held_VBN by_IN the_DT trustee_NN ,_, holders_NNS of_IN exchangeable_JJ shares_NNS are_VBP entitled_VBN to_TO vote_VB at_IN shareholder_NN meetings_NNS of_IN the_DT Company_NN ._.
As_IN at_IN 31_CD December_NNP 2003_CD 5,839,559_CD exchangeable_JJ shares_NNS remained_VBD unconverted_JJ ._.
The_DT Company_NN can_MD redeem_VB all_DT outstanding_JJ exchangeable_JJ shares_NNS for_IN ordinary_JJ shares_NNS after_IN 11_CD May_NNP 2011_CD ,_, or_CC earlier_JJR if_IN the_DT total_JJ number_NN of_IN exchangeable_JJ shares_NNS falls_VBZ below_IN 1_CD million_CD ._.
The_DT exchangeable_JJ shares_NNS are_VBP included_VBN as_IN part_NN of_IN share_NN capital_NN in_IN the_DT consolidated_JJ balance_NN sheet_NN to_TO present_VB a_DT true_JJ and_CC fair_JJ view_NN of_IN the_DT consolidated_JJ Groups_NNS capital_NN structure_NN ,_, which_WDT differs_VBZ from_IN the_DT Companies_NNS Act_NNP 1985_CD requirements_NNS to_TO reect_VB these_DT amounts_NNS as_IN minority_NN interests_NNS ,_, as_IN they_PRP will_MD become_VB ,_, and_CC are_VBP equivalent_JJ ,_, to_TO ordinary_JJ shares_NNS ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 57_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS 57_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 23_CD Called-up_JJ share_NN capital_NN continued_VBD Share_NN warrants_NNS On_IN 24_CD April_NNP 2002_CD the_DT Company_NN issued_VBN 741,812_CD share_NN warrants_NNS ,_, at_IN 4.88_CD per_IN warrant_NN ,_, and_CC on_IN 21_CD November_NNP 2002_CD the_DT Company_NN issued_VBD a_DT further_JJ 604,595_CD share_NN warrants_NNS ,_, at_IN 4.895_CD per_IN warrant_NN ,_, both_DT issues_NNS being_VBG made_VBN to_TO Technology_NNP Partnership_NNP Canada_NNP TPC_NNP ,_, pursuant_JJ to_TO an_DT agreement_NN between_IN BioChem_NNP and_CC the_DT Government_NN of_IN Canada_NNP GOC_NNP ._.
Each_DT warrant_NN grants_NNS a_DT right_NN to_TO subscribe_VB for_IN a_DT corresponding_JJ number_NN of_IN ordinary_JJ shares_NNS of_IN the_DT Company_NN within_IN five_CD years_NNS from_IN the_DT date_NN of_IN issue_NN of_IN the_DT warrant_NN ._.
Convertible_JJ loan_NN notes_VBZ The_DT $_$ 400_CD million_CD of_IN guaranteed_VBN convertible_JJ loan_NN notes_NNS due_JJ 2011_CD were_VBD issued_VBN on_IN 15_CD August_NNP 2001_CD by_IN Shire_NNP Finance_NNP Limited_NNP ,_, a_DT wholly_RB owned_VBN subsidiary_NN ._.
The_DT Groups_NNS Directors_NNS and_CC employees_NNS have_VBP been_VBN granted_VBN share_NN options_NNS over_IN ordinary_JJ shares_NNS under_IN the_DT following_JJ share_NN option_NN plans_NNS :_: the_DT Shire_NNP Pharmaceuticals_NNP Executive_NNP Share_NNP Option_NN Scheme_NNP Parts_NNP A_NNP and_CC B_NNP Executive_NNP Scheme_NNP ,_, the_DT Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 2000_CD Executive_NNP Share_NNP Option_NN Scheme_NNP Parts_NNP A_NNP and_CC B_NNP 2000_CD Executive_NNP Scheme_NNP ,_, the_DT Pharmavene_NNP 1991_CD Stock_NNP Option_NN Plan_NN SLI_NNP Plan_NNP ,_, the_DT Roberts_NNP Stock_NNP Option_NN Plans_NNS Roberts_NNP Plans_NNP ,_, the_DT BioChem_NNP Stock_NNP Option_NN Plan_NN BioChem_NNP Plan_NNP ,_, the_DT Shire_NNP Pharmaceuticals_NNP Sharesave_NNP Scheme_NNP Sharesave_NNP Scheme_NNP and_CC the_DT Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Employee_NNP Stock_NNP Purchase_NNP Plan_NNP Stock_NNP Purchase_NNP Plan_NNP ._.
The_DT highest_JJS and_CC lowest_JJS market_NN prices_NNS during_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD were_VBD 5.42_CD and_CC 2.93_CD respectively_RB ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 61_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS 61_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 23_CD Called-up_JJ share_NN capital_NN continued_VBD Notes_NNS :_: i_FW Options_NNPS granted_VBN under_IN the_DT Executive_NNP Scheme_NNP are_VBP subject_JJ to_TO performance_NN criteria_NNS and_CC can_MD not_RB be_VB exercised_VBN in_IN full_JJ unless_IN the_DT Companys_NNP share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN at_IN least_JJS 20.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ._.
If_IN the_DT Companys_NNP share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN 14.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ,_, 60_CD %_NN of_IN the_DT options_NNS may_MD be_VB exercised_VBN ._.
If_IN these_DT conditions_NNS are_VBP not_RB met_VBN after_IN the_DT initial_JJ three_CD years_NNS ,_, they_PRP are_VBP thereafter_RB tested_VBN quarterly_JJ by_IN reference_NN to_TO share_VB price_NN growth_NN over_IN the_DT extended_JJ period_NN ._.
If_IN the_DT share_NN price_NN does_VBZ not_RB meet_VB these_DT conditions_NNS at_IN any_DT time_NN ,_, none_NN of_IN the_DT options_NNS will_MD become_VB exercisable_JJ ._.
ii_FW Options_NNPS granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP vest_NN six_CD weeks_NNS prior_RB to_TO the_DT expiry_NN date_NN ._.
Options_NNS granted_VBN under_IN this_DT scheme_NN are_VBP subject_JJ to_TO performance_NN criteria_NNS ._.
In_IN respect_NN of_IN any_DT option_NN granted_VBN prior_RB to_TO August_NNP 2002_CD ,_, if_IN Shires_NNP share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN at_IN least_JJS 20.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ,_, the_DT option_NN will_MD be_VB exercisable_JJ in_IN full_JJ ._.
If_IN it_PRP increases_VBZ by_IN at_IN least_JJS 14.5_CD %_NN per_IN annum_NN over_IN the_DT same_JJ three-year_JJ measurement_NN period_NN ,_, the_DT option_NN may_MD be_VB exercised_VBN on_IN 60_CD %_NN of_IN the_DT shares_NNS covered_VBN by_IN the_DT option_NN ._.
If_IN these_DT conditions_NNS are_VBP not_RB met_VBN after_IN the_DT initial_JJ three-year_JJ measurement_NN period_NN ,_, they_PRP will_MD thereafter_RB be_VB tested_VBN quarterly_JJ by_IN reference_NN to_TO compound_VB annual_JJ share_NN price_NN growth_NN over_IN an_DT extended_JJ period_NN ._.
The_DT performance_NN criteria_NNS were_VBD reviewed_VBN in_IN 2002_CD to_TO ensure_VB the_DT criteria_NNS reected_VBD the_DT market_NN in_IN which_WDT Shire_NNP operates_VBZ ._.
Given_VBN Shires_NNPS development_NN it_PRP was_VBD considered_VBN appropriate_JJ that_IN an_DT EPS_NNP based_VBN measure_NN should_MD be_VB adopted_VBN in_IN place_NN of_IN share_NN price_NN growth_NN targets_NNS ._.
Therefore_RB ,_, the_DT performance_NN criteria_NNS was_VBD amended_VBN so_RB that_IN an_DT option_NN would_MD only_RB become_VB exercisable_JJ in_IN full_JJ if_IN Shires_NNP EPS_NNP growth_NN over_IN a_DT three_CD year_NN period_NN from_IN the_DT date_NN of_IN award_NN exceeds_VBZ the_DT UK_NNP Retail_NNP Price_NNP Index_NNP RPI_NNP on_IN average_NN a_DT year_NN for_IN the_DT following_VBG tranches_NNS of_IN grants_NNS :_: Options_NNS with_IN a_DT grant_NN value_NN of_IN up_RB to_TO 100_CD %_NN of_IN salary_NN RPI_NNP plus_CC 3_CD %_NN Directors_NNS ,_, RPI_NNP plus_CC 5_CD %_NN Between_IN 101_CD %_NN and_CC 200_CD %_NN of_IN salary_NN RPI_NNP plus_CC 5_CD %_NN Between_IN 201_CD %_NN and_CC 300_CD %_NN of_IN salary_NN RPI_NNP plus_CC 7_CD %_NN Over_IN 301_CD %_NN of_IN salary_NN RPI_NNP plus_CC 9_CD %_NN The_DT new_JJ EPS_NNP performance_NN criteria_NNS apply_VBP to_TO options_NNS granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP from_IN August_NNP 2002_CD ._.
After_IN consultation_NN with_IN some_DT of_IN its_PRP$ institutional_JJ shareholders_NNS ,_, the_DT Company_NN has_VBZ decided_VBN that_IN for_IN options_NNS granted_VBN under_IN the_DT scheme_NN from_IN 2004_CD onwards_NNS ,_, the_DT performance_NN condition_NN should_MD be_VB retested_VBN once_RB only_RB ,_, at_IN five_CD years_NNS after_IN the_DT grant_NN ._.
The_DT retest_NN will_MD be_VB applied_VBN only_RB where_WRB Shires_NNP EPS_NNP growth_NN has_VBZ fallen_VBN short_JJ of_IN the_DT minimum_JJ annual_JJ average_JJ percentage_NN increase_NN over_IN the_DT three-year_JJ period_NN from_IN grant_NN ._.
Hence_RB the_DT level_NN of_IN EPS_NNP growth_NN in_IN the_DT next_JJ two_CD years_NNS needs_VBZ to_TO be_VB consequentially_RB higher_JJR to_TO meet_VB the_DT test_NN ._.
The_DT EPS_NNP used_VBD will_MD be_VB the_DT fully_RB diluted_VBN EPS_NNP calculated_VBN under_IN US_NNP GAAP_NNP reporting_NN ._.
iii_FW These_DT options_NNS have_VBP been_VBN granted_VBN over_IN shares_NNS in_IN Shire_NNP Laboratories_NNPS Inc._NNP ._.
SLI_NNP ,_, formerly_RB Pharmavene_NNP Inc._NNP a_DT US_NNP company_NN acquired_VBN by_IN the_DT Group_NNP on_IN 23_CD March_NNP 1997_CD ._.
Exercise_NN of_IN these_DT options_NNS results_NNS in_IN the_DT option_NN holder_NN receiving_VBG ordinary_JJ shares_NNS in_IN the_DT Company_NN ._.
As_IN a_DT result_NN of_IN the_DT acquisition_NN of_IN SLI_NNP ,_, and_CC in_IN accordance_NN with_IN the_DT terms_NNS of_IN the_DT original_JJ SLI_NNP Plan_NNP ,_, all_DT options_NNS granted_VBN under_IN that_DT plan_NN became_VBD immediately_RB capable_JJ of_IN exercise_NN and_CC were_VBD not_RB subject_JJ to_TO performance_NN criteria_NNS ._.
iv_NN These_DT options_NNS have_VBP been_VBN granted_VBN over_IN shares_NNS in_IN Roberts_NNP Pharmaceutical_NNP Corporation_NNP ,_, a_DT US_NNP company_NN acquired_VBN by_IN the_DT Group_NNP on_IN 23_CD December_NNP 1999_CD ._.
As_IN a_DT result_NN of_IN the_DT acquisition_NN of_IN Roberts_NNP ,_, and_CC in_IN accordance_NN with_IN the_DT terms_NNS of_IN the_DT original_JJ Roberts_NNP Plan_NNP ,_, all_DT options_NNS granted_VBN under_IN that_DT plan_NN became_VBD immediately_RB capable_JJ of_IN exercise_NN and_CC were_VBD not_RB subject_JJ to_TO any_DT performance_NN criteria_NNS ._.
v_FW Following_VBG the_DT acquisition_NN of_IN BioChem_NNP on_IN 11_CD May_NNP 2001_CD ,_, the_DT BioChem_NNP Plan_NNP was_VBD amended_VBN such_JJ that_IN options_NNS over_IN BioChems_NNPS common_JJ stock_NN became_VBD options_NNS over_IN ordinary_JJ shares_NNS of_IN the_DT Company_NN ._.
All_DT BioChem_NNP options_NNS ,_, which_WDT were_VBD not_RB already_RB exercisable_JJ ,_, vested_JJ and_CC became_VBD exercisable_JJ as_IN a_DT result_NN of_IN the_DT acquisition_NN and_CC were_VBD not_RB subject_JJ to_TO any_DT performance_NN conditions_NNS ._.
vi_FW Options_NNPS granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP are_VBP granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 80_CD %_NN of_IN the_DT mid-market_JJ price_NN on_IN the_DT day_NN before_IN invitations_NNS are_VBP issued_VBN to_TO employees_NNS ._.
Employees_NNS may_MD enter_VB into_IN three_CD or_CC five-year_JJ savings_NNS contracts_NNS ._.
The_DT exercise_NN of_IN options_NNS under_IN this_DT Scheme_NN is_VBZ not_RB subject_JJ to_TO any_DT performance_NN criteria_NNS ._.
vii_FW Under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP options_NNS are_VBP granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 85_CD %_NN of_IN the_DT fair_JJ market_NN value_NN of_IN a_DT share_NN on_IN the_DT enrolment_NN date_NN the_DT first_JJ day_NN of_IN the_DT offering_NN period_NN or_CC the_DT exercise_NN date_NN the_DT last_JJ day_NN of_IN the_DT offering_NN period_NN ,_, whichever_WDT is_VBZ the_DT lower_JJR ._.
The_DT offering_NN period_NN is_VBZ for_IN 27_CD months_NNS ._.
The_DT exercise_NN of_IN options_NNS under_IN this_DT plan_NN is_VBZ not_RB subject_JJ to_TO any_DT performance_NN condition_NN ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 62_CD 62_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 24_CD Reserves_NNS Group_NNP Share_NNP Exchangeable_NNP Capital_NNP Other_JJ profit_NN and_CC premium_NN shares_NNS reserve_NN reserves_NNS loss_NN account_NN 000 000 000 000_CD 000_CD As_IN at_IN 1_CD January_NNP 2003_CD 3,214,512_CD 191,552_CD 2,755_CD 24,247_CD 709,577_NNP Exchange_NNP of_IN exchangeable_JJ shares_NNS 1,122_CD 1,127_CD Repurchase_NN of_IN ordinary_JJ shares_NNS 380_CD 31,808_CD Options_NNS exercised_VBN 3,061_CD Foreign_JJ exchange_NN 47,157_CD Retained_VBN loss_NN for_IN the_DT year_NN 363,355_CD As_IN at_IN 31_CD December_NNP 2003_CD 3,218,695_CD 190,425_CD 3,135_CD 24,247_CD 1,151,897_CD The_DT cumulative_JJ goodwill_NN resulting_VBG from_IN acquisitions_NNS that_WDT has_VBZ been_VBN written-off_JJ directly_RB to_TO reserves_NNS amounts_NNS to_TO 208,194,000_CD as_IN at_IN 31_CD December_NNP 2003_CD and_CC 31_CD December_NNP 2002_CD ._.
The_DT capital_NN and_CC other_JJ reserves_NNS arose_VBD in_IN relation_NN to_TO various_JJ Group_NNP reconstructions_NNS and_CC certain_JJ nancing_NN transactions_NNS ,_, and_CC are_VBP not_RB distributable_JJ ._.
Company_NN Share_NN Exchangeable_NNP Capital_NNP Other_JJ profit_NN and_CC premium_NN shares_NNS reserve_NN reserves_NNS loss_NN account_NN 000 000 000 000_CD 000_CD As_IN at_IN 1_CD January_NNP 2003_CD 3,215,437_CD 191,552_CD 1,674_CD 18,079_CD 15,930_CD Exchange_NNP of_IN exchangeable_JJ shares_NNS 1,122_CD 1,127_CD Repurchase_NN of_IN ordinary_JJ shares_NNS 380_CD 31,808_CD Options_NNS exercised_VBN 3,077_CD Foreign_JJ exchange_NN 16,071_CD Retained_VBN profit_NN for_IN the_DT year_NN 194,246_CD As_IN at_IN 31_CD December_NNP 2003_CD 3,219,636_CD 190,425_CD 2,054_CD 18,079_CD 130,437_CD 5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 63_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS 63_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 25_CD Reconciliation_NNP of_IN movement_NN in_IN Group_NNP shareholders_NNS funds_NNS 2003 2002 000 000_CD Loss_NN for_IN the_DT year_NN 363,355_CD 588,399_CD Other_JJ recognized_VBN gains_NNS and_CC losses_NNS relating_VBG to_TO the_DT year_NN 47,157_CD 62,739_CD 410,512_CD 651,138_CD Repurchase_NN of_IN ordinary_JJ share_NN capital_NN 31,808_CD Arenol_NNP loan_NN note_NN conversion_NN 955_CD Proceeds_NNS on_IN exercise_NN of_IN employee_NN share_NN options_NNS 3,114_CD 3,983_CD Net_JJ reduction_NN in_IN shareholders_NNS funds_NNS 439,206_CD 646,200_CD Opening_NN shareholders_NNS funds_NNS 2,747,706_CD 3,393,906_CD Closing_NN shareholders_NNS funds_NNS 2,308,500_CD 2,747,706_CD The_DT cumulative_JJ foreign_JJ exchange_NN differences_NNS on_IN translation_NN amount_NN to_TO 94,679,000_CD losses_NNS as_IN at_IN 31_CD December_NNP 2003_CD and_CC 47,522,00_CD losses_NNS as_IN at_IN 31_CD December_NNP 2002_CD ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 64_CD 64_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 26_CD Guarantees_NNS ,_, commitments_NNS and_CC contingencies_NNS a_DT Leases_NNP The_NNP Group_NNP leases_VBZ property_NN ,_, computer_NN and_CC ofce_NN equipment_NN and_CC motor_NN vehicles_NNS on_IN short-term_JJ operating_NN leases_NNS ._.
The_DT rents_NNS payable_JJ under_IN property_NN leases_NNS are_VBP subject_JJ to_TO renegotiation_NN at_IN various_JJ intervals_NNS specified_VBN in_IN the_DT leases_NNS ._.
The_DT Group_NNP pays_VBZ for_IN substantially_RB all_DT of_IN the_DT insurance_NN ,_, maintenance_NN and_CC repair_NN of_IN these_DT assets_NNS ._.
The_DT minimum_JJ annual_JJ rentals_NNS under_IN the_DT foregoing_VBG operating_NN leases_NNS are_VBP as_IN follows_VBZ :_: Group_NNP 2003_CD 2002_CD Land_NNP and_CC Motor_NNP Land_NNP and_CC Motor_NNP buildings_NNS Equipment_NNP vehicles_NNS buildings_NNS Equipment_NNP vehicles_NNS 000 000 000 000_CD 000_CD 000_CD Operating_NN leases_NNS which_WDT expire_VBP :_: within_IN 1_CD year_NN 30 538 973 179_CD 333_CD 50_CD within_IN 2_CD 5_CD years_NNS 1,010_CD 1,856_CD 1,756_CD 1,263_CD 1,827_CD 902_CD after_IN 5_CD years_NNS 1,600_CD 5_CD 245_CD 1_CD 2,640_CD 2,399_CD 2,729_CD 1,687_CD 2,161_CD 952_CD Company_NN 2003_CD 2002_CD Land_NNP and_CC Motor_NNP Land_NNP and_CC Motor_NNP buildings_NNS vehicles_NNS buildings_NNS vehicles_NNS 000 000 000 000_CD Operating_NN leases_NNS which_WDT expire_VBP :_: within_IN 1_CD year_NN 35_CD 22_CD within_IN 2_CD 5_CD years_NNS 145_CD 34_CD 145_CD 89_CD 145 69 145 111_CD 5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 65_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS 65_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 26_CD Guarantees_NNS ,_, commitments_NNS and_CC contingencies_NNS continued_VBD b_NN Guarantees_NNS and_CC collateral_NN Shire_NNP has_VBZ guaranteed_VBN the_DT building_NN lease_NN entered_VBD into_IN by_IN its_PRP$ wholly_RB owned_VBN subsidiary_NN ,_, Shire_NNP US_NNP Manufacturing_NNP Inc._NNP ._.
In_IN addition_NN ,_, as_RB at_IN 31_CD December_NNP 2003_CD the_DT Group_NNP had_VBD 3.8_CD million_CD of_IN cash_NN held_VBN as_IN collateral_NN for_IN this_DT lease_NN ._.
c_NN Letters_NNS of_IN credit_NN As_IN at_IN 31_CD December_NNP 2003_CD the_DT Group_NNP had_VBD a_DT number_NN of_IN irrevocable_JJ standby_JJ letters_NNS of_IN credit_NN totalling_VBG 24.5_CD million_CD ._.
d_LS Capital_NNP commitments_NNS i_FW Interests_NNPS in_IN companies_NNS and_CC partnerships_NNS The_DT Group_NNP has_VBZ undertaken_VBN to_TO subscribe_VB to_TO interests_NNS in_IN companies_NNS and_CC partnerships_NNS for_IN amounts_NNS totalling_VBG 25.0_CD million_CD 2002_CD :_: 23.9_CD million_CD ._.
As_IN at_IN 31_CD December_NNP 2003_CD an_DT amount_NN of_IN 20.5_CD million_CD 2002_CD :_: 17.0_CD million_CD has_VBZ been_VBN subscribed_VBN ,_, leaving_VBG an_DT outstanding_JJ commitment_NN of_IN 4.5_CD million_CD 2002_CD :_: 6.9_CD million_CD ._.
ii_FW Government_NN of_IN Canada_NNP In_IN 2001_CD ,_, the_DT Group_NNP signed_VBD a_DT ten-year_JJ non-cancellable_JJ contract_NN with_IN the_DT Government_NN of_IN Canada_NNP GOC_NNP to_TO assure_VB a_DT state_NN of_IN readiness_NN in_IN the_DT case_NN of_IN an_DT inuenza_NN pandemic_JJ worldwide_NN epidemic_NN and_CC to_TO provide_VB inuenza_NN vaccine_NN for_IN all_DT Canadian_JJ citizens_NNS in_IN such_JJ an_DT event_NN hereinafter_NN referred_VBD to_TO as_IN the_DT Pandemic_NNP contract_NN ._.
The_DT concept_NN of_IN a_DT state_NN of_IN readiness_NN against_IN an_DT inuenza_NN pandemic_JJ requires_VBZ the_DT development_NN of_IN sufficient_JJ infrastructure_NN and_CC capacity_NN in_IN Canada_NNP to_TO provide_VB for_IN domestic_JJ vaccine_NN needs_NNS in_IN the_DT event_NN of_IN an_DT inuenza_NN pandemic_NN ._.
The_DT Group_NNP is_VBZ committed_VBN to_TO provide_VB 32_CD million_CD doses_NNS of_IN single-strain_JJ monovalent_JJ u_NN vaccine_NN within_IN a_DT production_NN period_NN of_IN 16_CD weeks_NNS ._.
The_DT Group_NNP has_VBZ therefore_RB begun_VBN a_DT process_NN of_IN expanding_VBG its_PRP$ production_NN capacity_NN in_IN order_NN to_TO meet_VB this_DT objective_NN within_IN a_DT five-year_JJ period_NN ending_VBG January_NNP 2006_CD ._.
The_DT Group_NNP is_VBZ committed_VBN to_TO approximately_RB 7.8_CD million_CD CAN$_NNP 18.0_CD million_CD of_IN capital_NN expenditure_NN for_IN the_DT purpose_NN of_IN achieving_VBG the_DT level_NN of_IN pandemic_JJ readiness_NN required_VBN in_IN the_DT Pandemic_NNP contract_NN ._.
The_DT GOC_NNP has_VBZ agreed_VBN to_TO reimburse_VB the_DT Group_NNP 5.8_CD million_CD CAN$_NNP 13.5_CD million_CD ._.
At_IN the_DT end_NN of_IN the_DT contract_NN ,_, the_DT Group_NNP is_VBZ committed_VBN to_TO buy_VB back_RP any_DT unused_JJ and_CC unexpired_JJ materials_NNS and_CC capital_NN assets_NNS reimbursed_VBN by_IN the_DT GOC_NNP at_IN net_JJ book_NN value_NN that_WDT can_MD be_VB used_VBN for_IN production_NN of_IN trivalent_JJ vaccine_NN or_CC other_JJ products_NNS ._.
As_IN a_DT condition_NN of_IN the_DT Pandemic_NNP contract_NN ,_, Shire_NNP Biochem_NNP ,_, a_DT wholly_RB owned_VBN subsidiary_NN ,_, entered_VBD into_IN an_DT irrevocable_JJ standby_JJ letter_NN of_IN credit_NN of_IN 10.6_CD million_CD CAN$_NNP 24.5_CD million_CD ._.
The_DT standby_JJ letter_NN of_IN credit_NN is_VBZ collateralised_VBN by_IN an_DT equivalent_JJ amount_NN of_IN cash_NN ._.
iii_FW Vaccine_NN production_NN facility_NN In_IN addition_NN ,_, under_IN another_DT GOC_NNP contract_NN ,_, the_DT Group_NNP is_VBZ required_VBN to_TO supply_VB the_DT GOC_NNP with_IN a_DT substantial_JJ proportion_NN of_IN its_PRP$ annual_JJ inuenza_NN vaccine_NN requirements_NNS over_IN a_DT ten-year_JJ period_NN ending_VBG March_NNP 2011_CD ._.
Subject_JJ to_TO mutual_JJ agreement_NN ,_, the_DT contract_NN can_MD be_VB renewed_VBN for_IN a_DT further_JJ period_NN of_IN between_IN one_CD and_CC ten_CD years_NNS ._.
The_DT Group_NNP is_VBZ also_RB committed_VBN to_TO the_DT expansion_NN of_IN its_PRP$ vaccine_NN production_NN facility_NN located_VBN in_IN Quebec_NNP City_NNP ._.
A_DT new_JJ building_NN will_MD be_VB located_VBN alongside_IN the_DT existing_VBG vaccine_NN production_NN facility_NN in_IN the_DT Quebec_NNP Metro_NNP High_NNP Tech_NNP Park_NNP for_IN an_DT estimated_VBN 21.0_CD million_CD CAN$_NNP 48.8_CD million_CD ._.
Construction_NN of_IN this_DT facility_NN commenced_VBD in_IN November_NNP 2003_CD ._.
It_PRP is_VBZ expected_VBN that_IN this_DT facility_NN will_MD be_VB operational_JJ in_IN 2006_CD ._.
iv_NN TPC_NNP research_NN facility_NN In_IN March_NNP 2000_CD ,_, the_DT Group_NNP entered_VBD into_IN a_DT funding_NN agreement_NN with_IN TPC_NNP ,_, a_DT Canadian_JJ governmental_JJ agency_NN ,_, hereinafter_NN referred_VBD to_TO as_IN the_DT TPC_NNP agreement_NN relating_VBG to_TO the_DT research_NN and_CC development_NN of_IN recombinant_JJ protein_NN vaccines_NNS ._.
The_DT TPC_NNP agreement_NN has_VBZ as_IN its_PRP$ objective_NN the_DT creation_NN in_IN Canada_NNP of_IN skilled_JJ scientific_JJ and_CC technological_JJ jobs_NNS in_IN the_DT research_NN and_CC development_NN eld_NN ,_, the_DT local_JJ manufacture_NN of_IN developed_JJ products_NNS ,_, capital_NN investment_NN and_CC financial_JJ return_NN on_IN investment_NN ._.
The_DT TPC_NNP agreed_VBD to_TO a_DT total_JJ contribution_NN not_RB to_TO exceed_VB 34.6_CD million_CD CAN$_NNP 80.0_CD million_CD ._.
Such_JJ contribution_NN is_VBZ repayable_JJ to_TO the_DT TPC_NNP in_IN the_DT form_NN of_IN royalties_NNS on_IN the_DT net_JJ sales_NNS value_NN gross_JJ invoiced_JJ amounts_NNS less_RBR discounts_NNS ,_, taxes_NNS and_CC delivery_NN costs_NNS if_IN the_DT products_NNS become_VBP commercialised_JJ ._.
The_DT Group_NNP is_VBZ obligated_VBN to_TO pay_VB such_JJ royalties_NNS in_IN the_DT period_NN to_TO 31_CD December_NNP 2016_CD ._.
No_DT amounts_NNS have_VBP been_VBN accrued_VBN with_IN respect_NN to_TO this_DT obligation_NN ,_, as_IN the_DT conditions_NNS for_IN repayment_NN have_VBP not_RB yet_RB been_VBN met_VBN ._.
As_IN a_DT condition_NN of_IN the_DT TPC_NNP agreement_NN ,_, the_DT Group_NNP has_VBZ an_DT obligation_NN to_TO build_VB a_DT vaccine_NN research_NN facility_NN in_IN Canada_NNP ._.
The_DT construction_NN of_IN the_DT vaccine_NN research_NN center_NN in_IN Laval_NNP ,_, Canada_NNP will_MD represent_VB an_DT investment_NN of_IN approximately_RB 15.4_CD million_CD CAN$_NNP 35.6_CD million_CD and_CC should_MD be_VB completed_VBN in_IN December_NNP 2004_CD ._.
The_DT TPC_NNP agreement_NN requires_VBZ the_DT Group_NNP to_TO comply_VB with_IN certain_JJ conditions_NNS as_IN outlined_VBN in_IN the_DT agreement_NN ._.
Any_DT violation_NN of_IN such_JJ conditions_NNS allows_VBZ the_DT TPC_NNP to_TO declare_VB the_DT Group_NNP in_IN default_NN and_CC may_MD result_VB in_IN repayment_NN of_IN all_DT previous_JJ funding_NN ._.
v_NN METHYPATCH_NNP In_IN connection_NN with_IN the_DT Groups_NNS purchase_NN of_IN METHYPATCH_NNP in_IN 2003_CD ,_, the_DT Group_NNP has_VBZ obligation_NN to_TO make_VB certain_JJ payments_NNS on_IN the_DT achievement_NN of_IN milestones_NNS ._.
This_DT will_MD require_VB up_RP to_TO 27.9_CD million_CD $_$ 50.0_CD million_CD on_IN registration_NN and_CC a_DT further_JJ 41.9_CD million_CD $_$ 75.0_CD million_CD dependent_JJ upon_IN certain_JJ sales_NNS targets_NNS being_VBG achieved_VBN ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 66_CD 66_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 26_CD Guarantees_NNS ,_, commitments_NNS and_CC contingencies_NNS continued_VBD vi_FW DRAXIS_NNP In_IN connection_NN with_IN the_DT Groups_NNS purchase_NN of_IN a_DT range_NN of_IN products_NNS from_IN DRAXIS_NNP Health_NNP Inc_NNP ,_, in_IN 2003_CD ,_, the_DT Group_NNP has_VBZ an_DT obligation_NN to_TO make_VB certain_JJ milestone_NN payments_NNS if_IN no_DT generic_JJ event_NN occurs_VBZ for_IN certain_JJ products_NNS purchased_VBN ._.
The_DT milestone_NN payments_NNS could_MD reach_VB an_DT amount_NN of_IN 1.7_CD million_CD CAN$_NNP 4.0_CD million_CD if_IN no_DT generic_JJ events_NNS have_VBP occurred_VBN for_IN those_DT products_NNS by_IN 22_CD January_NNP 2007_CD ._.
e_LS Contingent_JJ liabilities_NNS Shire_NNP is_VBZ involved_VBN in_IN various_JJ legal_JJ proceedings_NNS considered_VBN typical_JJ to_TO its_PRP$ business_NN ,_, including_VBG those_DT set_VBN out_RP below_IN ._.
Although_IN there_EX can_MD be_VB no_DT assurance_NN regarding_VBG the_DT outcome_NN of_IN any_DT of_IN the_DT legal_JJ proceedings_NNS referred_VBD to_TO below_IN ,_, Shire_NNP believes_VBZ that_IN they_PRP will_MD not_RB have_VB a_DT materially_RB adverse_JJ effect_NN on_IN the_DT Groups_NNS financial_JJ position_NN ._.
i_FW Phentermine_NNP Shire_NNP US_NNP Inc._NNP ._.
SUS_NNP ,_, a_DT wholly_RB owned_VBN subsidiary_NN ,_, is_VBZ a_DT defendant_NN in_IN 429_CD lawsuits_NNS still_RB pending_VBG in_IN both_DT US_NNP federal_JJ and_CC state_NN courts_NNS which_WDT seek_VBP damages_NNS for_IN ,_, among_IN other_JJ things_NNS ,_, personal_JJ injury_NN arising_VBG from_IN phentermine_NN products_NNS supplied_VBD for_IN the_DT treatment_NN of_IN obesity_NN by_IN SUS_NNP and_CC several_JJ other_JJ pharmaceutical_JJ companies_NNS ._.
SUS_NNP ,_, formerly_RB known_VBN as_IN Shire_NNP Richwood_NNP Inc._NNP has_VBZ been_VBN sued_VBN as_IN a_DT manufacturer_NN and_CC distributor_NN of_IN phentermine_NN ,_, an_DT anorectic_NN used_VBN in_IN the_DT short-term_JJ treatment_NN of_IN obesity_NN and_CC one_CD of_IN the_DT products_NNS addressed_VBN by_IN the_DT lawsuits_NNS ._.
The_DT suits_NNS relate_VBP to_TO phentermine_VB either_CC alone_RB or_CC together_RB with_IN fenuramine_NN or_CC dexenuramine_NN ._.
The_DT lawsuits_NNS generally_RB allege_VBP the_DT following_VBG claims_NNS :_: the_DT defendants_NNS marketed_VBN phentermine_NN and_CC other_JJ products_NNS for_IN the_DT treatment_NN of_IN obesity_NN and_CC misled_VBD users_NNS about_IN the_DT products_NNS and_CC dangers_NNS associated_VBN with_IN them_PRP :_: the_DT defendants_NNS failed_VBD adequately_RB to_TO test_NN phentermine_NN individually_RB and_CC when_WRB taken_VBN in_IN combination_NN with_IN the_DT other_JJ drugs_NNS :_: and_CC the_DT defendants_NNS knew_VBD or_CC should_MD have_VB known_VBN about_IN the_DT negative_JJ effects_NNS of_IN the_DT drugs_NNS and_CC should_MD have_VB informed_VBN the_DT public_JJ about_IN such_JJ risks_NNS and_CC or_CC failed_VBD to_TO provide_VB appropriate_JJ warning_NN labels_NNS ._.
SUS_NNP has_VBZ been_VBN named_VBN as_IN a_DT defendant_NN in_IN a_DT total_NN of_IN 4,226_CD such_JJ phentermine_NN lawsuits_NNS ,_, in_IN respect_NN of_IN which_WDT SUS_NNP has_VBZ been_VBN dismissed_VBN as_IN a_DT defendant_NN in_IN 3,797_CD cases_NNS ._.
Shire_NNP is_VBZ awaiting_VBG the_DT furtherance_NN of_IN proceedings_NNS in_IN the_DT remaining_VBG 429_CD pending_VBG lawsuits_NNS ._.
SUS_NNP became_VBD involved_VBN with_IN phentermine_NN through_IN its_PRP$ acquisition_NN of_IN certain_JJ assets_NNS of_IN Rexar_NNP Pharmacal_NNP Corporation_NNP Rexar_NNP in_IN January_NNP 1994_CD ._.
In_IN addition_NN to_TO SUS_NNP potentially_RB incurring_VBG liability_NN as_IN a_DT result_NN of_IN its_PRP$ own_JJ production_NN of_IN Oby-Cap_NNP ,_, a_DT phentermine_JJ product_NN ,_, the_DT plaintiffs_NNS may_MD additionally_RB seek_VB to_TO impose_VB liability_NN on_IN SUS_NNP as_IN successor_NN to_TO Rexar_NNP ._.
SUS_NNP intends_VBZ to_TO defend_VB vigorously_RB all_PDT the_DT lawsuits_NNS ._.
SUS_NNP denies_VBZ liability_NN on_IN a_DT number_NN of_IN grounds_NNS including_VBG lack_NN of_IN scientific_JJ evidence_NN that_IN phentermine_NN ,_, properly_RB prescribed_VBN ,_, causes_VBZ the_DT alleged_JJ side_NN effects_NNS and_CC that_IN SUS_NNP did_VBD not_RB promote_VB phentermine_NN for_IN long-term_JJ combined_VBN use_NN as_IN part_NN of_IN the_DT fen_NN phen_NN diet_NN ._.
Accordingly_RB ,_, SUS_NNP intends_VBZ to_TO defend_VB vigorously_RB any_DT and_CC all_DT claims_NNS made_VBN against_IN the_DT Group_NNP in_IN respect_NN of_IN phentermine_NN ._.
Legal_JJ expenses_NNS to_TO date_NN have_VBP been_VBN paid_VBN by_IN Eon_NNP ,_, the_DT supplier_NN to_TO SUS_NNP ,_, or_CC Eons_NNS insurance_NN carriers_NNS but_CC such_JJ insurance_NN is_VBZ now_RB exhausted_VBN ._.
Eon_NNP has_VBZ agreed_VBN to_TO defend_VB and_CC indemnify_VB SUS_NNP in_IN this_DT litigation_NN pursuant_JJ to_TO an_DT agreement_NN dated_VBN 30_CD November_NNP 2000_CD between_IN Eon_NNP and_CC SUS_NNP ._.
``_`` ii_FW ADDERALL_NNP XR_NNP Shires_NNP extended_VBD release_NN ''_'' ``_`` once_RB daily_JJ ''_'' ''_'' version_NN of_IN ADDERALL_NNP ,_, ADDERALL_NNP XR_NNP is_VBZ covered_VBN by_IN US_NNP patent_NN No._NN ''_'' In_IN January_NNP 2003_CD the_DT Group_NNP was_VBD notied_VBN that_IN Barr_NNP Laboratories_NNPS ,_, Inc._NNP ._.
Barr_NNP had_VBD submitted_VBN an_DT Abbreviated_NNP New_NNP Drug_NNP Application_NNP ANDA_NNP under_IN the_DT Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB a_DT generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT Groups_NNS 819_CD Patent_NN ._.
The_DT notication_NN alleged_VBD that_IN the_DT 819_CD Patent_NN is_VBZ not_RB infringed_VBN by_IN Barr_NNP 's_POS extended_JJ release_NN mixed_JJ amphetamine_NN salt_NN product_NN ,_, which_WDT is_VBZ the_DT subject_NN of_IN Barrs_NNP ANDA_NNP ._.
On_IN 24_CD February_NNP 2003_CD Shire_NNP Laboratories_NNPS Inc._NNP ._.
Shire_NNP Laboratories_NNPS led_VBD suit_NN against_IN Barr_NNP in_IN the_DT United_NNP States_NNPS District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP alleging_VBG that_IN Barrs_NNP ANDA_NNP infringes_VBZ the_DT '_'' 819_CD Patent_NN ._.
The_DT Group_NNP is_VBZ seeking_VBG a_DT ruling_NN that_WDT Barrs_VBZ ANDA_NNP infringes_VBZ the_DT 819_CD Patent_NN and_CC should_MD not_RB be_VB approved_VBN before_IN the_DT expiration_NN date_NN of_IN the_DT 819_CD Patent_NN ._.
The_DT Group_NNP is_VBZ also_RB seeking_VBG an_DT injunction_NN to_TO prevent_VB Barr_NNP from_IN commercialising_VBG its_PRP$ ANDA_NNP product_NN before_IN the_DT expiration_NN of_IN the_DT 819_CD Patent_NN ,_, damages_NNS in_IN the_DT event_NN that_IN Barr_NNP should_MD engage_VB in_IN such_JJ commercialisation_NN ,_, as_RB well_RB its_PRP$ legal_JJ fees_NNS and_CC costs_NNS ._.
Barr_NNP has_VBZ counterclaimed_VBN for_IN a_DT declaration_NN that_IN its_PRP$ ANDA_NNP product_NN will_MD not_RB infringe_VB the_DT claims_NNS of_IN the_DT 819_CD Patent_NN ._.
Barr_NNP is_VBZ also_RB seeking_VBG its_PRP$ legal_JJ fees_NNS ,_, costs_NNS and_CC expenses_NNS ._.
On_IN 12_CD August_NNP 2003_CD Shire_NNP Laboratories_NNP was_VBD issued_VBN a_DT new_JJ US_NNP patent_NN No._NN ._.
6,605,300_CD the_DT 300_CD Patent_NN covering_VBG ADDERALL_NNP XR_NNP ._.
In_IN August_NNP 2003_CD Shire_NNP was_VBD notied_VBN that_IN Barr_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT 300_CD Patent_NN and_CC alleging_VBG that_IN the_DT 300_CD Patent_NN is_VBZ invalid_JJ ._.
In_IN September_NNP 2003_CD Shire_NNP Laboratories_NNPS led_VBD a_DT lawsuit_NN in_IN the_DT United_NNP States_NNPS District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP against_IN Barr_NNP alleging_VBG that_IN Barrs_NNP ANDA_NNP infringes_VBZ the_DT 300_CD Patent_NN ._.
The_DT Group_NNP is_VBZ seeking_VBG a_DT ruling_NN that_WDT Barrs_VBZ ANDA_NNP infringes_VBZ the_DT 300_CD Patent_NN and_CC should_MD not_RB be_VB approved_VBN before_IN the_DT expiration_NN date_NN of_IN the_DT 300_CD Patent_NN ._.
The_DT Group_NNP is_VBZ also_RB seeking_VBG an_DT injunction_NN to_TO prevent_VB Barr_NNP from_IN commercialising_VBG its_PRP$ ANDA_NNP product_NN before_IN the_DT expiration_NN of_IN the_DT 300_CD Patent_NN ,_, damages_NNS in_IN the_DT event_NN that_IN Barr_NNP should_MD engage_VB in_IN such_JJ commercialisation_NN ,_, as_RB well_RB its_PRP$ legal_JJ fees_NNS and_CC costs_NNS ._.
By_IN way_NN of_IN a_DT counterclaim_NN Barr_NNP is_VBZ seeking_VBG a_DT declaration_NN that_IN the_DT 300_CD Patent_NN is_VBZ invalid_JJ and_CC Barr_NNP has_VBZ also_RB asked_VBN for_IN its_PRP$ legal_JJ fees_NNS ,_, costs_NNS and_CC expenses_NNS ._.
The_DT lawsuits_NNS against_IN Barr_NNP with_IN respect_NN to_TO the_DT 819_CD and_CC 300_CD Patents_NNP were_VBD consolidated_VBN in_IN December_NNP 2003_CD and_CC a_DT trial_NN date_NN scheduled_VBN for_IN January_NNP 2006_CD ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 67_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS 67_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 26_CD Guarantees_NNS ,_, commitments_NNS and_CC contingencies_NNS continued_VBD Barr_NNP may_MD not_RB launch_VB a_DT generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP before_IN it_PRP receives_VBZ final_JJ approval_NN of_IN its_PRP$ ANDA_NNP from_IN the_DT FDA_NNP ._.
The_DT lawsuits_NNS triggered_VBD stays_NNS of_IN FDA_NNP approval_NN of_IN up_RB to_TO 30_CD months_NNS from_IN the_DT Groups_NNS receipt_NN of_IN Barrs_NNP notices_NNS to_TO allow_VB the_DT court_NN to_TO resolve_VB the_DT suits_NNS ._.
Even_RB if_IN Barr_NNP receives_VBZ a_DT tentative_JJ approval_NN from_IN the_DT FDA_NNP ,_, it_PRP can_MD not_RB lawfully_RB launch_VB its_PRP$ generic_JJ version_NN before_IN the_DT earlier_JJR of_IN the_DT expiration_NN of_IN the_DT latest_JJS stay_NN February_NNP 2006_CD or_CC a_DT district_NN court_NN decision_NN in_IN its_PRP$ favor_NN ._.
In_IN the_DT event_NN that_IN the_DT Group_NNP does_VBZ not_RB prevail_VB ,_, then_RB Barr_NNP could_MD be_VB in_IN a_DT position_NN to_TO market_VB its_PRP$ extended_JJ release_NN mixed_JJ amphetamine_NN salt_NN product_NN upon_IN FDA_NNP final_JJ approval_NN of_IN its_PRP$ ANDA_NNP following_VBG the_DT expiry_NN of_IN the_DT existing_VBG Hatch-Waxman_NNP exclusivity_NN in_IN October_NNP 2004_CD ._.
In_IN November_NNP 2003_CD Shire_NNP was_VBD notied_VBN that_IN Impax_NNP Laboratories_NNPS Impax_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN dates_NNS of_IN the_DT 819_CD and_CC 300_CD Patents_NNP and_CC alleging_VBG that_IN the_DT 819_CD and_CC 300_CD Patents_NNP are_VBP not_RB infringed_VBN by_IN Impaxs_NNP extended_VBD release_NN mixed_JJ amphetamine_NN salt_NN product_NN ,_, the_DT subject_NN of_IN Impaxs_NNP ANDA_NNP ._.
In_IN December_NNP 2003_CD ,_, Shire_NNP Laboratories_NNPS led_VBD suit_NN against_IN Impax_NNP for_IN infringement_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ._.
The_DT Group_NNP is_VBZ seeking_VBG a_DT ruling_NN that_WDT Impaxs_VBZ ANDA_NNP infringes_VBZ the_DT 819_CD and_CC 300_CD Patents_NNP and_CC should_MD not_RB be_VB approved_VBN before_IN the_DT expiration_NN dates_NNS of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ._.
The_DT Group_NNP is_VBZ also_RB seeking_VBG an_DT injunction_NN to_TO prevent_VB Impax_NNP from_IN commercialising_VBG its_PRP$ ANDA_NNP product_NN before_IN the_DT expiration_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ,_, damages_NNS in_IN the_DT event_NN that_WDT Impax_NNP should_MD engage_VB in_IN such_JJ commercialisation_NN ,_, as_RB well_RB its_PRP$ legal_JJ fees_NNS and_CC costs_NNS ._.
Impaxs_NNP afrmative_JJ defences_NNS include_VBP noninfringement_NN and_CC invalidity_NN of_IN both_DT the_DT 819_CD and_CC 300_CD Patents_NNP ._.
Impax_NNP is_VBZ also_RB requesting_VBG that_IN costs_NNS be_VB assessed_VBN against_IN the_DT Group_NNP ._.
Impax_NNP may_MD not_RB launch_VB a_DT generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP before_IN it_PRP receives_VBZ final_JJ approval_NN of_IN its_PRP$ ANDA_NNP from_IN the_DT FDA_NNP ._.
The_DT lawsuit_NN triggered_VBD a_DT stay_NN of_IN FDA_NNP approval_NN of_IN up_RB to_TO 30_CD months_NNS from_IN the_DT Groups_NNS receipt_NN of_IN Impaxs_NNP notice_NN to_TO allow_VB the_DT court_NN to_TO resolve_VB the_DT suit_NN ._.
Even_RB if_IN Impax_NNP receives_VBZ a_DT tentative_JJ approval_NN from_IN the_DT FDA_NNP ,_, it_PRP can_MD not_RB lawfully_RB launch_VB its_PRP$ generic_JJ version_NN before_IN the_DT earlier_JJR of_IN the_DT expiration_NN of_IN the_DT stay_NN May_NNP 2006_CD or_CC a_DT district_NN court_NN decision_NN in_IN its_PRP$ favor_NN ._.
In_IN the_DT event_NN that_IN the_DT Group_NNP does_VBZ not_RB prevail_VB ,_, then_RB Impax_NNP could_MD be_VB in_IN a_DT position_NN to_TO market_VB its_PRP$ extended_JJ release_NN mixed_JJ amphetamine_NN salt_NN product_NN upon_IN FDA_NNP final_JJ approval_NN of_IN its_PRP$ ANDA_NNP following_VBG the_DT expiry_NN of_IN the_DT existing_VBG Hatch-Waxman_NNP exclusivity_NN in_IN October_NNP 2004_CD and_CC upon_IN expiry_NN of_IN any_DT exclusivity_NN that_IN Barr_NNP may_MD hold_VB ._.
iii_FW CARBATROL_NNP In_IN August_NNP 2003_CD the_DT Group_NNP was_VBD notied_VBN that_IN Nostrum_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
Nostrum_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT HatchWaxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ version_NN of_IN the_DT 300_CD mg_NN strength_NN of_IN CARBATROL_NNP prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT Groups_NNS US_NNP patents_NNS for_IN CARBATROL_NNP ,_, US_NNP patent_NN No._NN ._.
5,912,013_CD the_DT 013_CD Patent_NN and_CC US_NNP patent_NN No._NN ._.
The_DT notication_NN alleges_VBZ that_IN the_DT 013_CD and_CC 570_CD Patents_NNP are_VBP not_RB infringed_VBN by_IN Nostrums_NNP 300_CD mg_NN extended_VBN release_NN carbamazepine_NN product_NN ,_, the_DT subject_NN of_IN Nostrums_NNPS ANDA_NNP ._.
This_DT dosage_JJ strength_NN represents_VBZ half_NN of_IN Shires_NNP current_JJ sales_NNS in_IN epilepsy_NN ._.
On_IN 18_CD September_NNP 2003_CD Shire_NNP Laboratories_NNPS Inc._NNP served_VBD suit_NN against_IN Nostrum_NNP in_IN the_DT United_NNP States_NNPS District_NNP Court_NNP for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP for_IN infringement_NN of_IN these_DT two_CD patents_NNS ._.
The_DT Group_NNP is_VBZ seeking_VBG a_DT ruling_NN that_WDT Nostrums_VBZ ANDA_NNP infringes_VBZ the_DT 013_CD and_CC 570_CD Patents_NNP and_CC should_MD not_RB be_VB approved_VBN before_IN the_DT expiration_NN date_NN of_IN the_DT 013_CD and_CC 570_CD Patents_NNP ._.
The_DT Group_NNP is_VBZ also_RB seeking_VBG an_DT injunction_NN to_TO prevent_VB Nostrum_NNP from_IN commercialising_VBG its_PRP$ ANDA_NNP product_NN before_IN the_DT expiration_NN of_IN the_DT 013_CD and_CC 570_CD Patents_NNP ,_, damages_NNS in_IN the_DT event_NN that_WDT Nostrum_NNP should_MD engage_VB in_IN such_JJ commercialisation_NN ,_, as_RB well_RB its_PRP$ legal_JJ fees_NNS and_CC costs_NNS ._.
On_IN 23_CD January_NNP 2004_CD the_DT Group_NNP amended_VBD the_DT complaint_NN to_TO delete_VB the_DT allegations_NNS with_IN respect_NN to_TO the_DT 013_CD Patent_NN ._.
By_IN way_NN of_IN counterclaims_NNS Nostrum_NNP is_VBZ seeking_VBG a_DT declaration_NN that_IN the_DT 570_CD and_CC 013_CD Patents_NNP are_VBP not_RB infringed_VBN by_IN Nostrums_NNP ANDA_NNP product_NN as_RB well_RB as_IN actual_JJ and_CC punitive_JJ damages_NNS for_IN alleged_JJ abuse_NN of_IN process_NN by_IN Shire_NNP ._.
Nostrum_NNP may_MD not_RB launch_VB a_DT generic_JJ version_NN of_IN CARBATROL_NNP before_IN it_PRP receives_VBZ final_JJ approval_NN of_IN its_PRP$ ANDA_NNP from_IN the_DT FDA_NNP ._.
The_DT lawsuit_NN triggered_VBD a_DT stay_NN of_IN FDA_NNP approval_NN of_IN up_RB to_TO 30_CD months_NNS from_IN Shires_NNP receipt_NN of_IN Nostrums_NNP notice_NN to_TO allow_VB the_DT court_NN to_TO resolve_VB the_DT suit_NN ._.
Even_RB if_IN Nostrum_NNP receives_VBZ tentative_JJ approval_NN from_IN the_DT FDA_NNP for_IN its_PRP$ ANDA_NNP ,_, it_PRP can_MD not_RB lawfully_RB launch_VB its_PRP$ generic_JJ version_NN before_IN the_DT earlier_JJR of_IN the_DT expiration_NN of_IN the_DT stay_NN February_NNP 2006_CD or_CC a_DT district_NN court_NN decision_NN in_IN its_PRP$ favor_NN ._.
In_IN the_DT event_NN that_IN the_DT Group_NNP does_VBZ not_RB prevail_VB ,_, then_RB Nostrum_NNP could_MD be_VB in_IN a_DT position_NN to_TO market_VB its_PRP$ 300_CD mg_NN extended_VBN release_NN carbamazepine_NN product_NN upon_IN FDA_NNP final_JJ approval_NN of_IN its_PRP$ ANDA_NNP ._.
iv_NN Other_JJ matters_NNS In_IN addition_NN ,_, the_DT Group_NNP is_VBZ involved_VBN in_IN claims_NNS and_CC lawsuits_NNS in_IN the_DT normal_JJ course_NN of_IN business_NN ._.
It_PRP is_VBZ not_RB possible_JJ at_IN this_DT time_NN to_TO determine_VB the_DT ultimate_JJ outcome_NN of_IN any_DT of_IN these_DT claims_NNS ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 68_CD 68_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 27_CD Pension_NN arrangements_NNS The_DT Group_NNP has_VBZ a_DT number_NN of_IN dened_VBN contribution_NN retirement_NN plans_NNS that_WDT together_RB cover_VBP substantially_RB all_DT employees_NNS ._.
The_DT company_NN contribution_NN is_VBZ xed_VBN as_IN a_DT set_VBN percentage_NN of_IN employees_NNS pay_VBP ._.
The_DT pension_NN cost_NN charge_NN for_IN the_DT dened_VBN contribution_NN schemes_NNS for_IN the_DT year_NN was_VBD 9,824,000_CD 2002_CD :_: 4,702,000_CD ._.
The_DT closing_NN creditor_NN in_IN respect_NN of_IN pension_NN premiums_NNS at_IN 31_CD December_NNP 2003_CD is_VBZ 605,000_CD 31_CD December_NNP 2002_CD :_: 306,000_CD ._.
The_DT dened_VBN benefit_NN plan_NN operated_VBN by_IN the_DT Group_NNP was_VBD a_DT Supplemental_NNP Executive_NNP Retirement_NNP Plan_NNP SERP_NNP for_IN certain_JJ US_NNP employees_NNS of_IN the_DT acquired_VBN company_NN ,_, Roberts_NNP Pharmaceutical_NNP Corporation_NNP ,_, who_WP met_VBD certain_JJ age_NN and_CC service_NN requirements_NNS ._.
The_DT plan_NN was_VBD discontinued_VBN in_IN 2000_CD and_CC there_EX were_VBD no_DT contributions_NNS payable_JJ in_IN respect_NN of_IN the_DT years_NNS 2003_CD and_CC 2002_CD ._.
The_DT Group_NNP paid_VBD a_DT lump_NN sum_NN of_IN 11.3_CD million_CD $_$ 18.0_CD million_CD into_IN the_DT SERP_NNP ,_, which_WDT was_VBD accounted_VBN for_IN as_IN a_DT fair_JJ value_NN adjustment_NN on_IN the_DT acquisition_NN of_IN Roberts_NNP Pharmaceutical_NNP Corporation_NNP to_TO make_VB good_JJ the_DT deficit_NN on_IN this_DT scheme_NN at_IN the_DT time_NN of_IN acquisition_NN ._.
This_DT lump_NN sum_NN payment_NN has_VBZ led_VBN to_TO the_DT Group_NNP having_VBG no_DT future_JJ liability_NN under_IN the_DT SERP_NNP ,_, which_WDT has_VBZ been_VBN closed_VBN to_TO new_JJ members_NNS with_IN contributions_NNS no_RB longer_RB payable_JJ by_IN existing_VBG members_NNS ._.
The_DT asset_NN and_CC liability_NN of_IN 6.7_CD million_CD and_CC 5.0_CD million_CD respectively_RB are_VBP shown_VBN in_IN notes_NNS 18_CD ,_, 20_CD and_CC 21_CD respectively_RB ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 69_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS 69_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 28_CD Notes_NNS to_TO the_DT consolidated_JJ cash_NN ow_NN statement_NN a_DT Reconciliation_NNP of_IN operating_VBG loss_NN to_TO net_JJ cash_NN inow_NN from_IN operating_VBG activities_NNS 2003 2002 000 000_CD Group_NNP operating_NN loss_NN 299,237_CD 533,145_CD Exchange_NNP gains_NNS 962_CD Depreciation_NN 13,404_CD 9,073_CD Amortisation_NNP of_IN intangible_JJ xed_JJ assets_NNS 120,705_CD 153,979_CD profit_NN on_IN sale_NN of_IN discontinued_VBN operations_NNS 698_CD 2,006_CD profit_NN loss_NN on_IN sale_NN of_IN tangible_JJ xed_JJ assets_NNS 100_CD 854_CD Write-off_NN of_IN xed_JJ asset_NN investments_NNS 9,491_CD 5,809_CD Write-off_NN of_IN intangible_JJ xed_JJ assets_NNS 442,815_CD 631,447_CD Write-off_NN of_IN tangible_JJ xed_JJ assets_NNS 5,965_CD Decrease_NN increase_NN in_IN stocks_NNS 3,320_CD 1,485_CD Increase_VBP decrease_NN in_IN debtors_NNS 27,868_CD 51,832_CD Increase_VBP decrease_NN in_IN creditors_NNS 12,478_CD 14,999_CD Net_JJ cash_NN inow_NN from_IN operating_VBG activities_NNS 280,275_CD 302,321_CD The_DT company_NN ,_, which_WDT was_VBD acquired_VBN during_IN 2002_CD ,_, contributed_VBD 3.6_CD million_CD US$_$ 5.8_CD million_CD outow_NN to_TO the_DT Groups_NNS net_JJ operating_NN cashows_NNS and_CC utilized_VBN 3.5_CD million_CD US$_$ 5.7_CD million_CD for_IN capital_NN expenditure_NN and_CC financial_JJ investments_NNS in_IN that_DT year_NN ._.
b_NN Analysis_NN and_CC reconciliation_NN of_IN net_JJ debt_NN Acquired_VBN Other_JJ Start_NNP of_IN in_IN year_NN non-cash_JJ Exchange_NNP End_NN of_IN year_NN excl_NN ._.
cash_NN Cash_NN ow_NN changes_NNS movement_NN year_NN Year_NN ended_VBD 31_CD December_NNP 2002 000 000 000_CD 000 000 000_CD Cash_NN at_IN bank_NN and_CC in_IN hand_NN 81,434_CD 493,102_CD 16,104_CD 558,432_CD Debt_NN due_JJ within_IN one_CD year_NN 3,008_CD 2,005_CD 565_CD 49_CD 389_CD Finance_NNP leases_NNS 243_CD 74_CD 7_CD 162_CD 78,426_CD 243_CD 495,181_CD 565_CD 16,048_CD 557,881_CD Debt_NN due_JJ after_IN one_CD year_NN 269,883_CD 1,173_CD 389_CD 26,342_CD 244,325_CD Finance_NNP leases_NNS 3,926_CD 169_CD 3,757_CD 191,457_CD 4,169_CD 494,008_CD 954_CD 10,463_CD 309,799_CD Current_JJ assets_NNS investments_NNS 497,397_CD 254,561_CD 87_CD 46,385_CD 196,364_CD Net_JJ funds_NNS 305,940_CD 4,169_CD 239,447_CD 867_CD 35,922_CD 506,163_CD 5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 70_CD 70_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 28_CD Notes_NNS to_TO the_DT consolidated_JJ cash_NN ow_NN statement_NN continued_VBD b_NN Analysis_NN and_CC reconciliation_NN of_IN net_JJ debt_NN continued_VBD 2003 2002 000 000_CD Increase_VBP in_IN cash_NN in_IN the_DT year_NN 124,578_CD 493,102_CD Cash_NN outow_NN from_IN decrease_NN in_IN debt_NN and_CC lease_NN nancing_NN 18,213_CD 906_CD Cash_NN inow_NN from_IN decrease_NN in_IN liquid_JJ resources_NNS 17,848_CD 254,561_CD Change_NNP in_IN net_JJ debt_NN resulting_VBG from_IN cash_NN ows_NNS 124,943_CD 239,447_CD Leases_NNPS and_CC current_JJ asset_NN investments_NNS acquired_VBN with_IN subsidiary_NN undertakings_NNS 4,169_CD Arenol_NNP loan_NN note_NN conversion_NN 954_CD Qualia_NNP Computing_NNP Inc._NNP joint_JJ venture_NN 87_CD Translation_NN difference_NN 46,451_CD 35,922_CD Movement_NNP in_IN net_JJ funds_NNS in_IN year_NN 78,492_CD 200,223_CD Net_JJ funds_NNS at_IN beginning_NN of_IN year_NN 506,163_CD 305,940_CD Net_JJ funds_NNS at_IN end_NN of_IN year_NN 584,655_CD 506,163_CD c_NN Major_JJ non-cash_JJ transactions_NNS There_EX are_VBP no_DT major_JJ non-cash_JJ transactions_NNS in_IN 2003_CD ._.
29_CD Related_VBN party_NN transactions_NNS Transactions_NNS with_IN Directors_NNS of_IN the_DT Company_NN are_VBP disclosed_VBN in_IN the_DT Directors_NNS report_VBP on_IN pages_NNS 12_CD and_CC 13_CD ._.
In_IN accordance_NN with_IN Financial_NNP Reporting_NNP Standard_NNP No._NN ._.
8_CD related_JJ party_NN disclosures_NNS ,_, transactions_NNS with_IN other_JJ companies_NNS in_IN ,_, and_CC investee_NN related_VBN parties_NNS of_IN ,_, the_DT Shire_NNP Pharmaceuticals_NNP Group_NNP have_VBP not_RB been_VBN disclosed_VBN in_IN these_DT financial_JJ statements_NNS ._.
5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 71_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Shire_NNP head_NN ofce_NN and_CC main_JJ operating_NN locations_NNS 71_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Shire_NNP US_NNP ,_, Inc._NNP ._.
Chief_NNP Executive_NNP officer_NN :_: Matthew_NNP Emmens_NNP EVP_NNP and_CC General_NNP Manager_NNP ,_, North_NNP America_NNP :_: Hampshire_NNP International_NNP Business_NNP Park_NNP Greg_NNP Flexter_NNP Chineham_NNP ,_, Basingstoke_NNP One_CD Riverfront_NNP Place_NNP Hampshire_NNP RG24_NNP 8EP_NNP ,_, UK_NNP Newport_NNP ,_, KY_NNP 41071_CD ,_, USA_NNP Tel_NNP 44_CD 0_CD 1256 894 000_CD Tel_NNP 1_CD 800 828 2088_CD Fax_NNP 44_CD 0_CD 1256 894 708_CD Tel_NNP 1_CD 859 669 8000_CD Fax_NN 1_CD 859 669 8414_CD Shire_NNP Pharmaceuticals_NNP Limited_NNP Managing_VBG Director_NNP :_: John_NNP Freeman_NNP Shire_NNP US_NNP Manufacturing_NNP ,_, Inc._NNP ._.
Hampshire_NNP International_NNP Business_NNP Park_NNP EVP_NNP Global_NNP Supply_NNP Chain_NNP &_CC Quality_NNP :_: John_NNP Lee_NNP Chineham_NNP ,_, Basingstoke_NNP 11200_CD Gundry_NNP Lane_NNP Hampshire_NNP RG24_NNP 8EP_NNP ,_, UK_NNP Owings_NNP Mills_NNP ,_, MD_NNP 21117_CD ,_, USA_NNP Tel_NNP 44_CD 0_CD 1256 894 000_CD Tel_NNP 1_CD 410 413 1000_CD Fax_NNP 44_CD 0_CD 1256 894 708_CD Fax_NN 1_CD 410 413 2000_CD Shire_NNP Pharmaceuticals_NNP Ireland_NNP Limited_NNP Shire_NNP Laboratories_NNPS ,_, Inc._NNP ._.
Director_NNP and_CC General_NNP Manager_NNP :_: Brian_NNP Martin_NNP President_NNP and_CC Chief_NNP Executive_NNP officer_NN :_: 2nd_VB Floor_NNP ,_, Building_NNP 1A_NNP Jack_NNP Khattar_NNP Citylink_NNP Business_NNP Park_NNP 1550_CD East_NNP Gude_NNP Drive_NNP Old_NNP Naas_NNP Road_NNP Rockville_NNP ,_, MD_NNP 20850_CD ,_, USA_NNP Dublin_NNP 12_CD ,_, Ireland_NNP Tel_NNP 1_CD 301 838 2500_CD Tel_NNP 353_CD 1_CD 429_CD 7700_CD Fax_NN 1_CD 301 838 2501_CD Fax_NNP 353_CD 1_CD 429_CD 7701_CD Shire_NNP Pharmaceutical_NNP Development_NNP ,_, Inc._NNP ._.
Shire_NNP Pharmaceutical_NNP Contracts_NNPS Limited_NNP Senior_NNP Vice_NNP President_NNP :_: Simon_NNP Tulloch_NNP Singapore_NNP representative_NN ofce_NN 1801_CD Research_NNP Blvd._NNP ._.
Suite_NN 600_CD Managing_VBG Director_NNP :_: Tony_NNP Ooi_NNP Rockville_NNP ,_, MD_NNP 20850_CD ,_, USA_NNP LiFung_NNP Centre_NNP Tel_NNP 1_CD 240 453 6400_CD 58_CD Toh_NNP Guan_NNP Road_NNP #_# 03-09A_CD Fax_NN 1_CD 240 453 6404_CD Singapore_NNP 608829_CD Tel_NNP 65 6665 2795_CD Shire_NNP Biologics_NNPS Inc._NNP ._.
Fax_NN 65 6665 2797_CD Canada_NNP President_NNP :_: Randal_NNP Chase_NNP Shire_NNP Deutschland_NNP GmbH_NNP &_CC Co_NNP KG_NNP 275_CD ,_, Armand-Frappier_NNP Blvd_NNP General_NNP Manager_NNP :_: Leonhard_NNP Terp_NNP Laval_NNP ,_, Quebec_NNP ,_, Canada_NNP H7V_NNP 4A7_NNP Siegburger_NNP Strasse_NNP 126_CD Tel_NNP 1_CD 450 978 7800_CD D-50679_NNP Kln_NNP ,_, Germany_NNP Fax_NNP 1_CD 450 978 7755_CD Tel_NNP 49 221 88047_CD 30_CD 2323_CD du_NNP Parc_NNP Technologique_NNP Blvd_NNP Fax_NNP 49 221 88047_CD 41_CD Sainte-Foy_NNP ,_, Quebec_NNP ,_, Canada_NNP G1P_NNP 4RB_NNP Tel_NNP 1_CD 418 650 0010_CD Shire_NNP France_NNP S._NNP A._NNP Fax_NNP 1_CD 418 650 0080_CD General_NNP Manager_NNP :_: Vincent_NNP Lucet_NNP 88_CD ,_, rue_NN du_NNP Dme_NNP Shire_NNP Biologics_NNPS Inc._NNP 92514_CD Boulogne-Billancourt_NNP US_NNP Cedex_NNP ,_, Paris_NNP ,_, France_NNP Senior_NNP Vice_NNP President_NNP R&D_NNP :_: Ronald_NNP Ellis_NNP Tel_NNP :_: 33_CD 1_CD 46_CD 10_CD 90_CD 00_CD 30_CD Bearfoot_NNP Rd_NNP Fax_NNP :_: 33_CD 1_CD 46_CD 08_CD 21_CD 49_CD Northborough_NNP MA_NNP 01532_CD ,_, USA_NNP Shire_NNP Italia_NNP S._NNP p._NNP A_NNP Tel_NNP 1_CD 508 351-9944_CD General_NNP Manager_NNP :_: Charles_NNP Marchetti_NNP Fax_NNP 1_CD 508 351-9675_CD Via_NNP Provinciale_NNP Lucchese_NNP ,_, 70_CD Sesto_NNP Fiorentino_NNP ,_, 50019_CD Firenze_NNP ,_, Italy_NNP Shire_NNP BioChem_NNP Inc._NNP ._.
Tel_NNP 39_CD 0_CD 5530_CD 250_CD 50_CD 275_CD ,_, Armand-Frappier_NNP Blvd_NNP Fax_NNP 39_CD 0_CD 5530_CD 250_CD 51_CD Laval_NNP ,_, Quebec_NNP ,_, Canada_NNP H7V_NNP 4A7_NNP Tel_NNP 1_CD 450 978-7800_CD Shire_NNP Pharmaceuticals_NNP Iberica_NNP SL_NNP Fax_NNP 1_CD 450 978-7755_CD Managing_VBG Director_NNP :_: Jos_NNP Antonio_NNP Senz_NNP fide_NNP Broto_NNP Paseo_NNP Pintor_NNP Rosales_NNP num_NN ._.
40_CD ,_, Bajo_NNP Izda_NNP ,_, 28008_CD Madrid_NNP ,_, Spain_NNP Tel_NNP 34 915 500691_CD Fax_NNP 34 915 493 695_CD 5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 72_CD 72_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Shareholder_NN information_NN Registered_NNP ofce_NN address_NN Hampshire_NNP International_NNP Business_NNP Park_NNP Chineham_NNP ,_, Basingstoke_NNP Hampshire_NNP ,_, RG24_NNP 8EP_NNP ,_, UK_NNP Registered_NNP in_IN England_NNP No._NN ._.
2883758_CD Investor_NNP relations_NNS Cla_NNP Rosenfeld_NNP Tel_NNP 44_CD 0_CD 1256 892160_CD Fax_NNP 44_CD 0_CD 1256 894712_CD Email_NNP investorrelations@uk_NNP ._.
com_NN Registrars_NNPS and_CC transfer_VB ofce_JJ All_DT administrative_JJ enquiries_NNS relating_VBG to_TO shareholdings_NNS should_MD be_VB addressed_VBN to_TO Lloyds_NNP TSB_NNP Registrars_NNPS ,_, clearly_RB stating_VBG the_DT registered_JJ shareholder_NN 's_POS name_NN and_CC address_NN ._.
Lloyds_NNP TSB_NNP Registrars_NNPS The_DT Causeway_NNP ,_, Worthing_NNP West_NNP Sussex_NNP ,_, BN99_NNP 6DA_NNP ,_, UK_NNP Designed_NNP and_CC produced_VBN by_IN Bostock_NNP and_CC Pollitt_NNP Limited_NNP 5766_CD shire_NN SFS_NNP artwork_NN 11_CD ._.
qxd_NN 22_CD 6_CD 04_CD 4:10_CD pm_NN Page_NNP 74_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Head_NNP Ofce_NNP Hampshire_NNP International_NNP Business_NNP Park_NNP Chineham_NNP ,_, Basingstoke_NNP Hampshire_NNP RG24_NNP 8EP_NNP T_NNP :_: 44_CD 0_CD 1256 894 000_CD F_NN :_: 44_CD 0_CD 1256 894 708_CD www_NN ._.
com_NN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2003_CD Shire_NNP :_: a_DT focused_JJ global_JJ pharmaceutical_JJ company_NN Focusing_VBG on_IN a_DT bright_JJ future_NN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN The_DT Shire_NNP mission_NN Our_PRP$ mission_NN is_VBZ to_TO become_VB the_DT leading_VBG company_NN in_IN meeting_VBG the_DT needs_NNS of_IN the_DT specialist_NN physician_NN ._.
We_PRP want_VBP to_TO achieve_VB this_DT by_IN developing_VBG and_CC Contents_NNS marketing_NN products_NNS of_IN the_DT highest_JJS quality_NN 01_CD Financial_NNP highlights_VBZ 02_CD Chairmans_NNPS statement_NN for_IN the_DT treatment_NN of_IN serious_JJ diseases_NNS ,_, 04_CD Chief_NNP Executive_NNP Ofcers_NNP review_NN 06_CD Product_NNP portfolio_NN 07_CD Product_NN development_NN pipeline_NN which_WDT are_VBP treated_VBN by_IN medical_JJ specialists_NNS ._.
08_CD Operating_NN review_NN 22_CD CSR_NNP :_: Corporate_NNP and_CC social_JJ responsibility_NN We_PRP aim_VBP to_TO provide_VB high_JJ quality_NN and_CC effective_JJ 24_CD Financial_NNP review_NN 28_CD Board_NNP of_IN Directors_NNS products_NNS that_WDT enhance_VBP the_DT health_NN and_CC 30_CD The_DT Executive_NNP Committee_NNP 32_CD Directors_NNS remuneration_JJ report_NN 44_CD Corporate_JJ governance_NN quality_NN of_IN life_NN of_IN people_NNS around_IN the_DT world_NN statement_NN and_CC contribute_VBP to_TO the_DT long-term_JJ business_NN Financial_NNP Statements_NNP 48_CD Statement_NN of_IN Directors_NNS responsibilities_NNS Report_NNP of_IN success_NN of_IN our_PRP$ Company_NN ,_, to_TO the_DT benefit_NN independent_JJ auditors_NNS 49_CD Consolidated_NNP balance_NN sheets_NNS of_IN all_DT our_PRP$ stakeholders_NNS ._.
50_CD Consolidated_NNP statement_NN of_IN operations_NNS 51_CD Consolidated_NNP statements_NNS of_IN We_PRP are_VBP driven_VBN by_IN the_DT needs_NNS of_IN all_DT our_PRP$ changes_NNS in_IN shareholders_NNS equity_NN 52_CD Consolidated_NNP statements_NNS of_IN cash_NN ows_NNS stakeholders_NNS :_: patients_NNS ,_, their_PRP$ families_NNS and_CC 53_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS caregivers_NNS ,_, doctors_NNS and_CC medical_JJ specialists_NNS ,_, 87_CD Five-year_JJ review_NN 88_CD Summary_NNP financial_JJ statement_NN employees_NNS and_CC partner_NN companies_NNS ,_, the_DT 93_CD Notes_NNS to_TO summary_NN financial_JJ statement_NN community_NN in_IN which_WDT we_PRP live_VBP and_CC work_VBP and_CC ,_, Other_JJ 94_CD Shire_NNP head_NN ofce_NN and_CC main_JJ of_IN course_NN ,_, our_PRP$ shareholders_NNS ._.
operating_VBG locations_NNS 95_CD Shareholder_NN information_NN 96_CD Trade_NNP marks_NNS Cautionary_JJ statements_NNS We_PRP also_RB want_VBP to_TO be_VB the_DT employer_NN of_IN choice_NN in_IN our_PRP$ sector_NN ,_, attracting_VBG and_CC retaining_VBG highly_RB skilled_JJ and_CC talented_JJ people_NNS ,_, who_WP play_VBP an_DT active_JJ part_NN in_IN the_DT development_NN of_IN our_PRP$ Company_NN ,_, by_IN rewarding_JJ excellence_NN and_CC recognizing_VBG individual_JJ contributions_NNS ._.
ROYALTIES_NNS 203.6_CD 02_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Chairmans_NNPS statement_NN We_PRP have_VBP achieved_VBN clear_JJ success_NN to_TO date_NN and_CC through_IN greater_JJR focus_NN expect_VBP more_JJR to_TO follow_VB through_IN 2004_CD and_CC beyond_IN The_DT international_JJ pharmaceutical_JJ industry_NN has_VBZ 2003_CD results_NNS changed_VBD considerably_RB during_IN the_DT last_JJ decade_NN In_IN 2003_CD ,_, Shire_NNP once_RB again_RB produced_VBN strong_JJ and_CC this_DT continued_VBN in_IN 2003_CD ._.
Our_PRP$ view_NN at_IN Shire_NNP financial_JJ results_NNS ._.
Income_NN from_IN continuing_VBG is_VBZ that_IN ,_, whatever_WDT their_PRP$ size_NN ,_, successful_JJ operations_NNS ,_, before_IN income_NN taxes_NNS and_CC equity_NN pharmaceutical_JJ companies_NNS now_RB require_VBP focus_NN ,_, method_NN investees_NNS ,_, increased_VBD 17_CD %_NN to_TO US$_$ 384.5_CD particularly_RB in_IN their_PRP$ product_NN markets_NNS ,_, customer_NN million_CD ._.
Revenues_NNS were_VBD up_RB 19_CD %_NN to_TO US$_$ 1,237.1_CD base_NN ,_, research_NN and_CC development_NN and_CC cost_NN control_NN ._.
Diluted_JJ earnings_NNS per_IN ordinary_JJ share_NN Unsurprisingly_NNP ,_, these_DT are_VBP areas_NNS that_IN we_PRP focused_VBD was_VBD 54.2_CD cents_NNS ._.
on_IN in_IN 2003_CD and_CC will_MD continue_VB to_TO do_VB so_RB in_IN the_DT current_JJ year_NN ._.
We_PRP have_VBP achieved_VBN clear_JJ success_NN Signicantly_NNP ,_, Shires_NNP cash_NN position_NN remained_VBD strong_JJ to_TO date_NN and_CC through_IN greater_JJR focus_NN expect_VBP more_RBR with_IN net_JJ cash_NN of_IN US$_$ 1,036_CD million_CD ,_, an_DT increase_NN to_TO follow_VB in_IN 2004_CD and_CC beyond_IN ._.
of_IN US$_$ 230_CD million_CD on_IN 2002_CD ,_, which_WDT will_MD be_VB used_VBN for_IN future_JJ expansion_NN ._.
Within_IN his_PRP$ short_JJ time_NN as_IN Chief_NNP Executive_NNP officer_NN ,_, Matthew_NNP Emmens_NNP has_VBZ shaped_VBN Shire_NNP for_IN its_PRP$ The_NNP Board_NNP future_NN ._.
Our_PRP$ newly_RB deployed_VBN strategic_JJ model_NN We_PRP continue_VBP to_TO develop_VB the_DT Shire_NNP Board_NNP to_TO is_VBZ designed_VBN to_TO optimise_VB the_DT opportunities_NNS for_IN match_NN the_DT demands_NNS of_IN what_WP is_VBZ now_RB a_DT large_JJ ,_, us_PRP and_CC deal_VB with_IN future_JJ challenges_NNS within_IN the_DT international_JJ business_NN in_IN a_DT changing_VBG industry_NN ._.
Shire_NNP will_MD position_VB itself_PRP as_IN the_DT leading_VBG pharmaceutical_JJ marketplace_NN ._.
company_NN in_IN meeting_VBG the_DT needs_NNS of_IN the_DT specialist_NN physician_NN with_IN a_DT focus_NN on_IN fewer_JJR ,_, later_RB stage_NN and_CC In_IN line_NN with_IN newly_RB published_VBN regulations_NNS on_IN lower_JJR risk_NN projects_NNS ._.
This_DT means_VBZ that_IN we_PRP dont_VBP corporate_JJ governance_NN ,_, Shire_NNP has_VBZ talked_VBN to_TO a_DT invent_VB products_NNS but_CC acquire_VB them_PRP ._.
Therefore_RB we_PRP range_VBP of_IN shareholders_NNS and_CC taken_VBN advice_NN on_IN how_WRB are_VBP focusing_VBG on_IN not_RB only_RB the_DT type_NN of_IN deals_NNS that_WDT to_TO best_JJS meet_VB these_DT guidelines_NNS ._.
A_DT program_NN of_IN give_VB us_PRP a_DT good_JJ pipeline_NN ,_, but_CC how_WRB to_TO best_JJS develop_VB implementation_NN is_VBZ underway_JJ and_CC more_RBR detail_NN can_MD Dr_VB James_NNP Cavanaugh_NNP them_PRP with_IN ultimate_JJ market_NN success_NN in_IN mind_NN ._.
be_VB found_VBN in_IN the_DT corporate_JJ governance_NN statement_NN Chairman_NNP We_PRP will_MD continue_VB to_TO enhance_VB our_PRP$ positions_NNS in_IN of_IN this_DT document_NN on_IN page_NN 44_CD ._.
the_DT key_JJ areas_NNS of_IN Central_NNP Nervous_NNP System_NNP CNS_NNP ,_, Gastrointestinal_NNP GI_NNP and_CC renal_JJ medicine_NN ,_, while_IN In_IN March_NNP 2003_CD ,_, Matthew_NNP Emmens_NNP was_VBD appointed_VBN remaining_VBG alert_JJ for_IN new_JJ therapeutic_JJ areas_NNS that_WDT as_IN Chief_NNP Executive_NNP officer_NN ._.
He_PRP has_VBZ a_DT strong_JJ would_MD benefit_VB from_IN our_PRP$ expertise_NN ._.
track_NN record_NN of_IN success_NN over_IN an_DT international_JJ pharmaceutical_JJ career_NN spanning_VBG nearly_RB 30_CD years_NNS ._.
Shires_NNS sales_NNS force_NN continues_VBZ to_TO deliver_VB impressive_JJ Matthew_NNP was_VBD a_DT founder_NN of_IN the_DT joint_JJ venture_NN Astra_NNP results_NNS and_CC its_PRP$ reputation_NN amongst_IN specialist_NN Merck_NNP Inc._NNP in_IN the_DT US_NNP ,_, and_CC later_RB its_PRP$ President_NNP and_CC physicians_NNS makes_VBZ it_PRP a_DT partner_NN of_IN choice_NN when_WRB Chief_NNP Executive_NNP ._.
Before_IN joining_VBG Shire_NNP ,_, he_PRP was_VBD it_PRP comes_VBZ to_TO potential_JJ acquisitions_NNS and_CC in-licensing_JJ President_NNP of_IN the_DT global_JJ pharmaceutical_JJ business_NN projects_NNS and_CC products_NNS ._.
Our_PRP$ strong_JJ cash_NN position_NN of_IN Merck_NNP KGaA_NNP in_IN Germany_NNP ._.
gives_VBZ us_PRP considerable_JJ exibility_NN in_IN looking_VBG at_IN potential_JJ mergers_NNS and_CC acquisitions_NNS M&A_NNP opportunities_NNS and_CC we_PRP have_VBP identied_VBN a_DT small_JJ number_NN of_IN highly_RB attractive_JJ targets_NNS ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Chairmans_NNPS statement_NN 03_CD We_PRP are_VBP confident_JJ of_IN delivering_VBG sustained_VBN growth_NN in_IN 2004_CD and_CC beyond_IN ,_, following_VBG the_DT momentum_NN we_PRP developed_VBD in_IN 2003_CD In_IN July_NNP 2003_CD ,_, Shires_NNP Board_NNP appointed_VBD Robin_NNP People_NNP Buchanan_NNP as_IN a_DT new_JJ non-executive_JJ Director_NNP ._.
Shire_NNP had_VBD 1,815_CD employees_NNS worldwide_JJ as_IN He_PRP is_VBZ a_DT member_NN of_IN the_DT Companys_NNP Remuneration_NNP of_IN 31_CD December_NNP 2003_CD ._.
Robin_NNP is_VBZ the_DT Senior_JJ Partner_NNP of_IN the_DT in_IN the_DT importance_NN of_IN hiring_VBG well-qualied_JJ ,_, London_NNP ofce_NN of_IN business_NN consultants_NNS Bain_NNP experienced_VBD staff_NN with_IN proven_JJ records_NNS of_IN success_NN ._.
&_CC Company_NNP and_CC a_DT member_NN of_IN the_DT rms_NNS The_DT Groups_NNS future_JJ progress_NN depends_VBZ upon_IN worldwide_JJ management_NN committee_NN ._.
Since_IN joining_VBG its_PRP$ ability_NN to_TO attract_VB and_CC retain_VB such_JJ individuals_NNS ._.
Bain_NNP &_CC Company_NNP in_IN 1982_CD ,_, he_PRP has_VBZ been_VBN involved_VBN Shire_NNP will_MD continue_VB to_TO apply_VB and_CC develop_VB a_DT strong_JJ in_IN strategy_NN development_NN and_CC organization_NN advice_NN focus_NN on_IN staff_NN recruitment_NN and_CC development_NN for_IN Bains_NNP clients_NNS in_IN most_JJS industry_NN sectors_NNS ,_, at_IN all_DT levels_NNS ._.
Current_JJ trading_NN and_CC future_JJ prospects_NNS On_IN 10_CD March_NNP 2004_CD ,_, we_PRP announced_VBD that_IN The_DT Company_NN is_VBZ trading_VBG in_IN line_NN with_IN our_PRP$ David_NNP Kappler_NNP will_MD join_VB the_DT Shire_NNP Board_NNP as_IN expectations_NNS ._.
Shire_NNP has_VBZ well-established_JJ positions_NNS a_DT non-executive_JJ Director_NNP in_IN April_NNP and_CC will_MD take_VB in_RP growing_VBG markets_NNS ,_, a_DT well_RB dened_VBN strategy_NN ,_, strong_JJ over_IN the_DT Chairmanship_NN of_IN the_DT Audit_NNP Committee_NNP cash_NN resources_NNS and_CC a_DT promising_JJ pipeline_NN of_IN late_JJ in_IN July_NNP 2004_CD ._.
David_NNP recently_RB retired_VBD as_IN Chief_NNP stage_NN drugs_NNS ._.
Consequently_RB ,_, we_PRP are_VBP confident_JJ Financial_JJ officer_NN of_IN Cadbury_NNP Schweppes_NNP plc_NN ,_, of_IN delivering_VBG sustained_VBN growth_NN in_IN 2004_CD ,_, following_VBG the_DT FTSE_NNP and_CC NYSE_NNP listed_VBD global_JJ confectionery_NN the_DT momentum_NN we_PRP developed_VBD in_IN 2003_CD ._.
and_CC beverages_NNS group_NN ,_, where_WRB he_PRP held_VBD a_DT range_NN of_IN senior_JJ finance_NN positions_NNS during_IN his_PRP$ almost_RB 40-year_JJ career_NN with_IN the_DT group_NN ._.
While_IN welcoming_VBG Matthew_NNP ,_, Robin_NNP and_CC David_NNP ,_, I_PRP would_MD also_RB like_VB to_TO thank_VB Francesco_NNP Bellini_NNP and_CC Grard_NNP Veilleux_NNP for_IN the_DT contribution_NN they_PRP have_VBP made_VBN to_TO the_DT Board_NNP ,_, having_VBG completed_VBN their_PRP$ two-year_JJ contracts_NNS with_IN Shire_NNP ._.
04_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Chief_NNP Executive_NNP Ofcers_NNP review_NN Our_PRP$ opportunities_NNS lie_VBP in_IN addressing_VBG underserved_JJ markets_NNS and_CC growing_VBG products_NNS beyond_IN what_WP the_DT consensus_NN of_IN opinion_NN might_MD be_VB In_IN 2003_CD ,_, Shire_NNP once_RB again_RB delivered_VBN a_DT very_RB Our_PRP$ model_NN emphasises_VBZ the_DT D_NNP in_IN R&D_NNP ._.
During_IN the_DT summer_NN ,_, our_PRP$ R_NN is_VBZ based_VBN on_IN nding_NN products_NNS invented_VBD we_PRP began_VBD implementing_VBG a_DT new_JJ strategy_NN aimed_VBN by_IN others_NNS ._.
I_PRP believe_VBP this_DT is_VBZ a_DT sound_JJ idea_NN because_IN at_IN ensuring_VBG continued_JJ future_JJ growth_NN ._.
Since_IN its_PRP$ in_IN house_NN R&D_NNP has_VBZ not_RB met_VBN the_DT needs_NNS of_IN the_DT inception_NN ,_, Shire_NNP has_VBZ grown_VBN through_IN acquisitions_NNS ,_, larger_JJR companies_NNS ._.
During_IN 2003_CD ,_, slightly_RB less_JJR than_IN subsequent_JJ product_NN development_NN and_CC effective_JJ one-half_NN of_IN all_DT products_NNS marketed_VBN by_IN large_JJ marketing_NN ._.
This_DT idea_NN remains_VBZ the_DT foundation_NN pharmaceutical_JJ companies_NNS were_VBD not_RB invented_VBN of_IN our_PRP$ model_NN ._.
Some_DT could_MD say_VB that_IN it_PRP is_VBZ back_RB there_RB ._.
This_DT percentage_NN has_VBZ increased_VBN steadily_RB to_TO the_DT future_NN in_IN that_IN we_PRP will_MD search_VB take_VB the_DT re_NN over_IN the_DT last_JJ decade_NN ._.
Conversely_RB ,_, approximately_RB from_IN research_NN ,_, and_CC then_RB develop_VB and_CC market_NN ._.
70_CD %_NN of_IN all_DT Phase_NN III_NNP projects_NNS were_VBD developed_VBN But_CC at_IN this_DT point_NN in_IN our_PRP$ history_NN ,_, this_DT would_MD be_VB by_IN non-major_JJ pharmaceutical_JJ companies_NNS ._.
The_DT Group_NNP has_VBZ migrated_VBN from_IN Our_PRP$ conclusion_NN is_VBZ that_IN pre-clinical_JJ research_NN this_DT simple_JJ idea_NN ,_, and_CC making_VBG this_DT proven_JJ concept_NN is_VBZ becoming_VBG less_RBR predictable_JJ and_CC the_DT creativity_NN viable_JJ in_IN todays_NNS larger_JJR organization_NN has_VBZ kept_VBN may_MD lie_VB in_IN a_DT diffuse_NN cross-section_NN of_IN smaller_JJR us_PRP very_RB busy_JJ ._.
companies_NNS or_CC in_IN products_NNS that_WDT are_VBP too_RB small_JJ to_TO contribute_VB in_IN a_DT meaningful_JJ way_NN to_TO the_DT major_JJ Starting_VBG in_IN July_NNP ,_, we_PRP began_VBD exiting_VBG certain_JJ companies_NNS ._.
Therefore_RB ,_, we_PRP are_VBP focusing_VBG our_PRP$ businesses_NNS ,_, changing_VBG our_PRP$ organisational_JJ structure_NN ,_, licensing_NN efforts_NNS on_IN products_NNS or_CC projects_NNS in_IN the_DT and_CC reshaping_VBG our_PRP$ leadership_NN ._.
It_PRP is_VBZ critical_JJ that_IN later_JJ stages_NNS of_IN development_NN with_IN potential_JJ peak_NN we_PRP simplify_VBP ,_, create_VBP a_DT unied_JJ culture_NN and_CC ,_, most_JJS sales_NNS of_IN US$_$ 150_CD million_CD to_TO US$_$ 500_CD million_CD ._.
importantly_RB ,_, integrate_VB our_PRP$ drug_NN development_NN and_CC This_DT seems_VBZ to_TO keep_VB us_PRP below_IN what_WP is_VBZ relevant_JJ commercial_JJ activities_NNS ._.
I_PRP believe_VBP that_IN these_DT actions_NNS to_TO large_JJ Pharma_NNP ,_, but_CC meaningful_JJ to_TO us_PRP ._.
are_VBP the_DT fundamental_JJ underpinnings_NNS that_WDT will_MD enable_VB the_DT organization_NN to_TO create_VB value_NN in_IN the_DT longer_JJR term_NN ._.
Exiting_VBG Businesses_NNS As_IN we_PRP announced_VBD in_IN August_NNP ,_, we_PRP intend_VBP to_TO exit_NN Matthew_NNP Emmens_NNP Our_PRP$ goal_NN is_VBZ clear_JJ we_PRP plan_VBP to_TO lead_VB where_WRB we_PRP our_PRP$ vaccines_NNS business_NN ._.
We_PRP have_VBP had_VBN numerous_JJ CEO_NNP choose_VB to_TO compete_VB ._.
Our_PRP$ opportunities_NNS lie_VBP in_IN expressions_NNS of_IN interest_NN and_CC are_VBP currently_RB addressing_VBG underserved_JJ markets_NNS and_CC growing_VBG examining_VBG the_DT options_NNS which_WDT will_MD best_JJS suit_NN products_NNS beyond_IN what_WP the_DT consensus_NN of_IN opinion_NN our_PRP$ shareholders_NNS and_CC the_DT Companys_NNPS interests_NNS ._.
We_PRP have_VBP done_VBN this_DT consistently_RB in_IN In_IN pursuing_VBG these_DT options_NNS we_PRP expect_VBP to_TO have_VB the_DT past_NN ._.
We_PRP have_VBP learned_VBN that_IN with_IN the_DT right_JJ completed_VBN the_DT process_NN by_IN the_DT middle_NN of_IN 2004_CD ._.
products_NNS ,_, small_JJ ,_, agile_JJ and_CC focused_VBD sales_NNS forces_NNS We_PRP have_VBP closed_VBN our_PRP$ early_JJ stage_NN research_NN lead_NN can_MD deliver_VB impressive_JJ results_NNS ._.
optimisation_NN unit_NN in_IN Canada_NNP and_CC closed_VBD US_NNP manufacturing_NN and_CC distribution_NN sites_NNS ._.
Strategic_NNP actions_NNS in_IN 2003_CD Focused_VBN R&D_NNP Mergers_NNPS and_CC acquisitions_NNS and_CC out-licensing_JJ We_PRP have_VBP re-focused_VBN our_PRP$ Research_NN and_CC Development_NNP In_IN addition_NN ,_, as_IN a_DT result_NN of_IN exiting_VBG oncology_NN and_CC R&D_NNP resources_NNS and_CC technology_NN to_TO concentrate_VB anti-infective_JJ research_NN ,_, we_PRP announced_VBD that_IN we_PRP on_IN areas_NNS where_WRB we_PRP have_VBP a_DT commercial_JJ presence_NN would_MD examine_VB opportunities_NNS to_TO out-license_JJ and_CC on_IN a_DT concentrated_JJ number_NN of_IN high-potential_JJ ,_, the_DT oncology_NN project_NN ,_, TROXATYL_NNP and_CC to_TO seek_VB late-stage_JJ products_NNS ._.
After_IN a_DT thorough_JJ evaluation_NN a_DT partner_NN for_IN the_DT HIV_NNP project_NN ,_, SPD754_CD both_DT of_IN our_PRP$ pipeline_NN ,_, we_PRP currently_RB have_VBP six_CD products_NNS in_IN Phase_NN II_NNP projects_NNS ._.
We_PRP continue_VBP to_TO expect_VB both_DT registration_NN ,_, two_CD in_IN Phase_NN III_NNP and_CC two_CD in_IN Phase_NN II_NNP to_TO be_VB completed_VBN in_IN the_DT middle_NN of_IN 2004_CD ._.
of_IN development_NN ._.
This_DT strategy_NN aims_VBZ to_TO deliver_VB the_DT combined_VBN benefit_NN of_IN increased_VBN returns_NNS and_CC Our_PRP$ geographic_JJ focus_NN is_VBZ on_IN the_DT US_NNP and_CC Europe_NNP ._.
Therefore_RB ,_, we_PRP successfully_RB out-licensed_VBD the_DT Japanese_JJ marketing_NN and_CC development_NN rights_NNS to_TO AGRYLIN_NNP and_CC FOSRENOL_NNP to_TO two_CD companies_NNS with_IN an_DT established_VBN presence_NN in_IN this_DT market_NN ._.
Furthermore_RB ,_, we_PRP have_VBP signicantly_RB enhanced_VBN our_PRP$ M&A_NNP effort_NN by_IN targeting_VBG acquisitions_NNS in_IN the_DT US_NNP ,_, including_VBG larger_JJR scale_NN transactions_NNS ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Chief_NNP Executive_NNP Ofcers_NNP review_NN 05_CD Shire_NNP is_VBZ stronger_JJR than_IN ever_RB ,_, I_PRP am_VBP confident_JJ that_IN the_DT implementation_NN of_IN our_PRP$ strategic_JJ initiatives_NNS will_MD position_VB us_PRP well_RB for_IN growth_NN Re-organisation_NN Patent_NN challenges_NNS Given_VBN Shires_NNP merger_NN history_NN and_CC rapid_JJ It_PRP is_VBZ inevitable_JJ that_IN Shire_NNP will_MD receive_VB challenges_NNS ,_, development_NN ,_, it_PRP was_VBD inevitable_JJ that_IN a_DT complex_JJ particularly_RB from_IN generic_JJ manufacturers_NNS ,_, structure_NN had_VBD developed_VBN ._.
In_IN order_NN to_TO better_JJR to_TO its_PRP$ drugs_NNS portfolio_NN it_PRP is_VBZ a_DT reection_NN of_IN todays_NNS integrate_VBP ,_, co-ordinate_JJ and_CC rationalise_JJ our_PRP$ pharmaceutical_JJ industry_NN ._.
Our_PRP$ position_NN is_VBZ clear_JJ :_: business_NN activities_NNS ,_, we_PRP have_VBP embarked_VBN on_IN a_DT wide_JJ we_PRP will_MD vigorously_RB defend_VB our_PRP$ Intellectual_NNP reaching_VBG strategic_JJ change_NN program_NN ._.
The_DT aim_NN Property_NN ,_, including_VBG patents_NNS ._.
is_VBZ to_TO move_VB the_DT Group_NNP from_IN a_DT silo_NN structure_NN to_TO a_DT globally_RB integrated_VBN organization_NN composed_VBN of_IN Corporate_JJ social_JJ responsibility_NN cross-functional_JJ teams_NNS with_IN clear_JJ accountability_NN Our_PRP$ approach_NN to_TO corporate_JJ social_JJ responsibility_NN for_IN delivering_VBG results_NNS ._.
The_DT business_NN will_MD also_RB be_VB CSR_NNP has_VBZ also_RB developed_VBN during_IN the_DT year_NN with_IN serviced_VBN by_IN support_NN functions_NNS that_WDT will_MD be_VB global_JJ the_DT establishment_NN of_IN our_PRP$ CSR_NNP Committee_NNP led_VBD in_IN their_PRP$ outlook_NN ._.
I_PRP have_VBP changed_VBN our_PRP$ management_NN by_IN our_PRP$ Chief_NNP Financial_NNP officer_NN Angus_NNP Russell_NNP ,_, model_NN to_TO accomplish_VB this_DT ._.
This_DT resulted_VBD in_IN changes_NNS and_CC the_DT setting_NN of_IN 2004_CD objectives_NNS ._.
We_PRP will_MD to_TO the_DT composition_NN of_IN the_DT Executive_NNP Committee_NNP continue_VBP to_TO report_VB regularly_RB on_IN these_DT activities_NNS ._.
and_CC the_DT addition_NN of_IN two_CD management_NN components_NNS The_DT Portfolio_NNP Review_NNP Committee_NNP PRC_NNP Future_NNP development_NN and_CC Portfolio_NN Teams_NNS ._.
I_PRP chair_NN both_CC the_DT Executive_NNP Shire_NNP is_VBZ stronger_JJR than_IN ever_RB and_CC I_PRP am_VBP confident_JJ Committee_NNP and_CC the_DT PRC_NNP and_CC the_DT Portfolio_NN that_IN the_DT implementation_NN of_IN our_PRP$ strategic_JJ Teams_NNP report_NN to_TO the_DT PRC_NNP ._.
initiatives_NNS will_MD position_VB us_PRP well_RB for_IN future_JJ growth_NN ._.
The_DT Company_NN has_VBZ a_DT promising_JJ future_NN with_IN The_DT US_NNP is_VBZ the_DT worlds_NNS largest_JJS pharmaceuticals_NNS a_DT strong_JJ product_NN franchise_NN ,_, an_DT energetic_JJ market_NN ,_, where_WRB we_PRP already_RB generate_VBP 69_CD %_NN of_IN our_PRP$ management_NN team_NN and_CC several_JJ very_RB promising_JJ revenues_NNS and_CC where_WRB more_JJR than_IN 50_CD %_NN of_IN our_PRP$ projects_NNS in_IN the_DT late_JJ stages_NNS of_IN development_NN that_IN employees_NNS are_VBP based_VBN ._.
In_IN recognition_NN of_IN this_DT ,_, should_MD be_VB ready_JJ for_IN launch_NN in_IN the_DT near_JJ to_TO mid_VB we_PRP will_MD establish_VB a_DT new_JJ corporate_JJ ofce_NN in_IN Wayne_NNP ,_, term_NN ._.
Our_PRP$ aim_NN during_IN the_DT forthcoming_JJ year_NN is_VBZ Pennsylvania_NNP ._.
In_IN addition_NN to_TO the_DT vaccine_NN sites_NNS in_IN to_TO continue_VB to_TO strengthen_VB Shires_NNP position_NN in_IN Canada_NNP and_CC the_DT US_NNP that_WDT will_MD be_VB exited_VBN ,_, we_PRP will_MD its_PRP$ marketplaces_NNS and_CC to_TO develop_VB the_DT Company_NN close_RB our_PRP$ Newport_NNP ,_, Kentucky_NNP and_CC Rockville_NNP ,_, into_IN one_CD of_IN the_DT leading_VBG specialty_NN pharmaceutical_JJ Maryland_NNP sites_NNS ._.
The_DT introduction_NN of_IN the_DT Portfolio_NNP Teams_NNPS and_CC the_DT The_DT year_NN 2003_CD was_VBD exciting_JJ and_CC challenging_JJ ._.
housing_NN of_IN R&D_NNP and_CC US_NNP commercial_JJ functions_NNS The_DT dedication_NN and_CC professionalism_NN of_IN our_PRP$ under_IN one_CD roof_NN will_MD improve_VB communication_NN employees_NNS made_VBD our_PRP$ success_NN possible_JJ ._.
and_CC focus_VB ,_, and_CC speed_VB up_RP the_DT process_NN of_IN making_VBG Their_PRP$ hard_JJ work_NN and_CC innovative_JJ approach_NN will_MD decisions_NNS ._.
Other_JJ key_JJ corporate_JJ functions_NNS such_JJ continue_VBP to_TO ensure_VB success_NN for_IN the_DT Company_NN as_IN Business_NNP Development_NNP and_CC Human_NNP Resources_NNPS in_IN the_DT years_NNS ahead_RB ._.
will_MD also_RB be_VB located_VBN in_IN the_DT new_JJ US_NNP ofce_NN ._.
Shires_NNP UK_NNP Basingstoke_NNP ofce_NN will_MD remain_VB the_DT Companys_NNPS headquarters_NN but_CC all_DT Executive_NNP Committee_NNP members_NNS will_MD have_VB ofces_NNS in_IN both_DT locations_NNS to_TO ensure_VB management_NN is_VBZ spending_VBG time_NN where_WRB the_DT day-to-day_JJ business_NN needs_NNS are_VBP greatest_JJS ._.
The_DT International_NNP division_NN will_MD continue_VB to_TO be_VB led_VBN from_IN the_DT UK_NNP and_CC appropriate_JJ significant_JJ R&D_NNP presence_NN will_MD also_RB be_VB maintained_VBN in_IN Basingstoke_NNP to_TO serve_VB the_DT European_JJ markets_NNS ._.
We_PRP foresee_VBP having_VBG just_RB four_CD major_JJ North_JJ American_JJ facilities_NNS by_IN the_DT end_NN of_IN 2005_CD compared_VBN with_IN 14_CD at_IN the_DT beginning_NN of_IN 2003_CD ._.
06_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Product_NNP portfolio_NN Product_NNP portfolio_NN :_: Delivering_VBG high_JJ quality_NN treatments_NNS to_TO meet_VB patients_NNS needs_VBZ ADDERALL_NNP ADDERALL_NNP XR_NNP ADEPT_NNP AGRYLIN_NNP ADDERALL_NNP mixed_JJ amphetamine_NN ADDERALL_NNP XR_NNP mixed_JJ amphetamine_NN ADEPT_NNP 4_CD %_NN icodextrin_NN solution_NN ._.
ADDERALL_NNP XR_NNP is_VBZ indicated_VBN ADEPT_NNP is_VBZ indicated_VBN for_IN use_NN as_IN an_DT AGRYLIN_NNP is_VBZ indicated_VBN for_IN the_DT treatment_NN release_NN product_NN indicated_VBD for_IN the_DT for_IN the_DT treatment_NN of_IN ADHD_NNP and_CC is_VBZ a_DT intraperitoneal_JJ instillate_NN for_IN reduction_NN of_IN essential_JJ thrombocythemia_NN ._.
treatment_NN of_IN attention_NN deficit_NN once-daily_RB formulation_NN of_IN ADDERALL_NNP ._.
of_IN adhesions_NNS following_VBG abdominal_JJ Research_NNP indicates_VBZ that_IN a_DT key_JJ benefit_NN hyperactivity_NN disorder_NN ADHD_NNP ._.
It_PRP offers_VBZ convenience_NN to_TO patients_NNS and_CC surgery_NN ._.
It_PRP acts_VBZ by_IN providing_VBG a_DT temporary_JJ of_IN AGRYLIN_NNP is_VBZ its_PRP$ platelet_NN selectivity_NN ,_, caregivers_NNS ,_, and_CC the_DT potential_NN for_IN separation_NN of_IN peritoneal_JJ surfaces_NNS targeting_VBG only_RB those_DT cells_NNS that_WDT develop_VBP improved_VBN compliance_NN ._.
CALCICHEW_NNP CARBATROL_NNP PENTASA_NNP PROAMATINE_NNP CALCICHEW_NNP range_NN calcium_NN carbonate_NN ._.
PENTASA_NNP PROAMATINE_NNP midodrine_NN The_DT CALCICHEW_NNP range_NN of_IN products_NNS CARBATROL_NNP is_VBZ marketed_VBN for_IN the_DT is_VBZ indicated_VBN for_IN the_DT induction_NN of_IN hydrochloride_NN ._.
PROAMATINE_NNP are_VBP calcium_NN supplements_NNS with_IN or_CC treatment_NN of_IN epilepsy_NN ,_, combining_VBG remission_NN and_CC treatment_NN of_IN patients_NNS is_VBZ indicated_VBN for_IN the_DT treatment_NN of_IN without_IN vitamin_NN D_NNP used_VBD as_IN adjunctive_JJ proven_JJ medication_NN with_IN advanced_VBN with_IN mild_JJ to_TO moderately_RB active_JJ symptomatic_JJ orthostatic_JJ hypotension_NN ._.
drug_NN delivery_NN technology_NN to_TO enable_VB ulcerative_JJ colitis_NNS ,_, using_VBG a_DT unique_JJ a_DT convenient_JJ twice-daily_JJ treatment_NN ._.
REMINYL_NNP SOLARAZE_NNP ZEFFIX_NNP 3TC_NNP REMINYL_NNP galantamine_NN hydrobromide_NN ._.
3TC_CD ,_, also_RB marketed_VBN REMINYL_NNP is_VBZ indicated_VBN for_IN the_DT SOLARAZE_NNP is_VBZ indicated_VBN for_IN the_DT is_VBZ indicated_VBN for_IN the_DT treatment_NN as_IN EPIVIR_NNP ,_, in_IN combination_NN with_IN other_JJ symptomatic_JJ treatment_NN of_IN mild_JJ to_TO treatment_NN of_IN actinic_JJ keratosis_NN ,_, of_IN chronic_JJ hepatitis_NN B_NNP infection_NN antiretroviral_JJ agents_NNS is_VBZ indicated_VBN for_IN the_DT moderately_RB severe_JJ dementia_NN of_IN the_DT a_DT pre-cancerous_JJ skin_NN condition_NN ._.
associated_VBN with_IN evidence_NN treatment_NN of_IN human_JJ immunodeciency_NN Alzheimer_NNP type_NN ._.
REMINYL_NNP differs_VBZ from_IN of_IN hepatitis_NNP B_NNP viral_JJ replication_NN virus_NN HIV_NNP infection_NN ._.
Lamivudine_NNP is_VBZ a_DT other_JJ compounds_NNS in_IN its_PRP$ class_NN in_IN that_DT and_CC acute_JJ liver_NN inammation_NN ._.
component_NN of_IN the_DT combination_NN HIV_NNP it_PRP has_VBZ a_DT dual_JJ mechanism_NN of_IN action_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NNP Project_NNP development_NN pipeline_NN 07_CD Project_NN development_NN pipeline_NN :_: During_IN 2003_CD significant_JJ progress_NN was_VBD made_VBN ._.
Shire_NNP now_RB has_VBZ six_CD projects_NNS in_IN registration_NN Indication_NNP Product_NNP Preclinical_NNP Phase_NN I_PRP Phase_NN II_NNP Phase_NN III_NNP Registration_NNP CNS_NNP Bipolar_NNP disorder_NN BIPOTROL_NNP SPD417_NNP Adult_NNP ADHD_NNP ADDERALL_NNP XR_NNP ADHD_NNP METHYPATCH_NNP ADHD_NNP SPD503_CD ADHD_NNP SPD473_CD ADHD_NNP SPD465_CD ADHD_NNP SPD483_NNP Gastrointestinal_NNP IBD_NNP PENTASA_NNP 500mg_CD IBD_NNP SPD476_NNP IBD_NNP SPD480_NNP Strategic_NNP Products_NNPS Essential_NNP XAGRID_NNP thrombocythemia_NN Hyperphosphatemia_NNP FOSRENOL_NNP Projects_NNPS available_JJ for_IN out-licensing_JJ Acute_JJ myeloid_JJ TROXATYL_NNP leukemia_NN Pancreatic_NNP cancer_NN HIV_NNP SPD754_NNP HIV_NNP SPD756_NNP Hepatitis_NNP C_NNP SPD760_NNP IBD_NNP :_: Inammatory_JJ bowel_NN disease_NN 08_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN Operating_VBG review_NN :_: Shire_NNP had_VBD an_DT excellent_JJ and_CC development_NN portfolios_NNS ._.
Continued_VBN products_NNS and_CC a_DT number_NN of_IN progressions_NNS in_IN Product_NNP Highlights_NNS ADDERALL_NNP XR_NNP is_VBZ one_CD of_IN the_DT most_RBS REMINYL_JJ continued_VBN to_TO perform_VB 2003_CD prescriptions_NNS for_IN AGRYLIN_NNP widely_RB prescribed_VBD ADHD_NNP treatments_NNS well_RB in_IN 2003_CD with_IN a_DT 63_CD %_NN prescription_NN anagrelide_NN hydrochloride_NN ,_, in_IN the_DT US_NNP with_IN a_DT 23_CD %_NN market_NN share_NN growth_NN in_IN the_DT UK_NNP ,_, and_CC 60_CD %_NN in_IN the_DT for_IN reduction_NN of_IN elevated_JJ platelet_NN and_CC 49_CD %_NN prescription_NN growth_NN over_IN US_NNP over_IN 2002_CD ._.
count_NN ,_, grew_VBD 7_CD %_NN over_IN 2002_CD ._.
2002_CD ,_, despite_IN increasing_VBG competitive_JJ pressures_NNS in_IN this_DT market_NN ._.
PROAMATINEs_NNP US_NNP prescription_NN PENTASA_NNP for_IN the_DT treatment_NN of_IN CARBATROL_NNP benefited_VBD from_IN a_DT growth_NN was_VBD 2_CD %_NN in_IN 2003_CD following_VBG ulcerative_JJ colitis_NN represented_VBD 10_CD %_NN of_IN re-launch_NN in_IN the_DT US_NNP epilepsy_NN market_NN loss_NN of_IN US_NNP market_NN exclusivity_NN during_IN Shires_NNP product_NN sales_NNS and_CC maintained_VBN in_IN early_JJ 2003_CD ._.
A_DT 5_CD %_NN prescription_NN the_DT last_JJ quarter_NN of_IN 2003_CD ._.
an_DT 11_CD %_NN share_NN of_IN the_DT mesalamine_NN increase_NN over_IN 2002_CD resulted_VBD ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN 09_CD year_NN in_IN 2003_CD across_IN both_DT marketed_VBN prescription_NN growth_NN for_IN the_DT key_JJ marketed_VBN the_DT development_NN portfolio_NN were_VBD achieved_VBN Project_NNP Highlights_NNS FOSRENOL_NNP lanthanum_NN carbonate_NN XAGRID_NNP anagrelide_NN hydrochloride_NN ,_, Early_RB in_IN 2004_CD a_DT regulatory_JJ ling_NN a_DT phosphate-binder_NN for_IN use_NN in_IN patients_NNS for_IN reduction_NN of_IN elevated_JJ platelet_NN was_VBD made_VBN to_TO the_DT US_NNP Food_NNP and_CC Drug_NNP with_IN end-stage_JJ renal_JJ disease_NN ESRD_NNP count_NN received_VBD a_DT Positive_NNP Opinion_NNP Administration_NNP FDA_NNP for_IN BIPOTROL_NNP received_VBD its_PRP$ first_JJ European_JJ approval_NN from_IN the_DT Committee_NNP for_IN Proprietary_NNP carbamazepine_NN ,_, previously_RB known_VBN from_IN Reference_NNP Member_NNP State_NNP RMS_NNP ,_, Medicinal_NNP Products_NNPS CPMP_NNP for_IN use_NN as_IN SPD417_NNP ,_, an_DT extended_JJ release_NN Sweden_NNP ,_, in_IN March_NNP 2004_CD ._.
formulation_NN of_IN carbamazepine_NN for_IN letters_NNS were_VBD also_RB received_VBN from_IN the_DT the_DT treatment_NN of_IN bipolar_NN disorder_NN ._.
FDA_NNP for_IN FOSRENOL_NNP and_CC the_DT expanded_VBN indication_NN for_IN use_NN of_IN ADDERALL_NNP XR_NNP in_IN adults_NNS with_IN attention_NN deficit_NN hyperactivity_NN disorder_NN ADHD_NNP ._.
Clinical_JJ programs_NNS were_VBD SPD503_CD and_CC SPD473_CD ,_, both_DT nonSPD476_NNP a_DT high_JJ strength_NN mesalamine_NN initiated_VBN for_IN ADDERALL_NNP XR_NNP and_CC stimulant_NN treatments_NNS for_IN ADHD_NNP ,_, based_VBN formulation_NN for_IN the_DT treatment_NN AGRYLIN_NNP to_TO satisfy_VB requests_NNS for_IN entered_VBN Phase_NN III_NNP and_CC II_NNP of_IN of_IN ulcerative_JJ colitis_NN entered_VBD Phase_NN III_NNP data_NNS leading_VBG to_TO a_DT possible_JJ grant_NN development_NN respectively_RB ._.
Data_NNP for_IN AGRYLIN_NNP were_VBD submitted_VBN in_IN March_NNP 2004_CD ._.
10_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: CNS_NNP Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: CNS_NNP 11_CD Central_NNP nervous_JJ system_NN CNS_NNP :_: Shire_NNP has_VBZ established_VBN itself_PRP as_IN a_DT specialist_NN leader_NN in_IN the_DT development_NN and_CC commercialisation_NN of_IN CNS_NNP therapies_NNS A_DT strong_JJ ADHD_NNP franchise_NN market_NN ._.
Combined_VBN ,_, over_IN 35.3_CD million_CD Shire_NNP continues_VBZ to_TO build_VB its_PRP$ portfolio_NN of_IN products_NNS prescriptions_NNS have_VBP been_VBN written_VBN for_IN ADDERALL_NNP for_IN the_DT treatment_NN of_IN attention_NN deficit_NN hyperactivity_NN and_CC ADDERALL_NNP XR_NNP over_IN the_DT franchises_NNS eightdisorder_NN ADHD_NNP ,_, one_CD of_IN the_DT most_RBS common_JJ year_NN history_NN ._.
ADDERALL_NNP XR_NNP also_RB received_VBD childhood_NN psychiatric_JJ disorders_NNS ._.
marketing_NN approval_NN in_IN Canada_NNP in_IN early_JJ 2004_CD and_CC is_VBZ now_RB available_JJ on_IN prescription_NN ._.
Approximately_RB 3_CD to_TO 7_CD %_NN of_IN male_NN and_CC female_JJ children_NNS in_IN the_DT US_NNP are_VBP affected_VBN by_IN ADHD_NNP ._.
The_DT success_NN of_IN ADDERALL_NNP XR_NNP has_VBZ been_VBN built_VBN These_DT children_NNS are_VBP often_RB inattentive_JJ ,_, impulsive_JJ on_IN a_DT thorough_JJ understanding_NN of_IN ADHD_NNP patient_NN ADDERALL_NNP XR_NNP or_CC hyperactive_JJ ,_, difficulties_NNS that_WDT affect_VBP their_PRP$ ability_NN needs_VBZ ,_, a_DT strong_JJ heritage_NN of_IN assessing_VBG the_DT safety_NN ADDERALL_NNP XR_NNP has_VBZ become_VBN to_TO function_VB normally_RB in_IN home_NN ,_, academic_JJ or_CC social_JJ and_CC efcacy_NN of_IN potential_JJ treatments_NNS ,_, continued_VBD one_CD of_IN the_DT most_RBS widely_RB settings_NNS ._.
Moreover_RB ,_, as_IN many_JJ as_IN two-thirds_NNS of_IN investment_NN in_IN development_NN ,_, and_CC a_DT highly_RB focused_VBN prescribed_VBN ADHD_NNP treatments_NNS children_NNS with_IN ADHD_NNP may_MD continue_VB to_TO exhibit_VB commercial_JJ organization_NN ._.
In_IN addition_NN ,_, Shire_NNP has_VBZ in_IN the_DT US_NNP ._.
While_IN there_EX is_VBZ no_DT cure_NN cultivated_VBN and_CC sponsored_VBN a_DT national_JJ faculty_NN of_IN key_NN for_IN ADHD_NNP ,_, it_PRP can_MD usually_RB be_VB successfully_RB managed_VBN physician_NN educators_NNS and_CC led_VBD initiatives_NNS to_TO help_VB with_IN a_DT combination_NN of_IN treatments_NNS ,_, including_VBG physicians_NNS diagnose_NN ,_, treat_NN ,_, and_CC optimise_JJ therapy_NN educational_JJ approaches_NNS ,_, psychological_JJ and_CC for_IN patients_NNS with_IN ADHD_NNP ._.
Several_JJ studies_NNS were_VBD behavioural_JJ therapies_NNS ,_, and_CC medication_NN ._.
presented_VBN and_CC published_VBN during_IN 2003_CD :_: details_NNS can_MD be_VB requested_VBN from_IN Shire_NNP ._.
All_DT of_IN these_DT activities_NNS ADDERALL_NNP and_CC ADDERALL_NNP XR_NNP mixed_JJ resulted_VBD in_IN a_DT 49_CD %_NN increase_NN in_IN US_NNP ADDERALL_NNP XR_NNP amphetamine_JJ salts_NNS constitute_VBP the_DT market-leading_JJ prescriptions_NNS over_IN 2002_CD ,_, despite_IN increasing_VBG franchise_NN for_IN prescriptions_NNS in_IN ADHD_NNP ._.
Immediatecompetitive_JJ pressures_NNS in_IN this_DT market_NN ._.
release_NN ADDERALL_NNP was_VBD launched_VBN in_IN the_DT US_NNP in_IN 1996_CD and_CC was_VBD Shires_NNP ADHD_NNP brand_NN leader_NN ADDERALL_NNP XR_NNP Adult_NNP :_: Shire_NNP can_MD foresee_VB significant_JJ until_IN the_DT end_NN of_IN 2001_CD ._.
Applying_VBG Shires_NNP patented_VBD opportunities_NNS in_IN this_DT relatively_RB untreated_JJ sector_NN MICROTROL_NNP extended_VBD release_NN technology_NN ,_, Shire_NNP of_IN the_DT market_NN ._.
According_VBG to_TO the_DT National_NNP Institute_NNP developed_VBD and_CC launched_VBD ADDERALL_NNP XR_NNP in_IN 2001_CD ,_, for_IN Mental_NNP Health_NNP ,_, an_DT estimated_VBN 8.2_CD million_CD adults_NNS a_DT novel_NN formulation_NN of_IN ADDERALL_NNP ,_, to_TO provide_VB suffer_VBP from_IN ADHD_NNP ,_, but_CC only_RB 600,000_CD are_VBP treated_VBN ._.
an_DT all-day_JJ treatment_NN ,_, with_IN one_CD morning_NN dose_NN ._.
Currently_RB ,_, an_DT estimated_VBN 17_CD %_NN of_IN ADDERALL_NNP XR_NNP ADDERALL_NNP XR_NNP has_VBZ a_DT rapid_JJ onset_NN of_IN action_NN ,_, prescriptions_NNS are_VBP for_IN patients_NNS older_JJR than_IN 18_CD years_NNS ._.
controlling_VBG symptoms_NNS throughout_IN the_DT day_NN ._.
After_IN submitting_VBG a_DT supplemental_JJ New_NNP Drug_NNP ADDERALL_NNP XR_NNP has_VBZ since_IN become_VBN one_CD of_IN the_DT Application_NNP sNDA_NNP for_IN use_NN of_IN ADDERALL_NNP XR_NNP most_RBS widely_RB prescribed_VBN ADHD_NNP treatments_NNS in_IN the_DT in_IN adults_NNS ,_, Shire_NNP received_VBD an_DT Approvable_JJ letter_NN US_NNP with_IN approximately_RB 11_CD million_CD prescriptions_NNS from_IN the_DT Food_NNP and_CC Drug_NNP Administration_NNP FDA_NNP IMS_NNP Health_NNP data_NNS ,_, January_NNP 2004_CD and_CC a_DT 23_CD %_NN share_NN of_IN the_DT US_NNP prescription_NN ADHD_NNP in_IN October_NNP 2003_CD ._.
Dr_NNP Frank_NNP Lopez_NNP Neuro-development_NNP Paediatrician_NNP Childrens_NNP Developmental_NNP Centre_NNP ,_, Maitland_NNP ,_, Florida_NNP Ive_NNP worked_VBD with_IN many_JJ different_JJ We_PRP particularly_RB rely_VBP on_IN pharmaceutical_JJ companies_NNS over_IN ADDERALL_NNP and_CC ADDERALL_NNP XR_NNP the_DT last_JJ 18_CD years_NNS ,_, but_CC none_NN to_TO treat_VB young_JJ people_NNS at_IN our_PRP$ as_IN responsive_JJ and_CC supportive_JJ developmental_JJ center_NN ._.
Whether_IN its_PRP$ top_JJ management_NN ,_, or_CC the_DT Ive_NNP seen_VBN hundreds_NNS of_IN kids_NNS make_VBP representative_NN who_WP looks_VBZ after_IN huge_JJ strides_NNS as_IN a_DT result_NN of_IN taking_VBG our_PRP$ center_NN ,_, you_PRP can_MD see_VB that_IN this_DT drug_NN they_PRP do_VBP better_JJR at_IN they_PRP really_RB care_VB about_IN the_DT quality_NN school_NN ,_, they_PRP relate_VBP to_TO people_NNS of_IN their_PRP$ products_NNS ,_, and_CC about_IN the_DT better_JJR ,_, and_CC their_PRP$ families_NNS nd_VBP quality_NN of_IN the_DT information_NN they_PRP it_PRP much_RB easier_JJR to_TO live_VB a_DT normal_JJ provide_VBP about_IN them_PRP ._.
12_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: CNS_NNP CNS_NNP ADHD_NNP :_: Shire_NNP continues_VBZ to_TO strengthen_VB its_PRP$ ADHD_NNP portfolio_NN Responses_NNS to_TO the_DT FDAs_NNS letter_NN were_VBD submitted_VBN METHYPATCH_NNP methylphenidate_NN :_: In_IN early_RB in_IN February_NNP 2004_CD ._.
A_DT six-month_JJ review_NN period_NN 2003_CD ,_, Shire_NNP acquired_VBD the_DT worldwide_JJ sales_NNS and_CC is_VBZ anticipated_VBN ._.
Upon_IN approval_NN the_DT adult_NN indication_NN marketing_NN rights_NNS to_TO METHYPATCH_NNP ,_, a_DT transdermal_NN is_VBZ expected_VBN to_TO qualify_VB for_IN three-years_JJ Hatchdelivery_NNP system_NN for_IN the_DT once-daily_JJ treatment_NN of_IN Waxman_NNP marketing_NN exclusivity_NN ._.
ADHD_NNP ,_, from_IN Noven_NNP Pharmaceuticals_NNP Inc._NNP ._.
Noven_NNP ._.
Subsequently_RB ,_, Noven_NNP received_VBD a_DT Not_RB Approvable_JJ ADDERALL_NNP XR_NNP Paediatric_NNP Exclusivity_NNP :_: Shire_NNP letter_NN from_IN the_DT FDA_NNP in_IN response_NN to_TO its_PRP$ New_NNP Drug_NNP is_VBZ evaluating_VBG ADDERALL_NNP XR_NNP in_IN adolescents_NNS Application_NNP NDA_NNP ._.
Shire_NNP and_CC Noven_NNP are_VBP to_TO in_IN response_NN to_TO a_DT paediatric_JJ Written_VBN Request_NN undertake_VB further_RB clinical_JJ investigations_NNS to_TO assist_VB received_VBN from_IN the_DT US_NNP FDA_NNP in_IN 2003_CD ._.
This_DT clinical_JJ in_IN addressing_VBG the_DT questions_NNS raised_VBN by_IN the_DT FDA_NNP ._.
program_NN could_MD extend_VB the_DT existing_VBG HatchWaxman_NNP marketing_NN exclusivity_NN from_IN October_NNP Additional_JJ life_NN cycle_NN projects_NNS for_IN the_DT ADHD_NNP 2004_CD to_TO April_NNP 2005_CD ._.
franchise_NN were_VBD introduced_VBN in_IN early_JJ 2003_CD ._.
SPD465_CD ,_, currently_RB in_IN Phase_NN I_PRP development_NN ,_, is_VBZ targeted_VBN to_TO Strengthening_VBG our_PRP$ ADHD_NNP portfolio_NN offer_VBP an_DT augmented_JJ duration_NN of_IN effect_NN ._.
SPD483_CD ,_, Shire_NNP continues_VBZ to_TO grow_VB its_PRP$ existing_VBG ADHD_NNP another_DT ADHD_NNP candidate_NN ,_, is_VBZ in_IN the_DT Pre-clinical_JJ portfolio_NN while_IN developing_VBG new_JJ products_NNS that_WDT Phase_NN of_IN development_NN ._.
will_MD complement_VB its_PRP$ ADDERALL_NNP franchise_NN :_: SPD473_CD a_DT Phase_NN II_NNP proof-of-concept_JJ study_NN SPD503_CD guanfacine_NN ,_, currently_RB in_IN Phase_NN III_NNP in_IN ADHD_NNP is_VBZ underway_NN ._.
This_DT non-stimulant_JJ mixed_JJ development_NN for_IN children_NNS and_CC adolescents_NNS ,_, monoamine_JJ re-uptake_NN inhibitor_NN has_VBZ a_DT unique_JJ is_VBZ an_DT established_VBN non-stimulant_JJ ,_, non-scheduled_JJ mode_NN of_IN action_NN ,_, affecting_VBG three_CD neurotransmitters_NNS compound_VBP that_DT has_VBZ been_VBN re-formulated_VBN by_IN Shire_NNP that_WDT may_MD be_VB implicated_VBN in_IN ADHD_NNP noradrenaline_NN ,_, for_IN use_NN in_IN ADHD_NNP ._.
It_PRP may_MD offer_VB potential_JJ in_IN the_DT serotonin_NN and_CC dopamine_NN ._.
This_DT makes_VBZ it_PRP an_DT treatment_NN of_IN adult_NN ADHD_NNP ._.
attractive_JJ candidate_NN for_IN ADHD_NNP treatment_NN ._.
Alzheimers_NNP disease_NN Alzheimers_NNP disease_NN is_VBZ the_DT most_RBS common_JJ cause_NN of_IN dementia_NN ,_, affecting_VBG approximately_RB 20_CD million_CD people_NNS worldwide_JJ ,_, mainly_RB those_DT aged_VBN 65_CD or_CC older_JJR ._.
It_PRP is_VBZ a_DT progressive_JJ disorder_NN that_WDT gradually_RB robs_VBZ individuals_NNS of_IN their_PRP$ ability_NN to_TO remember_VB ,_, learn_VB new_JJ information_NN and_CC perform_VB basic_JJ activities_NNS of_IN daily_JJ living_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: CNS_NNP 13_CD CNS_NNP Epilepsy_NNP :_: Epilepsy_NNP is_VBZ estimated_VBN to_TO affect_VB approximately_RB 2.3_CD million_CD people_NNS in_IN the_DT US_NNP REMINYL_NNP is_VBZ one_CD of_IN the_DT fastest-growing_JJ products_NNS Bipolar_NNP disorder_NN for_IN treating_VBG mild_JJ to_TO moderately_RB severe_JJ dementia_NN Bipolar_NNP disorder_NN ,_, also_RB known_VBN as_IN manic_JJ depression_NN ,_, of_IN the_DT Alzheimer_NNP type_NN ,_, with_IN approvals_NNS in_IN more_JJR is_VBZ a_DT mood_NN disorder_NN that_WDT can_MD cause_VB extreme_JJ swings_NNS than_IN 25_CD countries_NNS ._.
REMINYL_NNP was_VBD developed_VBN by_IN between_IN high_JJ mania_NN and_CC low_JJ depression_NN Shire_NNP and_CC Johnson_NNP &_CC Johnson_NNP Pharmaceutical_NNP moods_NNS ._.
The_DT high_JJ and_CC low_JJ phases_NNS of_IN the_DT illness_NN are_VBP Research_NNP &_CC Development_NNP under_IN a_DT co-development_NN called_VBN episodes_NNS and_CC can_MD be_VB so_RB extreme_JJ that_IN they_PRP and_CC licensing_NN agreement_NN ._.
Currently_RB available_JJ can_MD result_VB in_IN hospitalisation_NN ._.
This_DT condition_NN has_VBZ in_IN both_DT tablet_NN and_CC oral_JJ solution_NN ,_, Shire_NNP receives_VBZ historically_RB been_VBN under-diagnosed_JJ and_CC underroyalties_NNS on_IN sales_NNS of_IN REMINYL_NNP from_IN Janssen_NNP treated_VBD ._.
An_DT estimated_VBN 1.5_CD million_CD people_NNS in_IN the_DT CARBATROL_NNP Pharmaceutica_NNP NV_NNP worldwide_NN ,_, except_IN in_IN the_DT UK_NNP US_NNP suffer_VBP from_IN bipolar_JJ disorder_NN ,_, yet_RB only_RB 650,000_CD CARBATROL_NNP is_VBZ an_DT extended_JJ and_CC Ireland_NNP where_WRB Shire_NNP obtained_VBD full_JJ marketing_NN are_VBP undergoing_VBG treatment_NN ._.
release_NN carbamazepine_NN rights_NNS in_IN April_NNP 2004_CD ._.
In_IN 2003_CD REMINYL_NNP continued_VBD formulation_NN for_IN the_DT treatment_NN to_TO perform_VB well_RB in_IN the_DT UK_NNP with_IN a_DT 63_CD %_NN prescription_NN In_IN February_NNP 2004_CD Shire_NNP made_VBD a_DT NDA_NNP ling_NN of_IN epilepsy_NN ._.
The_DT reduced_VBN dosing_NN growth_NN over_IN 2002_CD ._.
for_IN BIPOTROL_NNP previously_RB known_VBN as_IN SPD417_NNP ,_, frequency_NN compared_VBN to_TO other_JJ an_DT extended_JJ release_NN carbamazepine_NN formulation_NN ,_, carbamazepine_NN products_NNS Epilepsy_NNP for_IN use_NN in_IN bipolar_NN disorder_NN ._.
BIPOTROL_NNP has_VBZ shown_VBN makes_VBZ it_PRP more_RBR patient-friendly_RB ._.
Epilepsy_NNP is_VBZ estimated_VBN to_TO affect_VB approximately_RB clear_JJ potential_NN as_IN a_DT mood_NN stabilizer_NN with_IN a_DT highly_RB 2.3_CD million_CD people_NNS in_IN the_DT US_NNP ,_, making_VBG it_PRP one_CD favourable_JJ side-effect_JJ prole_NN ,_, and_CC upon_IN approval_NN of_IN the_DT most_RBS common_JJ neurological_JJ disorders_NNS ._.
would_MD be_VB the_DT first_JJ carbamazepine-based_JJ product_NN Carbamazepine_NNP is_VBZ a_DT widely_RB prescribed_VBN indicated_VBN for_IN the_DT acute_JJ treatment_NN of_IN manic_JJ and_CC anti-epileptic_JJ drug_NN ,_, and_CC is_VBZ a_DT mainstay_NN of_IN mixed_JJ episodes_NNS in_IN patients_NNS with_IN bipolar_JJ disorder_NN ._.
In_IN 1998_CD ,_, Shire_NNP In_IN the_DT US_NNP ,_, BIPOTROL_NNP is_VBZ expected_VBN to_TO receive_VB launched_VBN CARBATROL_NNP ,_, an_DT extended_JJ release_NN three-years_JJ exclusivity_NN under_IN the_DT US_NNP Hatchformulation_NNP of_IN carbamazepine_NN that_IN uses_VBZ the_DT Waxman_NNP Act_NNP ._.
patented_JJ MICROTROL_NNP delivery_NN system_NN technology_NN ._.
It_PRP is_VBZ a_DT twice-daily_JJ extended-release_NN Discontinued_VBN research_NN projects_NNS formulation_NN which_WDT makes_VBZ it_PRP more_RBR patient-friendly_JJ During_IN 2003_CD development_NN of_IN SPD451_CD ,_, than_IN immediate_JJ release_NN formulations_NNS on_IN the_DT a_DT potential_JJ Parkinsons_NNP disease_NN treatment_NN ,_, market_NN ,_, which_WDT require_VBP dosing_JJ three_CD or_CC four_CD times_NNS was_VBD discontinued_VBN ._.
CARBATROL_NNP can_MD be_VB administered_VBN as_IN a_DT capsule_NN or_CC sprinkled_VBN on_IN food_NN ._.
CARBATROL_NNP benefited_VBD from_IN a_DT re-launch_NN in_IN the_DT US_NNP early_RB in_IN 2003_CD ,_, in_IN addition_NN a_DT 100mg_JJ dosage_NN strength_NN was_VBD launched_VBN in_IN January_NNP 2004_CD ._.
Increased_VBN promotional_JJ efforts_NNS and_CC better_JJR dosing_NN exibility_NN resulted_VBD in_IN a_DT 5_CD %_NN increase_NN in_IN prescriptions_NNS ._.
Dr_NNP David_NNP Ficker_NNP Assistant_NNP Professor_NNP of_IN Neurology_NNP University_NNP of_IN Cincinnati_NNP Medical_NNP Center_NNP ._.
Director_NNP of_IN Epilepsy_NNP Monitoring_NN Unit_NN at_IN University_NNP Hospital_NNP Cincinnati_NNP ,_, Ohio_NNP Carbamazepine_NNP is_VBZ still_RB the_DT best_JJS CARBATROL_JJ combines_NNS the_DT thing_NN on_IN the_DT market_NN for_IN most_JJS best_JJS features_NNS of_IN carbamazepine_NN people_NNS with_IN partial_JJ epilepsy_NN ._.
in_IN a_DT form_NN thats_VBZ very_RB effective_JJ and_CC has_VBZ very_RB few_JJ side_NN effects_NNS ._.
I_PRP think_VBP most_RBS doctors_NNS would_MD choose_VB it_PRP ._.
14_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: Renal_NNP Renal_NNP :_: Making_VBG a_DT difference_NN FOSRENOLs_NNS extensive_JJ clinical_JJ research_NN program_NN involved_VBN more_JJR than_IN 1,750_CD patients_NNS Hyperphosphatemia_NNP :_: A_NNP serious_JJ disease_NN This_DT program_NN has_VBZ demonstrated_VBN that_IN Patients_NNPS with_IN end-stage_JJ renal_JJ disease_NN ESRD_NNP FOSRENOL_NNP is_VBZ an_DT effective_JJ phosphate-binder_NN often_RB suffer_VBP from_IN hyperphosphatemia_NN ,_, high_JJ with_IN a_DT proven_JJ safety_NN prole_NN for_IN long-term_JJ use_NN ._.
phosphate_NN levels_NNS in_IN the_DT blood_NN caused_VBN by_IN the_DT FOSRENOL_NNP is_VBZ formulated_VBN as_IN a_DT convenient_JJ inability_NN of_IN the_DT kidneys_NNS and_CC dialysis_NN to_TO lter_VB chewable_JJ tablet_NN ,_, which_WDT eliminates_VBZ the_DT need_NN for_IN out_IN excess_JJ phosphate_NN absorbed_VBN from_IN the_DT diet_NN ._.
water_NN to_TO aid_NN in_IN swallowing_VBG ,_, an_DT important_JJ factor_NN for_IN Even_RB with_IN a_DT low-phosphate_JJ diet_NN as_IN many_JJ as_IN ESRD_NNP patients_NNS due_JJ to_TO their_PRP$ restricted_VBN uid_NN intake_NN ._.
80_CD %_NN of_IN the_DT 225,000_CD European_JJ and_CC the_DT 275,000_CD US_NNP dialysis_NN patients_NNS develop_VBP hyperphosphatemia_NN In_IN March_NNP 2004_CD ,_, Shire_NNP announced_VBD that_IN it_PRP had_VBD and_CC need_VBP treatment_NN with_IN a_DT phosphate-binder_NN ._.
acquired_VBD the_DT rights_NNS to_TO the_DT global_JJ patents_NNS for_IN The_DT most_RBS well_RB known_VBN consequences_NNS of_IN FOSRENOL_NNP ,_, excluding_VBG Japan_NNP ,_, from_IN AnorMED_NNP hyperphosphatemia_NN are_VBP a_DT range_NN of_IN bone_NN Inc._NNP for_IN a_DT consideration_NN of_IN up_RB to_TO US$_$ 31_CD million_CD ._.
diseases_NNS that_WDT can_MD cause_VB bone_NN pain_NN ,_, skeletal_JJ The_DT agreement_NN also_RB provides_VBZ a_DT 12-month_JJ deformities_NNS and_CC fractures_NNS ._.
Hyperphosphatemia_NNP option_NN to_TO purchase_VB the_DT Japanese_JJ patents_NNS for_IN is_VBZ also_RB associated_VBN with_IN the_DT development_NN of_IN US$_$ 6_CD million_CD ,_, to_TO be_VB paid_VBN upon_IN approval_NN of_IN the_DT cardiovascular_JJ disease_NN ,_, which_WDT accounts_VBZ for_IN product_NN in_IN Japan_NNP ._.
nearly_RB 50_CD %_NN of_IN all_DT deaths_NNS in_IN dialysis_NN patients_NNS ._.
Some_DT of_IN the_DT currently_RB available_JJ phosphateApproval_JJ letter_NN binders_NNS may_MD worsen_VB these_DT complications_NNS ._.
Following_VBG a_DT Marketing_NNP Authorisation_NNP Application_NNP MAA_NNP in_IN Sweden_NNP ,_, Shire_NNP received_VBD a_DT regulatory_JJ FOSRENOL_NNP approval_NN in_IN March_NNP 2004_CD ._.
Further_JJ European_JJ Shire_NNP is_VBZ developing_VBG FOSRENOL_NNP as_IN a_DT phosphateapprovals_NNS will_MD be_VB sought_VBN during_IN the_DT year_NN via_IN binder_NN in_IN ESRD_NNP patients_NNS who_WP receive_VBP dialysis_NN ._.
the_DT Mutual_NNP Recognition_NNP Procedure_NNP MRP_NNP ._.
FOSRENOL_NNP works_VBZ by_IN binding_JJ to_TO dietary_VB Assuming_VBG a_DT positive_JJ response_NN from_IN these_DT phosphate_NN in_IN the_DT gastrointestinal_JJ tract_NN :_: once_RB regulatory_JJ authorities_NNS product_NN launches_NNS are_VBP bound_VBN ,_, the_DT FOSRENOL_NNP phosphate_NN complex_JJ planned_VBN throughout_IN Europe_NNP during_IN the_DT second_NN can_MD not_RB readily_RB pass_VB through_IN the_DT intestinal_JJ lining_NN half_NN of_IN 2004_CD ._.
into_IN the_DT blood_NN stream_NN and_CC is_VBZ eliminated_VBN from_IN the_DT body_NN ._.
As_IN a_DT consequence_NN ,_, overall_JJ phosphate_NN Approvable_JJ letter_NN absorption_NN from_IN the_DT diet_NN is_VBZ decreased_VBN In_IN early_JJ 2003_CD in_IN response_NN to_TO its_PRP$ NDA_NNP Shire_NNP signicantly_RB ._.
Shire_NNP has_VBZ conducted_VBN an_DT extensive_JJ received_VBD an_DT Approvable_JJ letter_NN ._.
Shire_NNP supplied_VBD clinical_JJ research_NN program_NN for_IN FOSRENOL_NNP the_DT FDA_NNP with_IN responses_NNS in_IN January_NNP 2004_CD ._.
involving_VBG more_JJR than_IN 1,750_CD patients_NNS ,_, some_DT of_IN A_DT six-month_JJ review_NN period_NN is_VBZ anticipated_VBN ._.
whom_WP have_VBP been_VBN treated_VBN for_IN up_RB to_TO four_CD years_NNS ._.
Launch_NN of_IN FOSRENOL_NNP in_IN the_DT US_NNP is_VBZ hoped_VBN for_IN during_IN the_DT second_JJ half_NN of_IN 2004_CD ._.
Dr_NNP Hartmut_NNP Malluche_NNP Professor_NNP and_CC Chief_NNP of_IN Nephrology_NNP University_NNP of_IN Kentucky_NNP ,_, Lexington_NNP ,_, Kentucky_NNP One_CD of_IN the_DT long-term_JJ sidestop_NN the_DT phosphate_NN being_VBG effects_NNS of_IN kidney_NN disease_NN absorbed_VBN into_IN the_DT bloodis_NNS that_IN the_DT kidneys_NNS nd_VBP it_PRP stream_NN ._.
Other_JJ currently_RB increasingly_RB difficult_JJ to_TO lter_VB available_JJ products_NNS ,_, such_JJ out_IN phosphates_NNS in_IN the_DT blood_NN ._.
as_IN aluminium_NN and_CC calcium_NN This_DT can_MD cause_VB real_JJ problems_NNS ,_, containing_VBG binders_NNS ,_, have_VBP including_VBG bone_NN disorders_NNS ,_, been_VBN problematic_JJ ._.
FOSRENOL_NNP and_CC heart_NN disease_NN ,_, which_WDT is_VBZ part_NN of_IN a_DT new_JJ generation_NN is_VBZ actually_RB one_CD of_IN the_DT main_JJ of_IN aluminium_NN and_CC calcium_NN causes_NNS of_IN death_NN in_IN dialysis_NN free_JJ binders_NNS which_WDT has_VBZ patients_NNS ._.
A_DT patient_NN with_IN undergone_VBN extensive_JJ clinical_JJ this_DT condition_NN has_VBZ to_TO take_VB studies_NNS and_CC has_VBZ a_DT proven_VBN a_DT phosphate-binder_NN to_TO safety_NN and_CC efcacy_NN prole_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: Renal_JJ 15_CD Renal_NNP :_: Shires_NNP Global_NNP Marketing_NNP teams_NNS are_VBP actively_RB laying_VBG the_DT groundwork_NN for_IN a_DT successful_JJ launch_NN of_IN FOSRENOL_NNP Through_IN a_DT wide_JJ variety_NN of_IN activities_NNS Shires_VBZ FOSRENOL_NNP has_VBZ also_RB been_VBN shown_VBN to_TO signicantly_RB Global_JJ Marketing_NNP teams_NNS are_VBP actively_RB laying_VBG reduce_VB and_CC maintain_VB blood_NN phosphate_NN levels_NNS the_DT groundwork_NN for_IN a_DT successful_JJ launch_NN of_IN in_IN a_DT study_NN of_IN Chinese_JJ ESRD_NNP patients_NNS with_IN FOSRENOL_NNP ,_, including_VBG working_VBG with_IN opinion_NN hyperphosphatemia_NN American_NNP Society_NNP of_IN leaders_NNS in_IN renal_JJ medicine_NN ._.
Shire_NNP has_VBZ also_RB been_VBN Nephrology_NNP 36th_NNP Annual_JJ Meeting_VBG ,_, November_NNP 2003_CD ._.
working_VBG to_TO ensure_VB that_IN the_DT results_NNS of_IN studies_NNS on_IN the_DT efcacy_NN and_CC safety_NN of_IN FOSRENOL_NNP Out-licensed_VBD in_IN Japan_NNP are_VBP disseminated_VBN ._.
In_IN December_NNP 2003_CD ,_, the_DT rights_NNS to_TO develop_VB ,_, market_NN and_CC sell_VB FOSRENOL_NNP in_IN Japan_NNP were_VBD out-licensed_JJ FOSRENOL_NNP During_IN 2003_CD ,_, data_NNS reported_VBN by_IN Shire_NNP from_IN the_DT to_TO Bayer_NNP Yakuhin_NNP ,_, in_IN line_NN with_IN Shires_NNP strategy_NN to_TO First_JJ European_JJ approval_NN ongoing_JJ clinical_JJ program_NN for_IN FOSRENOL_NNP ,_, focus_VB its_PRP$ presence_NN in_IN North_NNP America_NNP and_CC Europe_NNP ._.
received_VBN in_IN March_NNP 2004_CD ._.
showed_VBD that_IN continued_VBN ,_, long-term_JJ one-year_JJ Bayer_NNP Yakuhin_NNP in_IN Japan_NNP already_RB has_VBZ an_DT active_JJ treatment_NN with_IN FOSRENOL_NNP controls_VBZ levels_NNS program_NN to_TO manage_VB renovascular_JJ disease_NN of_IN blood_NN phosphate_NN ,_, which_WDT are_VBP frequently_RB raised_VBN and_CC expects_VBZ to_TO launch_VB another_DT major_JJ drug_NN in_IN in_IN ESRD_NNP patients_NNS data_NNS presented_VBN at_IN the_DT National_NNP Japan_NNP that_WDT will_MD be_VB sold_VBN in_IN dialysis_NN centres_VBZ one_CD Kidney_NNP Foundation_NNP Annual_JJ Meeting_VBG ,_, April_NNP 2003_CD ._.
year_NN or_CC more_JJR ahead_RB of_IN FOSRENOL_NNP ._.
Sustained_VBN efcacy_NN and_CC a_DT good_JJ safety_NN prole_NN during_IN three_CD years_NNS of_IN treatment_NN has_VBZ also_RB been_VBN demonstrated_VBN World_NNP Congress_NNP of_IN Nephrology_NNP ,_, June_NNP 2003_CD ._.
Results_NNS of_IN the_DT first-ever_JJ multicentre_NN paired_VBD bone-biopsy_JJ study_NN investigating_VBG the_DT effects_NNS of_IN phosphate-binders_NNS on_IN bone_NN in_IN dialysis_NN patients_NNS showed_VBD that_IN after_IN one_CD year_NN of_IN treatment_NN ESRD_NNP patients_NNS treated_VBD with_IN FOSRENOL_NNP had_VBD normalised_VBN markers_NNS of_IN bone_NN disease_NN Kidney_NNP International_NNP ,_, June_NNP 2003_CD ._.
FOSRENOL_NNP has_VBZ also_RB been_VBN shown_VBN to_TO rapidly_RB initiate_VB significant_JJ reductions_NNS in_IN blood_NN phosphate_NN within_IN one_CD week_NN of_IN starting_VBG therapy_NN ._.
Blood_NNP phosphate_NN was_VBD effectively_RB controlled_VBN to_TO target_VB levels_NNS and_CC FOSRENOL_NNP was_VBD a_DT welltolerated_JJ therapy_NN American_NNP Journal_NNP of_IN Kidney_NNP Diseases_NNPS ,_, June_NNP 2003_CD ._.
16_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: Gastrointestinal_NNP Gastrointestinal_NNP GI_NNP :_: developing_VBG a_DT worldwide_JJ portfolio_NN The_DT GI_NNP therapeutic_JJ area_NN is_VBZ one_CD of_IN Shires_NNP core_NN areas_NNS of_IN strategic_JJ focus_NN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: Gastrointestinal_NNP 17_CD Gastrointestinal_NNP :_: ulcerative_JJ colitis_NN is_VBZ estimated_VBN to_TO affect_VB more_JJR than_IN 1.2_CD million_CD people_NNS worldwide_JJ Ulcerative_NNP colitis_VBZ Shire_NNP holds_VBZ the_DT key_JJ worldwide_NN rights_NNS from_IN Ulcerative_JJ colitis_NN UC_NNP ,_, a_DT type_NN of_IN inammatory_JJ Giuliani_NNP S._NNP p._NNP A._NN to_TO develop_VB and_CC market_VB SPD476_NNP ,_, bowel_NN disease_NN ,_, is_VBZ a_DT chronic_NN ,_, relapsing_VBG disease_NN which_WDT Shire_NNP took_VBD into_IN Phase_NN III_NNP development_NN in_IN which_WDT part_NN ,_, or_CC all_DT ,_, of_IN the_DT large_JJ intestine_JJ during_IN 2003_CD ._.
This_DT novel_NN proprietary_NN formulation_NN becomes_VBZ inamed_JJ and_CC often_RB ulcerated_JJ ._.
targets_NNS the_DT release_NN of_IN mesalamine_NN to_TO the_DT bowel_NN This_DT condition_NN is_VBZ estimated_VBN to_TO affect_VB more_JJR than_IN that_DT enables_VBZ even_RB delivery_NN of_IN high_JJ doses_NNS of_IN 1.2_CD million_CD people_NNS worldwide_JJ ._.
Patients_NNS experience_VBP mesalamine_NN to_TO the_DT colon_NN ._.
Based_VBN on_IN this_DT prole_NN ,_, intermittent_JJ attacks_NNS separated_VBN by_IN periods_NNS of_IN SPD476_NNP may_MD offer_VB a_DT reduced_VBN tablet_NN burden_NN for_IN remission_NN ._.
Clinical_JJ features_NNS include_VBP diarrhoea_NN ,_, UC_NNP patients_NNS ,_, which_WDT may_MD promote_VB greater_JJR patientPENTASA_NN bleeding_NN and_CC abdominal_JJ pain_NN and_CC within_IN 10_CD years_NNS compliance_NN and_CC offer_VB a_DT better_JJR quality_NN of_IN life_NN ._.
A_DT new_JJ 500mg_JJ PENTASA_NNP of_IN diagnosis_NN approximately_RB 25_CD %_NN of_IN patients_NNS are_VBP strength_NN was_VBD led_VBN with_IN required_VBN to_TO undergo_VB surgery_NN ._.
Shire_NNP also_RB acquired_VBD from_IN Giuliani_NNP S._NNP p._NNP A._NN rights_NNS the_DT FDA_NNP in_IN March_NNP 2004_CD ._.
to_TO develop_VB ,_, manufacture_NN and_CC market_NN in_IN key_JJ The_DT mainstay_NN treatment_NN for_IN inammatory_JJ territories_NNS worldwide_VBP SPD480_NNP ,_, a_DT rectally_RB bowel_NN disease_NN is_VBZ mesalamine_JJ 5-ASA_NN products_NNS ._.
administered_VBN mesalamine_JJ aerosol_NN foam_NN for_IN the_DT In_IN the_DT US_NNP ,_, Shire_NNP markets_NNS PENTASA_NNP as_IN a_DT 250mg_JJ treatment_NN of_IN certain_JJ types_NNS of_IN UC_NNP ._.
This_DT formulation_NN capsule_NN that_WDT delivers_VBZ mesalamine_NN throughout_IN the_DT may_MD be_VB more_RBR acceptable_JJ and_CC easier_JJR to_TO use_VB than_IN small_JJ and_CC large_JJ bowel_NN ._.
A_DT 500mg_JJ PENTASA_NNP conventional_JJ liquid_NN enema_NN treatments_NNS ,_, thereby_RB capsule_NN was_VBD led_VBN with_IN the_DT FDA_NNP in_IN March_NNP 2004_CD ._.
offering_VBG the_DT potential_NN for_IN improved_VBN patient_JJ Upon_IN approval_NN this_DT new_JJ therapeutic_JJ option_NN will_MD compliance_NN ._.
SPD480_CD has_VBZ reached_VBN Phase_NN II_NNP reduce_VB the_DT current_JJ capsule_NN burden_NN required_VBN for_IN of_IN development_NN ._.
the_DT 250mg_JJ dosage_NN strength_NN and_CC may_MD offer_VB greater_JJR convenience_NN and_CC patient_NN compliance_NN ._.
Shire_NNP also_RB markets_VBZ COLAZIDE_NNP balsalazide_NN ,_, an_DT oral_JJ mesalamine_NN formulation_NN for_IN the_DT treatment_NN of_IN UC_NNP in_IN the_DT UK_NNP and_CC other_JJ European_JJ markets_NNS ._.
Growing_VBG the_DT franchise_NN Shire_NNP has_VBZ a_DT well-established_JJ pipeline_NN ,_, strong_JJ sales_NNS force_NN ,_, and_CC an_DT aggressive_JJ business_NN development_NN strategy_NN to_TO strengthen_VB its_PRP$ GI_NNP franchise_NN ._.
Shire_NNP is_VBZ actively_RB looking_VBG to_TO expand_VB its_PRP$ GI_NNP product_NN offering_NN and_CC continues_VBZ to_TO develop_VB its_PRP$ product_NN line_NN for_IN UC_NNP and_CC ,_, potentially_RB ,_, other_JJ forms_NNS of_IN Inammatory_NNP Bowel_NNP Disease_NNP IBD_NNP ._.
Dr_NNP Carmen_NNP Cuffari_NNP Assistant_NNP Professor_NNP of_IN Paediatrics_NNPS ,_, Division_NNP of_IN Gastroenterology_NNP ,_, Johns_NNP Hopkins_NNP Hospital_NNP Baltimore_NNP ,_, Maryland_NNP When_WRB youre_NN treating_VBG someone_NN of_IN it_PRP ,_, it_PRP needs_VBZ to_TO produce_VB minimal_JJ with_IN ulcerative_JJ colitis_NN you_PRP need_VBP side-effects_NNS ,_, and_CC it_PRP has_VBZ to_TO be_VB a_DT drug_NN that_WDT can_MD do_VB three_CD things_NNS :_: highly_RB effective_JJ in_IN an_DT oral_JJ form_NN ,_, it_PRP has_VBZ to_TO be_VB able_JJ to_TO deal_VB with_IN the_DT since_IN that_DT makes_VBZ it_PRP easy_JJ to_TO take_VB whole_JJ colon_NN area_NN ,_, not_RB just_RB part_NN and_CC easier_JJR for_IN patients_NNS to_TO stick_VB to_TO ._.
18_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: Additional_JJ Shire_NNP portfolio_NN Additional_JJ Shire_NNP portfolio_NN :_: Marketed_VBN products_NNS Shire_JJ markets_NNS a_DT diverse_JJ portfolio_NN to_TO meet_VB the_DT needs_NNS of_IN the_DT specialist_NN physician_NN Anti-Infectives_NNP Oncology_NNP Haematology_NNP HIV_NNP AGRYLIN_NNP Lamivudine_NNP forms_VBZ a_DT key_JJ component_NN in_IN most_JJS AGRYLIN_NNP is_VBZ marketed_VBN in_IN a_DT number_NN of_IN countries_NNS ,_, of_IN the_DT HIV_NNP combination_NN treatment_NN regimes_VBZ ._.
including_VBG the_DT US_NNP ,_, where_WRB it_PRP is_VBZ the_DT only_JJ product_NN Discovered_VBN by_IN Shire_NNP BioChem_NNP Inc._NNP ._.
Shire_NNP receives_VBZ specically_RB approved_VBN for_IN the_DT treatment_NN of_IN patients_NNS royalties_NNS from_IN GlaxoSmithKline_NNP plc_NN GSK_NNP on_IN the_DT with_IN elevated_JJ platelet_NN counts_VBZ secondary_JJ to_TO worldwide_VB sales_NNS of_IN lamivudine_NN and_CC any_DT products_NNS myeloproliferative_JJ disorders_NNS MPDs_NNS such_JJ containing_VBG lamivudine_NN COMBIVIR_NNP and_CC TRIZIVIR_NNP ,_, as_IN essential_JJ thrombocythemia_NN ET_NNP ._.
For_IN more_RBR with_IN the_DT exception_NN of_IN Canada_NNP where_WRB there_EX is_VBZ a_DT than_IN six_CD years_NNS AGRYLIN_NNP has_VBZ been_VBN safely_RB and_CC AGRYLIN_NNP marketing_NN partnership_NN with_IN GSK_NNP ._.
effectively_RB used_VBN by_IN patients_NNS to_TO lower_VB the_DT platelet_NN For_IN more_JJR than_IN six_CD years_NNS count_NN ._.
Platelets_NNS are_VBP involved_VBN in_IN blood_NN clotting_NN ._.
AGRYLIN_NNP has_VBZ been_VBN safely_RB Hepatitis_NNP B_NNP Lowering_VBG the_DT elevated_JJ platelet_NN count_NN helps_VBZ and_CC effectively_RB used_VBN by_IN patients_NNS Lamivudine_NNP is_VBZ also_RB indicated_VBN for_IN the_DT treatment_NN decrease_NN the_DT symptoms_NNS associated_VBN with_IN MPDs_NNS ,_, to_TO lower_VB platelets_NNS which_WDT are_VBP of_IN chronic_JJ hepatitis_NN B_NNP HBV_NNP associated_VBN including_VBG blood_NN vessel_NN blockages_NNS and_CC bleeding_VBG involved_VBN in_IN blood_NN clotting_NN ._.
with_IN evidence_NN of_IN hepatitis_NNP B_NNP viral_JJ replication_NN ,_, events_NNS ._.
In_IN March_NNP 2004_CD Shire_NNP submitted_VBD clinical_JJ and_CC is_VBZ marketed_VBN as_IN ZEFFIX_NNP and_CC various_JJ other_JJ data_NNS to_TO the_DT FDA_NNP in_IN response_NN to_TO a_DT paediatric_JJ trade_NN marks_NNS around_IN the_DT world_NN ._.
In_IN an_DT agreement_NN Written_VBN Request_NNP WR_NNP ._.
The_DT data_NNS are_VBP currently_RB similar_JJ to_TO that_DT for_IN lamivudine_NN for_IN the_DT treatment_NN under_IN review_NN by_IN the_DT FDA_NNP ._.
Satisfying_VBG the_DT of_IN HIV_NNP ,_, Shire_NNP receives_VBZ royalties_NNS on_IN sales_NNS of_IN conditions_NNS of_IN the_DT WR_NNP would_MD lead_VB to_TO a_DT six-month_JJ lamivudine_NN by_IN GSK_NNP for_IN HBV_NNP ,_, except_IN in_IN Canada_NNP extension_NN of_IN the_DT existing_VBG exclusivity_NN period_NN ,_, where_WRB Shire_NNP has_VBZ a_DT commercialisation_NN partnership_NN to_TO September_NNP 2004_CD ._.
with_IN GSK_NNP ._.
In_IN December_NNP 2003_CD ,_, Shire_NNP granted_VBD rights_NNS to_TO the_DT Pharmaceutical_NNP Division_NNP of_IN Kirin_NNP Brewery_NNP Company_NNP Ltd_NNP Kirin_NNP ,_, to_TO develop_VB ,_, market_NN and_CC sell_VB AGRYLIN_NNP in_IN Japan_NNP ,_, where_WRB AGRYLIN_NNP has_VBZ been_VBN designated_VBN as_IN an_DT orphan_JJ product_NN ie_NN a_DT product_NN used_VBN to_TO treat_VB rare_JJ illnesses_NNS ._.
With_IN a_DT leading_JJ share_NN in_IN the_DT Japanese_JJ hematology_NN market_NN ,_, as_RB well_RB as_IN a_DT strong_JJ clinical_JJ development_NN arm_NN ,_, Kirin_NNP is_VBZ the_DT ideal_JJ company_NN to_TO take_VB Shires_NNP product_NN forward_RB in_IN this_DT major_JJ world_NN market_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: Additional_JJ Shire_NNP portfolio_NN 19_CD Additional_JJ Shire_NNP portfolio_NN :_: Marketed_VBN products_NNS Shire_NNP made_VBD good_JJ progress_NN in_IN 2003_CD with_IN ADEPT_NNP ,_, which_WDT is_VBZ now_RB marketed_VBN in_IN 19_CD countries_NNS internationally_RB Vaccines_NNP ADEPT_NNP In_IN line_NN with_IN Shires_NNP business_NN strategy_NN announced_VBD ADEPT_NNP is_VBZ a_DT novel_NN solution_NN for_IN the_DT prevention_NN of_IN in_IN July_NNP 2003_CD to_TO focus_VB on_IN fewer_JJR ,_, later_RB stage_NN adhesions_NNS ,_, which_WDT occur_VBP in_IN up_RB to_TO 95_CD %_NN of_IN patients_NNS and_CC lower_JJR risk_NN projects_NNS ,_, Shire_NNP intends_VBZ to_TO exit_NN undergoing_VBG abdominal_JJ surgery_NN ._.
Adhesions_NNS are_VBP its_PRP$ vaccines_NNS business_NN by_IN the_DT middle_NN of_IN 2004_CD ._.
internal_JJ scars_NNS formed_VBN post-trauma_NN from_IN complex_JJ Shire_NNP is_VBZ currently_RB evaluating_VBG a_DT number_NN of_IN options_NNS ,_, processes_VBZ involving_VBG tissues_NNS that_WDT have_VBP been_VBN to_TO gain_VB maximum_NN benefit_NN for_IN Shire_NNP and_CC for_IN damaged_VBN during_IN surgery_NN ._.
They_PRP are_VBP a_DT major_JJ cause_NN its_PRP$ stakeholders_NNS ._.
of_IN pain_NN ,_, infertility_NN ,_, small_JJ bowel_NN obstruction_NN and_CC are_VBP a_DT potentially_RB fatal_JJ complication_NN of_IN abdominal_JJ ADEPTand_NNP SOLARAZE_NNP FLUVIRAL_NNP S_NNP F_NN ,_, a_DT split-virion_JJ inuenza_NN vaccine_NN for_IN surgery_NN ._.
Shire_NNP made_VBD good_JJ progress_NN in_IN 2003_CD with_IN The_DT launches_NNS of_IN ADEPT_NNP and_CC the_DT prevention_NN of_IN inuenza_NN infection_NN is_VBZ marketed_VBN ADEPT_NNP ,_, which_WDT is_VBZ now_RB marketed_VBN in_IN 19_CD countries_NNS SOLARAZE_NNP across_IN Europe_NNP have_VBP in_IN Canada_NNP ._.
During_IN 2003_CD ,_, Shire_NNP Biologics_NNPS won_VBD internationally_RB ._.
helped_VBD develop_VB capabilities_NNS for_IN additional_JJ u_NN vaccine_NN volumes_NNS from_IN the_DT Canadian_JJ selling_NN innovative_JJ products_NNS ._.
government_NN ,_, giving_VBG it_PRP as_RB much_RB as_IN a_DT 75_CD %_NN share_NN SOLARAZE_NNP of_IN the_DT national_JJ requirement_NN ,_, guaranteed_VBN for_IN five_CD SOLARAZE_NNP is_VBZ now_RB marketed_VBN by_IN Shire_NNP in_IN nine_CD years_NNS ._.
Shires_NNP ability_NN to_TO increase_VB its_PRP$ national_JJ market_NN European_JJ countries_NNS ,_, including_VBG successful_JJ share_NN from_IN 50_CD %_NN in_IN a_DT relatively_RB short_JJ period_NN of_IN time_NN launches_NNS in_IN Italy_NNP and_CC France_NNP in_IN 2003_CD ,_, and_CC is_VBZ is_VBZ the_DT result_NN of_IN the_DT high_JJ quality_NN of_IN its_PRP$ FLUVIRAL_NNP established_VBD as_IN the_DT leading_VBG topical_JJ treatment_NN for_IN product_NN ,_, outstanding_JJ service_NN levels_NNS ,_, and_CC Actinic_NNP Keratosis_NNP AK_NNP ,_, which_WDT if_IN left_VBN untreated_JJ could_MD competitive_JJ pricing_NN ._.
lead_NN to_TO squamous_JJ cell_NN carcinoma_NN ,_, a_DT form_NN of_IN skin_NN cancer_NN ,_, in_IN up_RB to_TO 16_CD %_NN of_IN patients_NNS ._.
SOLARAZE_NNP gel_NN Other_JJ specialist_NN products_NNS offers_VBZ an_DT alternative_NN to_TO existing_VBG treatment_NN options_NNS ,_, The_DT launches_NNS of_IN ADEPT_NNP and_CC SOLARAZE_NNP across_IN which_WDT may_MD cause_VB burning_NN or_CC peeling_VBG during_IN the_DT Europe_NNP have_VBP helped_VBN develop_VB capabilities_NNS for_IN treatment_NN of_IN AK_NNP lesions_NNS ._.
It_PRP is_VBZ particularly_RB useful_JJ selling_NN innovative_JJ products_NNS into_IN the_DT Secondary_JJ for_IN patients_NNS with_IN AK_NNP on_IN the_DT face_NN or_CC scalp_NN where_WRB Care_NNP sector_NN as_RB well_RB as_IN providing_VBG valuable_JJ other_JJ treatments_NNS like_IN cryotherapy_JJ freezing_NN experience_NN in_IN local_JJ and_CC national_JJ pricing_NN and_CC would_MD be_VB too_RB painful_JJ or_CC risk_NN leaving_VBG scarring_NN ._.
Dr_NNP Craig_NNP Kessler_NNP Director_NNP ,_, Coagulation_NNP and_CC Haemophilia_NNP Treatment_NNP Centre_NNP ,_, Georgetown_NNP University_NNP Medical_NNP Centre_NNP ,_, Bethesda_NNP ,_, MD_NNP What_WP sets_VBZ Shire_NNP apart_RB ,_, for_IN me_PRP ,_, in_IN the_DT blood_NN are_VBP too_RB high_JJ ,_, is_VBZ their_PRP$ determination_NN to_TO raise_VB can_MD cause_VB strokes_NNS ,_, bleeding_VBG awareness_NN of_IN essential_JJ and_CC miscarriages_NNS ._.
AGRYLIN_NNP thrombocythemia_NN and_CC other_JJ helps_VBZ lower_VB the_DT platelet_NN count_NN myeloproliferative_JJ disorders_NNS and_CC ,_, unlike_IN some_DT other_JJ MPDs_NNS ._.
These_DT are_VBP rare_JJ illnesses_NNS ,_, therapies_NNS ,_, it_PRP is_VBZ selective_JJ for_IN or_CC so-called_JJ orphan_JJ diseases_NNS ._.
AGRYLIN_NNP can_MD also_RB Essential_JJ thrombocythemia_NN ,_, be_VB used_VBN in_IN the_DT treatment_NN where_WRB the_DT levels_NNS of_IN platelets_NNS of_IN other_JJ MPDs_NNS ._.
20_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: Additional_JJ Shire_NNP portfolio_NN Additional_JJ Shire_NNP portfolio_NN :_: Marketed_VBN products_NNS and_CC drug_NN delivery_NN technologies_NNS CALCICHEW_NNP Drug_NNP delivery_NN technologies_NNS The_DT CALCICHEW_NNP range_NN of_IN calcium_NN and_CC Shire_NNP Laboratories_NNPS ,_, Inc._NNP ._.
SLI_NNP ,_, a_DT subsidiary_NN calcium_NN vitamin_NN D_NNP supplements_NNS are_VBP marketed_VBN of_IN the_DT Shire_NNP Group_NNP ,_, is_VBZ a_DT specialist_NN provider_NN as_IN adjuncts_NNS in_IN the_DT treatment_NN of_IN osteoporosis_NN ,_, of_IN innovative_JJ oral_JJ drug_NN delivery_NN technologies_NNS ._.
a_DT disease_NN characterised_VBN by_IN a_DT progressive_JJ loss_NN SLIs_NNS oral_JJ controlled-release_NN technologies_NNS include_VBP of_IN bone_NN mass_NN that_WDT renders_VBZ bone_NN fragile_JJ and_CC liable_JJ MICROTROL_NNP ,_, which_WDT consists_VBZ of_IN beadlets_NNS that_WDT to_TO fracture_NN ._.
More_JJR than_IN three_CD million_CD people_NNS in_IN the_DT can_MD be_VB coated_VBN to_TO provide_VB customised_JJ release_NN UK_NNP are_VBP estimated_VBN to_TO suffer_VB with_IN this_DT condition_NN ._.
proles_NNS such_JJ as_IN extended_JJ delivery_NN MICROTROL_NNP TM_NNP TM_NNP Osteoporosis_NNP affects_VBZ both_DT sexes_NNS but_CC is_VBZ more_RBR XR_NNP ,_, pulsed_VBD delivery_NN MICROTROL_NNP PR_NNP TM_NNP rapid_JJ and_CC profound_JJ in_IN women_NNS ,_, largely_RB as_IN a_DT result_NN or_CC delayed_VBN delivery_NN MICROTROL_NNP DR_NNP :_: TM_NNP of_IN the_DT decline_NN in_IN estrogen_NN production_NN following_VBG SOLUTROL_NNP ,_, a_DT proprietary_JJ matrix_NN tablet_NN which_WDT the_DT menopause_NN ._.
can_MD provide_VB extended_JJ release_NN of_IN highly_RB soluble_JJ and_CC pH_JJ dependent_JJ compounds_NNS :_: and_CC ENSOTROL_NNP PROAMATINE_NNP osmotic_JJ tablet_NN technology_NN which_WDT can_MD facilitate_VB Shire_NNP markets_NNS midodrine_JJ hydrochloride_NN ,_, as_IN absorption_NN of_IN poorly_RB soluble_JJ and_CC soluble_JJ PROAMATINE_NNP in_IN the_DT US_NNP ,_, AMATINE_NNP in_IN Canada_NNP compounds_NNS ._.
These_DT technologies_NNS can_MD be_VB applied_VBN and_CC MIDON_NNP in_IN the_DT Republic_NNP of_IN Ireland_NNP ,_, for_IN the_DT alone_JJ or_CC in_IN combination_NN with_IN SLIs_NNS bioavailability_NN treatment_NN of_IN symptomatic_JJ orthostatic_JJ hypotension_NN ,_, enhancement_NN systems_NNS ._.
The_DT bioavailability_NN which_WDT is_VBZ due_JJ to_TO a_DT marked_JJ fall_NN in_IN blood_NN pressure_NN enhancement_NN technologies_NNS include_VBP PROSCREEN_NNP ,_, TM_NNP on_IN standing_NN ,_, causing_VBG dizziness_NN ,_, weakness_NN and_CC OPTISCREEN_NNP ,_, RAPITROL_NNP and_CC EMUTROL_NNP ._.
In_IN September_NNP 2003_CD ,_, the_DT sevenyear_JJ marketing_NN exclusivity_NN period_NN in_IN the_DT US_NNP MICROTROL_NNP technology_NN was_VBD applied_VBN to_TO both_DT expired_VBD and_CC generic_JJ copies_NNS of_IN the_DT drug_NN have_VBP CARBATROL_NNP ,_, the_DT twice-daily_JJ formulation_NN since_IN been_VBN launched_VBN ._.
of_IN carbamazepine_NN and_CC ADDERALL_NNP XR_NNP ,_, the_DT once-daily_JJ formulation_NN of_IN ADDERALL_NNP ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: Additional_JJ Shire_NNP portfolio_NN 21_CD Additional_JJ Shire_NNP portfolio_NN :_: Development_NNP projects_NNS Oncology_NNP Haematology_NNP Projects_NNPS available_JJ for_IN partnering_VBG XAGRID_NNP Anti-infectives_NNS Anagrelide_NNP hydrochloride_NN is_VBZ being_VBG developed_VBN in_IN SPD754_NNP Europe_NNP XAGRID_NNP for_IN the_DT reduction_NN of_IN elevated_JJ Shire_NNP holds_VBZ the_DT worldwide_NN rights_NNS to_TO SPD754_CD ,_, platelet_NN count_NN in_IN the_DT chronic_JJ disorder_NN essential_JJ a_DT nucleoside_NN analog_NN reverse_VB transcriptase_NN thrombocythemia_NN ET_NNP ._.
During_IN 2003_CD ,_, a_DT positive_JJ inhibitor_NN NRTI_NNP that_IN selectively_RB blocks_NNS HIV-1_JJ opinion_NN was_VBD received_VBN from_IN the_DT Committee_NNP for_IN replication_NN ._.
Granted_VBN fast_JJ track_NN review_NN status_NN Proprietary_NNP Medicinal_NNP Products_NNPS CPMP_NNP ,_, the_DT by_IN the_DT FDA_NNP ,_, it_PRP has_VBZ demonstrated_VBN activity_NN scientific_JJ committee_NN of_IN the_DT European_JJ Medicines_NNP against_IN HIV_NNP strains_NNS resistant_JJ to_TO other_JJ nucleoside_NN Evaluation_NNP Agency_NNP EMEA_NNP ._.
XAGRID_NNP has_VBZ Orphan_JJ analogs_NNS ,_, including_VBG AZT_NNP and_CC 3TC_NNP ._.
Resistance_NNP Drug_NNP designation_NN in_IN Europe_NNP and_CC ,_, upon_IN marketing_NN to_TO SPD754_CD appears_VBZ to_TO develop_VB slowly_RB ._.
Currently_RB authorisation_NN approval_NN ,_, is_VBZ expected_VBN to_TO receive_VB in_IN Phase_NN II_NNP development_NN ,_, clinical_JJ studies_NNS to_TO date_VB up_RP to_TO 10_CD years_NNS marketing_VBG exclusivity_NN in_IN Europe_NNP ._.
have_VB shown_VBN it_PRP to_TO display_VB potent_JJ antiviral_JJ activity_NN and_CC to_TO be_VB well_RB tolerated_VBN ._.
As_IN announced_VBN in_IN July_NNP Vaccines_NNP 2003_CD ,_, Shire_NNP intends_VBZ to_TO seek_VB a_DT partner_NN for_IN SPD754_NNP ._.
Shire_NNP intends_VBZ to_TO exit_NN its_PRP$ vaccines_NNS business_NN by_IN A_DT number_NN of_IN opportunities_NNS have_VBP been_VBN investigated_VBN the_DT middle_NN of_IN 2004_CD ._.
The_DT current_JJ portfolio_NN includes_VBZ and_CC Shire_NNP aims_VBZ to_TO complete_VB this_DT process_NN by_IN the_DT five_CD projects_NNS ranging_VBG from_IN Phase_NN I_PRP to_TO Phase_NN III_NNP middle_NN of_IN 2004_CD ._.
of_IN development_NN ._.
SPD756_CD HIV_NNP and_CC SPD760_NNP Hepatitis_NNP C_NNP are_VBP also_RB now_RB available_JJ for_IN partnering_VBG ._.
Oncology_NNP Haematology_NNP TROXATYL_NNP TROXATYL_NNP troxacitabine_NN is_VBZ a_DT dioxolane_NN nucleoside_NN analog_NN in_IN development_NN for_IN the_DT treatment_NN of_IN pancreatic_JJ cancer_NN and_CC acute_JJ myelogenous_JJ leukemia_NN ._.
Phase_NN II_NNP is_VBZ the_DT highest_JJS development_NN phase_NN reached_VBD ._.
In_IN 2003_CD ,_, Shire_NNP announced_VBD that_IN it_PRP is_VBZ seeking_VBG to_TO out-license_JJ TROXATYL_NNP ._.
22_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN CSR_NNP :_: Corporate_NNP social_JJ responsibility_NN CSR_NNP :_: Corporate_NNP social_JJ responsibility_NN report_NN For_IN Shire_NNP ,_, CSR_NNP has_VBZ always_RB been_VBN inherent_JJ in_IN Progress_NNP made_VBD in_IN 2003_CD the_DT way_NN we_PRP run_VBP and_CC manage_VBP our_PRP$ business_NN dayDuring_VBG the_DT course_NN of_IN 2003_CD ,_, Shire_NNP has_VBZ engaged_VBN to-day_JJ ._.
As_IN a_DT healthcare_NN company_NN ,_, providing_VBG in_IN continuous_JJ improvement_NN of_IN its_PRP$ management_NN treatments_NNS that_WDT improve_VBP and_CC prolong_VBP peoples_NNS practices_NNS ,_, and_CC has_VBZ introduced_VBN structural_JJ changes_NNS lives_NNS ,_, we_PRP have_VBP always_RB taken_VBN our_PRP$ responsibility_NN to_TO as_IN part_NN of_IN its_PRP$ strategic_JJ review_NN ._.
These_DT have_VBP been_VBN society_NN very_RB seriously_RB ._.
This_DT responsibility_NN extends_VBZ handled_VBN sensitively_RB and_CC with_IN awareness_NN of_IN the_DT to_TO all_DT areas_NNS of_IN society_NN which_WDT our_PRP$ business_NN can_MD social_JJ impact_NN on_IN the_DT communities_NNS involved_VBN ._.
affect_VB :_: the_DT communities_NNS in_IN which_WDT we_PRP run_VBP our_PRP$ The_DT day-to-day_JJ values_NNS adopted_VBN by_IN the_DT Company_NN business_NN ,_, the_DT supplier_NN companies_NNS that_IN we_PRP partner_NN set_NN standards_NNS for_IN behavior_NN and_CC are_VBP an_DT active_JJ Shire_NNP prevents_VBZ undue_JJ with_IN ,_, our_PRP$ employees_NNS ,_, the_DT doctors_NNS and_CC physicians_NNS guide_NN for_IN all_DT business_NN managers_NNS and_CC employees_NNS ._.
environmental_JJ pollution_NN through_IN who_WP prescribe_VBP our_PRP$ medicines_NNS and_CC ,_, of_IN course_NN ,_, Shire_NNP rewards_VBZ individuals_NNS who_WP have_VBP especially_RB its_PRP$ state_NN of_IN the_DT art_NN equipment_NN the_DT patients_NNS whose_WP$ lives_NNS we_PRP directly_RB impact_NN as_IN demonstrated_VBN how_WRB they_PRP have_VBP lived_VBN any_DT one_CD ,_, in_IN place_NN at_IN its_PRP$ manufacturing_NN well_RB as_IN their_PRP$ care_NN providers_NNS and_CC support_NN groups_NNS ._.
or_CC all_DT ,_, of_IN the_DT four_CD values_NNS dynamism_NN ,_, integrity_NN ,_, site_NN in_IN Owing_NNP Mills_NNP ._.
Recognising_VBG that_IN our_PRP$ shareholders_NNS and_CC CSR_NNP caring_NN and_CC innovation_NN ._.
opinion_NN leaders_NNS wish_VBP to_TO know_VB more_JJR detail_NN about_IN our_PRP$ CSR_NNP related_JJ activities_NNS ,_, this_DT year_NN we_PRP are_VBP We_PRP have_VBP made_VBN progress_NN against_IN the_DT objectives_NNS producing_VBG a_DT standalone_NN CSR_NNP report_NN which_WDT that_IN we_PRP set_VBP in_IN 2003_CD ._.
Full_JJ details_NNS are_VBP in_IN the_DT will_MD be_VB available_JJ in_IN printed_VBN and_CC online_JJ versions_NNS ._.
separate_JJ CSR_NNP report_NN ,_, however_RB ,_, these_DT are_VBP some_DT of_IN the_DT highlights_VBZ :_: Development_NNP of_IN Shire_NNP CSR_NNP Committee_NNP We_PRP believe_VBP that_IN a_DT good_JJ CSR_NNP reputation_NN Strengthening_VBG our_PRP$ engagement_NN with_IN is_VBZ a_DT reection_NN of_IN good_JJ management_NN and_CC stakeholders_NNS :_: sound_JJ business_NN practices_NNS ._.
Our_PRP$ CSR_NNP Committee_NNP ,_, We_PRP conducted_VBD an_DT all_DT employee_NN survey_NN which_WDT was_VBD established_VBN during_IN the_DT year_NN ,_, therefore_RB during_IN the_DT year_NN and_CC gathered_VBD important_JJ and_CC comprises_VBZ line_NN managers_NNS who_WP represent_VBP the_DT helpful_JJ information_NN on_IN how_WRB we_PRP are_VBP managing_VBG functions_NNS that_WDT have_VBP most_RBS direct_JJ inuence_NN on_IN ,_, their_PRP$ careers_NNS ._.
and_CC involvement_NN with_IN ,_, our_PRP$ daily_JJ business_NN Relationship_NN management_NN is_VBZ at_IN the_DT heart_NN management_NN ._.
This_DT has_VBZ proved_VBN to_TO be_VB a_DT most_JJS of_IN the_DT Shire_NNP marketing_NN and_CC selling_NN model_NN Shire_NNP believes_VBZ in_IN partnering_VBG effective_JJ way_NN of_IN ensuring_VBG that_IN the_DT Company_NN both_DT during_IN the_DT year_NN we_PRP proved_VBD the_DT strength_NN of_IN with_IN the_DT NHS_NNP to_TO help_VB support_VB reports_NNS on_IN its_PRP$ CSR_NNP achievements_NNS and_CC understands_VBZ these_DT relationships_NNS in_IN the_DT US_NNP with_IN the_DT resilience_NN improved_VBD patient_JJ care_NN and_CC any_DT challenging_JJ CSR_NNP risks_NNS that_WDT may_MD arise_VB ._.
of_IN ADDERALL_NNP XRs_NNP performance_NN ,_, despite_IN access_NN to_TO important_JJ therapies_NNS ._.
the_DT launch_NN of_IN a_DT competitor_NN product_NN ._.
Over_IN 2002_CD 3_CD Shire_NNP therefore_RB The_DT CSR_NNP Committee_NNP is_VBZ led_VBN by_IN Angus_NNP Russell_NNP ,_, During_IN the_DT year_NN 2003_CD ,_, Matthew_NNP Emmens_NNP invested_VBD almost_RB 500K_CD to_TO the_DT Companys_NNP Chief_NNP Financial_NNP officer_NN and_CC Board_NNP the_DT Chief_NNP Executive_NNP officer_NN ,_, Angus_NNP Russell_NNP support_NN localized_VBD improvement_NN member_NN ._.
As_IN part_NN of_IN his_PRP$ role_NN he_PRP regularly_RB reports_VBZ the_DT Chief_NNP Financial_NNP officer_NN and_CC Cla_NNP Rosenfeld_NNP plans_VBZ in_IN dementia_NN service_NN matters_NNS of_IN relevance_NN to_TO the_DT Executive_NNP Committee_NNP the_DT Investor_NNP Relations_NNPS Head_NNP met_VBD investors_NNS provision_NN ._.
The_DT majority_NN of_IN this_DT and_CC to_TO the_DT Board_NNP and_CC offers_VBZ guidance_NN ,_, information_NN face_NN to_TO face_VB ,_, at_IN conferences_NNS and_CC answered_VBN investment_NN went_VBD into_IN supporting_VBG and_CC ,_, where_WRB necessary_JJ ,_, detailed_JJ briengs_NNS to_TO Board_NNP a_DT range_NN of_IN questions_NNS ._.
In_IN addition_NN ,_, Barry_NNP Price_NNP ,_, the_DT provision_NN of_IN 21_CD specialist_NN members_NNS ._.
The_DT CSR_NNP Committees_NNS main_JJ the_DT Companys_NNPS senior_JJ non-executive_JJ Director_NNP DementiaLink_NNP Nurses_NNPS around_IN responsibilities_NNS are_VBP to_TO :_: and_CC Chairman_NNP of_IN the_DT Remuneration_NNP Committee_NNP ,_, the_DT country_NN ,_, who_WP would_MD work_VB met_VBN and_CC consulted_VBN with_IN a_DT range_NN of_IN major_JJ within_IN a_DT local_JJ service_NN structure_NN facilitate_VBP an_DT effective_JJ and_CC cross-functional_JJ institutional_JJ shareholders_NNS ._.
to_TO help_VB shape_NN and_CC develop_VB that_DT implementation_NN of_IN Shires_NNP CSR_NNP policy_NN :_: service_NN to_TO improve_VB patient_NN care_NN ._.
advise_VB and_CC inform_VB the_DT Board_NNP on_IN business_NN risks_NNS related_VBN to_TO Social_NNP ,_, Environmental_NNP and_CC Ethical_NNP SEE_VBP matters_NNS :_: and_CC review_NN and_CC approve_VB Shires_NNP CSR_NNP disclosures_NNS ._.
The_DT understanding_NN ,_, assessment_NN and_CC reporting_NN of_IN SEE_VB risks_NNS is_VBZ embedded_VBN within_IN the_DT organizations_NNS overall_JJ framework_NN of_IN risk_NN management_NN and_CC further_JJ details_NNS can_MD be_VB found_VBN in_IN the_DT full_JJ CSR_NNP Report_NNP under_IN the_DT heading_VBG internal_JJ control_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN CSR_NNP :_: Corporate_NNP social_JJ responsibility_NN 23_CD This_DT year_NN we_PRP have_VBP made_VBN further_JJ progress_NN with_IN our_PRP$ approach_NN and_CC reporting_NN of_IN CSR_NNP Setting_VBG up_RP Group_NNP and_CC site_NN environmental_JJ and_CC Looking_VBG forward_RB health_NN and_CC safety_NN objectives_NNS and_CC targets_NNS This_DT year_NN ,_, the_DT Committee_NNP has_VBZ set_VBN a_DT number_NN Environmental_JJ health_NN and_CC safety_NN objectives_NNS of_IN CSR_NNP objectives_NNS for_IN 2004_CD for_IN each_DT area_NN of_IN were_VBD made_VBN part_NN of_IN the_DT Shire_NNP US_NNP Manufacturing_NNP impact_NN :_: Workplace_NNP ,_, Marketplace_NNP ,_, Environment_NNP facilitys_NNS overall_JJ goals_NNS and_CC inserted_VBN into_IN each_DT and_CC Community_NNP ._.
These_DT objectives_NNS provide_VBP and_CC every_DT departmental_JJ goal_NN ,_, not_RB only_RB in_IN 2003_CD the_DT overall_JJ direction_NN for_IN Shires_NNP improvements_NNS but_CC for_IN every_DT year_NN forward_RB ._.
and_CC measurement_NN of_IN CSR_NNP related_VBN progress_NN ._.
An_DT overall_JJ environmental_JJ health_NN and_CC safety_NN These_DT objectives_NNS are_VBP also_RB embedded_VBN in_IN the_DT strategy_NN encompassing_VBG regulatory_JJ ,_, individual_JJ and_CC respective_JJ functional_JJ areas_NNS as_IN part_NN of_IN the_DT site_NN issues_NNS was_VBD developed_VBN and_CC implemented_VBN ._.
Companys_NNP own_JJ emphasis_NN on_IN continuous_JJ The_DT goal_NN is_VBZ zero_CD reportable_JJ accidents_NNS and_CC improvement_NN ._.
You_PRP will_MD nd_VB details_NNS of_IN these_DT maintenance_NN of_IN total_JJ regulatory_JJ compliance_NN ._.
in_IN our_PRP$ standalone_NN CSR_NNP report_NN ._.
Key_NNP performance_NN indicators_NNS were_VBD developed_VBN and_CC are_VBP currently_RB published_VBN monthly_JJ to_TO the_DT site_NN We_PRP are_VBP pleased_VBN with_IN the_DT progress_NN made_VBN in_IN CSR_NNP and_CC management_NN ._.
this_DT year_NN but_CC aware_JJ that_IN there_EX are_VBP still_RB many_JJ ways_NNS Additional_JJ personnel_NNS were_VBD hired_VBN in_IN the_DT in_IN which_WDT we_PRP can_MD improve_VB further_RBR and_CC we_PRP are_VBP environment_NN health_NN and_CC safety_NN group_NN committed_VBN to_TO doing_VBG so_RB ._.
We_PRP welcome_VBP comments_NNS and_CC suggestions_NNS on_IN Shire_NNP has_VBZ a_DT policy_NN of_IN contributing_VBG Integrating_NNP CSR_NNP topics_NNS into_IN the_DT management_NN our_PRP$ CSR_NNP approach_NN as_IN we_PRP are_VBP always_RB looking_VBG to_TO funds_NNS raised_VBN by_IN employees_NNS of_IN our_PRP$ contractors_NNS and_CC suppliers_NNS at_IN ways_NNS for_IN continuous_JJ improvement_NN and_CC this_DT in_IN charity_NN sponsored_VBN events_NNS ._.
A_DT draft_NN set_NN of_IN principles_NNS is_VBZ under_IN discussion_NN year_NN we_PRP have_VBP set_VBN up_RP a_DT dedicated_VBN email_NN address_NN Paula_NNP Anken_NNP was_VBD one_CD of_IN many_JJ for_IN inclusion_NN in_IN all_DT supplier_NN contracts_NNS ._.
to_TO encourage_VB this_DT process_NN :_: of_IN the_DT Companys_NNP employees_NNS who_WP participated_VBD in_IN such_JJ events_NNS ._.
Improving_NN data_NNS gathering_NN and_CC reporting_VBG CSR@shire_NNP ._.
She_PRP ran_VBD the_DT London_NNP Marathon_NNP in_IN Enhancement_NNP of_IN the_DT Group_NNP community_NN 3hrs_VBZ 49_CD mins_NNS and_CC raised_VBD 2,400_CD and_CC health_NN and_CC safety_NN data_NNS gathering_NN For_IN copies_NNS of_IN the_DT full_JJ CSR_NNP report_NN ,_, please_VB send_VB for_IN the_DT Wessex_NNP Cancer_NNP Trust_NNP ._.
your_PRP$ name_NN and_CC address_NN details_NNS to_TO this_DT email_NN address_NN ,_, or_CC contact_VB us_PRP at_IN the_DT address_NN listed_VBN Building_NN up_IN employee_NN awareness_NN and_CC at_IN the_DT back_NN of_IN this_DT document_NN ._.
commitment_NN to_TO CSR_NNP Through_IN the_DT employee_NN survey_NN ,_, we_PRP have_VBP been_VBN able_JJ to_TO measure_VB current_JJ levels_NNS of_IN CSR_NNP awareness_NN and_CC have_VBP developed_VBN an_DT action_NN plan_NN for_IN 2004_CD to_TO sustain_VB and_CC continuously_RB improve_VB it_PRP ._.
In_IN addition_NN ,_, CSR_NNP matters_NNS have_VBP featured_VBN in_IN the_DT Company_NN induction_NN scheme_NN for_IN new_JJ joiners_NNS ,_, within_IN the_DT Company_NN newsletter_NN and_CC In_IN 2003_CD Shire_NNP waived_VBD its_PRP$ rights_NNS on_IN the_DT intranet_NN ._.
to_TO royalties_NNS on_IN the_DT sale_NN of_IN 3TC_NNP ,_, the_DT worlds_NNS most_RBS widely_RB used_VBN Improving_NN Shires_NNS ranking_VBG in_IN key_JJ CSR_NNP indices_NNS treatment_NN for_IN HIV_NNP in_IN sub-Saharan_JJ The_DT Company_NN continues_VBZ to_TO be_VB a_DT constituent_JJ Africa_NNP ,_, as_IN part_NN of_IN its_PRP$ agreement_NN of_IN the_DT FTSE4Good_CD index_NN :_: took_VBD part_NN for_IN the_DT with_IN GlaxoSmithKline_NNP ._.
second_JJ year_NN in_IN the_DT Business_NN in_IN the_DT Community_NNP Corporate_NNP Responsibility_NNP index_NN :_: has_VBZ had_VBN improved_VBN ratings_NNS awarded_VBN to_TO it_PRP by_IN Morley_NNP Fund_NNP Mangement_NNP and_CC by_IN PIRC_NNP and_CC moved_VBD to_TO fourth_JJ position_NN in_IN The_DT Guardian_NNP newspapers_NNS Giving_NNP List_NN index_NN of_IN top_JJ UK_NNP companies_NNS charitable_JJ contributions_NNS ._.
24_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NNP Financial_NNP review_NN For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD ,_, total_JJ revenues_NNS increased_VBN by_IN 19_CD %_NN to_TO $_$ 1,237.1_CD million_CD The_DT following_VBG review_NN should_MD be_VB read_VBN in_IN conjunction_NN ADDERALL_NNP with_IN the_DT Groups_NNS consolidated_JJ financial_JJ statements_NNS Sales_NNS of_IN ADDERALL_NNP for_IN the_DT year_NN ended_VBN and_CC related_VBN notes_NNS appearing_VBG elsewhere_RB in_IN this_DT 31_CD December_NNP 2003_CD were_VBD $_$ 61.1_CD million_CD 2002_CD :_: annual_JJ report_NN ._.
ADDERALL_NNP had_VBD a_DT 2_CD %_NN share_NN of_IN the_DT total_JJ US_NNP ADHD_NNP market_NN in_IN December_NNP 2003_CD ,_, Results_NNS of_IN operations_NNS compared_VBN with_IN 5_CD %_NN in_IN December_NNP 2002_CD ._.
The_DT fall_NN The_DT Group_NNP recorded_VBD net_JJ income_NN of_IN $_$ 276.1_CD million_CD in_IN market_NN share_NN was_VBD anticipated_VBN and_CC is_VBZ the_DT result_NN 2002_CD :_: $_$ 250.6_CD million_CD and_CC diluted_VBN earnings_NNS per_IN of_IN the_DT switch_NN of_IN patients_NNS to_TO either_DT ADDERALL_NNP XR_NNP ordinary_JJ share_NN of_IN 54.2_CD 2002_CD :_: 49.0_CD ._.
or_CC generic_JJ alternatives_NNS ._.
Total_JJ revenues_NNS AGRYLIN_NNP For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD ,_, total_JJ Sales_NNS of_IN AGRYLIN_NNP for_IN the_DT year_NN ended_VBD revenues_NNS increased_VBN by_IN 19_CD %_NN to_TO $_$ 1,237.1_CD million_CD ,_, 31_CD December_NNP 2003_CD were_VBD $_$ 132.5_CD million_CD ,_, compared_VBN to_TO $_$ 1,037.3_CD million_CD in_IN 2002_CD ._.
an_DT increase_NN of_IN 11_CD %_NN compared_VBN to_TO the_DT prior_JJ year_NN 2002_CD :_: $_$ 119.2_CD million_CD ._.
AGRYLIN_NNP had_VBD Revenue_NN is_VBZ primarily_RB derived_VBN from_IN sales_NNS of_IN a_DT 27_CD %_NN share_NN of_IN the_DT total_JJ US_NNP AGRYLIN_NNP ,_, Hydrea_NNP pharmaceutical_JJ products_NNS and_CC royalties_NNS earned_VBN and_CC generic_JJ hydroxyurea_NN prescription_NN market_NN on_IN products_NNS out-licensed_JJ to_TO third_JJ parties_NNS ._.
For_IN the_DT in_IN December_NNP 2003_CD December_NNP 2002_CD :_: 27_CD %_NN ._.
year_NN ended_VBD 31_CD December_NNP 2003_CD ,_, 83_CD %_NN of_IN revenues_NNS were_VBD in_IN respect_NN of_IN pharmaceutical_JJ product_NN sales_NNS PENTASA_NNP 2002_CD :_: 83_CD %_NN ._.
Sales_NNS of_IN PENTASA_NNP for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD were_VBD $_$ 99.3_CD million_CD ,_, a_DT Product_NNP sales_NNS an_DT increase_NN of_IN 14_CD %_NN compared_VBN to_TO the_DT prior_JJ For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD ,_, year_NN 2002_CD :_: $_$ 87.2_CD million_CD ._.
PENTASA_NNP had_VBD a_DT the_DT Groups_NNS product_NN sales_NNS increased_VBN by_IN 20_CD %_NN 17_CD %_NN share_NN of_IN the_DT total_JJ US_NNP oral_JJ mesalamine_NN Angus_NNP Russell_NNP to_TO $_$ 1,029.8_CD million_CD ,_, compared_VBN to_TO $_$ 859.4_CD million_CD olsalazine_NN prescription_NN market_NN in_IN December_NNP Chief_NNP Financial_NNP officer_NN in_IN the_DT prior_JJ year_NN ._.
The_DT following_VBG statements_NNS include_VBP references_NNS CARBATROL_NNP to_TO prescription_NN and_CC market_NN share_NN data_NNS for_IN key_JJ Sales_NNS of_IN CARBATROL_NNP for_IN the_DT year_NN ended_VBD products_NNS ._.
The_DT source_NN of_IN this_DT data_NN is_VBZ IMS_NNP Health_NNP 31_CD December_NNP 2003_CD were_VBD $_$ 52.4_CD million_CD ,_, December_NNP 2003_CD ._.
IMS_NNP Health_NNP is_VBZ a_DT leading_VBG global_JJ an_DT increase_NN of_IN 16_CD %_NN compared_VBN to_TO the_DT prior_JJ provider_NN of_IN business_NN intelligence_NN for_IN the_DT year_NN 2002_CD :_: $_$ 45.3_CD million_CD ._.
CARBATROL_NNP had_VBD pharmaceutical_JJ and_CC healthcare_NN industries_NNS ._.
a_DT 43_CD %_NN share_NN of_IN the_DT total_JJ US_NNP extended_VBD release_NN carbamazepine_NN prescription_NN market_NN in_IN December_NNP ADDERALL_NNP XR_NNP 2003_CD ,_, compared_VBN with_IN 36_CD %_NN in_IN December_NNP 2002_CD ._.
Sales_NNS of_IN ADDERALL_NNP XR_NNP for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD were_VBD $_$ 474.5_CD million_CD ,_, an_DT increase_NN of_IN 49_CD %_NN compared_VBN to_TO the_DT prior_JJ year_NN 2002_CD :_: $_$ 317.9_CD million_CD ._.
ADDERALL_NNP XR_NNP had_VBD a_DT 23_CD %_NN share_NN of_IN the_DT total_JJ US_NNP Attention_NN deficit_NN Hyperactivity_NNP Disorder_NNP ADHD_NNP market_NN in_IN December_NNP 2003_CD ,_, compared_VBN with_IN 18_CD %_NN in_IN December_NNP 2002_CD ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NNP Financial_NNP review_NN 25_CD PROAMATINE_NNP Capital_NNP structure_NN Sales_NNS of_IN PROAMATINE_NNP for_IN the_DT year_NN ended_VBD The_DT Group_NNP has_VBZ nanced_VBN its_PRP$ operations_NNS since_IN 31_CD December_NNP 2003_CD were_VBD $_$ 49.3_CD million_CD ,_, inception_NN through_IN private_JJ and_CC public_JJ offerings_NNS a_DT decrease_NN of_IN 3_CD %_NN compared_VBN to_TO prior_JJ year_NN of_IN equity_NN securities_NNS ,_, the_DT issuance_NN of_IN loan_NN notes_NNS 2002_CD :_: $_$ 50.9_CD million_CD ._.
At_IN the_DT end_NN of_IN the_DT third_JJ and_CC convertible_JJ notes_NNS ,_, collaborative_JJ licensing_NN quarter_NN of_IN 2003_CD ,_, sales_NNS of_IN PROAMATINE_NNP were_VBD and_CC development_NN fees_NNS ,_, product_NN sales_NNS and_CC subject_JJ to_TO generic_JJ competition_NN ,_, which_WDT caused_VBD investment_NN income_NN ._.
PROAMATINE_NNP had_VBD a_DT 15_CD %_NN share_NN of_IN the_DT total_JJ US_NNP PROAMATINE_NNP and_CC udrocortisone_JJ The_DT Groups_NNS funding_NN requirements_NNS depend_VBP on_IN a_DT acetate_NN prescription_NN market_NN in_IN December_NNP 2003_CD ,_, number_NN of_IN factors_NNS ,_, including_VBG the_DT Groups_NNS product_NN compared_VBN with_IN 25_CD %_NN in_IN December_NNP 2002_CD ._.
development_NN programs_NNS ,_, business_NN and_CC product_NN acquisitions_NNS ,_, the_DT level_NN of_IN resources_NNS required_VBN for_IN the_DT b_NN Royalties_NNS expansion_NN of_IN marketing_NN capabilities_NNS as_IN the_DT product_NN Royalty_NN revenue_NN increased_VBD 16_CD %_NN to_TO $_$ 203.6_CD million_CD base_NN expands_VBZ ,_, increased_VBD investment_NN in_IN trade_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD ,_, compared_VBN debtors_NNS and_CC stock_NN levels_NNS which_WDT may_MD arise_VB as_IN sales_NNS to_TO $_$ 174.8_CD million_CD in_IN 2002_CD ._.
levels_NNS increase_NN ,_, competitive_JJ and_CC technological_JJ developments_NNS ,_, the_DT timing_NN and_CC cost_NN of_IN obtaining_VBG Shire_NNP receives_VBZ royalties_NNS from_IN GSK_NNP on_IN worldwide_NN required_VBN regulatory_JJ approvals_NNS for_IN new_JJ products_NNS sales_NNS of_IN 3TC_NNP and_CC ZEFFIX_NNP ._.
Other_JJ royalties_NNS are_VBP and_CC the_DT continuing_VBG revenues_NNS generated_VBD from_IN primarily_RB in_IN respect_NN of_IN REMINYL_NNP ,_, a_DT product_NN sales_NNS of_IN key_JJ products_NNS ._.
marketed_VBN worldwide_JJ by_IN Johnson_NNP &_CC Johnson_NNP J&J_NNP ,_, with_IN the_DT exception_NN of_IN the_DT UK_NNP ,_, where_WRB During_IN the_DT year_NN the_DT Company_NN purchased_VBN and_CC a_DT commercialisation_NN partnership_NN with_IN J&J_NNP subsequently_RB canceled_VBD 7,592,778_CD ordinary_JJ existed_VBD throughout_IN 2003_CD ._.
shares_NNS for_IN a_DT total_JJ consideration_NN of_IN 31.8_CD million_CD $_$ 52.4_CD million_CD ,_, representing_VBG an_DT average_JJ price_NN Cost_NN of_IN sales_NNS and_CC net_JJ operating_NN expenses_NNS per_IN share_NN of_IN 4.12_CD $_$ 6.78_CD ._.
For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD cost_NN of_IN product_NN sales_NNS amounted_VBD to_TO 16_CD %_NN of_IN product_NN As_IN of_IN 31_CD December_NNP 2003_CD ,_, the_DT Group_NNP had_VBD cash_NN sales_NNS 2002_CD :_: 16_CD %_NN ._.
and_CC marketable_JJ securities_NNS of_IN $_$ 1,414.2_CD million_CD 2002_CD :_: $_$ 1,213.8_CD million_CD ,_, which_WDT consisted_VBD of_IN Research_NNP and_CC development_NN expenditure_NN increased_VBD immediately_RB available_JJ money_NN market_NN fund_NN 14_CD %_NN to_TO $_$ 215.8_CD million_CD in_IN 2003_CD ,_, representing_VBG balances_NNS and_CC investment_NN grade_NN securities_NNS ._.
Shires_NNP Total_NNP long-term_JJ debt_NN ,_, excluding_VBG capital_NN leases_NNS strategic_JJ priority_NN is_VBZ now_RB the_DT development_NN of_IN later_RB as_RB at_IN 31_CD December_NNP 2003_CD ,_, was_VBD $_$ 370.7_CD million_CD stage_NN ,_, lower_JJR risk_NN products_NNS ._.
As_IN a_DT result_NN of_IN this_DT 2002_CD :_: $_$ 401.0_CD million_CD ,_, of_IN which_WDT $_$ 370.2_CD million_CD focus_NN Shire_NNP closed_VBD its_PRP$ early_JJ stage_NN therapeutic_JJ 2002_CD :_: $_$ 400.0_CD million_CD was_VBD in_IN respect_NN of_IN research_NN unit_NN in_IN Canada_NNP ._.
These_DT convertible_JJ notes_NNS ,_, due_JJ 2011_CD ,_, were_VBD issued_VBN to_TO international_JJ Selling_NNP ,_, general_JJ and_CC administrative_JJ SG&A_NNP institutional_JJ investors_NNS and_CC bear_NN interest_NN at_IN a_DT rate_NN expenses_NNS increased_VBD from_IN $_$ 332.2_CD million_CD in_IN 2002_CD of_IN 2_CD %_NN per_IN annum_NN ._.
to_TO $_$ 376.9_CD million_CD in_IN 2003_CD ,_, an_DT increase_NN of_IN 13_CD %_NN in_IN contrast_NN with_IN product_NN sales_NNS growth_NN of_IN 20_CD %_NN Investors_NNS have_VBP the_DT right_NN to_TO require_VB the_DT issuer_NN for_IN the_DT period_NN ._.
SG&A_NNP expenses_NNS were_VBD 37_CD %_NN to_TO redeem_VB the_DT notes_NNS at_IN par_NN on_IN 21_CD August_NNP 2004_CD ,_, of_IN product_NN sales_NNS 2002_CD :_: 39_CD %_NN ._.
Subject_JJ to_TO certain_JJ conditions_NNS ,_, the_DT convertible_JJ notes_NNS will_MD be_VB callable_JJ after_IN 21_CD August_NNP The_DT depreciation_NN and_CC amortisation_NN charge_NN for_IN the_DT 2004_CD ._.
See_VB note_NN 15_CD i_FW to_TO the_DT consolidated_JJ financial_JJ year_NN ended_VBD 31_CD December_NNP 2003_CD was_VBD $_$ 86.7_CD million_CD statements_NNS for_IN further_JJ information_NN ._.
Included_VBN within_IN the_DT 2003_CD charge_NN are_VBP $_$ 27.5_CD million_CD of_IN intangible_JJ asset_NN During_IN the_DT second_JJ quarter_NN of_IN 2003_CD ,_, Shire_NNP impairments_NNS and_CC write-downs_NNS 2002_CD :_: $_$ 18.8_CD repurchased_VBN $_$ 29.8_CD million_CD of_IN the_DT $_$ 400_CD million_CD million_CD and_CC $_$ 16.7_CD million_CD of_IN tangible_JJ xed_JJ asset_NN 2_CD %_NN guaranteed_VBN convertible_JJ notes_NNS due_JJ 2011_CD ._.
write-downs_NNS 2002_CD :_: $_$ nil_JJ ._.
26_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NNP Financial_NNP review_NN Dividends_NNP Market_NNP risk_NN of_IN investments_NNS Reecting_VBG the_DT Groups_NNS stage_NN of_IN development_NN As_IN at_IN 31_CD December_NNP 2003_CD ,_, the_DT Group_NNP had_VBD and_CC cash_NN generative_JJ prole_NN ,_, the_DT Board_NNP intends_VBZ $_$ 73.2_CD million_CD 2002_CD :_: $_$ 72.0_CD million_CD of_IN investments_NNS to_TO declare_VB the_DT payment_NN of_IN the_DT Companys_NNP first_RB on_IN its_PRP$ books_NNS comprising_VBG equity_NN investment_NN funds_NNS ,_, interim_JJ dividend_NN of_IN one_CD penny_NN per_IN share_NN for_IN private_JJ companies_NNS and_CC public_JJ quoted_VBN companies_NNS ._.
the_DT six-months_JJ ending_VBG June_NNP 2004_CD ,_, with_IN a_DT view_NN The_DT public_JJ quoted_VBN companies_NNS are_VBP exposed_VBN to_TO growing_VBG the_DT dividend_NN progressively_RB ._.
No_DT financial_JJ instruments_NNS or_CC derivatives_NNS have_VBP been_VBN employed_VBN to_TO hedge_VB Treasury_NNP policies_NNS and_CC financial_JJ risk_NN this_DT risk_NN ._.
management_NN Shires_VBZ principal_JJ treasury_NN operations_NNS are_VBP managed_VBN Interest_NN rate_NN risk_NN by_IN the_DT corporate_JJ treasury_NN function_NN based_VBN in_IN Due_JJ to_TO the_DT proportion_NN of_IN xed_JJ rate_NN debt_NN ,_, the_DT the_DT UK_NNP ._.
All_DT treasury_NN operations_NNS are_VBP conducted_VBN Groups_NNS interest_NN charge_NN has_VBZ limited_VBN exposure_NN within_IN a_DT framework_NN of_IN policies_NNS and_CC procedures_NNS to_TO interest_NN rate_NN movements_NNS ._.
As_IN a_DT matter_NN of_IN policy_NN ,_, the_DT Group_NNP does_VBZ not_RB undertake_VB speculative_JJ Total_JJ debt_NN ,_, excluding_VBG capital_NN leases_NNS ,_, as_IN of_IN transactions_NNS that_WDT would_MD increase_VB currency_NN 31_CD December_NNP 2003_CD was_VBD $_$ 371.8_CD million_CD or_CC interest_NN rate_NN exposure_NN ._.
The_DT main_JJ component_NN and_CC agrees_VBZ policies_NNS for_IN managing_VBG these_DT risks_NNS was_VBD the_DT $_$ 370.2_CD million_CD 2002_CD :_: $_$ 400.0_CD million_CD and_CC they_PRP are_VBP summarised_VBN below_IN ._.
in_IN guaranteed_VBN convertible_JJ notes_NNS due_JJ 2011_CD ._.
Foreign_JJ currency_NN risk_NN The_DT convertible_JJ notes_NNS bear_VBP interest_NN of_IN 2_CD %_NN per_IN The_DT Group_NNP is_VBZ exposed_VBN to_TO movements_NNS in_IN foreign_JJ annum_NN ,_, payable_JJ semi-annually_RB ._.
This_DT interest_NN rate_NN exchange_NN rates_NNS against_IN the_DT US_NNP dollar_NN for_IN trading_NN is_VBZ xed_VBN over_IN the_DT period_NN of_IN the_DT debt_NN ,_, thus_RB reducing_VBG transactions_NNS and_CC the_DT translation_NN of_IN net_JJ assets_NNS any_DT cash_NN ow_NN risk_NN associated_VBN with_IN movements_NNS and_CC earnings_NNS of_IN non-US_JJ subsidiaries_NNS ._.
The_DT main_JJ in_IN interest_NN rates_NNS ._.
trading_NN currencies_NNS of_IN the_DT Group_NNP are_VBP the_DT US_NNP dollar_NN ,_, the_DT Canadian_JJ dollar_NN ,_, pounds_NNS sterling_NN and_CC the_DT The_DT interest_NN rate_NN risk_NN that_WDT has_VBZ been_VBN mitigated_VBN euro_NN ._.
The_DT financial_JJ statements_NNS of_IN foreign_JJ entities_NNS by_IN obtaining_VBG a_DT xed_JJ rate_NN debt_NN is_VBZ equivalent_JJ to_TO a_DT are_VBP translated_VBN using_VBG the_DT accounting_NN policies_NNS $_$ 3.7_CD million_CD saving_NN per_IN 1_CD %_NN rise_NN in_IN interest_NN rates_NNS described_VBN in_IN note_NN 2_CD j_NN to_TO the_DT consolidated_JJ per_IN annum_NN ._.
Conversely_RB ,_, a_DT fall_NN in_IN interest_NN rates_NNS by_IN financial_JJ statements_NNS ._.
1_CD %_NN would_MD effectively_RB cost_VB the_DT Group_NNP $_$ 3.7_CD million_CD ._.
The_DT Group_NNP reports_VBZ its_PRP$ results_NNS in_IN US_NNP dollars_NNS ._.
In_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD ,_, As_IN the_DT majority_NN of_IN the_DT Groups_NNS transactions_NNS are_VBP the_DT average_JJ interest_NN rate_NN received_VBN on_IN cash_NN also_RB denominated_VBD in_IN US_NNP dollars_NNS ,_, this_DT reduces_VBZ and_CC liquid_JJ investments_NNS was_VBD approximately_RB the_DT impact_NN of_IN currency_NN movements_NNS on_IN the_DT 1.18_CD %_NN per_IN annum_NN ._.
The_DT largest_JJS proportion_NN of_IN Groups_NNS results_NNS ._.
investments_NNS was_VBD in_IN US_NNP dollar_NN liquidity_NN funds_NNS ._.
A_DT small_JJ proportion_NN of_IN debt_NN is_VBZ denominated_VBN in_IN non-US_JJ dollar_NN currencies_NNS ._.
As_IN at_IN 31_CD December_NNP 2003_CD ,_, a_DT total_NN of_IN $_$ 1.5_CD million_CD was_VBD outstanding_JJ 31_CD December_NNP 2002_CD :_: $_$ 1.9_CD million_CD in_IN respect_NN of_IN loans_NNS denominated_VBN in_IN Canadian_JJ dollars_NNS ._.
The_DT exposure_NN to_TO foreign_JJ exchange_NN market_NN risk_NN is_VBZ managed_VBN and_CC monitored_VBN by_IN the_DT Group_NNP treasury_NN function_NN ._.
The_DT Group_NNP has_VBZ not_RB undertaken_VBN any_DT foreign_JJ currency_NN hedges_NNS through_IN the_DT use_NN of_IN forward_RB foreign_JJ exchange_NN contracts_NNS or_CC foreign_JJ exchange_NN derivatives_NNS during_IN the_DT year_NN to_TO 31_CD December_NNP 2003_CD ._.
Instead_RB ,_, exposures_NNS have_VBP been_VBN managed_VBN through_IN natural_JJ hedging_NN via_IN the_DT currency_NN denomination_NN of_IN cash_NN balances_NNS ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NNP Financial_NNP review_NN 27_CD Taxation_NNP Capital_NNP expenditure_NN For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD ,_, the_DT Expenditure_NN on_IN intangible_JJ xed_JJ assets_NNS of_IN income_NN tax_NN charge_NN increased_VBN by_IN $_$ 19.0_CD million_CD $_$ 47.0_CD million_CD comprised_VBN various_JJ product_NN to_TO $_$ 107.4_CD million_CD ._.
acquisitions_NNS including_VBG the_DT worldwide_JJ sales_NNS and_CC marketing_NN rights_NNS to_TO METHYPATCH_NNP for_IN A_DT reconciliation_NN of_IN the_DT current_JJ tax_NN charge_NN for_IN $_$ 25.0_CD million_CD ._.
2003_CD ,_, to_TO the_DT loss_NN before_IN tax_NN for_IN the_DT year_NN at_IN the_DT statutory_JJ tax_NN rate_NN of_IN 30_CD %_NN ,_, is_VBZ given_VBN in_IN note_NN 25_CD Capital_NNP expenditure_NN on_IN tangible_JJ xed_JJ assets_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS ._.
in_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD was_VBD $_$ 52.2_CD million_CD ._.
This_DT expenditure_NN included_VBD the_DT Cash_NN ows_VBZ purchase_NN of_IN a_DT new_JJ ofce_NN building_NN for_IN Shires_NNP UK_NNP As_IN of_IN 31_CD December_NNP 2003_CD cash_NN and_CC marketable_JJ based_VBN R&D_NNP operations_NNS ,_, further_JJ upgrades_NNS to_TO the_DT securities_NNS totalled_VBD $_$ 1,414.2_CD million_CD ,_, an_DT increase_NN US_NNP manufacturing_VBG facility_NN and_CC a_DT new_JJ enterprise_NN of_IN $_$ 200.4_CD million_CD from_IN $_$ 1,213.8_CD million_CD at_IN resource_NN planning_NN system_NN SAP_NNP ._.
Marketable_JJ securities_NNS consisted_VBD of_IN money_NN market_NN fund_NN balances_NNS and_CC investment_NN grade_NN securities_NNS ._.
For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD net_JJ cash_NN provided_VBN by_IN operating_VBG activities_NNS amounted_VBD to_TO $_$ 355.3_CD million_CD compared_VBN to_TO $_$ 345.1_CD million_CD in_IN 2002_CD ._.
During_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD ,_, cash_NN generated_VBD from_IN operations_NNS was_VBD used_VBN primarily_RB to_TO fund_VB the_DT Groups_NNS tax_NN payments_NNS ,_, capital_NN expenditures_NNS including_VBG the_DT purchase_NN of_IN intangible_JJ and_CC tangible_JJ xed_JJ assets_NNS ,_, repayment_NN of_IN debt_NN and_CC a_DT share_NN buy-back_NN program_NN ._.
28_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NNP Board_NNP of_IN Directors_NNS The_DT Board_NNP of_IN Directors_NNS 1_CD ._.
Dr_NNP James_NNP Cavanaugh_NNP 67_CD venture_NN between_IN Merck_NNP and_CC Astra_NNP AB_NNP 4_CD ._.
Dr_NNP Wilson_NNP Totten_NNP 48_CD Chairman_NNP and_CC non-executive_JJ Director_NNP of_IN Sweden_NNP ._.
He_PRP later_RB became_VBD President_NNP Chief_NNP scientific_JJ officer_NN Joined_VBD the_DT Board_NNP of_IN Shire_NNP on_IN 24_CD March_NNP and_CC Chief_NNP Executive_NNP officer_NN ._.
In_IN 1999_CD he_PRP Joined_VBD Shire_NNP on_IN 17_CD January_NNP 1998_CD 1997_CD and_CC was_VBD appointed_VBN as_IN non-executive_JJ joined_VBD Merck_NNP KGaA_NNP and_CC established_VBN EMD_NNP as_IN Group_NNP Research_NNP and_CC Development_NNP Chairman_NNP with_IN effect_NN from_IN 11_CD May_NNP 1999_CD ._.
Pharmaceuticals_NNS ,_, the_DT Companys_NNPS US_NNP Director_NNP ._.
Dr_NNP Totten_NNP is_VBZ a_DT medical_JJ doctor_NN and_CC Dr_NNP Cavanaugh_NNP is_VBZ President_NNP of_IN HealthCare_NNP prescription_NN pharmaceutical_JJ business_NN and_CC has_VBZ wide_JJ experience_NN in_IN the_DT pharmaceutical_JJ Ventures_NNP LLC_NNP ._.
Formerly_RB he_PRP was_VBD President_NNP was_VBD later_RB promoted_VBN to_TO President_NNP of_IN the_DT industry_NN covering_VBG all_DT phases_NNS of_IN drug_NN of_IN SmithKline_NNP &_CC French_NNP Laboratories_NNPS ,_, the_DT global_JJ prescription_NN business_NN and_CC moved_VBD development_NN ._.
He_PRP has_VBZ substantial_JJ US_NNP pharmaceutical_JJ division_NN of_IN SmithKline_NNP to_TO Germany_NNP to_TO run_VB the_DT prescription_NN division_NN experience_NN in_IN the_DT eld_NN of_IN worldwide_JJ drug_NN Beecham_NNP Corporation_NNP ._.
Prior_RB to_TO that_DT ,_, of_IN that_DT company_NN ._.
Mr_NNP Emmens_NNP is_VBZ a_DT graduate_NN development_NN ._.
He_PRP was_VBD Vice_NNP President_NNP of_IN he_PRP was_VBD President_NNP of_IN SmithKline_NNP Beecham_NNP of_IN Fairleigh_NNP Dickenson_NNP University_NNP New_NNP Clinical_NNP R&D_NNP with_IN Astra_NNP Charnwood_NNP from_IN Corporations_NNS clinical_JJ laboratory_NN business_NN Jersey_NNP ,_, US_NNP with_IN a_DT BS_NNP in_IN Business_NNP 1995_CD to_TO 1997_CD ,_, having_VBG previously_RB worked_VBN and_CC ,_, before_IN that_DT ,_, President_NNP of_IN Allergan_NNP Management_NNP ._.
Mr_NNP Emmens_NNP is_VBZ the_DT Chairman_NNP for_IN Fisons_NNP Pharmaceuticals_NNP from_IN 1989_CD International_NNP ._.
Prior_RB to_TO his_PRP$ industry_NN of_IN the_DT Executive_NNP Committee_NNP and_CC Portfolio_NNP to_TO 1995_CD ,_, and_CC prior_RB to_TO that_DT with_IN 3M_NNP Health_NNP experience_NN ,_, Dr_NNP Cavanaugh_NNP served_VBD as_IN Review_NNP Committee_NNP ._.
Dr_NNP Totten_NNP is_VBZ a_DT member_NN Deputy_NNP Assistant_NNP to_TO the_DT President_NNP of_IN the_DT of_IN the_DT Executive_NNP Committee_NNP and_CC the_DT US_NNP for_IN Health_NNP Affairs_NNPS on_IN the_DT White_NNP House_NNP 3_CD ._.
Mr_NNP Angus_NNP Russell_NNP 48_CD Portfolio_NNP Review_NNP Committee_NNP ._.
He_PRP is_VBZ nonChief_NNP Financial_NNP officer_NN executive_NN Chairman_NNP of_IN Diversa_NNP Corporation_NNP Joined_VBD Shire_NNP in_IN 1999_CD as_IN Group_NNP Finance_NNP 5_CD ._.
Dr_NNP Barry_NNP Price_NNP 60_CD and_CC Vicuron_NNP ,_, Inc._NNP and_CC a_DT non-executive_JJ Director_NNP ._.
Mr_NNP Russell_NNP previously_RB worked_VBD for_IN Senior_JJ non-executive_JJ Director_NNP Director_NNP of_IN MedImmune_NNP Inc._NNP and_CC Advancis_NNP ICI_NNP ,_, Zeneca_NNP and_CC AstraZeneca_NNP ._.
His_PRP$ last_JJ Joined_VBD the_DT Board_NNP of_IN Shire_NNP on_IN 16_CD January_NNP Pharmaceutical_NNP Corporation_NNP ._.
Dr_NNP Cavanaugh_NNP position_NN was_VBD Vice_NNP President_NNP Corporate_NNP 1996_CD having_VBG spent_VBN 28_CD years_NNS with_IN Glaxo_NNP was_VBD a_DT member_NN of_IN the_DT Remuneration_NNP Finance_NNP at_IN AstraZeneca_NNP plc._NNP ._.
Prior_RB to_TO this_DT ,_, holding_VBG a_DT succession_NN of_IN executive_NN positions_NNS Committee_NNP and_CC the_DT Audit_NNP Committee_NNP he_PRP held_VBD a_DT number_NN of_IN positions_NNS within_IN the_DT with_IN Glaxo_NNP Group_NNP Research_NNP ._.
He_PRP is_VBZ and_CC Chairman_NNP of_IN the_DT Nomination_NNP Zeneca_NNP Group_NNP from_IN 1993_CD until_IN 1999_CD ,_, Chairman_NNP of_IN Antisoma_NNP plc_NN and_CC Biowisdom_NNP Committee_NNP in_IN 2003_CD ._.
including_VBG Group_NNP Treasurer_NNP ,_, and_CC before_IN that_DT Ltd._NNP ._.
He_PRP is_VBZ also_RB on_IN the_DT Board_NNP of_IN Directors_NNS in_IN ICI_NNP from_IN 1980_CD until_IN 1992_CD ._.
Mr_NNP Russell_NNP is_VBZ of_IN Pharmagene_NNP plc._NN ._.
Mr_NNP Matthew_NNP Emmens_NNP 52_CD a_DT Chartered_NNP Accountant_NNP ,_, having_VBG qualied_VBN of_IN the_DT Remuneration_NNP Committee_NNP and_CC Chief_NNP Executive_NNP officer_NN with_IN Coopers_NNP &_CC Lybrand_NNP ,_, and_CC is_VBZ a_DT fellow_NN a_DT member_NN of_IN both_DT the_DT Audit_NNP Committee_NNP Joined_VBD Shire_NNP as_IN Chief_NNP Executive_NNP officer_NN of_IN the_DT Association_NNP of_IN Corporate_NNP Treasurers_NNPS ._.
and_CC the_DT Nomination_NNP Committee_NNP in_IN 2003_CD ._.
and_CC member_NN of_IN the_DT Board_NNP of_IN Shire_NNP on_IN Mr_NNP Russell_NNP is_VBZ a_DT member_NN of_IN the_DT Executive_NNP 12_CD March_NNP 2003_CD ._.
Mr_NNP Emmens_NNP began_VBD his_PRP$ Committee_NNP ._.
He_PRP is_VBZ also_RB a_DT non-executive_JJ career_NN in_IN international_JJ pharmaceuticals_NNS Director_NNP of_IN the_DT City_NNP of_IN London_NNP Investment_NN with_IN Merck_NNP &_CC Co_NNP ,_, Inc._NNP in_IN 1974_CD ._.
a_DT wide_JJ range_NN of_IN sales_NNS ,_, marketing_NN and_CC administrative_JJ positions_NNS before_IN volunteering_VBG to_TO help_VB establish_VB Astra_NNP Merck_NNP ,_, the_DT joint_JJ Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NNP Board_NNP of_IN Directors_NNS 29_CD 5_CD ._.
The_DT Hon_NNP James_NNP Andrews_NNP Grant_NNP 66_CD Mr_NNP Nordmann_NNP received_VBD his_PRP$ undergraduate_NN Ex-Board_NNP Members_NNP Mr_NNP Rolf_NNP Stahel_NNP Former_NNP Chief_NNP Executive_NNP Non-executive_JJ Director_NNP degree_NN from_IN The_DT Johns_NNP Hopkins_NNP University_NNP Joined_VBD Shire_NNP in_IN March_NNP 1994_CD as_IN Chief_NNP Executive_NNP Joined_VBD the_DT Board_NNP of_IN Shire_NNP on_IN 11_CD May_NNP 2001_CD and_CC a_DT MBA_NNP from_IN Fairleigh_NNP Dickinson_NNP from_IN Wellcome_NNP plc_NN where_WRB he_PRP worked_VBD for_IN 27_CD years_NNS as_IN a_DT non-executive_JJ Director_NNP ._.
Mr_NNP Nordmann_NNP is_VBZ also_RB a_DT Director_NNP in_IN Switzerland_NNP ,_, Italy_NNP ,_, Thailand_NNP ,_, Singapore_NNP and_CC the_DT merger_NN with_IN Shire_NNP ,_, Mr_NNP Grant_NNP had_VBD been_VBN of_IN Guilford_NNP Pharmaceuticals_NNP Inc._NNP ._.
Neurochem_NNP UK_NNP ._.
As_IN Regional_NNP Director_NNP of_IN Wellcome_NNP based_VBN in_IN Singapore_NNP ,_, Mr_NNP Stahel_NNP was_VBD responsible_JJ for_IN 18_CD Pacic_NNP a_DT Director_NNP of_IN BioChem_NNP Pharma_NNP Inc._NNP since_IN Inc._NNP and_CC Pharmaceutical_NNP Resources_NNPS Inc._NNP ._.
Rim_NN countries_NNS ._.
He_PRP is_VBZ a_DT partner_NN with_IN the_DT law_NN rm_NN Mr_NNP Nordmann_NNP was_VBD Chairman_NNP of_IN the_DT Audit_NNP he_PRP served_VBD as_IN Director_NNP of_IN Group_NNP Marketing_NNP reporting_VBG Stikeman_NNP Elliot_NNP in_IN Montreal_NNP ._.
Mr_NNP Grant_NNP sits_VBZ Committee_NNP and_CC a_DT member_NN of_IN the_DT to_TO the_DT Chief_NNP Executive_NNP ._.
A_DT Business_NN Studies_NNPS graduate_NN on_IN the_DT Boards_NNPS of_IN two_CD Canadian_JJ public_JJ Nomination_NNP Committee_NNP in_IN 2003_CD ._.
of_IN KSL_NNP Lucerne_NNP ,_, Switzerland_NNP ,_, he_PRP attended_VBD the_DT 97th_JJ Advanced_NNP Managers_NNPS Programme_NNP at_IN Harvard_NNP Business_NNP corporations_NNS ,_, in_IN addition_NN to_TO other_JJ private_JJ School_NNP ._.
On_IN 15_CD March_NNP 2001_CD Mr_NNP Stahel_NNP received_VBD the_DT corporations_NNS and_CC foundations_NNS and_CC councils_NNS 8_CD ._.
Mr_NNP Robin_NNP Buchanan_NNP 51_CD Chief_NNP Executive_NNP officer_NN of_IN the_DT Year_NN Award_NNP 2001_CD for_IN that_WDT are_VBP not_RB for_IN profit_NN organizations_NNS ._.
Non-executive_JJ Director_NNP the_DT global_JJ pharmaceutical_JJ industry_NN ._.
Mr_NNP Stahel_NNP stepped_VBD He_PRP attended_VBD McGill_NNP University_NNP receiving_VBG Joined_VBN the_DT Board_NNP of_IN Shire_NNP on_IN 30_CD July_NNP 2003_CD ._.
down_RB as_IN Chief_NNP Executive_NNP on_IN 12_CD March_NNP 2003_CD and_CC as_IN a_DT Director_NNP of_IN the_DT Company_NN on_IN 19_CD March_NNP 2003_CD ._.
a_DT BA_NNP in_IN Arts_NNS in_IN 1958_CD and_CC a_DT BCL_NNP in_IN Law_NNP He_PRP is_VBZ the_DT Senior_JJ Partner_NNP of_IN the_DT London_NNP ofce_NN in_IN 1961_CD ._.
Mr_NNP Grant_NNP was_VBD a_DT member_NN of_IN the_DT of_IN business_NN consultants_NNS Bain_NNP &_CC Company_NNP Dr_NNP Francesco_NNP Bellini_NNP non-executive_JJ Director_NNP Nomination_NNP Committee_NNP in_IN 2003_CD ._.
and_CC a_DT member_NN of_IN the_DT rms_NNS worldwide_VBP Joined_VBN the_DT Board_NNP of_IN Shire_NNP on_IN 11_CD May_NNP 2001_CD as_IN a_DT management_NN committee_NN ._.
Prior_RB to_TO his_PRP$ career_NN non-executive_JJ Director_NNP ._.
Dr_NNP Bellini_NNP is_VBZ Chairman_NNP of_IN Picchio_NNP International_NNP Inc._NNP and_CC Neurochem_NNP Inc._NNP 7_CD ._.
Mr_NNP Ronald_NNP Nordmann_NNP 62_CD with_IN Bain_NNP &_CC Company_NNP ,_, Mr_NNP Buchanan_NNP and_CC also_RB on_IN the_DT Board_NNP of_IN several_JJ companies_NNS and_CC Non-executive_JJ Director_NNP worked_VBD for_IN American_NNP Express_NNP International_NNP organizations_NNS such_JJ as_IN Molson_NNP Inc._NNP and_CC IndustrialJoined_VBD the_DT Board_NNP of_IN Shire_NNP on_IN 23_CD December_NNP Banking_NNP Corporation_NNP in_IN New_NNP York_NNP ,_, Alliance_NNP Life_NNP Insurance_NNP Co._NNP ._.
Formerly_RB ,_, he_PRP was_VBD 1999_CD having_VBG previously_RB served_VBN as_IN a_DT nonMcKinsey_NNP &_CC Company_NNP and_CC Deloitte_NNP &_CC Chairman_NNP and_CC CEO_NNP of_IN BioChem_NNP Pharma_NNP which_WDT he_PRP co-founded_VBD in_IN 1986_CD ._.
He_PRP stepped_VBD down_RP as_IN a_DT executive_NN Director_NNP of_IN Roberts_NNP Pharmaceutical_NNP Touche_NNP where_WRB he_PRP qualied_VBD as_IN a_DT Chartered_NNP Director_NNP of_IN the_DT Company_NN in_IN May_NNP 2003_CD ._.
Mr_NNP Buchanan_NNP currently_RB serves_VBZ has_VBZ been_VBN a_DT financial_JJ analyst_NN in_IN healthcare_NN as_IN a_DT non-executive_JJ Director_NNP of_IN Liberty_NNP Mr_NNP Grard_NNP Veilleux_NNP non-executive_JJ Director_NNP equities_NNS since_IN 1971_CD ._.
Mr_NNP Buchanan_NNP has_VBZ an_DT Joined_VBN the_DT Board_NNP of_IN Shire_NNP on_IN 11_CD May_NNP 2001_CD as_IN a_DT non-executive_JJ Director_NNP ._.
He_PRP was_VBD formerly_RB a_DT Director_NNP to_TO January_NNP 2000_CD he_PRP was_VBD an_DT analyst_NN and_CC MBA_NNP with_IN Distinction_NNP Baker_NNP Scholar_NNP from_IN of_IN BioChem_NNP since_IN 1999_CD ._.
He_PRP is_VBZ President_NNP of_IN Power_NNP partner_NN at_IN Deereld_NNP Management_NNP ._.
He_PRP is_VBZ Harvard_NNP Business_NNP School_NNP ._.
Mr_NNP Buchanan_NNP Communications_NNPS Inc._NNP and_CC Vice_NNP President_NNP of_IN Power_NNP currently_RB Co-President_NNP of_IN Global_NNP Health_NNP was_VBD a_DT member_NN of_IN the_DT Remuneration_NNP Corporation_NNP ,_, a_DT diversied_JJ management_NN and_CC holding_VBG Associates_NNPS and_CC has_VBZ held_VBN senior_JJ positions_NNS Committee_NNP in_IN 2003_CD ._.
company_NN ._.
Mr_NNP Veilleux_NNP is_VBZ a_DT Director_NNP of_IN several_JJ public_JJ and_CC private_JJ companies_NNS as_RB well_RB as_IN a_DT member_NN of_IN the_DT with_IN PaineWebber_NNP ,_, Oppenheimer_NNP &_CC Co._NNP ._.
Board_NNP of_IN Governors_NNP at_IN McGill_NNP University_NNP ._.
He_PRP has_VBZ F_NN Eberstadt_NNP &_CC Co._NNP and_CC Warner-Chilcott_NNP a_DT Masters_NNP Degree_NNP in_IN Public_NNP Administration_NNP from_IN Laboratories_NNPS ,_, a_DT division_NN of_IN Warner-Lambert_NNP ._.
Carleton_NNP University_NNP and_CC a_DT Bachelor_NNP of_IN Commerce_NNP from_IN Laval_NNP University_NNP ._.
Mr_NNP Veilleux_NNP was_VBD a_DT member_NN of_IN the_DT Remuneration_NNP Committee_NNP ._.
He_PRP stepped_VBD down_RP as_IN a_DT Director_NNP of_IN the_DT Company_NN in_IN May_NNP 2003_CD ._.
30_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN The_DT Executive_NNP Committee_NNP The_NNP Executive_NNP Committee_NNP 4_CD ._.
Mr_NNP Joseph_NNP Rus_NNP Chief_NNP Executive_NNP officer_NN Executive_NNP Vice_NNP President_NNP and_CC General_NNP Executive_NNP Vice_NNP President_NNP and_CC General_NNP Biography_NNP on_IN page_NN 28_CD ._.
Manager_NN ,_, North_NNP America_NNP Manager_NNP ,_, International_NNP Greg_NNP joined_VBD Shire_NNP in_IN April_NNP 2001_CD ,_, as_IN Senior_JJ Joseph_NNP joined_VBD Shire_NNP in_IN 1999_CD as_IN President_NNP 2_CD ._.
Mr_NNP Angus_NNP Russell_NNP 48_CD Vice_NNP President_NNP Marketing_NNP ,_, Shire_NNP US_NNP ,_, of_IN Shire_NNP Canada_NNP following_VBG more_JJR than_IN Chief_NNP Financial_NNP officer_NN bringing_VBG over_IN 22_CD years_NNS of_IN experience_NN 25_CD years_NNS experience_NN with_IN other_JJ leading_VBG Biography_NN on_IN page_NN 28_CD ._.
in_IN global_JJ and_CC domestic_JJ marketing_NN ,_, business_NN international_JJ pharmaceutical_JJ companies_NNS development_NN and_CC R&D_NNP ._.
Prior_RB to_TO joining_VBG both_DT in_IN Canada_NNP and_CC abroad_RB ._.
Dr_NNP Wilson_NNP Totten_NNP 48_CD Shire_NNP ,_, Greg_NNP was_VBD Vice_NNP President_NNP and_CC Head_NNP merger_NN of_IN Shire_NNP Pharmaceuticals_NNP and_CC Chief_NNP scientific_JJ officer_NN of_IN the_DT Neuroscience_NNP Business_NNP Unit_NNP for_IN BioChem_NNP Pharma_NNP in_IN May_NNP 2001_CD ,_, he_PRP was_VBD Biography_NNP on_IN page_NN 28_CD ._.
Novartis_NNP Pharmaceuticals_NNP ,_, with_IN accountability_NN appointed_VBN President_NNP and_CC CEO_NNP of_IN Shire_NNP for_IN US_NNP Marketing_NNP ,_, Sales_NNS and_CC Medical_JJ BioChem_NNP Inc._NNP 4_CD ._.
He_PRP began_VBD his_PRP$ career_NN in_IN the_DT Executive_NNP Vice_NNP President_NNP of_IN Corporate_JJ industry_NN with_IN Marion_NNP Laboratories_NNPS in_IN clinical_JJ In_IN 1972_CD Joseph_NNP began_VBD his_PRP$ career_NN in_IN sales_NNS Strategy_NNP &_CC Integration_NNP research_NN management_NN ,_, transitioning_VBG to_TO with_IN Warner_NNP Lambert_NNP Canada_NNP and_CC rose_VBD Joined_VBN Shire_NNP in_IN January_NNP 2000_CD as_IN Director_NNP a_DT leadership_NN role_NN in_IN New_NNP Product_NNP Marketing_NNP ._.
rapidly_RB to_TO managerial_JJ positions_NNS in_IN various_JJ of_IN Corporate_NNP Affairs_NNPS ._.
Prior_RB to_TO joining_VBG Shire_NNP In_IN 1991_CD he_PRP served_VBD as_IN Product_NNP Group_NNP departments_NNS ._.
Joseph_NNP was_VBD Vice_NNP President_NNP he_PRP was_VBD a_DT partner_NN at_IN Ernst_NNP &_CC Young_NNP and_CC Director_NNP ,_, Global_NNP Commercial_NNP Development_NNP of_IN the_DT Canadian_JJ Pharmaceutical_NNP Division_NNP also_RB a_DT member_NN of_IN its_PRP$ Global_NNP Executive_NNP for_IN Marion_NNP Merrell_NNP Dow_NNP and_CC subsequently_RB of_IN Hoffmann-La_NNP Roche_NNP Ltd_NNP between_IN 1994_CD Steering_NNP Group_NNP for_IN Life_NNP Sciences_NNPS ._.
was_VBD promoted_VBN to_TO Vice_NNP President_NNP ,_, Global_NNP and_CC 1998_CD ._.
He_PRP was_VBD previously_RB with_IN Arthur_NNP D_NNP Little_NNP ,_, Marketing_NNP and_CC Medical_NNP Research_NNP with_IN Management_NNP Consultancy_NNP ,_, where_WRB he_PRP Hoechst_NNP Marion_NNP Roussel_NNP ._.
Greg_NNP is_VBZ Educated_VBN in_IN Romania_NNP and_CC a_DT graduate_NN of_IN the_DT was_VBD a_DT European_JJ Director_NNP in_IN its_PRP$ Healthcare_NNP a_DT pharmacist_NN ._.
Executive_NNP Marketing_NNP Management_NNP Program_NNP and_CC Pharmaceuticals_NNP practice_NN ._.
of_IN the_DT University_NNP of_IN Western_NNP Ontario_NNP as_RB well_RB as_IN the_DT International_NNP Program_NNP at_IN the_DT Institute_NNP 5_CD ._.
Ms_NNP Tatjana_NNP May_NNP of_IN Management_NNP and_CC Development_NNP of_IN the_DT General_NNP Counsel_NNP and_CC Executive_NNP Vice_NNP University_NNP of_IN Lausanne_NNP ,_, Joseph_NNP is_VBZ multiPresident_NNP of_IN Global_NNP Legal_NNP Affairs_NNP lingual_NN ,_, speaking_VBG English_NNP ,_, Romanian_NNP and_CC Tatjana_NNP joined_VBD Shire_NNP in_IN May_NNP 2001_CD from_IN Hungarian_JJ with_IN a_DT knowledge_NN of_IN Italian_JJ ,_, AstraZeneca_NNP Plc_NNP formerly_RB Zeneca_NNP Group_NNP French_NNP and_CC German_NNP ._.
where_WRB she_PRP occupied_VBD the_DT position_NN of_IN Assistant_NNP General_NNP Counsel_NNP in_IN Corporate_NNP Headquarters_NNP ._.
Prior_RB to_TO joining_VBG AstraZeneca_NNP Tatjana_NNP worked_VBD at_IN Slaughter_NNP and_CC May_NNP ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN The_DT Executive_NNP Committee_NNP 31_CD 8_CD ._.
Mrs_NNP Anita_NNP Graham_NNP John_NNP has_VBZ held_VBN multi-plant_JJ responsibilities_NNS 11_CD ._.
Mr_NNP Richard_NNP fide_NNP Souza_NNP Executive_NNP Vice_NNP President_NNP of_IN and_CC led_VBD the_DT Worldwide_NNP Manufacturing_NNP Director_NNP International_NNP Human_NNP Resources_NNPS Functional_NNP Excellence_NNP Program_NNP while_IN Joined_NNP Shire_NNP in_IN September_NNP 2000_CD as_IN Anita_NNP joined_VBD Shire_NNP in_IN January_NNP 2004_CD at_IN Schwarz_NNP Pharma_NNP ._.
The_DT Shire_NNP US_NNP Director_NNP International_NNP ._.
Prior_RB to_TO this_DT he_PRP as_IN Executive_NNP Vice_NNP President_NNP of_IN Human_NNP Manufacturing_NNP facility_NN is_VBZ the_DT seventh_JJ worked_VBD as_IN President_NNP ,_, Pharmaceuticals_NNP Resources_NNPS ._.
Anita_NNP has_VBZ 10_CD years_NNS global_JJ HR_NNP pharmaceutical_JJ plant_NN for_IN which_WDT John_NNP Europe_NNP and_CC Asia_NNP in_IN Warner_NNP Lambert_NNP Parkeexperience_NNP spanning_VBG the_DT management_NN of_IN has_VBZ been_VBN responsible_JJ ._.
He_PRP was_VBD previously_RB with_IN SmithKline_NNP mergers_NNS and_CC acquisitions_NNS ,_, organisational_JJ Beecham_NNP for_IN 22_CD years_NNS ,_, where_WRB he_PRP was_VBD development_NN ,_, employee_NN relations_NNS and_CC John_NNP is_VBZ certied_VBN by_IN the_DT American_JJ Production_NN Chairman_NNP ,_, Pharmaceuticals_NNP Europe_NNP ._.
Prior_RB to_TO joining_VBG and_CC Inventory_NNP Control_NNP Society_NNP in_IN Production_NNP the_DT Shire_NNP team_NN Anita_NNP led_VBD the_DT global_JJ Human_NNP and_CC Inventory_NNP Management_NNP and_CC has_VBZ taught_VBN 12_CD ._.
Mr_NNP Mark_NNP Webster_NNP Resources_NNPS function_NN for_IN Cytyc_NNP Corporation_NNP ._.
core_NN elements_NNS of_IN Supply_NNP Chain_NNP Management_NNP Commercial_NNP Director_NNP Additionally_RB ,_, Anita_NNP held_VBD senior_JJ HR_NNP positions_NNS within_IN the_DT APICS_NNP organization_NN Responsible_JJ for_IN Global_NNP Business_NNP with_IN Serono_NNP ,_, Inc._NNP and_CC Scudder_NNP Kemper_NNP Development_NNP ,_, Mergers_NNPS &_CC Acquisitions_NNPS Investments_NNPS ,_, Inc._NNP 10_CD ._.
Mr_NNP Jack_NNP Khattar_NNP and_CC Strategic_NNP Marketing_NNP ._.
He_PRP has_VBZ worked_VBN President_NNP and_CC Chief_NNP Executive_NNP ,_, SLI_NNP in_IN the_DT pharmaceutical_JJ industry_NN for_IN 20_CD years_NNS Anita_NNP has_VBZ worked_VBN both_DT in_IN Europe_NNP and_CC in_IN Joined_VBN Shire_NNP as_IN President_NNP and_CC CEO_NNP in_IN a_DT number_NN of_IN general_JJ management_NN and_CC the_DT US_NNP ._.
She_PRP is_VBZ an_DT MBA_NNP graduate_NN and_CC was_VBD of_IN Shire_NNP Laboratories_NNPS Inc._NNP in_IN May_NNP 1999_CD ._.
senior_JJ sales_NNS and_CC marketing_NN roles_NNS in_IN the_DT UK_NNP ,_, educated_VBN both_DT at_IN the_DT New_NNP York_NNP University_NNP Jack_NNP came_VBD to_TO Shire_VB from_IN CIMA_NNP ,_, a_DT drug_NN Canada_NNP and_CC the_DT US_NNP ._.
Mark_NNP worked_VBD for_IN and_CC Cornell_NNP University_NNP ,_, New_NNP York_NNP ._.
delivery_NN company_NN ,_, where_WRB he_PRP had_VBD last_JJ Abbott_NNP Laboratories_NNPS for_IN 13_CD years_NNS ,_, where_WRB served_VBD as_IN Executive_NNP officer_NN and_CC the_DT immediately_RB before_IN joining_VBG Shire_NNP he_PRP held_VBD 9_CD ._.
Mr_NNP John_NNP Lee_NNP Chairman_NNP of_IN the_DT Operative_NNP Management_NNP the_DT post_NN of_IN Vice-President_NNP and_CC General_NNP Executive_NNP Vice_NNP President_NNP Global_NNP Supply_NNP Committee_NNP ._.
Jack_NNP held_VBD several_JJ marketing_NN Manager_NNP Anti-Virals_NNP ,_, Abbott_NNP Labs_NNPS USA_NNP ._.
Chain_NNP &_CC Quality_NNP and_CC business_NN development_NN positions_NNS at_IN He_PRP has_VBZ a_DT BSc_NNP Hons_NNP in_IN Chemistry_NNP from_IN John_NNP joined_VBD Shire_NNP in_IN April_NNP 2000_CD as_IN Senior_JJ Merck_NNP &_CC Co._NNP ._.
Novartis_NNP ,_, Playtex_NNP and_CC Kodak_NNP Durham_NNP University_NNP ._.
Vice_NNP President_NNP ,_, Operations_NNP having_VBG 31_CD years_NNS in_IN the_DT US_NNP ,_, Europe_NNP and_CC the_DT Middle_NNP East_NNP ._.
Ex-Executive_NNP Committee_NNP member_NN experience_NN in_IN the_DT Pharmaceutical_NNP Industry_NN ._.
In_IN 1985_CD ,_, he_PRP received_VBD his_PRP$ MBA_NNP from_IN the_DT Mr_NNP Bill_NNP Nuerge_NNP President_NNP and_CC Chief_NNP Executive_NNP ,_, John_NNP has_VBZ previously_RB held_VBN supply_NN chain_NN Wharton_NNP School_NNP of_IN the_DT University_NNP of_IN Shire_NNP US_NNP Inc._NNP responsibilities_NNS as_IN Vice_NNP President_NNP ,_, Pennsylvania_NNP ._.
Joined_VBN Shire_NNP US_NNP in_IN 1994_CD as_IN chief_JJ Operating_VBG officer_NN ._.
Operations_NNP for_IN Schwarz_NNP Pharma_NNP ,_, Central_NNP Bill_NNP has_VBZ over_IN 25_CD years_NNS experience_NN within_IN the_DT industry_NN and_CC has_VBZ held_VBN several_JJ senior_JJ pharmaceutical_JJ positions_NNS ._.
Pharmaceuticals_NNS ,_, The_DT Vitarine_NNP Company_NNP Bill_NNP holds_VBZ a_DT Bachelor_NNP of_IN Science_NNP degree_NN from_IN Purdue_NNP now_RB Eon_NNP and_CC Glenwood_NNP Laboratories_NNPS ._.
University_NNP and_CC a_DT MBA_NNP from_IN Indiana_NNP Wesleyan_NNP University_NNP ._.
32_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Directors_NNS remuneration_JJ report_NN Dear_NNP Shareholder_NN This_DT Report_NNP sets_VBZ out_RP the_DT Boards_NNPS approach_NN to_TO Directors_NNS During_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD the_DT Remuneration_NNP remuneration_NN ._.
It_PRP complies_VBZ with_IN :_: Committee_NNP continued_VBD its_PRP$ work_NN on_IN behalf_NN of_IN the_DT Board_NNP on_IN Directors_NNS remuneration_NN ._.
Following_VBG a_DT process_NN of_IN consultation_NN with_IN some_DT of_IN the_DT 1998_CD Combined_VBN Codes_NNP Principles_NNPS of_IN Good_JJ Governance_NN :_: our_PRP$ major_JJ shareholders_NNS the_DT Committee_NNP has_VBZ made_VBN some_DT changes_NNS the_DT Directors_NNS Remuneration_NNP Report_NNP Regulations_NNPS 2002_CD :_: and_CC to_TO its_PRP$ remuneration_NN policy_NN ._.
Among_IN these_DT changes_NNS are_VBP :_: the_DT requirements_NNS of_IN the_DT Listing_NNP Rules_NNP of_IN the_DT Financial_NNP Services_NNPS Authority_NNP ._.
the_DT introduction_NN of_IN new_JJ employment_NN contracts_NNS for_IN its_PRP$ executive_NN Directors_NNS which_WDT reduce_VBP the_DT two-year_JJ termination_NN provisions_NNS The_DT Board_NNP has_VBZ taken_VBN steps_NNS to_TO ensure_VB that_IN it_PRP complies_VBZ during_IN 2004_CD following_VBG a_DT change_NN in_IN control_NN to_TO one_CD year_NN :_: and_CC with_IN the_DT new_JJ Combined_NNP Code_NNP published_VBN in_IN 2003_CD ._.
reducing_VBG to_TO one_CD the_DT number_NN of_IN opportunities_NNS for_IN re-testing_VBG the_DT performance_NN conditions_NNS attached_VBN to_TO the_DT vesting_NN of_IN options_NNS ._.
Unaudited_JJ Information_NN The_DT Remuneration_NNP Committee_NNP The_NNP Company_NNP operates_VBZ in_IN a_DT highly-competitive_JJ multi-national_JJ The_DT Remuneration_NNP Committee_NNP is_VBZ responsible_JJ for_IN all_DT elements_NNS environment_NN ._.
In_IN 2003_CD approximately_RB 90_CD %_NN of_IN Shires_NNP revenues_NNS of_IN the_DT executive_NN Directors_NNS remuneration_NN ,_, as_RB well_RB as_IN their_PRP$ and_CC 80_CD %_NN of_IN its_PRP$ employees_NNS were_VBD based_VBN outside_IN the_DT UK_NNP ._.
most_JJS of_IN Shires_NNP revenues_NNS come_VBP from_IN the_DT US_NNP ._.
The_DT Committee_NNP has_VBZ never_RB espoused_VBN a_DT US_NNP pay_NN policy_NN but_CC it_PRP does_VBZ need_VB to_TO take_VB this_DT The_DT Company_NN considers_VBZ all_DT members_NNS of_IN the_DT Committee_NNP operating_NN environment_NN into_IN account_NN ._.
To_TO give_VB you_PRP a_DT perspective_NN on_IN to_TO be_VB independent_JJ ,_, although_IN the_DT constitution_NN of_IN the_DT Committee_NNP the_DT complexities_NNS we_PRP face_VBP ,_, Matthew_NNP Emmens_NNP ,_, who_WP was_VBD appointed_VBN will_MD be_VB reviewed_VBN in_IN light_NN of_IN the_DT new_JJ Combined_NNP Code_NNP in_IN 2004_CD ._.
Chief_NNP Executive_NNP officer_NN in_IN March_NNP 2003_CD ,_, is_VBZ American_JJ ._.
Although_IN his_PRP$ The_DT Chief_NNP Executive_NNP officer_NN attends_VBZ meetings_NNS of_IN the_DT Committee_NNP principal_NN base_NN with_IN Shire_NNP is_VBZ in_IN the_DT US_NNP and_CC his_PRP$ home_NN is_VBZ in_IN the_DT US_NNP ,_, at_IN its_PRP$ invitation_NN ,_, but_CC is_VBZ not_RB involved_VBN in_IN any_DT discussions_NNS on_IN his_PRP$ his_PRP$ remuneration_NN is_VBZ benchmarked_VBN against_IN the_DT UK_NNP market_NN ._.
The_DT Remuneration_NNP Committee_NNP is_VBZ committed_VBN to_TO a_DT continuing_VBG The_DT members_NNS of_IN the_DT Remuneration_NNP Committee_NNP during_IN 2003_CD were_VBD :_: dialogue_NN with_IN shareholders_NNS and_CC we_PRP strive_VBP to_TO accommodate_VB your_PRP$ views_NNS ._.
I_PRP hope_VBP that_IN this_DT report_NN and_CC our_PRP$ conversations_NNS provide_VBP Dr_NNP Barry_NNP Price_NNP ,_, who_WP is_VBZ the_DT Senior_JJ Independent_NNP Director_NNP of_IN the_DT helpful_JJ context_NN and_CC explanation_NN about_IN the_DT policies_NNS and_CC practical_JJ Company_NN and_CC Chairman_NN of_IN the_DT Committee_NNP :_: considerations_NNS that_WDT inuence_VBP our_PRP$ decisions_NNS ._.
Dr_NNP James_NNP Cavanaugh_NNP ,_, who_WP is_VBZ Chairman_NNP of_IN the_DT Company_NN :_: Mr_NNP Robin_NNP Buchanan_NNP ,_, who_WP joined_VBD the_DT Board_NNP and_CC the_DT Committee_NNP In_IN 2004_CD ,_, we_PRP will_MD continue_VB our_PRP$ work_NN on_IN remuneration_NN policy_NN ._.
in_IN July_NNP 2003_CD as_IN an_DT independent_JJ non-executive_JJ Director_NNP :_: and_CC The_NNP Board_NNP will_MD also_RB review_VB the_DT Committees_NNS constitution_NN to_TO ensure_VB Mr_NNP Grard_NNP Veilleux_NNP ,_, who_WP stepped_VBD down_RP as_IN a_DT Board_NNP and_CC all_DT members_NNS of_IN the_DT Committee_NNP are_VBP deemed_VBN to_TO be_VB independent_JJ Committee_NNP member_NN in_IN May_NNP 2003_CD ._.
as_IN dened_VBN by_IN the_DT new_JJ Combined_NNP Code_NNP ._.
The_DT Remuneration_NNP Committee_NNP was_VBD materially_RB assisted_VBN in_IN 2003_CD by_IN Mr_NNP Christian_NNP Proulx_NNP ,_, Senior_NNP VP_NNP Global_NNP Human_NNP Resources_NNPS ,_, Mr_NNP Jeff_NNP Devlin_NNP ,_, Director_NNP of_IN Corporate_NNP Affairs_NNPS and_CC Ms_NNPS Tatjana_NNP May_NNP ,_, General_NNP Counsel_NNP ._.
The_DT following_VBG external_JJ advisers_NNS were_VBD appointed_VBN by_IN ,_, and_CC materially_RB assisted_VBN ,_, the_DT Committee_NNP :_: Towers_NNP Perrin_NNP ,_, who_WP also_RB provided_VBD benets_NNS advice_NN in_IN the_DT UK_NNP and_CC US_NNP :_: Slaughter_NN and_CC May_NNP ,_, who_WP provided_VBD general_JJ legal_JJ advice_NN :_: and_CC Deloitte_NNP &_CC Touche_NNP LLP_NNP ,_, the_DT Companys_NNP auditors_NNS ,_, who_WP provided_VBD Dr_NNP Barry_NNP Price_NNP advice_NN in_IN relation_NN to_TO the_DT Companys_NNP Long_NNP Term_NNP Incentive_NNP Plan_NNP Chairman_NNP of_IN the_DT Remuneration_NNP Committee_NNP and_CC some_DT aspects_NNS of_IN Mr_NNP Stahels_NNP departure_NN arrangements_NNS ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Directors_NNS remuneration_JJ report_NN 33_CD Remuneration_NNP policy_NN 2_CD ._.
Annual_JJ Incentive_NNP Plan_NNP The_NNP Remuneration_NNP Committee_NNP considers_VBZ that_IN an_DT effective_JJ Shire_NNP operates_VBZ an_DT Annual_JJ Incentive_NNP Plan_NNP which_WDT rewards_VBZ remuneration_NN policy_NN is_VBZ an_DT important_JJ contributor_NN to_TO the_DT Companys_NNPS performance_NN ._.
The_DT plan_NN is_VBZ also_RB designed_VBN to_TO encourage_VB executives_NNS success_NN ._.
It_PRP directly_RB impacts_VBZ the_DT Companys_NNP ability_NN to_TO attract_VB ,_, retain_VB to_TO meet_VB stretch_JJ performance_NN objectives_NNS at_IN both_DT the_DT Group_NNP and_CC motivate_VB high-calibre_JJ executives_NNS who_WP embody_VBP the_DT Companys_NNPS and_CC the_DT personal_JJ level_NN ._.
values_NNS and_CC deliver_VB value_NN to_TO shareholders_NNS ._.
The_DT Remuneration_NNP Committee_NNP sets_VBZ individual_JJ executive_NN Director_NNP The_NNP Remuneration_NNP Committee_NNP is_VBZ responsible_JJ for_IN developing_VBG ,_, performance_NN objectives_NNS as_RB well_RB as_IN the_DT Group_NNP objectives_NNS at_IN the_DT reviewing_VBG and_CC implementing_VBG the_DT Companys_NNPS compensation_NN start_NN of_IN each_DT financial_JJ year_NN to_TO ensure_VB they_PRP are_VBP aligned_VBN ._.
The_DT Group_NNP and_CC benets_NNS policy_NN ._.
The_DT current_JJ policy_NN is_VBZ intended_VBN to_TO be_VB objectives_NNS apply_VB to_TO all_DT employees_NNS participating_VBG in_IN the_DT Companys_NNP durable_JJ and_CC its_PRP$ effectiveness_NN is_VBZ regularly_RB monitored_VBN by_IN the_DT Annual_JJ Incentive_NNP Plan_NNP ._.
Each_DT objective_NN ,_, whether_IN Group_NNP or_CC personal_JJ ,_, Remuneration_NNP Committee_NNP ._.
is_VBZ weighted_JJ and_CC is_VBZ described_VBN in_IN specic_JJ terms_NNS with_IN allocated_VBN deadlines_NNS ._.
The_DT 2003_CD Group_NNP performance_NN objectives_NNS included_VBD :_: The_DT policy_NN is_VBZ based_VBN on_IN the_DT following_VBG principles_NNS :_: growth_NN in_IN revenue_NN :_: Compensation_NNP is_VBZ market-driven_JJ and_CC benchmarked_VBN against_IN growth_NN in_IN net_JJ income_NN :_: the_DT FTSE_NNP 100_CD ,_, despite_IN the_DT fact_NN that_IN the_DT majority_NN of_IN employees_NNS ,_, progression_NN of_IN R&D_NNP portfolio_NN :_: and_CC including_VBG the_DT Chief_NNP Executive_NNP officer_NN ,_, are_VBP US-based_JJ ._.
The_DT annual_JJ incentive_NN plan_NN is_VBZ performance-related_JJ and_CC is_VBZ linked_VBN to_TO the_DT achievement_NN of_IN an_DT appropriate_JJ mix_NN of_IN Group_NNP and_CC The_DT Remuneration_NNP Committee_NNP assesses_VBZ performance_NN against_IN individual_JJ performance_NN targets_NNS ._.
The_DT Committee_NNP currently_RB aims_VBZ objectives_NNS in_IN the_DT first_JJ quarter_NN of_IN the_DT following_JJ year_NN ._.
The_DT annual_JJ for_IN the_DT performance-related_JJ elements_NNS of_IN executive_NN Director_NNP bonus_NN is_VBZ payable_JJ in_IN cash_NN and_CC is_VBZ not_RB pensionable_JJ ._.
Target_NN bonus_NN compensation_NN to_TO represent_VB over_IN half_NN of_IN total_JJ remuneration_NN ._.
is_VBZ paid_VBN where_WRB executive_JJ Directors_NNS have_VBP fully_RB achieved_VBN their_PRP$ Share-based_JJ compensation_NN is_VBZ a_DT key_JJ element_NN of_IN the_DT Companys_NNPS personal_JJ objectives_NNS and_CC the_DT Group_NNP objectives_NNS have_VBP been_VBN met_VBN remuneration_JJ policy_NN as_IN it_PRP aligns_VBZ the_DT interests_NNS of_IN the_DT Companys_NNPS in_IN full_JJ ._.
Maximum_NNP bonus_NN is_VBZ paid_VBN only_RB if_IN the_DT Remuneration_NNP executives_NNS with_IN the_DT interests_NNS of_IN its_PRP$ shareholders_NNS ._.
Committee_NNP determines_VBZ that_IN personal_JJ and_CC or_CC Group_NNP performance_NN Compensation_NNP and_CC benets_NNS arrangements_NNS are_VBP clear_JJ and_CC has_VBZ been_VBN exceptional_JJ ._.
Maximum_NNP bonus_NN payments_NNS are_VBP capped_VBN well_RB understood_VBN ._.
at_IN 100_CD %_NN of_IN salary_NN for_IN the_DT Chief_NNP Executive_NNP officer_NN and_CC 75_CD %_NN of_IN salary_NN for_IN other_JJ executive_JJ Directors_NNS ._.
Details_NNS of_IN the_DT bonus_NN structure_NN The_DT remuneration_NN package_NN and_CC the_DT relative_JJ weighting_NN of_IN objectives_NNS between_IN Group_NNP and_CC The_DT main_JJ elements_NNS of_IN the_DT remuneration_NN package_NN for_IN executive_JJ personal_JJ objectives_NNS are_VBP shown_VBN in_IN the_DT table_NN below_IN ._.
The_DT levels_NNS Directors_NNS and_CC senior_JJ management_NN are_VBP :_: of_IN target_NN and_CC maximum_NN bonuses_NNS have_VBP been_VBN set_VBN in_IN line_NN with_IN the_DT competitive_JJ market_NN in_IN the_DT UK_NNP ._.
Annual_JJ Incentive_NNP Plan_NNP :_: Target_NNP bonus_NN bonus_NN Weighting_NN of_IN target_NN as_IN a_DT %_NN of_IN as_IN a_DT %_NN of_IN bonus_NN objectives_NNS 3_CD ._.
Share_NN Options_NNS :_: salary_NN salary_NN Group_NNP Personal_NNP 4_CD ._.
Deferred_JJ Bonus_NN Plan_NN :_: and_CC Mr_NNP Matthew_NNP Emmens_NNP 55_CD %_NN 100_CD %_NN 80_CD %_NN 20_CD %_NN 6_CD ._.
Chief_NNP Executive_NNP officer_NN Mr_NNP Angus_NNP Russell_NNP 50_CD %_NN 75_CD %_NN 60_CD %_NN 40_CD %_NN 1_CD ._.
Salary_NNP Chief_NNP Financial_NNP officer_NN The_DT Remuneration_NNP Committee_NNP reviews_VBZ salaries_NNS annually_RB ._.
In_IN doing_VBG so_RB ,_, it_PRP looks_VBZ at_IN a_DT range_NN of_IN factors_NNS such_JJ as_IN competitive_JJ Dr_NNP Wilson_NNP Totten_NNP 50_CD %_NN 75_CD %_NN 60_CD %_NN 40_CD %_NN market_NN data_NNS provided_VBN by_IN independent_JJ external_JJ consultants_NNS ,_, Chief_NNP scientific_JJ officer_NN local_JJ market_NN conditions_NNS ,_, performance-related_JJ pay_NN increases_NNS across_IN the_DT Company_NN and_CC individual_JJ skills_NNS and_CC performance_NN ._.
The_DT bonus_NN awarded_VBN to_TO the_DT executive_NN Directors_NNS for_IN 2003_CD reects_VBZ The_DT Remuneration_NNP Committees_NNS policy_NN is_VBZ for_IN salary_NN to_TO be_VB set_VBN at_IN the_DT Group_NNP and_CC personal_JJ achievements_NNS and_CC amounted_VBD to_TO 53_CD %_NN the_DT median_NN of_IN the_DT appropriate_JJ comparator_NN group_NN unless_IN individual_NN of_IN salary_NN for_IN Mr_NNP Emmens_NNP ,_, 50.5_CD %_NN of_IN salary_NN for_IN Mr_NNP Russell_NNP and_CC performance_NN and_CC or_CC skills_NNS shortages_NNS require_VBP a_DT different_JJ approach_NN ._.
34_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Directors_NNS remuneration_JJ report_NN 3_CD ._.
Share_NN Options_NNS The_DT Committee_NNP is_VBZ of_IN the_DT view_NN that_IN re-testing_JJ should_MD be_VB retained_VBN Executive_NNP Directors_NNS are_VBP eligible_JJ to_TO participate_VB in_IN the_DT Companys_NNPS on_IN this_DT limited_JJ basis_NN in_IN order_NN to_TO maintain_VB the_DT Schemes_NNPS 2000_CD Executive_NNP Share_NNP Option_NN Scheme_NN ._.
Share_NN options_NNS ,_, which_WDT form_VBP international_JJ competitiveness_NN ._.
In_IN particular_JJ ,_, the_DT Committee_NNP part_NN of_IN the_DT executive_NN Directors_NNS long-term_JJ compensation_NN ,_, are_VBP used_VBN is_VBZ conscious_JJ of_IN the_DT fact_NN that_IN performance_NN tests_NNS are_VBP not_RB attached_VBN to_TO align_VB Directors_NNS interests_NNS with_IN those_DT of_IN shareholders_NNS and_CC to_TO to_TO the_DT vesting_NN of_IN options_NNS in_IN many_JJ markets_NNS and_CC that_IN ,_, in_IN the_DT US_NNP ,_, promote_VB sustained_VBN long-term_JJ company_NN performance_NN ._.
phased_VBD vesting_NN of_IN options_NNS is_VBZ also_RB common_JJ ._.
The_DT grant_NN of_IN options_NNS to_TO executive_JJ Directors_NNS is_VBZ wholly_RB at_IN the_DT The_NNP Committee_NNP is_VBZ aware_JJ that_IN some_DT shareholders_NNS oppose_VBP even_RB discretion_NN of_IN the_DT Remuneration_NNP Committee_NNP ._.
In_IN granting_VBG share_NN limited_JJ re-testing_NN and_CC ,_, as_IN with_IN all_DT remuneration_JJ policy_NN matters_NNS ,_, options_NNS ,_, the_DT Committee_NNP takes_VBZ into_IN account_NN the_DT advice_NN and_CC will_MD therefore_RB keep_VB this_DT aspect_NN of_IN policy_NN under_IN review_NN ._.
recommendations_NNS of_IN the_DT Chief_NNP Executive_NNP officer_NN ._.
The_DT face_NN value_NN of_IN options_NNS granted_VBN under_IN the_DT Scheme_NNP is_VBZ normally_RB capped_VBN at_IN three_CD Any_DT new_JJ option_NN scheme_NN established_VBN in_IN the_DT future_NN will_MD not_RB contain_VB times_NNS salary_NN per_IN year_NN for_IN executive_NN Directors_NNS and_CC senior_JJ managers_NNS ._.
This_DT annual_JJ grant_NN level_NN is_VBZ competitive_JJ in_IN the_DT UK_NNP market_NN and_CC is_VBZ consistent_JJ with_IN the_DT emphasis_NN the_DT Company_NN places_NNS on_IN share-based_JJ The_DT table_NN below_IN sets_NNS out_IN the_DT share_NN options_NNS that_WDT were_VBD granted_VBN remuneration_NN for_IN its_PRP$ executives_NNS ._.
In_IN exceptional_JJ circumstances_NNS ,_, to_TO executive_JJ Directors_NNS during_IN 2003_CD ._.
such_JJ as_IN on_IN the_DT appointment_NN of_IN the_DT new_JJ Chief_NNP Executive_NNP officer_NN ,_, Number_NN of_IN Executive_NNP Director_NNP and_CC ordinary_JJ Exercise_NNP Matthew_NNP Emmens_NNP ,_, this_DT grant_NN level_NN has_VBZ been_VBN exceeded_VBN ._.
share_NN option_NN scheme_NN Date_NNP of_IN grant_NN shares_NNS Price_NN The_DT current_JJ performance_NN measure_NN for_IN the_DT vesting_NN of_IN options_NNS was_VBD Mr_NNP Matthew_NNP Emmens_NNP introduced_VBD in_IN 2002_CD following_VBG consultation_NN with_IN major_JJ institutional_JJ 2000_CD Executive_NNP Scheme_NNP 18.03.03_CD 945,010_CD 3.6825_CD shareholders_NNS ._.
The_DT performance_NN tests_NNS for_IN executive_NN Directors_NNS Stock_NNP Purchase_NNP Plan_NNP 22.08.03_CD 2,098_CD 4.0900_CD options_NNS were_VBD toughened_VBN following_VBG this_DT consultation_NN process_NN ._.
Dr_NNP Wilson_NNP Totten_NNP The_NNP performance_NN tests_NNS are_VBP based_VBN on_IN real_JJ growth_NN in_IN diluted_JJ earnings_NNS 2000_CD Executive_NNP Scheme_NNP 04.03.03_CD 301,775_CD 3.3800_CD per_IN share_NN EPS_NNP as_IN measured_VBN by_IN diluted_JJ EPS_NNP and_CC as_IN reported_VBN in_IN the_DT Companys_NNP Form_NN 10-K_NN under_IN US_NNP GAAP_NNP ._.
This_DT measure_NN Mr_NNP Angus_NNP Russell_NNP is_VBZ favored_VBN by_IN the_DT Remuneration_NNP Committee_NNP because_IN it_PRP is_VBZ transparent_JJ 2000_CD Executive_NNP Scheme_NNP 04.03.03_CD 284,024_CD 3.3800_CD and_CC a_DT highly_RB relevant_JJ indicator_NN of_IN financial_JJ performance_NN ._.
A_DT grant_NN of_IN share_NN options_NNS to_TO Matthew_NNP Emmens_NNP was_VBD made_VBN on_IN The_DT minimum_JJ performance_NN test_NN attaching_VBG to_TO the_DT exercise_NN of_IN share_NN his_PRP$ appointment_NN as_IN Chief_NNP Executive_NNP officer_NN ._.
By_IN UK_NNP standards_NNS options_NNS for_IN executive_NN Directors_NNS is_VBZ higher_JJR than_IN for_IN other_JJ employees_NNS ._.
it_PRP is_VBZ substantial_JJ ,_, but_CC it_PRP is_VBZ considerably_RB lower_JJR than_IN he_PRP could_MD have_VB No_DT options_NNS vest_NN unless_IN Shires_NNP EPS_NNP meets_VBZ the_DT minimum_JJ growth_NN expected_VBN on_IN an_DT annual_JJ basis_NN in_IN the_DT US_NNP where_WRB options_NNS are_VBP typically_RB threshold_NN set_VBN at_IN 15_CD %_NN in_IN excess_NN of_IN the_DT Retail_NNP Price_NNP Index_NNP RPI_NNP granted_VBD with_IN no_DT performance_NN tests_NNS ._.
For_IN all_PDT his_PRP$ options_NNS to_TO vest_NN ,_, or_CC 5_CD %_NN on_IN average_NN a_DT year_NN in_IN the_DT three_CD years_NNS following_VBG the_DT date_NN Shires_VBZ EPS_NNP will_MD need_VB to_TO increase_VB by_IN an_DT average_NN of_IN 9_CD %_NN a_DT year_NN of_IN grant_NN ._.
In_IN the_DT case_NN of_IN an_DT annual_JJ grant_NN of_IN options_NNS worth_JJ three_CD in_IN excess_NN of_IN RPI_NNP ._.
times_NNS salary_NN ,_, Shires_NNP EPS_NNP must_MD grow_VB by_IN 21_CD %_NN in_IN excess_NN of_IN RPI_NNP or_CC on_IN average_JJ 7_CD %_NN a_DT year_NN in_IN the_DT three_CD years_NNS following_VBG the_DT date_NN Details_NNS of_IN the_DT Companys_NNP share_NN option_NN schemes_NNS are_VBP set_VBN out_IN of_IN grant_NN for_IN all_PDT the_DT options_NNS to_TO vest_NN ._.
below_IN and_CC in_IN note_NN 27_CD to_TO the_DT consolidated_JJ financial_JJ statements_NNS ._.
Performance_NNP conditions_NNS attaching_VBG to_TO previous_JJ executive_NN option_NN Grant_NNP %_NN of_IN salary_NN Three-year_JJ EPS_NNP growth_NN grants_NNS are_VBP detailed_VBN on_IN page_NN 41_CD in_IN the_DT audited_JJ section_NN of_IN this_DT Report_NNP ._.
Up_IN to_TO 100_CD %_NN Retail_NNP Price_NNP Index_NNP RPI_NNP plus_CC 15_CD %_NN for_IN executive_NN Directors_NNS Share_NN options_NNS under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP see_VBP note_NN vi_FW for_IN all_DT other_JJ employees_NNS it_PRP is_VBZ RPI_NNP plus_CC 9_CD %_NN on_IN page_NN 41_CD are_VBP offered_VBN at_IN a_DT discount_NN as_IN permitted_VBN by_IN paragraph_NN 101_CD %_NN to_TO 200_CD %_NN RPI_NNP plus_CC 15_CD %_NN 13.31_CD of_IN the_DT Listing_NNP Rules_NNPS ._.
Shares_NNP granted_VBN under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP are_VBP not_RB performance-related_JJ ._.
Long_NNP Term_NNP Incentive_NNP Plan_NNP The_NNP Long_NNP Term_NNP Incentive_NNP Plan_NNP the_DT Plan_NN was_VBD adopted_VBN at_IN the_DT The_DT 2000_CD Executive_NNP Share_NNP Option_NN Scheme_NN ,_, which_WDT was_VBD approved_VBN Companys_NNP 1998_CD Annual_JJ General_NNP Meeting_VBG and_CC amended_VBN in_IN 2000_CD ._.
by_IN shareholders_NNS in_IN 2000_CD ,_, contains_VBZ an_DT unlimited_JJ re-testing_JJ feature_NN Under_IN the_DT Plan_NN ,_, the_DT Remuneration_NNP Committee_NNP has_VBZ discretion_NN to_TO from_IN the_DT date_NN of_IN grant_NN ._.
The_DT Remuneration_NNP Committee_NNP ,_, after_IN make_VBP awards_NNS of_IN shares_NNS subject_JJ to_TO a_DT maximum_NN of_IN 100_CD %_NN of_IN salary_NN consultation_NN with_IN some_DT of_IN its_PRP$ major_JJ institutional_JJ shareholders_NNS a_DT year_NN ._.
Awards_NNS are_VBP made_VBN to_TO executive_JJ Directors_NNS and_CC senior_JJ in_IN 2003_CD ,_, has_VBZ decided_VBN that_IN ,_, for_IN options_NNS granted_VBN under_IN the_DT scheme_NN managers_NNS ._.
from_IN 2004_CD onwards_NNS ,_, the_DT performance_NN condition_NN should_MD be_VB retested_VBN once_RB only_RB ,_, at_IN five_CD years_NNS after_IN the_DT grant_NN ._.
The_DT re-test_NN will_MD be_VB The_DT performance_NN condition_NN attached_VBN to_TO the_DT vesting_NN of_IN the_DT applied_VBN only_RB where_WRB Shires_NNP EPS_NNP growth_NN has_VBZ not_RB met_VBN the_DT EPS_NNP test_NN share_NN awards_NNS made_VBN under_IN the_DT Plan_NN is_VBZ Shires_NNP Total_NNP Shareholder_NN described_VBD above_IN ._.
The_DT annual_JJ average_JJ growth_NN required_VBN over_IN the_DT Return_NN TSR_NNP relative_JJ to_TO the_DT FTSE_NNP 100_CD index_NN over_IN a_DT three-year_JJ first_JJ three_CD years_NNS must_MD be_VB achieved_VBN over_IN the_DT extended_JJ performance_NN period_NN ._.
The_DT Remuneration_NNP Committee_NNP considers_VBZ this_DT to_TO be_VB period_NN ._.
Hence_RB the_DT level_NN of_IN EPS_NNP growth_NN in_IN the_DT next_JJ two_CD years_NNS needs_VBZ an_DT appropriate_JJ measure_NN given_VBN that_IN Shire_NNP is_VBZ a_DT member_NN of_IN the_DT to_TO be_VB consequentially_RB higher_JJR to_TO meet_VB the_DT test_NN ._.
FTSE_NNP 100_CD and_CC the_DT same_JJ comparator_NN group_NN is_VBZ used_VBN for_IN remuneration_NN benchmarking_VBG purposes_NNS ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Directors_NNS remuneration_JJ report_NN 35_CD Under_IN the_DT Plan_NN :_: 6_CD ._.
Pension_NN and_CC other_JJ benets_NNS The_DT Companys_NNPS policy_NN is_VBZ to_TO ensure_VB that_IN pension_NN benets_NNS all_DT shares_NNS vest_NN if_IN Shires_NNP TSR_NNP is_VBZ in_IN the_DT top_JJ 10_CD %_NN of_IN the_DT FTSE_NNP 100_CD :_: are_VBP competitive_JJ in_IN the_DT markets_NNS in_IN which_WDT Shire_NNP operates_VBZ ._.
20_CD %_NN of_IN the_DT shares_NNS vest_NN if_IN Shires_NNP TSR_NNP is_VBZ at_IN the_DT median_NN of_IN the_DT Shire_NNP contributes_VBZ 30_CD %_NN of_IN the_DT Chief_NNP Executive_NNP Ofcers_NNP annual_JJ FTSE_NNP 100_CD ,_, with_IN vesting_VBG between_IN these_DT points_NNS on_IN a_DT linear_JJ salary_NN to_TO a_DT SERP_NNP and_CC 401_CD K_NNP Plan_NNP in_IN the_DT US_NNP ._.
In_IN the_DT UK_NNP ,_, Shire_NNP basis_NN :_: and_CC operates_VBZ a_DT dened_JJ contribution_NN scheme_NN ._.
The_DT Company_NN contributes_VBZ no_DT shares_NNS vest_NN if_IN Shires_NNP TSR_NNP is_VBZ below_IN the_DT median_NN of_IN the_DT 25_CD %_NN of_IN salary_NN for_IN the_DT Chief_NNP Financial_NNP officer_NN and_CC Group_NNP R&D_NNP FTSE_NNP 100_CD ._.
These_DT rates_NNS are_VBP in_IN line_NN with_IN market_NN practice_NN for_IN FTSE_NNP 100_CD companies_NNS ._.
The_DT implications_NNS of_IN the_DT The_DT Remuneration_NNP Committee_NNP determines_VBZ whether_IN and_CC to_TO what_WP forthcoming_JJ pension_NN tax_NN reforms_NNS will_MD be_VB considered_VBN during_IN extent_NN the_DT performance_NN condition_NN has_VBZ been_VBN met_VBN on_IN the_DT basis_NN of_IN the_DT course_NN of_IN the_DT year_NN ._.
data_NNS provided_VBN by_IN an_DT independent_JJ third_JJ party_NN ._.
To_TO date_NN ,_, all_DT awards_NNS made_VBN under_IN the_DT Plan_NN have_VBP been_VBN made_VBN as_IN a_DT conditional_JJ allocation_NN ,_, In_IN addition_NN to_TO salary_NN ,_, the_DT executive_NN Directors_NNS receive_VBP certain_JJ thereby_RB allowing_VBG ,_, at_IN the_DT Remuneration_NNP Committees_NNS discretion_NN ,_, benets_NNS in_IN kind_NN ,_, principally_RB a_DT car_NN or_CC car_NN allowance_NN ,_, life_NN insurance_NN ,_, for_IN a_DT cash_NN equivalent_NN to_TO be_VB paid_VBN on_IN maturity_NN of_IN the_DT award_NN ._.
Whilst_NNP private_JJ medical_JJ insurance_NN and_CC dental_JJ cover_NN ._.
These_DT benets_NNS are_VBP the_DT performance_NN period_NN is_VBZ measured_VBN over_IN three_CD years_NNS ,_, an_DT award_NN not_RB pensionable_JJ ._.
is_VBZ normally_RB transferred_VBN after_IN the_DT fourth_JJ anniversary_NN of_IN grant_NN to_TO the_DT extent_NN the_DT performance_NN condition_NN has_VBZ been_VBN met_VBN ._.
Service_NNP Contracts_NNPS The_NNP Committee_NNP has_VBZ made_VBN some_DT policy_NN changes_NNS to_TO its_PRP$ executive_NN Directors_NNS were_VBD granted_VBN awards_NNS under_IN the_DT Plan_NN in_IN 2003_CD as_IN Director_NNP contracts_NNS of_IN employment_NN following_VBG consultation_NN with_IN some_DT a_DT conditional_JJ allocation_NN ,_, as_IN dened_VBN in_IN the_DT Plan_NN ,_, as_IN follows_VBZ :_: of_IN the_DT Companys_NNP major_JJ shareholders_NNS in_IN 2003_CD ._.
New_NNP contracts_NNS for_IN the_DT Companys_NNP executive_NN Directors_NNS have_VBP been_VBN prepared_VBN and_CC Earliest_JJS date_NN contain_VBP the_DT following_JJ changes_NNS :_: Value_NN of_IN Total_JJ on_IN which_WDT an_DT conditional_JJ number_NN of_IN award_NN can_MD be_VB Date_NNP of_IN award_NN at_IN ordinary_JJ transferred_VBN to_TO a_DT reduction_NN in_IN the_DT amount_NN payable_JJ in_IN the_DT event_NN of_IN termination_NN award_NN grant_NN date_NN shares_NNS a_DT Director_NNP of_IN employment_NN within_IN 12-months_NNS of_IN a_DT change_NN of_IN control_NN ._.
Mr_NNP Matthew_NNP Emmens_NNP 20.03.03_CD 290,000_CD 80,960_CD 21.03.07_CD The_DT amount_NN payable_JJ is_VBZ reduced_VBN from_IN two_CD years_NNS to_TO one_CD years_NNS salary_NN and_CC the_DT cash_NN equivalent_NN of_IN one_CD years_NNS pension_NN ,_, car_NN and_CC Dr_NNP Wilson_NNP Totten_NNP 20.03.03_CD 170,000_CD 47,459_CD 21.03.07_CD other_JJ contractual_JJ benets_NNS ._.
Any_DT bonus_NN payable_JJ is_VBZ at_IN the_DT discretion_NN Mr_NNP Angus_NNP Russell_NNP 20.03.03_CD 160,000_CD 44,667_CD 21.03.07_CD of_IN the_DT Remuneration_NNP Committee_NNP and_CC is_VBZ capped_VBN at_IN the_DT contractual_JJ maximum_NN bonus_NN :_: and_CC 5_CD ._.
Deferred_JJ Bonus_NNP Plan_NNP the_DT amount_NN of_IN bonus_NN payable_JJ upon_IN termination_NN of_IN employment_NN Following_VBG consultation_NN with_IN some_DT of_IN its_PRP$ major_JJ shareholders_NNS and_CC in_IN other_JJ circumstances_NNS ,_, other_JJ than_IN for_IN cause_NN ,_, is_VBZ at_IN the_DT discretion_NN the_DT subsequent_JJ revision_NN of_IN the_DT design_NN of_IN the_DT Plan_NN ,_, the_DT Company_NN of_IN the_DT Remuneration_NNP Committee_NNP and_CC is_VBZ capped_VBN at_IN the_DT asked_VBN shareholders_NNS in_IN 2003_CD to_TO approve_VB a_DT Deferred_NNP Bonus_NNP Plan_NNP contractual_JJ target_NN bonus_NN ._.
in_IN which_WDT executive_JJ Directors_NNS can_MD participate_VB ._.
This_DT Plan_NN provides_VBZ for_IN participants_NNS to_TO use_VB up_RP to_TO 50_CD %_NN of_IN their_PRP$ annual_JJ bonus_NN to_TO buy_VB The_DT Remuneration_NNP Committees_NNS policy_NN continues_VBZ to_TO be_VB that_IN shares_NNS in_IN the_DT Company_NN ._.
The_DT Company_NN will_MD match_VB any_DT shares_NNS executive_JJ Directors_NNS service_NN contracts_NNS should_MD be_VB for_IN a_DT rolling_JJ term_NN bought_VBD ,_, but_CC the_DT matched_VBN shares_NNS will_MD vest_NN for_IN executive_NN Directors_NNS and_CC ,_, for_IN UK_NNP contracts_NNS ,_, incorporate_VB notice_NN periods_NNS of_IN 12-months_NNS ._.
only_RB if_IN the_DT Companys_NNPS EPS_NNP grows_VBZ by_IN more_JJR than_IN 15_CD %_NN in_IN excess_JJ The_DT Committee_NNP also_RB believes_VBZ that_IN the_DT Company_NN should_MD retain_VB of_IN RPI_NNP over_IN a_DT three-year_JJ period_NN 9_CD %_NN in_IN excess_NN of_IN RPI_NNP for_IN other_JJ the_DT right_NN to_TO make_VB a_DT payment_NN in_IN lieu_NN of_IN notice_NN to_TO a_DT Director_NNP ._.
Diluted_VBN EPS_NNP was_VBD chosen_VBN since_IN it_PRP is_VBZ consistent_JJ with_IN The_DT obligations_NNS on_IN the_DT executive_NN Directors_NNS in_IN respect_NN of_IN intellectual_JJ the_DT minimum_JJ performance_NN test_NN that_WDT applies_VBZ to_TO the_DT vesting_NN of_IN property_NN remain_VBP in_IN place_NN together_RB with_IN the_DT post-termination_JJ options_NNS see_VBP above_IN ._.
The_DT Committees_NNS view_VBP is_VBZ that_IN in_IN the_DT event_NN of_IN early_JJ termination_NN executive_NN Directors_NNS should_MD be_VB treated_VBN fairly_RB but_CC paid_VBD The_DT Remuneration_NNP Committee_NNP believes_VBZ that_IN this_DT Plan_NN will_MD no_RB more_RBR than_IN is_VBZ necessary_JJ ._.
Moreover_RB ,_, there_EX should_MD be_VB no_DT element_NN deliver_VBP value_NN to_TO shareholders_NNS by_IN encouraging_JJ executive_JJ share_NN of_IN reward_NN for_IN failure_NN ._.
The_DT Committee_NNP is_VBZ committed_VBN to_TO aligning_VBG executive_NN and_CC shareholder_NN interests_NNS and_CC is_VBZ considering_VBG the_DT introduction_NN The_DT executive_NN Directors_NNS contracts_NNS of_IN employment_NN ,_, which_WDT were_VBD of_IN a_DT shareholding_NN policy_NN ._.
revised_VBN to_TO reect_VB the_DT changes_NNS noted_VBD above_IN ,_, are_VBP dated_VBN 10_CD March_NNP 2004_CD in_IN the_DT case_NN of_IN each_DT of_IN Mr_NNP Russell_NNP and_CC Dr_NNP Totten_NNP and_CC 12_CD March_NNP 2004_CD in_IN the_DT case_NN of_IN Mr_NNP Emmens_NNP ._.
The_DT contract_NN for_IN Mr_NNP Stahel_NNP ,_, the_DT previous_JJ Chief_NNP Executive_NNP officer_NN ,_, was_VBD dated_VBN 28_CD February_NNP 2003_CD ._.
Mr_NNP Russells_NNPS and_CC Dr_NNP Tottens_NNP contracts_NNS require_VBP them_PRP to_TO give_VB the_DT Company_NN 12-months_NNS notice_NN and_CC expire_VB on_IN them_PRP reaching_VBG 65_CD ._.
Mr_NNP Emmens_NNP contract_NN requires_VBZ him_PRP to_TO give_VB the_DT Company_NN six-months_JJ notice_NN and_CC no_DT age_NN is_VBZ specified_VBN for_IN retirement_NN ._.
The_DT Company_NN is_VBZ required_VBN to_TO give_VB Mr_NNP Russell_NNP and_CC Dr_NNP Totten_NNP 12-months_NNS notice_NN of_IN termination_NN ,_, other_JJ than_IN if_IN termination_NN is_VBZ for_IN cause_NN ,_, whereas_IN it_PRP is_VBZ not_RB obliged_VBN to_TO give_VB Mr_NNP Emmens_NNP any_DT notice_NN ._.
36_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Directors_NNS remuneration_JJ report_NN Non-executive_JJ Directors_NNS and_CC the_DT Chairman_NNP Performance_NNP graph_NN Each_DT non-executive_JJ Director_NNP is_VBZ paid_VBN a_DT fee_NN for_IN serving_VBG as_IN a_DT Director_NNP The_NNP graph_NN below_IN sets_NNS out_IN the_DT Total_JJ Shareholder_NN Return_NN TSR_NNP for_IN and_CC additional_JJ fees_NNS are_VBP paid_VBN for_IN membership_NN or_CC Chairmanship_NN the_DT five_CD years_NNS ending_VBG 31_CD December_NNP 2003_CD ._.
The_DT graph_NN compares_VBZ of_IN the_DT Audit_NNP ,_, Remuneration_NNP and_CC or_CC Nomination_NNP Committee_NNP ._.
the_DT performance_NN of_IN a_DT holding_NN of_IN the_DT Companys_NNP shares_NNS with_IN that_DT The_DT Chairman_NNP of_IN the_DT Company_NN receives_VBZ a_DT separate_JJ fee_NN ._.
Fees_NNS are_VBP of_IN a_DT holding_NN of_IN shares_NNS in_IN the_DT FTSE_NNP UK_NNP Pharma_NNP and_CC Biotech_NNP Index_NNP determined_VBN by_IN the_DT Board_NNP and_CC are_VBP benchmarked_VBN against_IN nonover_NN the_DT relevant_JJ period_NN ,_, calculated_VBN in_IN accordance_NN with_IN the_DT executive_NN Director_NNP fees_NNS of_IN comparable_JJ companies_NNS ._.
Details_NNS of_IN fees_NNS Directors_NNS Remuneration_NNP Report_NNP Regulations_NNPS 2002_CD ._.
The_DT FTSE_NNP paid_VBD to_TO the_DT Chairman_NNP and_CC non-executive_JJ Directors_NNS in_IN 2003_CD are_VBP set_VBN UK_NNP Pharma_NNP and_CC Biotech_NNP Index_NNP has_VBZ been_VBN selected_VBN to_TO show_VB out_RP in_IN the_DT table_NN on_IN page_NN 37_CD ._.
shareholders_NNS how_WRB Shires_NNP TSR_NNP has_VBZ performed_VBN relative_JJ to_TO other_JJ companies_NNS in_IN its_PRP$ sector_NN over_IN a_DT five_CD year_NN period_NN ._.
The_DT fees_NNS paid_VBN to_TO non-executive_JJ Directors_NNS are_VBP not_RB performancerelated_JJ ._.
Non-executive_JJ Directors_NNS do_VBP not_RB participate_VB in_IN any_DT of_IN the_DT Five_CD Year_NN Historical_JJ TSR_NNP Performance_NNP Change_NNP in_IN the_DT Value_NNP Company_NNP share_NN schemes_NNS or_CC other_JJ employee_NN benefit_NN schemes_NNS and_CC of_IN a_DT Hypothetical_JJ 100_CD Holding_NNP Over_IN Five_CD Years_NNS ._.
FTSE_NNP UK_NNP no_DT options_NNS have_VBP been_VBN granted_VBN to_TO non-executive_JJ Directors_NNS in_IN their_PRP$ Pharma_NNP and_CC Biotech_NNP Index_NNP Comparison_NNP Based_VBD on_IN Spot_NNP Values_NNP ._.
capacity_NN as_IN non-executive_JJ Directors_NNS of_IN Shire_NNP ._.
Neither_CC the_DT Chairman_NNP nor_CC the_DT non-executive_JJ Directors_NNS are_VBP eligible_JJ to_TO join_VB the_DT Companys_NNPS 400_CD pension_NN scheme_NN ._.
350_CD The_DT Hon_NNP James_NNP Grant_NNP holds_VBZ share_NN options_NNS relating_VBG to_TO his_PRP$ service_NN with_IN Shire_NNP BioChem_NNP ,_, which_WDT merged_VBD with_IN Shire_NNP ._.
The_DT grant_NN of_IN these_DT 300_CD options_NNS was_VBD made_VBN on_IN the_DT same_JJ terms_NNS as_IN applied_VBN to_TO other_JJ employees_NNS ,_, at_IN the_DT time_NN ,_, including_VBG that_IN these_DT options_NNS are_VBP not_RB 250_CD subject_JJ to_TO any_DT performance_NN conditions_NNS ._.
200_CD The_DT Chairman_NNP and_CC the_DT non-executive_JJ Directors_NNS have_VBP letters_NNS of_IN appointment_NN detailing_VBG their_PRP$ specic_JJ terms_NNS of_IN engagement_NN which_WDT ,_, 150_CD other_JJ than_IN for_IN Dr_NNP Price_NNP ,_, are_VBP for_IN a_DT two-year_JJ term_NN which_WDT may_MD be_VB renewed_VBN ._.
Dr_NNP Prices_NNS re-appointment_NN in_IN January_NNP 2004_CD is_VBZ for_IN a_DT one_NN -_: 100_CD year_NN term_NN which_WDT may_MD be_VB renewed_VBN ._.
Details_NNS of_IN the_DT unexpired_JJ terms_NNS of_IN the_DT letters_NNS of_IN appointment_NN and_CC notice_NN periods_NNS are_VBP as_IN follows_VBZ :_: 50_CD Date_NN of_IN Date_NNP of_IN Notice_NNP Dec-98_NNP Dec-99_NNP Dec-00_NNP Dec-01_NNP Dec-02_NNP Dec-03_NNP Director_NNP appointment_NN term_NN expiry_JJ period_NN Dr_NNP James_NNP Cavanaugh_NNP 24.03.03_CD 23.03.05_CD 3_CD months_NNS Shire_NNP Pharmaceuticals_NNP Group_NNP PLC_NNP FTSE_NNP UK_NNP Pharma_NNP and_CC Biotech_NNP Index_NNP Dr_NNP Barry_NNP Price_NNP 25.01.04_CD 24.01.05_CD 3_CD months_NNS The_DT Hon_NNP James_NNP Grant_NNP 11.05.03_CD 10.05.05_CD 3_CD months_NNS Termination_NN payments_NNS Mr_NNP Rolf_NNP Stahel_NNP stepped_VBD down_RP as_IN Chief_NNP Executive_NNP officer_NN Mr_NNP Ronald_NNP Nordmann_NNP 23.12.03_CD 22.12.05_CD 3_CD months_NNS of_IN the_DT Company_NN in_IN March_NNP 2003_CD ._.
As_IN was_VBD disclosed_VBN in_IN the_DT 2002_CD Mr_NNP Robin_NNP Buchanan_NNP 30.07.03_CD 29.07.05_CD 3_CD months_NNS Remuneration_NNP Report_NNP ,_, the_DT Board_NNP decided_VBD to_TO pay_VB Mr_NNP Stahel_NNP in_IN accordance_NN with_IN the_DT payment_NN in_IN lieu_NN of_IN notice_NN provisions_NNS in_IN his_PRP$ Related_JJ party_NN transactions_NNS contract_NN of_IN employment_NN ._.
The_DT compensation_NN for_IN loss_NN of_IN ofce_NN Details_NNS of_IN transactions_NNS relating_VBG to_TO Mr_NNP John_NNP Spitznagel_NNP ,_, a_DT former_JJ payment_NN ,_, equating_VBG to_TO his_PRP$ contractual_JJ entitlement_NN ,_, amounted_VBD non-executive_JJ Director_NNP who_WP entered_VBD into_IN a_DT consultancy_NN agreement_NN to_TO 1,335,169_CD ._.
In_IN the_DT view_NN of_IN the_DT Remuneration_NNP Committee_NNP with_IN the_DT Company_NN ,_, and_CC The_DT Hon_NNP James_NNP Grant_NNP ,_, who_WP is_VBZ a_DT partner_NN and_CC the_DT Board_NNP this_DT payment_NN was_VBD justied_VBN given_VBN that_IN Mr_NNP Stahels_NNP of_IN a_DT Canadian_JJ law_NN rm_NN with_IN which_WDT the_DT Company_NN incurred_VBN contract_NN was_VBD terminated_VBN ,_, not_RB for_IN any_DT failure_NN on_IN his_PRP$ part_NN ,_, but_CC rather_RB professional_JJ fees_NNS during_IN the_DT year_NN ,_, are_VBP given_VBN in_IN note_NN 19_CD to_TO the_DT because_IN the_DT Board_NNP had_VBD reached_VBN the_DT view_NN that_IN shareholders_NNS would_MD consolidated_JJ financial_JJ statements_NNS ._.
benefit_NN from_IN the_DT appointment_NN of_IN a_DT successor_NN who_WP could_MD lead_VB the_DT Company_NN to_TO its_PRP$ next_JJ stage_NN of_IN development_NN ._.
Details_NNS of_IN Mr_NNP Stahels_NNP options_NNS ,_, LTIP_NNP awards_NNS ,_, emoluments_NNS for_IN 2003_CD and_CC pension_NN contributions_NNS are_VBP set_VBN out_RP in_IN the_DT next_JJ part_NN of_IN this_DT report_NN ,_, under_IN Audited_NNP Information_NNP ._.
Other_JJ remuneration_NN Mr_NNP Russell_NNP was_VBD appointed_VBN as_IN a_DT non-executive_JJ Director_NNP of_IN The_NNP City_NNP of_IN London_NNP Investment_NNP Trust_NNP plc_NN and_CC its_PRP$ associated_VBN companies_NNS ,_, The_DT City_NNP of_IN London_NNP European_NNP Trust_NNP Limited_NNP ,_, The_NNP City_NNP of_IN London_NNP Investments_NNPS Limited_NNP and_CC The_NNP City_NNP of_IN London_NNP Finance_NNP Company_NNP Limited_NNP during_IN 2003_CD ._.
In_IN this_DT capacity_NN ,_, he_PRP was_VBD paid_VBN 16,000_CD ._.
Mr_NNP Russell_NNP will_MD retain_VB this_DT remuneration_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Directors_NNS remuneration_JJ report_NN 37_CD Audited_JJ information_NN Aggregate_NNP Directors_NNS Remuneration_NNP The_DT total_JJ amounts_NNS for_IN Directors_NNS remuneration_NN were_VBD as_IN follows_VBZ :_: 2003 2002 000 000_CD Emoluments_NNP 2,256_CD 2,300_CD Money_NN purchase_NN pension_NN contributions_NNS 4,676_CD 383_CD Gains_NNS on_IN exercise_NN of_IN share_NN options_NNS 114_CD 2,962_CD Amounts_NNS receivable_JJ under_IN long-term_JJ incentive_NN schemes_NNS 276_CD Compensation_NNP for_IN loss_NN of_IN ofce_NN 1,335_CD 8,657_CD 5,645_CD Directors_NNS emoluments_VBZ Cash_NNP Non-cash_JJ benets_NNS benets_VBZ Total_JJ Total_JJ Salary_NNP Bonuses_NNS Fees_NNS in_IN kind_NN in_IN kind_NN 2003_CD 2002_CD Director_NNP 000 000 000 000_CD 000 000 000_CD Executive_NNP Mr_NNP Matthew_NNP Emmens_NNP ii_FW i_FW 446_FW 235_CD 14_CD 4_CD 699_CD Mr_NNP Angus_NNP Russell_NNP 320_CD 162_CD 10_CD 7_CD 499_CD 444_CD Dr_NNP Wilson_NNP Totten_NNP 340_CD 163_CD 11 17 531 481_CD Mr_NNP Rolf_NNP Stahel_NNP iii_FW 154_CD 124_CD 33_CD 311_CD 1,144_CD 1,260_CD 684_CD 35_CD 61_CD 2,040_CD 2,069_CD Non-executive_JJ Dr_NNP James_NNP Cavanaugh_NNP 54_CD 54_CD 45_CD Dr_NNP Barry_NNP Price_NNP 43_CD 43_CD 37_CD The_DT Hon_NNP James_NNP Grant_NNP 35_CD 35_CD 30_CD Mr_NNP Ronald_NNP Nordmann_NNP 45_CD 45_CD 34_CD Mr_NNP Robin_NNP Buchanan_NNP iv_VBD 16_CD 16_CD Dr_NNP Francesco_NNP Bellini_NNP v_NNP 11_CD 11_CD 30_CD Mr_NNP Grard_NNP Veilleux_NNP v_VBD 12_CD 12_CD 32_CD The_DT late_JJ Dr_NNP Bernard_NNP Canavan_NNP 23 216 216 231_CD Total_JJ 1,260_CD 684_CD 216_CD 35_CD 61_CD 2,256_CD 2,300_CD i_FW Paid_FW in_IN US$_$ ,_, Mr_NNP Emmens_NNP annual_JJ salary_NN in_IN 2003_CD was_VBD $_$ 935,018_CD ii_FW Appointed_VBN 12_CD March_NNP 2003_CD iii_FW Stepped_VBN down_RP on_IN 19_CD March_NNP 2003_CD iv_NN Appointed_VBN 30_CD July_NNP 2003_CD v_NN Stepped_VBD down_RP on_IN 10_CD May_NNP 2003_CD The_DT Remuneration_NNP Committee_NNP and_CC the_DT Board_NNP awarded_VBD Mr_NNP Stahel_NNP the_DT maximum_NN pro_JJ rated_VBN bonus_NN for_IN the_DT part_NN of_IN 2003_CD he_PRP worked_VBD prior_RB to_TO his_PRP$ departure_NN in_IN March_NNP 2003_CD ._.
Cash_NN benets_NNS in_IN kind_NN represent_VBP expense_NN allowances_NNS including_VBG dental_JJ costs_NNS and_CC non-cash_JJ benets_NNS represent_VBP emoluments_NNS ._.
Non-cash_JJ benets_NNS in_IN kind_NN consist_VBP of_IN a_DT car_NN and_CC private_JJ medical_JJ insurance_NN ._.
Details_NNS of_IN exercise_NN of_IN share_NN options_NNS are_VBP disclosed_VBN on_IN page_NN 39_CD ._.
Non-executive_JJ Director_NNP remuneration_NN is_VBZ to_TO from_IN the_DT date_NN of_IN resignation_NN appointment_NN ._.
38_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Directors_NNS remuneration_JJ report_NN Directors_NNS pension_NN entitlements_NNS Directors_NNS shareholdings_NNS The_DT following_JJ Directors_NNS are_VBP members_NNS of_IN money_NN purchase_NN schemes_NNS ._.
Directors_NNS who_WP held_VBD ofce_NN at_IN the_DT end_NN of_IN the_DT year_NN had_VBD interests_NNS Contributions_NNS paid_VBN by_IN the_DT Company_NN in_IN respect_NN of_IN 2003_CD were_VBD in_IN the_DT share_NN capital_NN of_IN the_DT Company_NN as_IN follows_VBZ :_: as_IN follows_VBZ :_: 31_CD December_NNP ,_, 31_CD December_NNP ,_, 2003_CD 2002_CD Notes_NNP 2003_CD 2002_CD Name_NN of_IN Director_NNP 000_CD 000_CD Dr_NNP James_NNP Cavanaugh_NNP i_FW 8,806,368_CD 8,806,368_CD Mr_NNP Matthew_NNP Emmens_NNP 138_CD Mr_NNP Matthew_NNP Emmens_NNP Mr_NNP Angus_NNP Russell_NNP 80_CD 56_CD Mr_NNP Angus_NNP Russell_NNP Dr_NNP Wilson_NNP Totten_NNP 85_CD 46_CD Dr_NNP Wilson_NNP Totten_NNP 6,061_CD 6,061_CD Mr_NNP Rolf_NNP Stahel_NNP 4,347_CD 216_CD Dr_NNP Barry_NNP Price_NNP 31,350_CD 31,350_CD stepped_VBD down_RB on_IN 19_CD March_NNP 2003_CD The_DT Hon_NNP James_NNP Grant_NNP ii_FW 4,551_CD 4,551_CD Dr_NNP Francesco_NNP Bellini_NNP 26_CD 65_CD Mr_NNP Ronald_NNP Nordmann_NNP 46,968_CD 46,968_CD stepped_VBD down_RB on_IN 10_CD May_NNP 2003_CD Mr_NNP Robin_NNP Buchanan_NNP 4,676_CD 383_CD All_DT interests_NNS are_VBP beneficial_JJ unless_IN otherwise_RB stated_VBN ._.
The_DT 2002_CD Remuneration_NNP Report_NNP disclosed_VBD that_IN the_DT Remuneration_NNP Committee_NNP and_CC the_DT Board_NNP decided_VBD ,_, in_IN recognition_NN of_IN Mr_NNP Stahels_NNP Notes_NNP exceptional_JJ services_NNS to_TO the_DT Company_NN over_IN the_DT nine_CD years_NNS of_IN his_PRP$ i_FW Dr_FW Cavanaugh_NNP is_VBZ President_NNP of_IN HealthCare_NNP Ventures_NNP LLC_NNP ,_, employment_NN to_TO make_VB an_DT additional_JJ one-off_JJ payment_NN to_TO a_DT dened_VBN which_WDT is_VBZ the_DT management_NN company_NN for_IN a_DT number_NN of_IN limited_JJ contribution_NN pension_NN arrangement_NN for_IN Mr_NNP Stahel_NNP of_IN 4.3_CD million_CD ._.
partnerships_NNS ,_, which_WDT have_VBP interests_NNS in_IN 8,690,090_CD ordinary_JJ shares_NNS ._.
Dr_NNP Cavanaugh_NNP is_VBZ also_RB the_DT beneficial_JJ owner_NN of_IN The_DT pension_NN payment_NN to_TO Dr_NNP Bellini_NNP ,_, the_DT former_JJ chief_NN executive_NN 116,278_CD ordinary_JJ shares_NNS ._.
of_IN BioChem_NNP Pharma_NNP Inc._NNP arose_VBD from_IN Dr_NNP Bellinis_NNP termination_NN arrangement_NN ,_, which_WDT was_VBD based_VBN on_IN his_PRP$ pre-merger_JJ employment_NN ii_FW On_IN 9_CD June_NNP 2003_CD The_DT Hon_NNP James_NNP Grant_NNP exercised_VBD an_DT option_NN contract_NN ._.
The_DT Companys_NNP obligation_NN to_TO make_VB pension_NN payments_NNS granted_VBN to_TO him_PRP under_IN the_DT BioChem_NNP Stock_NNP Option_NN Plan_NN to_TO Dr_NNP Bellini_NNP ended_VBD on_IN 13_CD May_NNP 2003_CD ._.
for_IN 31,859_CD shares_NNS at_IN the_DT option_NN price_NN of_IN 1.25_CD per_IN share_NN ._.
All_PDT these_DT shares_NNS were_VBD sold_VBN on_IN the_DT same_JJ day_NN at_IN a_DT price_NN of_IN 4.17_CD per_IN share_NN ._.
Directors_NNS share_VBP options_NNS Aggregate_JJ emoluments_NNS disclosed_VBN above_IN do_VBP not_RB include_VB any_DT amounts_NNS for_IN the_DT value_NN of_IN options_NNS to_TO acquire_VB ordinary_JJ shares_NNS in_IN the_DT Company_NN granted_VBN to_TO or_CC held_VBN by_IN the_DT Directors_NNS ._.
Directors_NNS and_CC employees_NNS have_VBP been_VBN granted_VBN options_NNS over_IN ordinary_JJ shares_NNS under_IN the_DT Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 2000_CD Executive_NNP Share_NNP Option_NN Scheme_NNP Parts_NNP A_NNP and_CC B_NNP 2000_CD Executive_NNP Scheme_NNP ,_, the_DT Shire_NNP Holdings_NNP Limited_NNP Share_NNP Option_NN Scheme_NN SHL_NNP Scheme_NNP ,_, the_DT Pharmavene_NNP 1991_CD Stock_NNP Option_NN Plan_NN SLI_NNP Plan_NNP ,_, the_DT Shire_NNP Pharmaceuticals_NNP Executive_NNP Share_NNP Option_NN Scheme_NNP Parts_NNP A_NNP and_CC B_NNP Executive_NNP Scheme_NNP ,_, the_DT Shire_NNP Pharmaceuticals_NNP Sharesave_NNP Scheme_NNP Sharesave_NNP Scheme_NNP ,_, the_DT Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Employee_NNP Stock_NNP Purchase_NNP Plan_NNP Stock_NNP Purchase_NNP Plan_NNP ,_, the_DT Roberts_NNP Stock_NNP Option_NN Plan_NNP Roberts_NNP Plan_NNP and_CC the_DT BioChem_NNP Stock_NNP Option_NN Plan_NN BioChem_NNP Plan_NNP ._.
There_EX have_VBP been_VBN no_DT variations_NNS to_TO the_DT terms_NNS and_CC conditions_NNS or_CC performance_NN criteria_NNS for_IN share_NN options_NNS during_IN the_DT financial_JJ year_NN except_IN as_IN detailed_VBN in_IN the_DT notes_NNS below_IN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Directors_NNS remuneration_JJ report_NN 41_CD Notes_NNP During_IN 2002_CD ,_, the_DT performance_NN criteria_NNS were_VBD again_RB reviewed_VBN i_FW Options_NNPS granted_VBN under_IN the_DT Executive_NNP Scheme_NNP are_VBP subject_JJ to_TO ensure_VB the_DT criteria_NNS reected_VBD the_DT market_NN in_IN which_WDT the_DT to_TO performance_NN criteria_NNS and_CC can_MD not_RB be_VB exercised_VBN in_IN full_JJ ,_, unless_IN Company_NN operates_VBZ ._.
Given_VBN the_DT Companys_NNPS development_NN the_DT Companys_NNPS share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN it_PRP was_VBD felt_VBN appropriate_JJ that_IN an_DT EPS_NNP based_VBN measure_NN should_MD of_IN at_IN least_JJS 20.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ be_VB adopted_VBN in_IN place_NN of_IN share_NN price_NN growth_NN targets_NNS ._.
If_IN the_DT Companys_NNP share_NN price_NN increases_NNS option_NN grants_NNS made_VBN from_IN August_NNP 2002_CD onwards_NNS will_MD only_RB at_IN a_DT compound_NN rate_NN of_IN 14.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ become_VBN exercisable_JJ in_IN full_JJ if_IN the_DT Companys_NNPS EPS_NNP growth_NN three-year_JJ measurement_NN period_NN ,_, 60_CD %_NN of_IN the_DT options_NNS may_MD be_VB exceeds_VBZ the_DT RPI_NNP over_IN a_DT three-year_JJ period_NN for_IN the_DT following_VBG exercised_VBN ._.
If_IN these_DT conditions_NNS are_VBP not_RB met_VBN after_IN the_DT initial_JJ three_CD tranches_NNS of_IN grants_NNS :_: years_NNS ,_, they_PRP are_VBP thereafter_RB tested_VBN quarterly_JJ by_IN reference_NN to_TO share_VB price_NN growth_NN over_IN the_DT extended_JJ period_NN ._.
If_IN the_DT share_NN price_NN does_VBZ Options_NNS with_IN a_DT grant_NN value_NN RPI_NNP plus_CC 9_CD %_NN not_RB meet_VB these_DT conditions_NNS at_IN any_DT time_NN ,_, none_NN of_IN the_DT options_NNS will_MD of_IN up_RB to_TO 100_CD %_NN of_IN salary_NN Directors_NNS ,_, RPI_NNP plus_CC 15_CD %_NN become_VBN exercisable_JJ ._.
Between_IN 101_CD %_NN and_CC ii_FW Options_NNPS granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP are_VBP granted_VBN 200_CD %_NN of_IN salary_NN RPI_NNP plus_CC 15_CD %_NN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 80_CD %_NN of_IN the_DT mid-market_NN Between_IN 201_CD %_NN and_CC price_NN on_IN the_DT day_NN before_IN invitations_NNS are_VBP issued_VBN to_TO employees_NNS ._.
300_CD %_NN of_IN salary_NN RPI_NNP plus_CC 21_CD %_NN Employees_NNS may_MD enter_VB into_IN three_CD or_CC five-year_JJ savings_NNS contracts_NNS ._.
The_DT exercise_NN of_IN options_NNS under_IN this_DT Scheme_NN is_VBZ not_RB subject_JJ Over_IN 301_CD %_NN of_IN salary_NN RPI_NNP plus_CC 27_CD %_NN to_TO any_DT performance_NN criteria_NNS ._.
The_DT adoption_NN of_IN the_DT new_JJ performance_NN criteria_NNS applies_VBZ to_TO iii_VB In_IN connection_NN with_IN the_DT termination_NN of_IN Mr_NNP Stahels_NNP employment_NN ,_, all_DT options_NNS granted_VBN from_IN August_NNP 2002_CD onwards_NNS ._.
The_DT 2000_CD the_DT Remuneration_NNP Committee_NNP agreed_VBD to_TO exercise_VB its_PRP$ discretion_NN Executive_NNP Scheme_NNP provides_VBZ for_IN the_DT performance_NN test_NN to_TO be_VB under_IN the_DT Rules_NNS of_IN the_DT respective_JJ option_NN schemes_NNS to_TO allow_VB re-applied_JJ annually_RB from_IN a_DT xed_JJ point_NN until_IN the_DT option_NN expires_VBZ ._.
Mr_NNP Stahel_NNP to_TO retain_VB these_DT options_NNS for_IN a_DT phased_VBN period_NN of_IN time_NN The_DT Remuneration_NNP Committee_NNP agreed_VBD at_IN the_DT end_NN of_IN 2003_CD 1_CD of_IN up_RB to_TO 2_CD 2_CD years_NNS following_VBG his_PRP$ termination_NN date_NN as_IN set_VBN out_RP that_IN ,_, from_IN 2004_CD ,_, for_IN future_JJ grants_NNS under_IN the_DT Scheme_NNP the_DT in_IN the_DT table_NN above_IN ._.
Mr_NNP Stahels_NNP options_NNS may_MD not_RB be_VB exercised_VBN performance_NN condition_NN should_MD be_VB re-tested_VBN once_RB only_RB ,_, if_IN he_PRP is_VBZ in_IN breach_NN of_IN certain_JJ post_NN termination_NN restrictive_JJ five_CD years_NNS after_IN the_DT grant_NN ._.
covenants_NNS and_CC or_CC if_IN he_PRP engages_VBZ in_IN activity_NN detrimental_JJ to_TO the_DT Company_NN over_IN that_DT period_NN ._.
v_FW Following_VBG the_DT acquisition_NN of_IN BioChem_NNP on_IN 11_CD May_NNP 2001_CD ,_, the_DT BioChem_NNP Plan_NNP was_VBD amended_VBN such_JJ that_IN options_NNS over_IN iv_NN Options_NNS granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP vest_NN BioChems_NNS common_JJ stock_NN became_VBD options_NNS over_IN ordinary_JJ six_CD weeks_NNS prior_RB to_TO the_DT expiry_NN date_NN ._.
Options_NNS granted_VBN under_IN the_DT shares_NNS of_IN the_DT Company_NN ._.
All_DT BioChem_NNP options_NNS ,_, which_WDT were_VBD 2000_CD Executive_NNP Scheme_NNP following_VBG the_DT Companys_NNPS 2000_CD Annual_JJ not_RB already_RB exercisable_JJ ,_, vested_JJ and_CC became_VBD exercisable_JJ General_NNP Meeting_VBG ,_, are_VBP subject_JJ to_TO performance_NN criteria_NNS and_CC as_IN a_DT result_NN of_IN the_DT acquisition_NN and_CC were_VBD not_RB subject_JJ to_TO any_DT can_MD not_RB be_VB exercised_VBN in_IN full_JJ ,_, unless_IN the_DT Companys_NNP share_NN price_NN performance_NN conditions_NNS ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS increases_NNS at_IN a_DT compound_NN rate_NN of_IN at_IN least_JJS 20.5_CD %_NN per_IN annum_NN will_MD be_VB granted_VBN under_IN the_DT BioChem_NNP Plan_NNP ._.
If_IN the_DT Companys_NNP share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN at_IN least_JJS 14.5_CD %_NN per_IN vi_FW Under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP options_NNS are_VBP granted_VBN with_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ,_, an_DT exercise_NN price_NN equal_JJ to_TO 85_CD %_NN of_IN the_DT fair_JJ market_NN value_NN of_IN 60_CD %_NN of_IN the_DT options_NNS will_MD be_VB exercisable_JJ ._.
If_IN these_DT conditions_NNS are_VBP a_DT share_NN on_IN the_DT enrolment_NN date_NN the_DT first_JJ day_NN of_IN the_DT offering_NN not_RB met_VBD after_IN the_DT initial_JJ three-year_JJ measurement_NN period_NN ,_, they_PRP period_NN or_CC the_DT exercise_NN date_NN the_DT last_JJ day_NN of_IN the_DT offering_NN period_NN ,_, will_MD thereafter_RB be_VB tested_VBN quarterly_JJ by_IN reference_NN to_TO compound_VB whichever_WDT is_VBZ the_DT lower_JJR ._.
The_DT offering_NN period_NN is_VBZ for_IN 27-months_NNS ._.
annual_JJ share_NN price_NN growth_NN over_IN an_DT extended_JJ period_NN ._.
If_IN the_DT The_DT exercise_NN of_IN options_NNS under_IN this_DT plan_NN are_VBP not_RB subject_JJ to_TO any_DT share_NN price_NN does_VBZ not_RB meet_VB these_DT conditions_NNS at_IN any_DT time_NN ,_, none_NN performance_NN condition_NN ._.
of_IN these_DT options_NNS will_MD become_VB exercisable_JJ ._.
The_DT market_NN price_NN of_IN the_DT ordinary_JJ shares_NNS at_IN 31_CD December_NNP 2003_CD At_IN the_DT Annual_JJ General_NNP Meeting_VBG of_IN the_DT Company_NN ,_, held_VBN on_IN was_VBD 5.42_CD and_CC the_DT range_NN during_IN the_DT year_NN was_VBD 2.93_CD to_TO 5.42_CD ._.
5_CD June_NNP 2001_CD ,_, a_DT resolution_NN was_VBD passed_VBN to_TO permit_VB the_DT grant_NN of_IN options_NNS under_IN the_DT 2000_CD Executive_NNP Scheme_NNP to_TO be_VB made_VBN subject_JJ to_TO performance_NN criteria_NNS being_VBG satisfied_JJ prior_RB to_TO the_DT date_NN of_IN grant_NN ._.
Subsequent_JJ to_TO the_DT passing_NN of_IN this_DT resolution_NN options_NNS have_VBP been_VBN granted_VBN based_VBN on_IN a_DT performance_NN criteria_NNS being_VBG satisfied_VBN before_IN grant_NN namely_RB that_IN the_DT Companys_NNP share_NN price_NN had_VBD increased_VBN by_IN an_DT annualised_JJ compound_NN rate_NN of_IN 20.5_CD %_NN over_IN a_DT minimum_JJ three-year_JJ period_NN ._.
42_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Directors_NNS remuneration_JJ report_NN Long_NNP Term_NNP Incentive_NNP Plan_NNP LTIP_NNP Long_NNP Term_NNP Incentive_NNP Plan_NNP maturities_NNS during_IN the_DT year_NN 2003_CD are_VBP as_IN follows_VBZ :_: Value_NN of_IN Actual_NNP Market_NNP award_NN at_IN performance_NN price_NN at_IN Value_NNP at_IN Date_NNP of_IN Initial_JJ award_NN grant_NN date_NN related_VBN maturity_NN maturity_NN Date_NNP of_IN Director_NNP award_NN made_VBD award_NN maturity_NN Mr_NNP Angus_NNP Russell_NNP 13.12.99_CD 12,436_CD 90,000_CD 9,203_CD 4.90_CD 45,141_CD 13.12.03_CD Dr_NNP Wilson_NNP Totten_NNP 08.04.99_CD 15,255_CD 71,000_CD 11,289_CD 4.13_CD 46,624_CD 08.03.03_CD Mr_NNP Rolf_NNP Stahel_NNP i_FW 08.04.99_CD 32,230_CD 150,000_CD 23,850_CD 3.68_CD 87,828_CD 18.03.03_CD 01.03.00_CD 35,785_CD 360,050_CD 26,084_CD 3.68_CD 96,054_CD 18.03.03_CD Total_JJ 275,647_CD Note_NN i_FW On_IN Mr_NNP Stahels_NNP termination_NN of_IN employment_NN ,_, the_DT Remuneration_NNP Committee_NNP determined_VBD in_IN accordance_NN with_IN the_DT LTIP_NNP Rules_NNPS in_IN respect_NN of_IN the_DT 1999_CD and_CC 2000_CD Awards_NNPS to_TO make_VB a_DT cash_NN equivalent_JJ payment_NN to_TO Mr_NNP Stahel_NNP on_IN the_DT basis_NN of_IN an_DT LTIP_NNP Award_NNP of_IN :_: a_DT 23,850_CD shares_NNS under_IN the_DT 1999_CD LTIP_NNP Award_NNP b_NN 26,084_CD shares_NNS under_IN the_DT 2000_CD LTIP_NNP Award_NNP ._.
The_DT Remuneration_NNP Committee_NNP further_JJ determined_VBD that_IN Mr_NNP Stahels_NNP 2001_CD and_CC 2002_CD LTIP_NNP awards_NNS would_MD lapse_NN and_CC no_DT payment_NN would_MD be_VB made_VBN to_TO Mr_NNP Stahel_NNP in_IN respect_NN of_IN either_DT of_IN them_PRP ._.
In_IN addition_NN to_TO the_DT above_JJ disclosure_NN ,_, the_DT following_VBG Directors_NNS who_WP served_VBD during_IN the_DT year_NN under_IN review_NN have_VBP exercised_VBN the_DT following_VBG long_JJ term_NN incentive_NN awards_NNS during_IN the_DT period_NN between_IN 1_CD January_NNP 2004_CD and_CC 12_CD March_NNP 2004_CD ._.
Long_NNP Term_NNP Incentive_NNP Plan_NNP maturities_NNS Value_NNP of_IN Actual_NNP award_NN at_IN performance_NN Value_NN at_IN Date_NNP of_IN Initial_JJ award_NN grant_NN date_NN related_VBN maturity_NN Date_NN of_IN Director_NNP award_NN made_VBD award_NN maturity_NN Mr_NNP Angus_NNP Russell_NNP i_FW 01.03.00_CD 1,789_CD 18,000_CD 1,296_CD 7,147_CD 02.03.04_CD Dr_NNP Wilson_NNP Totten_NNP i_FW 01.03.00_CD 19,881_CD 200,032_CD 14,398_CD 79,404_CD 02.03.04_CD Note_NN i_FW For_IN awards_NNS made_VBN under_IN the_DT LTIP_NNP prior_RB to_TO June_NNP 2001_CD ,_, performance_NN is_VBZ measured_VBN over_IN a_DT three-year_JJ period_NN but_CC the_DT performance_NN conditions_NNS are_VBP based_VBN on_IN criteria_NNS of_IN i_FW 50_CD %_NN TSR_NNP benchmarked_VBD against_IN FTSE_NNP mid-250_CD index_NN and_CC ii_FW 50_CD %_NN subject_NN to_TO an_DT EPS_NNP condition_NN measured_VBN against_IN the_DT diluted_VBN EPS_NNP of_IN the_DT Company_NN for_IN the_DT financial_JJ year_NN ended_VBD before_IN the_DT commencement_NN of_IN the_DT performance_NN period_NN and_CC the_DT diluted_VBN EPS_NNP of_IN the_DT Company_NN for_IN the_DT financial_JJ year_NN ended_VBN on_IN or_CC before_IN the_DT end_NN of_IN the_DT performance_NN period_NN ._.
Performance_NNP conditions_NNS attaching_VBG to_TO awards_NNS made_VBN under_IN the_DT Long_NNP Term_NNP Incentive_NNP Plan_NNP are_VBP detailed_VBN on_IN pages_NNS 34_CD to_TO 35_CD ._.
Approval_NN This_DT report_NN was_VBD approved_VBN by_IN the_DT Board_NNP of_IN Directors_NNS on_IN 12_CD March_NNP 2004_CD and_CC signed_VBN on_IN its_PRP$ behalf_NN by_IN :_: Dr_NNP Barry_NNP Price_NNP Chairman_NNP of_IN the_DT Remuneration_NNP Committee_NNP 44_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Corporate_JJ governance_NN statement_NN The_DT Company_NN is_VBZ committed_VBN to_TO high_JJ standards_NNS The_DT Board_NNP has_VBZ taken_VBN into_IN consideration_NN that_IN The_DT Hon_NNP James_NNP Grant_NNP of_IN corporate_JJ governance_NN is_VBZ a_DT partner_NN of_IN Stikeman_NNP Elliot_NNP ,_, a_DT Canadian_JJ law_NN rm_NN which_WDT ,_, from_IN time_NN The_NNP Board_NNP is_VBZ committed_VBN to_TO high_JJ standards_NNS of_IN corporate_JJ governance_NN ._.
to_TO time_NN ,_, provides_VBZ legal_JJ advice_NN to_TO the_DT Group_NNP ._.
The_DT Board_NNP considers_VBZ In_IN July_NNP 2003_CD ,_, the_DT new_JJ Combined_NNP Code_NNP on_IN Corporate_NNP Governance_NNP Mr_NNP Grant_NNP to_TO be_VB independent_JJ notwithstanding_IN his_PRP$ position_NN as_IN he_PRP is_VBZ was_VBD published_VBN and_CC will_MD take_VB effect_NN for_IN the_DT Company_NN for_IN the_DT not_RB involved_VBN in_IN the_DT provision_NN of_IN legal_JJ advice_NN to_TO the_DT Group_NNP and_CC financial_JJ year_NN commencing_VBG on_IN 1_CD January_NNP 2004_CD ._.
The_DT Company_NN is_VBZ not_RB engaged_VBN in_IN marketing_VBG the_DT services_NNS of_IN Stikeman_NNP Elliott_NNP to_TO the_DT has_VBZ already_RB taken_VBN steps_NNS to_TO comply_VB with_IN the_DT new_JJ Combined_NNP Code_NNP ,_, Group_NNP ._.
Mr_NNP Grant_NNP was_VBD a_DT board_NN member_NN of_IN BioChem_NNP Pharma_NNP Inc._NNP notwithstanding_IN that_DT it_PRP is_VBZ not_RB required_VBN to_TO do_VB so_RB until_IN its_PRP$ report_NN prior_RB to_TO its_PRP$ merger_NN with_IN the_DT Company_NN in_IN 2001_CD and_CC he_PRP brings_VBZ for_IN the_DT 2004_CD financial_JJ year_NN ._.
The_DT Companys_NNP compliance_NN with_IN a_DT wealth_NN of_IN experience_NN and_CC expertise_NN to_TO the_DT Board_NNP ._.
the_DT provisions_NNS of_IN the_DT new_JJ Combined_NNP Code_NNP is_VBZ described_VBN in_IN this_DT corporate_JJ governance_NN review_NN ._.
Board_NNP changes_NNS There_EX were_VBD several_JJ changes_NNS to_TO the_DT Board_NNP in_IN 2003_CD ._.
Mr_NNP Rolf_NNP Stahel_NNP ,_, Throughout_IN the_DT period_NN under_IN review_NN the_DT Company_NN has_VBZ ,_, in_IN the_DT the_DT Companys_NNP former_JJ Chief_NNP Executive_NNP stepped_VBD down_RB from_IN the_DT Directors_NNS opinion_NN ,_, i_FW applied_VBD the_DT principles_NNS of_IN the_DT Combined_NNP Board_NNP on_IN 19_CD March_NNP 2003_CD and_CC Dr_NNP Francesco_NNP Bellini_NNP and_CC Mr_NNP Grard_NNP Code_NNP in_IN effect_NN for_IN the_DT 2003_CD financial_JJ year_NN and_CC ii_FW complied_VBN with_IN Veilleux_NNP stepped_VBD down_RB from_IN the_DT Board_NNP as_IN non-executive_JJ Directors_NNS the_DT provisions_NNS of_IN the_DT Combined_NNP Code_NNP in_IN effect_NN for_IN the_DT 2003_CD on_IN 10_CD May_NNP 2003_CD ._.
Mr_NNP Matthew_NNP Emmens_NNP joined_VBD the_DT Board_NNP as_IN Chief_NNP financial_JJ year_NN ._.
Executive_NNP officer_NN on_IN 12_CD March_NNP 2003_CD and_CC Mr_NNP Robin_NNP Buchanan_NNP joined_VBD the_DT Board_NNP as_IN a_DT non-executive_JJ Director_NNP and_CC a_DT member_NN The_DT Board_NNP of_IN the_DT Remuneration_NNP Committee_NNP on_IN 30_CD July_NNP 2003_CD ._.
The_DT Board_NNP comprises_VBZ three_CD executive_NN and_CC five_CD non-executive_JJ Directors_NNS and_CC meets_VBZ at_IN least_JJS five_CD times_NNS a_DT year_NN ._.
Board_NNP meetings_NNS During_IN 2003_CD ,_, there_EX were_VBD 14_CD Board_NNP meetings_NNS of_IN which_WDT five_CD were_VBD The_DT Board_NNP has_VBZ overall_JJ responsibility_NN for_IN managing_VBG the_DT Company_NN face-to-face_JJ meetings_NNS and_CC the_DT remainder_NN held_VBN by_IN telephone_NN ._.
Board_NNP and_CC its_PRP$ strategic_JJ direction_NN and_CC seeks_VBZ to_TO provide_VB effective_JJ leadership_NN meetings_NNS are_VBP well_RB attended_VBN ._.
The_DT record_NN of_IN attendance_NN by_IN Directors_NNS and_CC the_DT control_NN required_VBN for_IN a_DT listed_VBN company_NN ._.
The_DT Board_NNP has_VBZ at_IN Board_NNP meetings_NNS is_VBZ set_VBN out_RP below_IN :_: formally_RB reserved_VBN specic_JJ matters_NNS to_TO itself_PRP for_IN determination_NN which_WDT include_VBP strategic_JJ issues_NNS ,_, budgeting_NN ,_, changes_NNS in_IN share_NN capital_NN ,_, Number_NN of_IN meetings_NNS Out_IN of_IN approval_NN of_IN the_DT Companys_NNPS financial_JJ statements_NNS and_CC entry_NN into_IN Directors_NNS attended_VBD possible_JJ %_NN material_NN contracts_NNS ._.
Matters_NNS not_RB formally_RB reserved_VBN to_TO the_DT Board_NNP are_VBP delegated_VBN to_TO the_DT Executive_NNP Committee_NNP and_CC to_TO various_JJ other_JJ Board_NNP James_NNP Cavanaugh_NNP Chairman_NNP 14_CD 14_CD 100_CD committees_NNS set_VBN out_RP below_IN ._.
The_DT Board_NNP receives_VBZ detailed_JJ information_NN Matthew_NNP Emmens_NNP Chief_NNP Executive_NNP officer_NN 11_CD 11_CD 100_CD from_IN executive_JJ Directors_NNS ,_, the_DT Company_NNP Secretary_NNP and_CC other_JJ senior_JJ appointed_VBN 12_CD March_NNP 2003_CD managers_NNS to_TO enable_VB it_PRP to_TO exercise_VB its_PRP$ responsibility_NN ._.
Angus_NNP Russell_NNP Chief_NNP Financial_NNP officer_NN 14_CD 14_CD 100_CD Dr_NNP Wilson_NNP Totten_NNP 14_CD 14_CD 100_CD All_DT Directors_NNS have_VBP access_NN to_TO the_DT advice_NN and_CC guidance_NN of_IN the_DT Dr_NNP Barry_NNP Price_NNP 14_CD 14_CD 100_CD Company_NNP Secretary_NNP and_CC are_VBP encouraged_VBN to_TO seek_VB independent_JJ The_DT Hon_NNP James_NNP Grant_NNP 13_CD 14_CD 93_CD advice_NN at_IN the_DT Companys_NNP expense_NN ,_, where_WRB they_PRP feel_VBP it_PRP is_VBZ appropriate_JJ ._.
Ronald_NNP Nordmann_NNP 14_CD 14_CD 100_CD The_DT Board_NNP is_VBZ of_IN the_DT opinion_NN that_IN each_DT of_IN its_PRP$ members_NNS has_VBZ the_DT Robin_NNP Buchanan_NNP 5_CD 6_CD 83_CD knowledge_NN ,_, aptitude_NN and_CC experience_NN to_TO perform_VB the_DT functions_NNS appointed_VBN 30_CD July_NNP 2003_CD required_VBN of_IN a_DT Director_NNP of_IN a_DT listed_VBN company_NN ._.
Rolf_NNP Stahel_NNP stepped_VBD down_RP 19_CD March_NNP 2003_CD 3_CD 3_CD 100_CD Dr_NNP Francesco_NNP Bellini_NNP 4_CD 5_CD 80_CD Biographical_NNP details_NNS of_IN the_DT members_NNS of_IN the_DT Board_NNP are_VBP shown_VBN stepped_VBD down_RB 10_CD May_NNP 2003_CD on_IN pages_NNS 28_CD and_CC 29_CD ._.
Grard_NNP Veilleux_NNP 3_CD 5_CD 60_CD stepped_VBD down_RB 10_CD May_NNP 2003_CD Independent_NNP Directors_NNS The_DT Board_NNP considers_VBZ Dr_NNP James_NNP Cavanaugh_NNP ,_, Dr_NNP Barry_NNP Price_NNP ,_, The_DT non-executive_JJ Directors_NNS have_VBP met_VBN informally_RB during_IN the_DT year_NN The_DT Hon_NNP James_NNP Grant_NNP ,_, Mr_NNP Ronald_NNP Nordmann_NNP and_CC Mr_NNP Robin_NNP without_IN the_DT Chairman_NNP and_CC Chief_NNP Executive_NNP officer_NN present_JJ but_CC not_RB Buchanan_NNP to_TO be_VB independent_JJ non-executive_JJ Directors_NNS ._.
The_DT Board_NNP as_IN part_NN of_IN a_DT structured_JJ program_NN ._.
It_PRP is_VBZ intended_VBN that_IN such_JJ views_NNS each_DT of_IN these_DT non-executive_JJ Directors_NNS to_TO be_VB independent_JJ meetings_NNS will_MD be_VB formalised_VBN in_IN 2004_CD ._.
of_IN management_NN ,_, independent_JJ in_IN judgement_NN and_CC character_NN ,_, and_CC free_JJ from_IN any_DT business_NN or_CC other_JJ relationship_NN which_WDT could_MD materially_RB Chairman_NNP and_CC Chief_NNP Executive_NNP officer_NN interfere_VB with_IN the_DT exercise_NN of_IN their_PRP$ independent_JJ judgement_NN ._.
The_DT ofces_NNS of_IN Chairman_NNP and_CC Chief_NNP Executive_NNP officer_NN are_VBP held_VBN separately_RB ._.
The_DT Chairman_NNP ,_, Dr_NNP James_NNP Cavanaugh_NNP ,_, is_VBZ responsible_JJ The_NNP Board_NNP considered_VBD its_PRP$ non-executive_JJ Chairman_NNP ,_, Dr_NNP James_NNP for_IN the_DT conduct_NN of_IN the_DT Board_NNP and_CC ensures_VBZ that_IN Board_NNP discussions_NNS Cavanaugh_NNP ,_, to_TO be_VB an_DT independent_JJ non-executive_JJ Director_NNP are_VBP conducted_VBN in_IN such_JJ a_DT way_NN that_IN all_DT views_NNS are_VBP taken_VBN into_IN account_NN ,_, in_IN 2003_CD ._.
Dr_NNP Cavanaugh_NNP is_VBZ a_DT member_NN of_IN the_DT Companys_NNP Audit_NNP so_IN that_IN no_DT individual_JJ Director_NNP or_CC small_JJ group_NN of_IN Directors_NNS and_CC Remuneration_NNP Committees_NNS and_CC is_VBZ Chairman_NNP of_IN the_DT Companys_NNP dominates_VBZ proceedings_NNS ._.
The_DT Chief_NNP Executive_NNP officer_NN has_VBZ the_DT Nomination_NNP Committee_NNP ._.
As_IN the_DT new_JJ Combined_NNP Code_NNP contemplates_VBZ general_JJ responsibility_NN for_IN running_VBG the_DT business_NN on_IN a_DT day-to-day_JJ that_IN the_DT Chairman_NNP should_MD no_RB longer_RB be_VB considered_VBN to_TO be_VB basis_NN and_CC chairs_VBZ the_DT Executive_NNP Committee_NNP ._.
independent_JJ ,_, the_DT Company_NN will_MD address_VB this_DT by_IN changing_VBG the_DT constitution_NN of_IN the_DT Audit_NNP and_CC Remuneration_NNP Committees_NNS in_IN 2004_CD ._.
The_DT roles_NNS and_CC responsibilities_NNS of_IN the_DT Chairman_NNP and_CC the_DT Chief_NNP Executive_NNP officer_NN are_VBP clearly_RB dened_VBN ,_, separate_JJ and_CC have_VBP been_VBN approved_VBN by_IN the_DT Board_NNP ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Corporate_JJ governance_NN statement_NN 45_CD Senior_NNP non-executive_JJ Director_NNP The_DT Audit_NNP Committee_NNP met_VBD on_IN four_CD occasions_NNS during_IN 2003_CD ._.
Dr_NNP Barry_NNP Price_NNP is_VBZ the_DT nominated_VBN senior_JJ independent_JJ Mr_NNP Ronald_NNP Nordmann_NNP was_VBD the_DT Chairman_NNP of_IN the_DT Audit_NNP Committee_NNP non-executive_JJ Director_NNP ._.
in_IN 2003_CD and_CC Dr_NNP Barry_NNP Price_NNP and_CC Dr_NNP James_NNP Cavanaugh_NNP were_VBD members_NNS of_IN the_DT Committee_NNP in_IN 2003_CD ._.
All_DT members_NNS attended_VBD Supply_NN of_IN information_NN all_DT meetings_NNS in_IN 2003_CD ._.
The_DT executive_NN Directors_NNS and_CC the_DT Company_NNP Secretary_NNP are_VBP responsible_JJ for_IN ensuring_VBG that_IN detailed_VBN information_NN is_VBZ provided_VBN Mr_NNP Nordmann_NNP has_VBZ been_VBN a_DT financial_JJ analyst_NN for_IN over_IN 30_CD years_NNS to_TO Board_NNP members_NNS in_IN advance_NN of_IN any_DT scheduled_VBN Board_NNP meeting_NN ._.
and_CC accordingly_RB is_VBZ considered_VBN by_IN the_DT Board_NNP to_TO have_VB recent_JJ and_CC Before_IN decisions_NNS are_VBP made_VBN consideration_NN is_VBZ given_VBN to_TO the_DT adequacy_NN relevant_JJ financial_JJ experience_NN ._.
of_IN information_NN available_JJ to_TO the_DT Board_NNP and_CC ,_, if_IN necessary_JJ ,_, decisions_NNS are_VBP deferred_VBN if_IN further_JJ information_NN is_VBZ required_VBN ._.
ii_FW Remuneration_NNP Committee_NNP The_NNP Remuneration_NNP Committee_NNP determines_VBZ on_IN behalf_NN of_IN the_DT Board_NNP Re-appointment_NN the_DT policy_NN for_IN the_DT setting_NN of_IN remuneration_NN and_CC incentivisation_NN Non-executive_JJ Directors_NNS are_VBP appointed_VBN for_IN a_DT term_NN of_IN two_CD years_NNS ,_, of_IN the_DT executive_NN Directors_NNS and_CC other_JJ senior_JJ executives_NNS and_CC the_DT subject_NN to_TO shareholder_NN approval_NN ._.
Re-appointment_NN of_IN non-executive_JJ xing_NN of_IN the_DT terms_NNS of_IN their_PRP$ employment_NN ._.
The_DT Remuneration_NNP Directors_NNS following_VBG the_DT expiry_NN of_IN such_JJ two-year_JJ period_NN is_VBZ subject_JJ Committee_NNP may_MD engage_VB external_JJ consultants_NNS to_TO advise_VB on_IN any_DT to_TO satisfactory_JJ performance_NN and_CC to_TO Board_NNP approval_NN ._.
At_IN each_DT Annual_JJ General_NNP Meeting_VBG ,_, any_DT Director_NNP who_WP has_VBZ been_VBN The_DT remuneration_NN of_IN non-executive_JJ Directors_NNS is_VBZ determined_VBN appointed_VBN by_IN the_DT Board_NNP is_VBZ required_VBN to_TO seek_VB re-election_NN ,_, together_RB by_IN the_DT Board_NNP ._.
with_IN ,_, but_CC not_RB exceeding_VBG ,_, one-third_NN of_IN the_DT other_JJ Directors_NNS for_IN the_DT time_NN being_VBG ._.
Accordingly_RB ,_, no_DT Director_NNP should_MD serve_VB for_IN more_JJR than_IN The_DT Directors_NNS remuneration_NN report_NN appears_VBZ on_IN pages_NNS 32_CD to_TO 43_CD three_CD years_NNS without_IN being_VBG subject_JJ to_TO re-election_NN by_IN shareholders_NNS ._.
and_CC provides_VBZ further_JJ information_NN on_IN the_DT role_NN of_IN this_DT Committee_NNP ._.
Performance_NNP appraisals_NNS The_DT Remuneration_NNP Committee_NNP met_VBD on_IN 10_CD occasions_NNS in_IN 2003_CD ._.
The_DT new_JJ Combined_NNP Code_NNP will_MD require_VB the_DT Company_NN to_TO describe_VB Dr_NNP Barry_NNP Price_NNP chaired_VBD the_DT Remuneration_NNP Committee_NNP in_IN 2003_CD how_WRB performance_NN evaluation_NN of_IN the_DT Board_NNP ,_, its_PRP$ Committees_NNS and_CC Dr_NNP James_NNP Cavanaugh_NNP was_VBD a_DT member_NN of_IN this_DT Committee_NNP and_CC its_PRP$ Directors_NNS has_VBZ been_VBN conducted_VBN ._.
Mr_NNP Grard_NNP Veilleux_NNP was_VBD a_DT member_NN until_IN he_PRP stepped_VBD down_RB monitored_JJ overall_JJ Board_NNP and_CC individual_JJ Director_NNP performance_NN from_IN the_DT Board_NNP on_IN 10_CD May_NNP 2003_CD ._.
Mr_NNP Robin_NNP Buchanan_NNP joined_VBD the_DT during_IN 2003_CD ,_, a_DT more_RBR formal_JJ performance_NN evaluation_NN for_IN the_DT Board_NNP ,_, Remuneration_NNP Committee_NNP on_IN 30_CD July_NNP 2003_CD ._.
Mr_NNP Veilleux_NNP was_VBD unable_JJ its_PRP$ Committees_NNS and_CC for_IN each_DT Director_NNP will_MD be_VB introduced_VBN in_IN 2004_CD ._.
to_TO attend_VB two_CD of_IN the_DT six_CD Remuneration_NNP Committee_NNP meetings_NNS which_WDT took_VBD place_NN before_IN he_PRP stepped_VBD down_RB from_IN the_DT Board_NNP ,_, but_CC otherwise_RB Committees_NNS of_IN the_DT Board_NNP all_DT members_NNS attended_VBD all_DT meetings_NNS ._.
The_DT Board_NNP has_VBZ established_VBN the_DT Audit_NNP Committee_NNP ,_, the_DT Remuneration_NNP Committee_NNP ,_, the_DT Nomination_NNP Committee_NNP and_CC the_DT Executive_NNP iii_FW Nomination_NNP Committee_NNP Committee_NNP ._.
Each_DT committee_NN has_VBZ its_PRP$ own_JJ written_VBN terms_NNS of_IN reference_NN The_DT Nomination_NNP Committee_NNP is_VBZ responsible_JJ for_IN identifying_VBG and_CC that_WDT have_VBP been_VBN approved_VBN by_IN the_DT Board_NNP ._.
The_DT terms_NNS of_IN reference_NN nominating_NN ,_, for_IN the_DT approval_NN of_IN the_DT Board_NNP ,_, candidates_NNS to_TO ll_VB for_IN the_DT Audit_NNP ,_, Remuneration_NNP and_CC Nomination_NNP Committees_NNS have_VBP vacancies_NNS to_TO the_DT Board_NNP ._.
This_DT Committee_NNP meets_VBZ as_IN required_VBN recently_RB been_VBN revised_VBN and_CC updated_VBN in_IN light_NN of_IN new_JJ regulatory_JJ and_CC in_IN 2003_CD was_VBD chaired_VBN by_IN Dr_NNP James_NNP Cavanaugh_NNP ._.
Mr_NNP Ronald_NNP requirements_NNS in_IN the_DT US_NNP and_CC the_DT release_NN of_IN best_JJS practice_NN guidance_NN Nordmann_NNP ,_, The_DT Hon_NNP James_NNP Grant_NNP and_CC Dr_NNP Barry_NNP Price_NNP also_RB served_VBD in_IN the_DT UK_NNP ._.
The_DT terms_NNS of_IN reference_NN of_IN the_DT Audit_NNP ,_, Nomination_NNP and_CC on_IN this_DT Committee_NNP in_IN 2003_CD ._.
All_DT members_NNS attended_VBD all_DT meetings_NNS Remuneration_NNP Committees_NNS will_MD be_VB made_VBN available_JJ on_IN the_DT Companys_NNPS in_IN 2003_CD ._.
website_NN in_IN 2004_CD ._.
Details_NNS of_IN each_DT committee_NN are_VBP as_IN follows_VBZ :_: When_WRB considering_VBG appointments_NNS to_TO the_DT Board_NNP ,_, the_DT Nomination_NNP i_FW Audit_NNP Committee_NNP Committee_NNP takes_VBZ into_IN account_NN the_DT skills_NNS ,_, knowledge_NN and_CC The_DT Audit_NNP Committee_NNP is_VBZ required_VBN ,_, amongst_IN other_JJ things_NNS ,_, to_TO review_VB experience_NN of_IN the_DT existing_VBG members_NNS of_IN the_DT Board_NNP and_CC determines_VBZ the_DT effectiveness_NN of_IN internal_JJ control_NN systems_NNS ,_, to_TO monitor_VB the_DT the_DT capabilities_NNS which_WDT are_VBP required_VBN of_IN any_DT new_JJ Director_NNP ._.
relationship_NN with_IN external_JJ auditors_NNS including_VBG discussing_VBG the_DT scope_NN The_DT Nomination_NNP Committee_NNP retains_VBZ the_DT services_NNS of_IN executive_NN of_IN the_DT audit_NN and_CC any_DT issues_NNS arising_VBG from_IN it_PRP ,_, to_TO review_VB the_DT Companys_NNPS search_NN consultants_NNS to_TO assist_VB it_PRP in_IN the_DT identication_NN and_CC nomination_NN statutory_JJ accounts_NNS and_CC other_JJ financial_JJ statements_NNS and_CC information_NN of_IN new_JJ Board_NNP candidates_NNS ._.
and_CC to_TO review_VB the_DT business_NN risks_NNS faced_VBN by_IN the_DT Company_NN ._.
The_DT Audit_NNP Committee_NNP also_RB proposes_VBZ to_TO shareholders_NNS the_DT appointment_NN or_CC the_DT iv_NNP Executive_NNP Committee_NNP re-appointment_NN of_IN the_DT external_JJ auditors_NNS and_CC is_VBZ responsible_JJ for_IN The_DT Executive_NNP Committee_NNP has_VBZ the_DT day-to-day_JJ management_NN recommending_VBG their_PRP$ remuneration_NN ._.
of_IN the_DT Company_NN delegated_VBD to_TO it_PRP by_IN the_DT Board_NNP and_CC operates_VBZ within_IN clear_JJ and_CC formal_JJ parameters_NNS ._.
The_DT Executive_NNP Committee_NNP meets_VBZ The_DT Audit_NNP Committee_NNP is_VBZ also_RB required_VBN to_TO approve_VB any_DT audit_NN at_IN least_JJS monthly_JJ ._.
The_DT Chief_NNP Executive_NNP officer_NN is_VBZ the_DT Chairman_NNP of_IN and_CC non-audit_JJ services_NNS provided_VBN by_IN the_DT Companys_NNP auditors_NNS ._.
the_DT Executive_NNP Committee_NNP ,_, which_WDT in_IN 2003_CD consisted_VBD of_IN nine_CD senior_JJ Any_DT such_JJ services_NNS are_VBP either_RB approved_VBN by_IN the_DT Audit_NNP Committee_NNP ,_, executives_NNS including_VBG the_DT three_CD executive_NN Directors_NNS ._.
The_DT Executive_NNP or_CC if_IN between_IN scheduled_VBN Audit_NNP Committee_NNP meetings_NNS ,_, by_IN the_DT Committee_NNP reports_NNS to_TO and_CC seeks_VBZ guidance_NN from_IN the_DT Board_NNP on_IN Chairman_NNP of_IN the_DT Audit_NNP Committee_NNP who_WP has_VBZ been_VBN delegated_VBN a_DT regular_JJ basis_NN ._.
responsibility_NN for_IN doing_VBG so_RB or_CC are_VBP provided_VBN under_IN a_DT pre-approval_JJ policy_NN adopted_VBN by_IN the_DT Audit_NNP Committee_NNP ._.
The_DT Audit_NNP Committee_NNP Directors_NNS remuneration_NN is_VBZ informed_VBN at_IN each_DT meeting_NN of_IN services_NNS approved_VBN by_IN the_DT Chairman_NNP The_NNP Companys_NNP remuneration_NN policy_NN is_VBZ described_VBN in_IN the_DT Directors_NNS or_CC provided_VBN under_IN the_DT pre-approval_JJ policy_NN ._.
These_DT procedures_NNS are_VBP remuneration_JJ report_NN on_IN pages_NNS 32_CD to_TO 43_CD ._.
The_DT report_NN details_NNS the_DT level_NN intended_VBN to_TO safeguard_VB auditor_NN objectivity_NN and_CC independence_NN ._.
of_IN remuneration_NN for_IN Directors_NNS and_CC the_DT basis_NN upon_IN which_WDT executive_JJ remuneration_NN is_VBZ xed_VBN ._.
46_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Corporate_JJ governance_NN statement_NN Executive_NNP remuneration_NNP Code_NNP of_IN Ethics_NNPS The_DT remuneration_NN of_IN the_DT members_NNS of_IN the_DT Executive_NNP Committee_NNP ,_, The_DT Company_NN is_VBZ committed_VBN to_TO the_DT maintenance_NN of_IN high_JJ ethical_JJ other_JJ than_IN the_DT executive_NN Directors_NNS ,_, is_VBZ determined_VBN by_IN the_DT Chief_NNP standards_NNS in_IN its_PRP$ dealings_NNS with_IN all_DT persons_NNS with_IN whom_WP it_PRP is_VBZ involved_VBN ._.
Executive_NNP officer_NN within_IN policy_NN guidelines_NNS set_VBN down_RP by_IN the_DT The_DT Groups_NNS Code_NNP of_IN Ethics_NNPS was_VBD reviewed_VBN and_CC updated_VBN in_IN 2003_CD Remuneration_NNP Committee_NNP and_CC is_VBZ dependent_JJ on_IN performance_NN ._.
and_CC the_DT amended_VBN version_NN was_VBD approved_VBN by_IN the_DT Board_NNP in_IN December_NNP 2003_CD ._.
The_DT Code_NNP of_IN Ethics_NNPS applies_VBZ to_TO all_DT Directors_NNS and_CC Relations_NNS with_IN shareholders_NNS employees_NNS and_CC is_VBZ available_JJ for_IN review_NN on_IN the_DT Companys_NNP website_NN ._.
The_DT Company_NN is_VBZ committed_VBN to_TO maintaining_VBG constructive_JJ relationships_NNS with_IN shareholders_NNS ._.
The_DT Chief_NNP Executive_NNP officer_NN and_CC Financial_JJ disclosure_NN ,_, internal_JJ control_NN and_CC the_DT role_NN the_DT Chief_NNP Financial_NNP officer_NN ,_, supported_VBN by_IN other_JJ senior_JJ executives_NNS ,_, of_IN the_DT auditors_NNS arrange_VBP individual_JJ and_CC group_NN meetings_NNS with_IN major_JJ shareholders_NNS The_DT Board_NNP has_VBZ ,_, through_IN the_DT Audit_NNP Committee_NNP ,_, established_VBD formal_JJ throughout_IN the_DT year_NN to_TO discuss_VB the_DT Companys_NNPS strategy_NN and_CC and_CC transparent_JJ arrangements_NNS for_IN financial_JJ reporting_NN ,_, internal_JJ performance_NN and_CC to_TO understand_VB the_DT views_NNS of_IN major_JJ shareholders_NNS ,_, control_NN and_CC external_JJ auditing_NN ._.
The_DT Audit_NNP Committees_NNS terms_NNS which_WDT are_VBP then_RB communicated_VBN to_TO the_DT Board_NNP as_IN a_DT whole_NN ._.
of_IN reference_NN extend_VBP to_TO the_DT Companys_NNPS risk_NN management_NN activities_NNS The_DT Chairman_NNP and_CC the_DT senior_JJ independent_JJ non-executive_JJ Director_NNP as_IN a_DT whole_JJ and_CC not_RB just_RB the_DT financial_JJ aspects_NNS of_IN internal_JJ control_NN ._.
also_RB are_VBP available_JJ to_TO meet_VB with_IN major_JJ shareholders_NNS ._.
All_DT employees_NNS can_MD raise_VB any_DT concerns_NNS in_IN any_DT of_IN these_DT areas_NNS with_IN The_DT Company_NN maintains_VBZ a_DT ow_NN of_IN information_NN to_TO its_PRP$ shareholders_NNS the_DT Chairman_NNP of_IN the_DT Audit_NNP Committee_NNP in_IN the_DT strictest_JJS confidence_NN ._.
through_IN the_DT announcement_NN of_IN quarterly_JJ results_NNS and_CC the_DT provision_NN The_DT Company_NN operates_VBZ a_DT whistle-blowing_JJ policy_NN which_WDT is_VBZ the_DT of_IN annual_JJ reports_NNS ._.
The_DT Companys_NNP website_NN at_IN www_NN ._.
com_NN also_RB framework_NN for_IN a_DT condential_JJ process_NN through_IN which_WDT all_DT employees_NNS provides_VBZ information_NN about_IN the_DT Company_NN and_CC its_PRP$ business_NN and_CC is_VBZ are_VBP able_JJ to_TO report_VB concerns_NNS relating_VBG to_TO financial_JJ disclosure_NN ,_, internal_JJ regularly_RB updated_VBN ._.
The_DT Companys_NNP Investor_NNP Relations_NNPS department_NN control_NN and_CC other_JJ compliance_NN issues_NNS in_IN good_JJ faith_NN without_IN fear_NN acts_NNS as_IN a_DT contact_NN point_NN for_IN investors_NNS throughout_IN the_DT year_NN ._.
In_IN addition_NN ,_, the_DT Audit_NNP Committee_NNP has_VBZ introduced_VBN a_DT procedure_NN for_IN the_DT receipt_NN and_CC monitoring_NN of_IN The_DT Company_NN holds_VBZ its_PRP$ Annual_JJ General_NNP Meeting_VBG in_IN London_NNP complaints_NNS relating_VBG to_TO internal_JJ controls_NNS ._.
at_IN which_WDT shareholders_NNS are_VBP given_VBN the_DT opportunity_NN to_TO ask_VB questions_NNS of_IN the_DT Directors_NNS ._.
i_FW Financial_NNP reporting_VBG The_DT Board_NNP has_VBZ ultimate_JJ responsibility_NN for_IN the_DT preparation_NN Balanced_JJ and_CC timely_JJ assessment_NN of_IN positions_NNS and_CC prospects_NNS of_IN accounts_NNS and_CC for_IN the_DT monitoring_NN of_IN systems_NNS of_IN internal_JJ The_DT Company_NN strives_VBZ to_TO give_VB timely_JJ assessments_NNS of_IN matters_NNS financial_JJ control_NN ._.
The_DT Board_NNP strives_VBZ to_TO present_VB a_DT balanced_JJ and_CC that_DT impact_NN on_IN its_PRP$ business_NN and_CC financial_JJ position_NN and_CC to_TO present_VB understandable_JJ assessment_NN of_IN the_DT Companys_NNP position_NN and_CC scientific_JJ and_CC other_JJ price-sensitive_JJ data_NNS in_IN a_DT balanced_JJ way_NN ._.
Before_IN its_PRP$ prospects_NNS and_CC endeavors_NNS to_TO present_VB scientific_JJ and_CC other_JJ it_PRP was_VBD required_VBN under_IN SEC_NNP rules_NNS ,_, the_DT Company_NN voluntarily_RB adopted_VBN price-sensitive_JJ information_NN in_IN a_DT balanced_JJ way_NN ._.
The_DT Company_NNP quarterly_JJ financial_JJ reporting_NN ,_, which_WDT is_VBZ not_RB obligatory_JJ in_IN the_DT UK_NNP ._.
publishes_VBZ quarterly_JJ financial_JJ reports_NNS so_IN that_IN its_PRP$ shareholders_NNS can_MD monitor_VB the_DT Companys_NNPS financial_JJ position_NN regularly_RB ._.
Corporate_JJ social_JJ responsibility_NN CSR_NNP The_NNP Company_NNP recognizes_VBZ the_DT impact_NN that_IN its_PRP$ business_NN may_MD have_VB On_IN behalf_NN of_IN the_DT Board_NNP ,_, the_DT Audit_NNP Committee_NNP has_VBZ the_DT responsibility_NN on_IN people_NNS and_CC the_DT environment_NN as_RB well_RB as_IN the_DT social_JJ implications_NNS for_IN reviewing_VBG the_DT effectiveness_NN of_IN the_DT system_NN of_IN internal_JJ financial_JJ of_IN its_PRP$ operations_NNS on_IN the_DT general_JJ community_NN ._.
The_DT Company_NN controls_NNS and_CC the_DT audit_NN process_NN ._.
The_DT Audit_NNP Committee_NNP has_VBZ therefore_RB attaches_VBZ great_JJ importance_NN to_TO social_JJ and_CC environmental_JJ independent_JJ access_NN to_TO the_DT auditors_NNS throughout_IN the_DT year_NN in_IN issues_NNS and_CC to_TO ethical_JJ business_NN practices_NNS ._.
Accordingly_RB ,_, ultimate_JJ addition_NN to_TO presentations_NNS from_IN the_DT auditors_NNS on_IN a_DT quarterly_JJ basis_NN ._.
responsibility_NN for_IN them_PRP is_VBZ taken_VBN at_IN the_DT highest_JJS levels_NNS ._.
The_DT Board_NNP Any_DT significant_JJ findings_NNS or_CC identied_JJ risks_NNS are_VBP closely_RB examined_VBN reviews_VBZ the_DT Companys_NNP approach_NN to_TO corporate_JJ social_JJ responsibility_NN and_CC are_VBP reported_VBN to_TO the_DT Board_NNP with_IN recommendations_NNS for_IN action_NN ._.
generally_RB and_CC the_DT specic_JJ business_NN risks_NNS related_VBN to_TO Social_NNP ,_, Environmental_NNP and_CC Ethical_NNP SEE_VBP matters_NNS ._.
The_DT Company_NN has_VBZ established_VBN a_DT Disclosure_NNP Committee_NNP which_WDT is_VBZ chaired_VBN by_IN the_DT Chief_NNP Financial_NNP officer_NN ._.
Its_PRP$ membership_NN comprises_VBZ The_DT Board_NNP receives_VBZ advice_NN and_CC information_NN from_IN the_DT CSR_NNP senior_JJ managers_NNS from_IN legal_JJ ,_, finance_NN and_CC risk_NN ._.
Its_PRP$ responsibility_NN is_VBZ Committee_NNP to_TO make_VB this_DT assessment_NN ._.
The_DT CSR_NNP Committee_NNP ,_, to_TO establish_VB and_CC maintain_VB controls_NNS and_CC other_JJ procedures_NNS to_TO ensure_VB which_WDT is_VBZ chaired_VBN by_IN the_DT Chief_NNP Financial_NNP officer_NN ,_, was_VBD established_VBN that_IN information_NN disclosed_VBN to_TO investors_NNS is_VBZ recorded_VBN ,_, summarised_VBN during_IN 2003_CD ._.
It_PRP meets_VBZ three_CD times_NNS a_DT year_NN and_CC is_VBZ responsible_JJ for_IN and_CC reported_VBD accurately_RB and_CC to_TO monitor_VB the_DT effectiveness_NN of_IN these_DT setting_VBG the_DT policies_NNS and_CC procedures_NNS that_WDT manage_VBP SEE_VB issues_NNS ,_, procedures_NNS ._.
The_DT Disclosure_NNP Committee_NNP also_RB has_VBZ the_DT responsibility_NN risks_NNS and_CC opportunities_NNS ._.
SEE_VB risks_NNS are_VBP managed_VBN within_IN the_DT overall_JJ for_IN the_DT review_NN and_CC oversight_NN of_IN the_DT Companys_NNP periodic_JJ reporting_NN ._.
framework_NN of_IN risk_NN management_NN ,_, explained_VBD below_IN under_IN the_DT heading_VBG internal_JJ control_NN ._.
This_DT year_NN the_DT Company_NN has_VBZ decided_VBN to_TO produce_VB a_DT standalone_JJ report_NN on_IN CSR_NNP ._.
This_DT is_VBZ available_JJ on_IN request_NN or_CC from_IN the_DT Shire_NNP website_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Corporate_JJ governance_NN statement_NN 47_CD Following_VBG the_DT enactment_NN of_IN the_DT Sarbanes-Oxley_NNP Act_NNP 2002_CD in_IN the_DT The_DT internal_JJ review_NN of_IN the_DT Companys_NNPS control_VBP procedures_NNS and_CC US_NNP ,_, the_DT Chief_NNP Executive_NNP officer_NN and_CC the_DT Chief_NNP Financial_NNP officer_NN compliance_NN with_IN them_PRP is_VBZ mostly_RB undertaken_VBN through_IN internal_JJ audit_NN ._.
are_VBP required_VBN to_TO complete_VB formal_JJ certications_NNS ,_, which_WDT confirm_VBP ,_, The_DT Companys_NNP outsourced_VBD internal_JJ audit_NN function_NN was_VBD operational_JJ inter_NN alia_NN ,_, that_WDT :_: throughout_IN 2003_CD ._.
The_DT majority_NN of_IN internal_JJ audit_NN work_NN during_IN 2003_CD has_VBZ been_VBN concentrated_VBN on_IN internal_JJ financial_JJ controls_NNS and_CC on_IN the_DT annual_JJ report_NN in_IN the_DT US_NNP on_IN Form_NN 10-K_NN does_VBZ not_RB contain_VB any_DT achieving_VBG compliance_NN with_IN Sarbanes-Oxley_NNP Act_NNP requirements_NNS ,_, material_NN misstatements_NNS or_CC omissions_NNS :_: which_WDT is_VBZ required_VBN by_IN 31_CD December_NNP 2004_CD ._.
This_DT will_MD continue_VB in_IN financial_JJ information_NN reported_VBN in_IN Form_NN 10-K_JJ fairly_RB presents_VBZ 2004_CD ._.
The_DT Audit_NNP Committee_NNP ,_, which_WDT is_VBZ responsible_JJ for_IN monitoring_VBG the_DT financial_JJ condition_NN ,_, results_NNS of_IN operations_NNS and_CC cash_NN ows_VBZ the_DT activity_NN of_IN the_DT internal_JJ audit_NN function_NN ,_, has_VBZ reviewed_VBN the_DT of_IN the_DT Company_NN :_: effectiveness_NN of_IN the_DT internal_JJ audit_NN during_IN 2003_CD ._.
the_DT Chief_NNP Executive_NNP officer_NN and_CC the_DT Chief_NNP Financial_NNP officer_NN are_VBP responsible_JJ for_IN determining_VBG and_CC maintaining_VBG disclosure_NN controls_NNS Although_IN the_DT Board_NNP and_CC the_DT Audit_NNP Committee_NNP receive_VBP reports_NNS and_CC procedures_NNS :_: and_CC on_IN areas_NNS of_IN significant_JJ risk_NN to_TO the_DT Company_NN and_CC related_VBN internal_JJ the_DT Chief_NNP Executive_NNP officer_NN and_CC the_DT Chief_NNP Financial_NNP officer_NN have_VBP controls_NNS ,_, there_EX are_VBP limitations_NNS in_IN any_DT system_NN of_IN internal_JJ control_NN indicated_VBD in_IN Form_NN 10-K_JJ whether_IN there_EX were_VBD any_DT significant_JJ and_CC accordingly_RB even_RB the_DT most_RBS effective_JJ system_NN can_MD provide_VB only_JJ changes_NNS in_IN the_DT Companys_NNP internal_JJ control_NN over_IN financial_JJ reporting_NN ._.
reasonable_JJ and_CC not_RB absolute_JJ assurance_NN ._.
Such_JJ a_DT system_NN is_VBZ designed_VBN to_TO manage_VB rather_RB than_IN eliminate_VB the_DT risk_NN of_IN failure_NN to_TO achieve_VB The_DT Chief_NNP Executive_NNP officer_NN and_CC the_DT Chief_NNP Financial_NNP officer_NN have_VBP business_NN objectives_NNS and_CC can_MD only_RB provide_VB reasonable_JJ and_CC not_RB completed_VBN these_DT certications_NNS and_CC they_PRP will_MD be_VB led_VBN with_IN the_DT SEC_NNP absolute_JJ assurance_NN against_IN material_NN misstatement_NN or_CC loss_NN ._.
in_IN the_DT US_NNP as_IN part_NN of_IN the_DT Company_NN 's_POS annual_JJ report_NN in_IN the_DT US_NNP ._.
Whilst_NNP there_EX is_VBZ no_DT formal_JJ requirement_NN for_IN these_DT certications_NNS to_TO be_VB given_VBN iii_FW External_NNP auditing_NN in_IN connection_NN with_IN the_DT accounts_NNS prepared_VBN in_IN accordance_NN with_IN UK_NNP The_NNP Audit_NNP Committee_NNP reviews_VBZ the_DT scope_NN and_CC results_NNS of_IN the_DT GAAP_NNP ,_, the_DT UK_NNP statutory_JJ financial_JJ statements_NNS have_VBP been_VBN prepared_JJ audit_NN and_CC non-audit_JJ services_NNS provided_VBN by_IN the_DT auditors_NNS ,_, the_DT cost_NN using_VBG the_DT same_JJ processes_NNS ._.
effectiveness_NN and_CC the_DT independence_NN and_CC objectivity_NN of_IN the_DT auditors_NNS ._.
ii_FW Risk_NN management_NN and_CC internal_JJ control_NN Going_VBG concern_NN basis_NN The_NNP Board_NNP ,_, in_IN accordance_NN with_IN the_DT Turnbull_NNP Guidance_NNP on_IN internal_JJ After_IN making_VBG enquiries_NNS ,_, the_DT Directors_NNS have_VBP formed_VBN a_DT judgement_NN ,_, control_NN ,_, recognizes_VBZ its_PRP$ overall_JJ responsibility_NN to_TO maintain_VB a_DT sound_NN at_IN the_DT time_NN of_IN approving_VBG the_DT financial_JJ statements_NNS ,_, that_IN there_EX is_VBZ system_NN of_IN internal_JJ control_NN to_TO safeguard_VB shareholders_NNS investments_NNS a_DT reasonable_JJ expectation_NN that_IN the_DT Group_NNP has_VBZ adequate_JJ resources_NNS and_CC the_DT Companys_NNPS assets_NNS and_CC to_TO regularly_RB review_VB its_PRP$ effectiveness_NN ._.
to_TO continue_VB in_IN operational_JJ existence_NN for_IN the_DT foreseeable_JJ future_NN ._.
The_DT Board_NNP has_VBZ reviewed_VBN both_DT the_DT key_JJ risks_NNS faced_VBN by_IN the_DT Company_NN For_IN this_DT reason_NN the_DT Directors_NNS continue_VBP to_TO adopt_VB the_DT going_VBG concern_NN and_CC the_DT effectiveness_NN of_IN the_DT Companys_NNP internal_JJ control_NN systems_NNS basis_NN in_IN preparing_VBG the_DT financial_JJ statements_NNS ._.
Outside_IN of_IN its_PRP$ review_NN ,_, the_DT Board_NNP delegates_NNS responsibility_NN to_TO the_DT Audit_NNP Committee_NNP for_IN more_RBR regular_JJ review_NN of_IN both_DT key_JJ risks_NNS and_CC internal_JJ controls_NNS and_CC for_IN monitoring_VBG the_DT activities_NNS of_IN the_DT internal_JJ audit_NN function_NN ._.
The_DT Audit_NNP Committee_NNP has_VBZ kept_VBN these_DT areas_NNS under_IN review_NN in_IN 2003_CD ._.
The_DT Company_NN has_VBZ an_DT integrated_JJ risk_NN management_NN and_CC internal_JJ audit_NN function_NN ._.
The_DT Head_NNP of_IN Risk_NNP and_CC Audit_NNP ,_, whose_WP$ appointment_NN was_VBD confirmed_VBN by_IN the_DT Audit_NNP Committee_NNP ,_, reports_VBZ to_TO the_DT Chief_NNP Financial_NNP officer_NN and_CC attends_VBZ and_CC presents_VBZ regularly_RB at_IN Audit_NNP Committee_NNP meetings_NNS ._.
The_DT Head_NNP of_IN Risk_NNP and_CC Audit_NNP also_RB has_VBZ direct_JJ access_NN to_TO the_DT Chairman_NNP ,_, the_DT Chairman_NNP of_IN the_DT Audit_NNP Committee_NNP and_CC the_DT other_JJ members_NNS of_IN the_DT Audit_NNP Committee_NNP ._.
The_DT Company_NN has_VBZ an_DT ongoing_JJ process_NN for_IN identifying_VBG ,_, evaluating_VBG and_CC managing_VBG the_DT significant_JJ risks_NNS that_IN it_PRP faces_VBZ ._.
This_DT process_NN has_VBZ been_VBN in_IN operation_NN throughout_IN the_DT period_NN under_IN review_NN and_CC up_RB to_TO the_DT date_NN of_IN the_DT signing_NN of_IN the_DT accounts_NNS ._.
This_DT includes_VBZ analysis_NN of_IN the_DT impact_NN on_IN the_DT operation_NN of_IN key_JJ risks_NNS and_CC the_DT action_NN being_VBG taken_VBN to_TO avoid_VB or_CC reduce_VB each_DT risk_NN ._.
The_DT risk_NN schedule_NN allocates_VBZ responsibility_NN for_IN management_NN of_IN each_DT key_JJ risk_NN to_TO appropriate_JJ senior_JJ executives_NNS ._.
The_DT Company_NN also_RB has_VBZ a_DT system_NN of_IN control_NN procedures_NNS ._.
Compliance_NN with_IN these_DT procedures_NNS is_VBZ monitored_VBN through_IN a_DT system_NN of_IN internal_JJ review_NN and_CC regular_JJ reports_NNS on_IN financial_JJ performance_NN ._.
Any_DT significant_JJ issues_NNS arising_VBG are_VBP reported_VBN to_TO the_DT Audit_NNP Committee_NNP ._.
48_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Statement_NN of_IN Directors_NNS responsibilities_NNS Report_NNP of_IN independent_JJ auditors_NNS Statement_NN of_IN Directors_NNS responsibilities_NNS The_DT Directors_NNS are_VBP responsible_JJ for_IN keeping_VBG proper_JJ accounting_NN UK_NNP company_NN law_NN requires_VBZ the_DT Directors_NNS to_TO prepare_VB financial_JJ records_NNS which_WDT disclose_VBP with_IN reasonable_JJ accuracy_NN at_IN any_DT statements_NNS for_IN each_DT financial_JJ year_NN which_WDT give_VBP a_DT true_JJ and_CC fair_JJ time_NN the_DT financial_JJ position_NN of_IN the_DT Company_NN and_CC enable_VB them_PRP view_VB of_IN the_DT state_NN of_IN affairs_NNS of_IN the_DT Company_NN and_CC the_DT Group_NNP to_TO ensure_VB that_IN the_DT financial_JJ statements_NNS comply_VBP with_IN the_DT as_RB at_IN the_DT end_NN of_IN the_DT financial_JJ year_NN and_CC of_IN the_DT profit_NN or_CC loss_NN Companies_NNS Act_NNP 1985_CD ._.
They_PRP are_VBP also_RB responsible_JJ for_IN the_DT system_NN of_IN the_DT Group_NNP for_IN that_DT period_NN ._.
In_IN preparing_VBG those_DT financial_JJ of_IN internal_JJ control_NN ,_, for_IN safeguarding_VBG the_DT assets_NNS of_IN the_DT Company_NN statements_NNS ,_, the_DT Directors_NNS are_VBP required_VBN to_TO :_: and_CC hence_RB for_IN taking_VBG reasonable_JJ steps_NNS for_IN the_DT prevention_NN and_CC detection_NN of_IN fraud_NN and_CC other_JJ irregularities_NNS ._.
select_JJ suitable_JJ accounting_NN policies_NNS and_CC then_RB apply_VB them_PRP consistently_RB :_: make_VB judgements_NNS and_CC estimates_NNS that_WDT are_VBP reasonable_JJ and_CC prudent_JJ :_: and_CC state_NN whether_IN applicable_JJ accounting_NN standards_NNS have_VBP been_VBN followed_VBN ._.
Report_NNP of_IN independent_JJ auditors_NNS In_IN our_PRP$ opinion_NN the_DT consolidated_JJ financial_JJ statements_NNS present_JJ fairly_RB ,_, To_TO the_DT Shareholders_NNS of_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN :_: in_IN all_DT material_NN respects_VBZ ,_, the_DT financial_JJ position_NN of_IN the_DT companies_NNS We_PRP have_VBP audited_VBN the_DT accompanying_VBG consolidated_JJ balance_NN sheets_NNS as_IN of_IN December_NNP 31_CD ,_, 2003_CD and_CC 2002_CD ,_, and_CC the_DT results_NNS of_IN their_PRP$ of_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN and_CC its_PRP$ subsidiaries_NNS as_IN of_IN operations_NNS and_CC their_PRP$ cash_NN ows_VBZ for_IN each_DT of_IN the_DT three_CD years_NNS in_IN the_DT December_NNP 31_CD ,_, 2003_CD and_CC 2002_CD ,_, and_CC the_DT related_JJ consolidated_JJ period_NN ended_VBD December_NNP 31_CD ,_, 2003_CD ,_, in_IN conformity_NN with_IN accounting_NN statements_NNS of_IN operations_NNS ,_, comprehensive_JJ income_NN ,_, changes_NNS principles_NNS generally_RB accepted_VBN in_IN the_DT United_NNP States_NNPS of_IN America_NNP ._.
in_IN shareholders_NNS equity_NN ,_, and_CC cash_NN ows_NNS for_IN each_DT of_IN the_DT three_CD Also_RB ,_, in_IN our_PRP$ opinion_NN ,_, the_DT financial_JJ statement_NN schedule_NN ,_, when_WRB years_NNS in_IN the_DT period_NN ended_VBD December_NNP 31_CD ,_, 2003_CD ._.
These_DT financial_JJ considered_VBN in_IN relation_NN to_TO the_DT basic_JJ consolidated_JJ financial_JJ statements_NNS are_VBP the_DT responsibility_NN of_IN the_DT Companys_NNP management_NN ._.
statements_NNS taken_VBN as_IN a_DT whole_NN ,_, presents_VBZ fairly_RB in_IN all_DT material_NN respects_VBZ Our_PRP$ responsibility_NN is_VBZ to_TO express_VB an_DT opinion_NN on_IN these_DT financial_JJ the_DT information_NN set_VBN forth_RB therein_RB ._.
statements_NNS and_CC schedules_NNS based_VBN on_IN our_PRP$ audits_NN ._.
We_PRP conducted_VBD our_PRP$ audits_NN in_IN accordance_NN with_IN auditing_NN standards_NNS generally_RB accepted_VBN in_IN the_DT United_NNP States_NNPS of_IN America_NNP ._.
Those_DT standards_NNS require_VBP that_IN we_PRP plan_VBP and_CC perform_VBP the_DT audit_NN to_TO obtain_VB reasonable_JJ assurance_NN about_IN whether_IN the_DT financial_JJ statements_NNS are_VBP free_JJ of_IN material_NN misstatement_NN ._.
An_DT audit_NN includes_VBZ examining_VBG ,_, on_IN a_DT test_NN basis_NN ,_, evidence_NN supporting_VBG the_DT amounts_NNS and_CC disclosures_NNS in_IN the_DT financial_JJ statements_NNS ._.
An_DT audit_NN also_RB includes_VBZ assessing_VBG the_DT accounting_NN principles_NNS used_VBN and_CC significant_JJ estimates_NNS made_VBN by_IN Deloitte_NNP &_CC Touche_NNP LLP_NNP management_NN ,_, as_RB well_RB as_IN evaluating_VBG the_DT overall_JJ financial_JJ statement_NN Reading_VBG ,_, England_NNP presentation_NN ._.
We_PRP believe_VBP that_IN our_PRP$ audits_NN provide_VB a_DT reasonable_JJ March_NNP 10_CD ,_, 2004_CD basis_NN for_IN our_PRP$ opinion_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Consolidated_NNP balance_NN sheets_NNS 49_CD In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN share_NN data_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2003_CD 2002_CD Notes_NNS $_$ 000_CD $_$ 000_CD Assets_NNPS Current_JJ assets_NNS :_: Cash_NN and_CC cash_NN equivalents_NNS 1,103,286_CD 880,973_CD Restricted_VBN cash_NN 6,795_CD 16,745_CD Marketable_JJ securities_NNS 5_CD 304,129_CD 316,126_CD Accounts_NNPS receivable_NN ,_, net_JJ 6_CD 215,690_CD 138,397_CD Inventories_NNS 7_CD 45,258_CD 49,216_CD Deferred_JJ tax_NN asset_NN 25_CD 64,532_CD 34,849_CD Prepaid_NN expenses_NNS and_CC other_JJ current_JJ assets_NNS 8_CD 48,017_CD 30,790_CD Total_JJ current_JJ assets_NNS 1,787,707_CD 1,467,096_CD Investments_NNP 9_CD 73,153_CD 71,962_CD Property_NN ,_, plant_NN and_CC equipment_NN ,_, net_JJ 10_CD 161,225_CD 135,234_CD Goodwill_NNP ,_, net_JJ 11_CD 225,860_CD 203,767_CD Other_JJ intangible_JJ assets_NNS ,_, net_JJ 11_CD 307,882_CD 301,084_CD Deferred_JJ tax_NN asset_NN 25_CD 6,216_CD Other_JJ non-current_JJ assets_NNS 12_CD 22,953_CD 23,264_CD Total_JJ assets_NNS 2,578,780_CD 2,208,623_CD Liabilities_NNS and_CC shareholders_NNS equity_NN Current_JJ liabilities_NNS :_: Current_JJ installments_NNS of_IN long-term_JJ debt_NN 15_CD 1,054_CD 888_CD Accounts_NNPS payable_JJ and_CC accrued_VBN expenses_NNS 13_CD 215,494_CD 184,107_CD Other_JJ current_JJ liabilities_NNS 14_CD 37,127_CD 16,725_CD Total_JJ current_JJ liabilities_NNS from_IN continuing_VBG operations_NNS 253,675_CD 201,720_CD Current_JJ liabilities_NNS from_IN discontinued_VBN operations_NNS 4_CD 12,784_CD Total_JJ current_JJ liabilities_NNS 253,675_CD 214,504_CD Long-term_JJ debt_NN ,_, excluding_VBG current_JJ installments_NNS 15_CD 376,781_CD 407,302_CD Deferred_JJ tax_NN liability_NN 25_CD 1,400_CD Other_JJ non-current_JJ liabilities_NNS 16_CD 23,798_CD 13,651_CD Total_JJ liabilities_NNS 655,654_CD 635,457_CD Shareholders_NNS equity_NN :_: Common_JJ stock_NN ,_, 5p_JJ par_NN value_NN :_: 800,000,000_CD shares_NNS authorized_VBN :_: and_CC 477,894,726_CD 2002_CD :_: 484,344,412_CD shares_NNS issued_VBN and_CC outstanding_JJ 39,521_CD 40,051_CD Exchangeable_JJ shares_NNS :_: 5,839,559_CD 2002_CD :_: 5,874,112_CD shares_NNS issued_VBN and_CC outstanding_JJ 270,667_CD 272,523_CD Additional_JJ paid-in_JJ capital_NN 983,356_CD 1,027,499_CD Accumulated_VBN other_JJ comprehensive_JJ income_NN loss_NN 79,007_CD 41,431_CD Retained_VBN earnings_NNS 550,575_CD 274,524_CD Total_JJ shareholders_NNS equity_NN 1,923,126_CD 1,573,166_CD Total_JJ liabilities_NNS and_CC shareholders_NNS equity_NN 2,578,780_CD 2,208,623_CD The_DT accompanying_JJ notes_NNS are_VBP an_DT integral_JJ part_NN of_IN these_DT consolidated_JJ financial_JJ statements_NNS ._.
50_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Consolidated_NNP statements_NNS of_IN operations_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN share_NN data_NNS 2003 2002 2001_CD Year_NN ended_VBD December_NNP 31_CD ,_, Notes_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD Revenues_NNS Product_NNP sales_NNS 1,029,838_CD 859,388_CD 699,351_CD Licensing_NN and_CC development_NN 3,677_CD 3,064_CD 5,498_CD Royalties_NNS 203,573_CD 174,812_CD 145,155_CD Other_JJ revenues_NNS 13_CD 34_CD 2,952_CD Total_JJ revenues_NNS 1,237,101_CD 1,037,298_CD 852,956_CD Costs_NNS and_CC expenses_NNS Cost_NN of_IN product_NN sales_NNS 163,114_CD 133,682_CD 112,006_CD Research_NNP and_CC development_NN 21_CD 215,781_CD 189,179_CD 171,029_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ 3_CD ,_, 11_CD 463,592_CD 387,399_CD 305,544_CD Other_JJ charges_NNS 22_CD BioChem_NNP merger_NN :_: Restructuring_NN charges_NNS 8,809_CD Asset_NNP impairments_NNS 20,890_CD Merger_NNP transaction_NN expenses_NNS 83,470_CD Loss_NN on_IN the_DT disposition_NN of_IN facility_NN 8,100_CD Total_JJ operating_NN expenses_NNS 842,487_CD 710,260_CD 709,848_CD Operating_NN income_NN 394,614_CD 327,038_CD 143,108_CD Interest_NN income_NN 16,856_CD 19,536_CD 19,667_CD Interest_NN expense_NN 9,470_CD 9,252_CD 12,035_CD Other_JJ expense_NN ,_, net_JJ 23_CD 17,539_CD 8,262_CD 52,933_CD Total_JJ other_JJ expense_NN income_NN ,_, net_JJ 10,153_CD 2,022_CD 45,301_CD Income_NN from_IN continuing_VBG operations_NNS before_IN income_NN taxes_NNS ,_, equity_NN in_IN losses_NNS earnings_NNS of_IN equity_NN method_NN investees_NNS and_CC discontinued_VBN operations_NNS 384,461_CD 329,060_CD 97,807_CD Income_NN taxes_NNS 25_CD 107,353_CD 88,350_CD 67,781_CD Equity_NN in_IN losses_NNS earnings_NNS of_IN equity_NN method_NN investees_VBZ 26_CD 1,057_CD 1,668_CD 1,985_CD Income_NN from_IN continuing_VBG operations_NNS 276,051_CD 242,378_CD 32,011_CD Income_NN from_IN discontinued_VBN operations_NNS net_NN of_IN income_NN tax_NN expense_NN of_IN $_$ nil_CD ,_, $_$ 3,588_CD and_CC $_$ 3,963_CD respectively_RB 4_CD 6,108_CD 6,748_CD Gain_NN on_IN disposition_NN of_IN discontinued_VBN operations_NNS net_NN of_IN income_NN tax_NN expense_NN of_IN $_$ nil_CD ,_, $_$ 1,224_CD and_CC $_$ nil_JJ respectively_RB 4_CD 2,083_CD Net_JJ income_NN 276,051_CD 250,569_CD 38,759_CD Earnings_NNS per_IN share_NN basic_JJ 20_CD Income_NN from_IN continuing_VBG operations_NNS 55.4_CD 48.4_CD 6.5_CD Income_NN from_IN discontinued_VBN operations_NNS 1.6_CD 1.4_CD 55.4_CD 50.0_CD 7.9_CD Earnings_NNS per_IN share_NN diluted_VBN 20_CD Income_NN from_IN continuing_VBG operations_NNS 54.2_CD 47.4_CD 6.4_CD Income_NN from_IN discontinued_VBN operations_NNS 1.6_CD 1.3_CD 54.2_CD 49.0_CD 7.7_CD Weighted_VBN average_JJ number_NN of_IN shares_NNS Basic_JJ 498,212,826_CD 500,687,594_CD 492,594,226_CD Diluted_NNP 518,967,395_CD 522,418,246_CD 504,875,587_CD The_DT accompanying_JJ notes_NNS are_VBP an_DT integral_JJ part_NN of_IN these_DT consolidated_JJ financial_JJ statements_NNS ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Consolidated_NNP statements_NNS of_IN changes_NNS in_IN shareholders_NNS equity_NN 51_CD In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN share_NN data_NNS Accumulated_VBN other_JJ Common_JJ Exchangeable_JJ Accumulated_NNP compreCommon_NNP stock_NN Exchangeable_JJ shares_NNS Additional_JJ deficit_NN hensive_JJ Total_JJ stock_NN number_NN shares_NNS number_NN paid-in_NN retained_VBD income_NN shareholders_NNS amount_NN shares_NNS amount_NN shares_NNS capital_NN earnings_NNS losses_NNS equity_NN $_$ 000_CD 000s_CD $_$ 000_CD 000s_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD As_IN of_IN December_NNP 31_CD ,_, 2000_CD 40,292_CD 488,015_CD 1,209,448_CD 14,804_CD 60,550_CD 1,174,386_CD Net_JJ income_NN 38,759_CD 38,759_CD Foreign_JJ currency_NN translation_NN 32,507_CD 32,507_CD Issue_NN of_IN shares_NNS for_IN acquisitions_NNS 3,662_CD 51,876_CD 802,256_CD 17,292_CD 798,594_CD Issue_NN of_IN common_JJ stock_NN for_IN conversion_NN of_IN loan_NN note_NN 22_CD 295_CD 1,522_CD 1,544_CD Issue_NN costs_NNS 18_CD 18_CD Exchange_NNP of_IN exchangeable_JJ shares_NNS 2,414_CD 33,940_CD 524,870_CD 11,313_CD 522,456_CD Options_NNS exercised_VBN 795_CD 11,443_CD 69,397_CD 70,192_CD Stock_NN option_NN compensation_NN and_CC warrants_NNS 6,780_CD 6,780_CD Tax_NNP benefit_NN associated_VBN with_IN exercise_NN of_IN stock_NN options_NNS 3,805_CD 3,805_CD Unrealized_JJ holding_VBG gain_NN on_IN available-for-sale_JJ investments_NNS 48_CD 48_CD As_IN of_IN December_NNP 31_CD ,_, 2001_CD 39,861_CD 481,817_CD 277,386_CD 5,979_CD 1,014,796_CD 23,955_CD 93,009_CD 1,262,989_CD Net_JJ income_NN 250,569_CD 250,569_CD Foreign_JJ currency_NN translation_NN 50,314_CD 50,314_CD Issue_NN of_IN common_JJ stock_NN for_IN conversion_NN of_IN loan_NN note_NN 21_CD 268_CD 1,479_CD 1,500_CD Exchange_NNP of_IN exchangeable_JJ shares_NNS 22_CD 315_CD 4,863_CD 105_CD 4,841_CD Options_NNS exercised_VBN 147_CD 1,944_CD 5,861_CD 6,008_CD Stock_NN option_NN compensation_NN 166_CD 166_CD Tax_NNP benefit_NN associated_VBN with_IN exercise_NN of_IN stock_NN options_NNS 688_CD 688_CD Unrealized_JJ holding_VBG gain_NN on_IN available_JJ for_IN sale_NN investments_NNS 1,264_CD 1,264_CD As_IN of_IN December_NNP 31_CD ,_, 2002_CD 40,051_CD 484,344_CD 272,523_CD 5,874_CD 1,027,499_CD 274,524_CD 41,431_CD 1,573,166_CD Net_JJ income_NN 276,051_CD 276,051_CD Foreign_JJ currency_NN translation_NN 114,116_CD 114,116_CD Redemption_NN of_IN common_JJ stock_NN 625_CD 7,593_CD 51,767_CD 52,392_CD Exchange_NNP of_IN exchangeable_JJ shares_NNS 8_CD 104_CD 1,856_CD 34_CD 1,848_CD Options_NNS exercised_VBN 87_CD 1,040_CD 5,108_CD 5,195_CD Stock_NN option_NN compensation_NN and_CC warrants_NNS 24_CD 24_CD Tax_NNP benefit_NN associated_VBN with_IN exercise_NN of_IN stock_NN options_NNS 692_CD 692_CD Unrealized_JJ holding_VBG gain_NN on_IN available_JJ for_IN sale_NN investments_NNS -_: 6,322_CD 6,322_CD As_IN of_IN December_NNP 31_CD ,_, 2003_CD 39,521_CD 477,895_CD 270,667_CD 5,840_CD 983,356_CD 550,575_CD 79,007_CD 1,923,126_CD The_DT accompanying_JJ notes_NNS are_VBP an_DT integral_JJ part_NN of_IN these_DT consolidated_JJ financial_JJ statements_NNS ._.
Consolidated_NNP statements_NNS of_IN comprehensive_JJ income_NN In_IN thousands_NNS of_IN US_NNP dollars_NNS 2003 2002 2001_CD Year_NN ended_VBD December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Net_JJ income_NN 276,051_CD 250,569_CD 38,759_CD Other_JJ comprehensive_JJ income_NN loss_NN :_: Foreign_JJ currency_NN translation_NN 114,116_CD 50,314_CD 32,507_CD Unrealized_JJ holding_NN gains_NNS on_IN available_JJ for_IN sale_NN securities_NNS 6,322_CD 1,264_CD 48_CD Comprehensive_JJ income_NN 396,489_CD 302,147_CD 6,300_CD The_DT components_NNS of_IN accumulated_VBN other_JJ comprehensive_JJ income_NN loss_NN as_IN of_IN December_NNP 31_CD ,_, 2003_CD and_CC 2002_CD are_VBP as_IN follows_VBZ :_: December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2003_CD 2002_CD $_$ 000_CD $_$ 000_CD Foreign_JJ currency_NN translation_NN 71,421_CD 42,695_CD Unrealized_JJ holding_NN gains_NNS on_IN available_JJ for_IN sale_NN securities_NNS 7,586_CD 1,264_CD Accumulated_VBN other_JJ comprehensive_JJ income_NN loss_NN 79,007_CD 41,431_CD There_EX are_VBP no_DT material_NN tax_NN effects_NNS related_VBN to_TO the_DT items_NNS included_VBD above_RB ._.
The_DT accompanying_JJ notes_NNS are_VBP an_DT integral_JJ part_NN of_IN these_DT consolidated_JJ financial_JJ statements_NNS ._.
52_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Consolidated_NNP statements_NNS of_IN cash_NN ows_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS 2003 2002 2001_CD Year_NN ended_VBD December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Cash_NN ows_VBZ from_IN operating_VBG activities_NNS :_: Net_JJ income_NN from_IN continuing_VBG operations_NNS 276,051_CD 242,378_CD 32,011_CD Adjustments_NNS to_TO reconcile_VB net_JJ income_NN to_TO net_JJ cash_NN provided_VBN by_IN operating_VBG activities_NNS :_: Depreciation_NN and_CC amortization_NN 42,474_CD 36,434_CD 45,809_CD Increase_VBP decrease_NN in_IN provision_NN for_IN doubtful_JJ accounts_NNS and_CC discounts_NNS 3,268_CD 1,139_CD 3,015_CD Increase_VBP decrease_NN in_IN provision_NN for_IN rebates_NNS and_CC returns_NNS 17,089_CD 2,297_CD 35,526_CD Stock_NN option_NN compensation_NN options_NNS 24_CD 166_CD 2,278_CD Stock_NN option_NN compensation_NN warrants_NNS 4,502_CD Tax_NNP benefit_NN of_IN stock_NN option_NN compensation_NN ,_, charged_VBN directly_RB to_TO equity_NN 692_CD 688_CD 3,805_CD Increase_VBP decrease_NN in_IN deferred_JJ tax_NN asset_NN 22,067_CD 9,884_CD 2,275_CD Non-cash_JJ exchange_NN gains_NNS and_CC losses_NNS 8,558_CD 12,495_CD 1,017_CD Gain_NNP loss_NN on_IN sale_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 169_CD 1,376_CD 8,112_CD Loss_NN on_IN sale_NN of_IN intangible_JJ assets_NNS 2,052_CD Write-down_NN of_IN long-term_JJ investments_NNS 15,616_CD 8,732_CD 61,596_CD Write-down_NN of_IN intangible_JJ assets_NNS 27,489_CD 18,777_CD 25,393_CD Write-down_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 6,026_CD Write-down_NN of_IN assets_NNS held_VBN for_IN resale_NN 10,689_CD Equity_NN in_IN earnings_NNS of_IN equity_NN method_NN investees_VBZ 1,057_CD 1,668_CD 1,985_CD Other_JJ elements_NNS 1,468_CD 1,788_CD Changes_NNS in_IN operating_VBG assets_NNS and_CC liabilities_NNS ,_, net_NN of_IN acquisitions_NNS :_: Increase_VB decrease_NN in_IN accounts_NNS receivable_JJ 57,932_CD 61,159_CD 52,033_CD Decrease_NN increase_NN in_IN inventory_NN 7,387_CD 3,543_CD 5,278_CD Increase_VBP decrease_NN in_IN prepayments_NNS and_CC other_JJ current_JJ assets_NNS 13,024_CD 9,801_CD 29,124_CD Increase_VBP in_IN property_NN plant_NN and_CC equipment_NN held_VBN for_IN resale_NN 12,470_CD Decrease_NN in_IN other_JJ assets_NNS 311_CD 2,905_CD 823_CD Decrease_NN increase_NN in_IN accounts_NNS and_CC notes_NNS payable_JJ and_CC other_JJ liabilities_NNS 3,822_CD 13,581_CD 27,970_CD Increase_VBP decrease_NN in_IN deferred_JJ revenue_NN 19,372_CD 17,409_CD 17,409_CD Dividend_NN received_VBN from_IN equity_NN method_NN investees_VBZ 2,289_CD Net_JJ cash_NN provided_VBN by_IN operating_VBG activities_NNS 355,268_CD 345,058_CD 195,483_CD Cash_NN ows_VBZ from_IN investing_VBG activities_NNS :_: Decrease_NN Increase_VB in_IN short-term_JJ deposits_NNS 11,997_CD 407,653_CD 367,206_CD Purchase_NN of_IN subsidiary_NN undertakings_NNS 17,300_CD Purchase_NN of_IN long-term_JJ investments_NNS 5,643_CD 5,933_CD 20,351_CD Purchase_NN of_IN intangible_JJ assets_NNS 47,049_CD 24,032_CD 35,986_CD Purchase_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 52,165_CD 22,647_CD 13,604_CD Proceeds_NNS from_IN sale_NN of_IN long-term_JJ investments_NNS 1,000_CD 4,108_CD Proceeds_NNS from_IN sale_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 1,262_CD 721_CD 7,081_CD Proceeds_NNS from_IN sale_NN of_IN intangible_JJ assets_NNS 4,556_CD Proceeds_NNS from_IN sale_NN of_IN a_DT business_NN 71,000_CD Movements_NNS in_IN restricted_JJ cash_NN 9,950_CD 16,745_CD Net_JJ cash_NN used_VBN in_IN provided_VBN by_IN investing_VBG activities_NNS 80,648_CD 396,825_CD 425,510_CD Cash_NN ows_VBZ from_IN nancing_VBG activities_NNS :_: Redemption_NN proceeds_NNS from_IN 2_CD %_NN convertible_JJ loan_NN notes_NNS 29,775_CD 400,000_CD Payment_NN of_IN debt_NN issuance_NN costs_NNS 9,000_CD Repayment_NN of_IN long-term_JJ debt_NN ,_, capital_NN leases_NNS and_CC notes_NNS 579_CD 3,381_CD 207,762_CD Proceeds_NNS from_IN issue_NN of_IN common_JJ stock_NN ,_, net_JJ 1,526_CD Proceeds_NNS from_IN exercise_NN of_IN options_NNS 5,195_CD 6,008_CD 70,192_CD Payments_NNS for_IN redemption_NN of_IN common_JJ stock_NN 52,392_CD Net_JJ cash_NN used_VBN in_IN provided_VBN by_IN nancing_VBG activities_NNS 77,551_CD 2,627_CD 254,956_CD Effect_NN of_IN foreign_JJ exchange_NN rate_NN changes_NNS on_IN cash_NN and_CC cash_NN equivalents_NNS 25,244_CD 6,964_CD 1,509_CD Net_JJ increase_NN in_IN cash_NN and_CC cash_NN equivalents_NNS 222,313_CD 751,474_CD 23,420_CD Cash_NN ows_NNS used_VBN in_IN discontinued_VBN operations_NNS 11,459_CD 1,354_CD Net_JJ increase_NN in_IN cash_NN and_CC cash_NN equivalents_NNS 222,313_CD 762,933_CD 24,774_CD Cash_NN and_CC cash_NN equivalents_NNS at_IN beginning_NN of_IN period_NN 880,973_CD 118,040_CD 93,266_CD Cash_NN and_CC cash_NN equivalents_NNS at_IN end_NN of_IN period_NN 1,103,286_CD 880,973_CD 118,040_CD Supplemental_NNP information_NN associated_VBN with_IN continuing_VBG operations_NNS :_: Interest_NN paid_VBD 7,716_CD 8,101_CD 11,122_CD Income_NN taxes_NNS paid_VBD 118,527_CD 101,779_CD 65,773_CD Non_NNP cash_NN activities_NNS :_: Common_JJ stock_NN issued_VBN on_IN conversion_NN of_IN zero-coupon_JJ note_NN 1,500_CD 1,544_CD Capital_NNP leases_NNS assumed_VBD on_IN acquisition_NN of_IN subsidiaries_NNS 6,266_CD The_DT accompanying_JJ notes_NNS are_VBP an_DT integral_JJ part_NN of_IN these_DT consolidated_JJ financial_JJ statements_NNS ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 53_CD In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 1_CD Description_NN of_IN operations_NNS Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Shire_NNP and_CC its_PRP$ subsidiaries_NNS collectively_RB referred_VBD to_TO as_IN the_DT Company_NN is_VBZ a_DT global_JJ pharmaceutical_JJ company_NN with_IN a_DT strategic_JJ focus_NN on_IN meeting_VBG the_DT needs_NNS of_IN the_DT specialist_NN physician_NN ._.
The_DT Company_NN has_VBZ a_DT particular_JJ interest_NN in_IN innovative_JJ therapies_NNS that_WDT are_VBP prescribed_VBN by_IN specialist_NN doctors_NNS as_IN opposed_VBN to_TO primary_JJ care_NN physicians_NNS ._.
The_DT Company_NN is_VBZ focusing_VBG on_IN the_DT development_NN of_IN late_JJ stage_NN projects_NNS and_CC marketing_NN products_NNS in_IN the_DT areas_NNS of_IN central_JJ nervous_JJ system_NN CNS_NNP ,_, gastrointestinal_JJ GI_NNP and_CC renal_JJ ._.
Geographically_NNP ,_, the_DT Company_NN has_VBZ operations_NNS in_IN the_DT worlds_NNS key_JJ pharmaceutical_JJ markets_NNS ,_, namely_RB North_NNP America_NNP and_CC Europe_NNP ._.
The_DT Companys_NNP corporate_JJ head_NN ofce_NN is_VBZ based_VBN in_IN Basingstoke_NNP ,_, UK_NNP ._.
The_DT Companys_NNPS business_NN is_VBZ organized_VBN across_IN five_CD operating_NN segments_NNS :_: US_NNP ,_, International_NNP covering_VBG territories_NNS outside_IN of_IN the_DT US_NNP ,_, Research_NNP &_CC Development_NNP R&D_NNP ,_, Biologics_NNP and_CC Corporate_NNP ._.
Revenues_NNS are_VBP derived_VBN primarily_RB from_IN three_CD sources_NNS :_: sales_NNS of_IN products_NNS by_IN the_DT Companys_NNP own_JJ sales_NNS and_CC marketing_NN operations_NNS ,_, royalties_NNS where_WRB Shire_NNP has_VBZ out-licensed_JJ products_NNS to_TO third_JJ parties_NNS and_CC licensing_NN and_CC development_NN fees_NNS ._.
In_IN May_NNP 2001_CD ,_, Shire_NNP merged_VBD with_IN BioChem_NNP Pharma_NNP ,_, Inc._NNP ._.
BioChem_NNP ,_, an_DT international_JJ pharmaceutical_JJ company_NN based_VBN in_IN Laval_NNP ,_, Canada_NNP ._.
This_DT brought_VBD anti-infective_JJ projects_NNS to_TO Shire_NNP as_RB well_RB as_IN a_DT royalty_NN stream_NN on_IN sales_NNS of_IN 3TC_NNP and_CC ZEFFIX_NNP ,_, out-licensed_JJ to_TO GlaxoSmithKline_NNP GSK_NNP ._.
In_IN September_NNP 2002_CD ,_, Shire_NNP acquired_VBD APS_NNP ,_, subsequently_RB renamed_VBN Shire_NNP US_NNP Manufacturing_NNP Inc._NNP ._.
SUMI_NNP ,_, which_WDT includes_VBZ a_DT state-of-the-art_JJ manufacturing_NN facility_NN located_VBN in_IN Owings_NNP Mills_NNP ,_, Maryland_NNP ._.
It_PRP is_VBZ expected_VBN that_IN the_DT SUMI_NNP facility_NN will_MD become_VB a_DT primary_JJ or_CC secondary_JJ manufacturer_NN for_IN ADDERALL_NNP XR_NNP ,_, CARBATROL_NNP ,_, PENTASA_NNP and_CC DEXTROSTAT_NNP in_IN 2004_CD ._.
This_DT will_MD mitigate_VB Shires_NNP supply_NN risk_NN in_IN the_DT US_NNP ,_, in_IN line_NN with_IN the_DT Companys_NNPS policy_NN of_IN dual_JJ sourcing_VBG key_JJ products_NNS ._.
In_IN February_NNP 2003_CD ,_, the_DT Company_NN acquired_VBD the_DT worldwide_JJ sales_NNS and_CC marketing_NN rights_NNS to_TO METHYPATCH_NNP ,_, a_DT methylphenidate_NN transdermal_JJ delivery_NN system_NN for_IN the_DT once-daily_JJ treatment_NN of_IN attention_NN deficit_NN hyperactivity_NN disorder_NN ADHD_NNP from_IN Noven_NNP Pharmaceuticals_NNP Inc._NNP ._.
Also_RB during_IN 2003_CD ,_, the_DT Company_NN acquired_VBD five_CD products_NNS for_IN the_DT Canadian_JJ market_NN from_IN DRAXIS_NNP Health_NNP Inc._NNP and_CC certain_JJ international_JJ rights_NNS to_TO VANIQA_NNP from_IN Women_NNP First_NNP Healthcare_NNP ,_, Inc._NNP ._.
Following_VBG a_DT detailed_JJ strategic_JJ review_NN conducted_VBN in_IN 2003_CD ,_, the_DT Company_NN has_VBZ revised_VBN its_PRP$ strategic_JJ priority_NN ._.
Shire_NNP will_MD search_VB ,_, develop_VB and_CC market_VB but_CC will_MD not_RB invent_VB ._.
The_DT Company_NN will_MD seek_VB to_TO acquire_VB products_NNS with_IN substantive_JJ patent_NN protection_NN rather_RB than_IN just_RB three_CD years_NNS Hatch-Waxman_NNP exclusivity_NN ._.
The_DT Company_NN will_MD also_RB focus_VB its_PRP$ in-licensing_JJ and_CC merger_NN and_CC acquisition_NN M&A_NNP efforts_NNS on_IN the_DT US_NNP market_NN ,_, and_CC obtain_VB European_JJ rights_NNS whenever_WRB possible_JJ ._.
Shire_NNP has_VBZ refocused_VBN its_PRP$ Research_NNP and_CC Development_NNP R&D_NNP efforts_NNS and_CC technology_NN to_TO concentrate_VB on_IN areas_NNS where_WRB it_PRP has_VBZ a_DT commercial_JJ presence_NN and_CC is_VBZ creating_VBG the_DT exibility_NN to_TO add_VB new_JJ therapeutic_JJ areas_NNS based_VBN on_IN product_NN acquisition_NN opportunities_NNS ._.
The_DT strategic_JJ review_NN thoroughly_RB evaluated_VBD the_DT Groups_NNS pipeline_NN and_CC refocused_VBN resources_NNS on_IN four_CD projects_NNS ,_, which_WDT are_VBP currently_RB in_IN Phase_NN II_NNP and_CC III_NNP of_IN development_NN ._.
This_DT approach_NN aims_VBZ to_TO deliver_VB the_DT combined_VBN benefit_NN of_IN increased_VBN returns_NNS and_CC lower_JJR risks_NNS ._.
The_DT implementation_NN of_IN these_DT actions_NNS has_VBZ resulted_VBN in_IN :_: the_DT exit_NN from_IN early_JJ stage_NN therapeutic_JJ research_NN ,_, which_WDT was_VBD completed_VBN in_IN the_DT third_JJ quarter_NN of_IN 2003_CD :_: the_DT planned_JJ exit_NN from_IN the_DT vaccines_NNS business_NN ,_, which_WDT Shire_NNP is_VBZ targeting_VBG to_TO achieve_VB around_IN mid-year_JJ 2004_CD ._.
These_DT changes_NNS have_VBP implications_NNS for_IN both_DT the_DT Groups_NNS organizational_JJ structure_NN and_CC operating_VBG sites_NNS ._.
The_DT Company_NN has_VBZ a_DT new_JJ global_JJ management_NN structure_NN aimed_VBN at_IN close_JJ interaction_NN between_IN development_NN ,_, marketing_NN and_CC sales_NNS ,_, and_CC new_JJ people_NNS in_IN key_JJ positions_NNS reporting_VBG directly_RB to_TO the_DT Chief_NNP Executive_NNP officer_NN ._.
In_IN addition_NN ,_, the_DT Company_NN has_VBZ advanced_VBN its_PRP$ plans_NNS to_TO reduce_VB the_DT number_NN of_IN North_JJ American_JJ sites_NNS from_IN fourteen_CD to_TO four_CD ,_, including_VBG the_DT opening_NN of_IN a_DT new_JJ US_NNP headquarters_NN ofce_NN on_IN the_DT East_NNP Coast_NNP ._.
Pennsylvania_NNP is_VBZ currently_RB being_VBG considered_VBN in_IN this_DT regard_NN ._.
The_DT Company_NN will_MD close_VB its_PRP$ sites_NNS in_IN Newport_NNP ,_, Kentucky_NNP and_CC Rockville_NNP ,_, Maryland_NNP ._.
Shires_NNP world_NN headquarters_NN will_MD continue_VB to_TO be_VB located_VBN in_IN Basingstoke_NNP ,_, UK_NNP ._.
The_DT cost_NN of_IN the_DT planned_VBN reorganization_NN in_IN 2004_CD is_VBZ estimated_VBN at_IN approximately_RB $_$ 55_CD million_CD split_NN between_IN retaining_VBG and_CC relocating_VBG key_JJ staff_NN to_TO the_DT new_JJ US_NNP headquarters_NN ,_, and_CC site_NN closure_NN costs_NNS and_CC other_JJ relocation_NN expenses_NNS ._.
The_DT majority_NN of_IN these_DT costs_NNS will_MD be_VB charged_VBN as_IN part_NN of_IN operating_NN expenses_NNS ._.
It_PRP is_VBZ anticipated_VBN that_IN these_DT changes_NNS will_MD improve_VB both_DT the_DT efficiency_NN of_IN operation_NN and_CC the_DT cost_NN structure_NN of_IN the_DT Group_NNP going_VBG forward_RB ._.
54_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 1_CD Description_NN of_IN operations_NNS continued_VBD The_DT Companys_NNPS principal_JJ revenues_NNS in_IN the_DT relevant_JJ markets_NNS include_VBP :_: in_IN the_DT US_NNP ,_, ADDERALL_NNP XR_NNP and_CC ADDERALL_NNP for_IN the_DT treatment_NN of_IN ADHD_NNP ,_, AGRYLIN_NNP for_IN the_DT treatment_NN of_IN elevated_JJ blood_NN platelets_NNS ,_, PENTASA_NNP for_IN the_DT treatment_NN of_IN ulcerative_JJ colitis_NNS ,_, CARBATROL_NNP for_IN the_DT treatment_NN of_IN epilepsy_NN and_CC PROAMATINE_NNP for_IN the_DT treatment_NN of_IN orthostatic_JJ hypotension_NN ._.
In_IN addition_NN ,_, the_DT Company_NN receives_VBZ royalties_NNS on_IN sales_NNS of_IN REMINYL_NNP for_IN the_DT treatment_NN of_IN Alzheimers_NNP disease_NN ,_, marketed_VBN by_IN Janssen_NNP ,_, and_CC on_IN EPIVIR_NNP ,_, COMBIVIR_NNP and_CC TRIZIVIR_NNP for_IN the_DT treatment_NN of_IN HIV_NNP AIDS_NNP and_CC EPIVIR-HBV_NNP for_IN the_DT treatment_NN of_IN hepatitis_NNP B_NNP ,_, each_DT marketed_VBN by_IN GSK_NNP :_: in_IN the_DT UK_NNP and_CC the_DT Republic_NNP of_IN Ireland_NNP ,_, the_DT CALCICHEW_NNP range_NN ,_, used_VBN primarily_RB as_IN adjuncts_NNS in_IN the_DT treatment_NN of_IN osteoporosis_NN ,_, and_CC REMINYL_NNP ,_, which_WDT is_VBZ co-promoted_VBN by_IN Janssen-Cilag_NNP :_: in_IN Canada_NNP ,_, 3TC_NNP for_IN the_DT treatment_NN of_IN HIV_NNP AIDS_NNP ,_, COMBIVIR_NNP and_CC HEPTOVIR_NNP all_DT marketed_VBN in_IN partnership_NN with_IN GSK_NNP :_: AMATINE_NNP and_CC FLUVIRAL_NNP S_NNP F_NN ,_, a_DT vaccine_NN for_IN the_DT prevention_NN of_IN inuenza_NN :_: and_CC in_IN the_DT Rest_VB of_IN the_DT World_NNP ,_, royalties_NNS on_IN the_DT sales_NNS of_IN ZEFFIX_NNP for_IN the_DT treatment_NN of_IN hepatitis_NNP B_NNP ,_, marketed_VBN by_IN GSK_NNP ,_, and_CC royalties_NNS on_IN sales_NNS of_IN REMINYL_NNP marketed_VBN by_IN Johnson_NNP &_CC Johnson_NNP ._.
In_IN addition_NN ,_, the_DT Company_NN has_VBZ a_DT number_NN of_IN projects_NNS in_IN later_JJ stage_NN development_NN including_VBG :_: FOSRENOL_NNP for_IN the_DT treatment_NN of_IN high_JJ blood_NN phosphate_NN levels_NNS associated_VBN with_IN kidney_NN failure_NN ._.
The_DT Company_NN submitted_VBD the_DT first_JJ regulatory_JJ submission_NN for_IN FOSRENOL_NNP under_IN the_DT European_JJ Mutual_JJ Recognition_NN procedure_NN on_IN March_NNP 13_CD ,_, 2001_CD and_CC a_DT New_NNP Drug_NNP Application_NNP NDA_NNP with_IN the_DT US_NNP FDA_NNP on_IN April_NNP 30_CD ,_, 2002_CD ._.
The_DT Company_NN received_VBD an_DT approvable_JJ letter_NN from_IN the_DT US_NNP FDA_NNP on_IN March_NNP 3_CD ,_, 2003_CD :_: XAGRID_NNP in_IN the_DT EU_NNP which_WDT is_VBZ the_DT trade_NN name_NN of_IN AGRYLIN_NNP in_IN the_DT EU_NNP ._.
On_IN July_NNP 25_CD ,_, 2003_CD ,_, the_DT Company_NN received_VBD a_DT positive_JJ Committee_NNP for_IN Proprietary_NNP Medicinal_NNP Products_NNPS opinion_NN :_: Adult_NN indication_NN for_IN ADDERALL_NNP XR_NNP ._.
The_DT Company_NN received_VBD an_DT approvable_JJ letter_NN from_IN the_DT US_NNP FDA_NNP on_IN October_NNP 20_CD ,_, 2003_CD :_: METHYPATCH_NNP ,_, a_DT transdermal_JJ delivery_NN system_NN for_IN the_DT once_RB daily_JJ treatment_NN of_IN ADHD_NNP ._.
Shire_NNP and_CC Noven_NNP are_VBP working_VBG closely_RB to_TO supply_VB the_DT FDA_NNP with_IN appropriate_JJ Phase_NN III_NNP data_NNS requested_VBD in_IN their_PRP$ non-approvable_JJ letter_NN issued_VBN on_IN April_NNP 28_CD ,_, 2003_CD :_: BIPOTROL_NNP SPD417_NNP for_IN bipolar_JJ disorder_NN ._.
In_IN February_NNP 2004_CD Shire_NNP led_VBD an_DT NDA_NNP for_IN this_DT indication_NN :_: SPD503_CD guanfacine_NN for_IN ADHD_NNP ,_, in_IN Phase_NN III_NNP :_: and_CC SPD476_NNP for_IN ulcerative_JJ colitis_NNS in_IN Phase_NN II_NNP ._.
2_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS a_DT Basis_NN of_IN preparation_NN The_DT accompanying_VBG consolidated_JJ financial_JJ statements_NNS include_VBP the_DT accounts_NNS of_IN Shire_NNP and_CC all_DT of_IN its_PRP$ subsidiary_NN undertakings_NNS after_IN elimination_NN of_IN intercompany_NN accounts_NNS and_CC transactions_NNS ._.
b_NN Use_NN of_IN estimates_NNS in_IN consolidated_JJ financial_JJ statements_NNS The_DT preparation_NN of_IN consolidated_JJ financial_JJ statements_NNS ,_, in_IN conformity_NN with_IN US_NNP generally_RB accepted_VBD accounting_NN principles_NNS ,_, requires_VBZ management_NN to_TO make_VB estimates_NNS and_CC assumptions_NNS that_WDT affect_VBP the_DT reported_VBN amounts_NNS of_IN assets_NNS and_CC liabilities_NNS ,_, the_DT disclosure_NN of_IN contingent_JJ assets_NNS and_CC liabilities_NNS at_IN the_DT date_NN of_IN the_DT consolidated_JJ financial_JJ statements_NNS and_CC reported_VBD amounts_NNS of_IN revenues_NNS and_CC expenses_NNS during_IN the_DT reporting_NN period_NN ._.
Actual_JJ results_NNS could_MD differ_VB from_IN those_DT estimates_NNS ._.
Estimates_NNS and_CC assumptions_NNS are_VBP primarily_RB made_VBN in_IN relation_NN to_TO provisions_NNS for_IN product_NN returns_NNS ,_, valuation_NN of_IN intangible_JJ assets_NNS ,_, contingent_JJ liabilities_NNS and_CC sales_NNS deductions_NNS ._.
c_NN Revenue_NN recognition_NN The_DT Company_NN recognizes_VBZ revenue_NN when_WRB :_: there_EX is_VBZ persuasive_JJ evidence_NN of_IN an_DT agreement_NN or_CC arrangement_NN :_: delivery_NN of_IN products_NNS has_VBZ occurred_VBN or_CC services_NNS have_VBP been_VBN rendered_VBN :_: the_DT sellers_NNS price_NN to_TO the_DT buyer_NN is_VBZ xed_VBN or_CC determinable_JJ :_: and_CC collectability_NN is_VBZ reasonably_RB assured_VBN ._.
The_DT Companys_NNPS principal_JJ revenue_NN streams_NNS and_CC their_PRP$ respective_JJ accounting_NN treatments_NNS are_VBP discussed_VBN below_IN :_: i_FW Product_NNP sales_NNS Revenue_NN for_IN the_DT sales_NNS of_IN products_NNS is_VBZ recognized_VBN upon_IN shipment_NN to_TO customers_NNS or_CC at_IN the_DT time_NN of_IN delivery_NN i._FW e._FW FOB_FW destination_NN depending_VBG on_IN the_DT terms_NNS of_IN sale_NN ._.
Provisions_NNS for_IN rebates_NNS ,_, product_NN returns_NNS and_CC discounts_NNS to_TO customers_NNS are_VBP provided_VBN for_IN as_IN reductions_NNS to_TO revenue_NN in_IN the_DT same_JJ period_NN as_IN the_DT related_JJ sales_NNS are_VBP recorded_VBN ._.
The_DT Company_NN monitors_NNS and_CC tracks_VBZ the_DT amount_NN of_IN rebates_NNS ,_, product_NN returns_NNS and_CC discounts_NNS to_TO customers_NNS based_VBN on_IN historical_JJ experience_NN to_TO estimate_VB the_DT amount_NN of_IN reduction_NN to_TO revenue_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 55_CD In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 2_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS continued_VBD ii_FW Licensing_NN and_CC development_NN fees_NNS Licensing_VBG and_CC development_NN fees_NNS represent_VBP revenues_NNS derived_VBN from_IN product_NN out-licensing_JJ agreements_NNS and_CC from_IN contract_NN research_NN and_CC development_NN agreements_NNS ._.
Initial_JJ license_NN fees_NNS received_VBN in_IN connection_NN with_IN product_NN out-licensing_JJ agreements_NNS ,_, even_RB where_WRB such_JJ fees_NNS are_VBP non-refundable_JJ and_CC not_RB creditable_JJ against_IN future_JJ royalty_NN payments_NNS ,_, are_VBP deferred_VBN and_CC recognized_VBN over_IN the_DT period_NN of_IN the_DT license_NN term_NN ,_, or_CC the_DT period_NN of_IN the_DT associated_VBN collaborative_JJ assistance_NN ._.
In_IN circumstances_NNS where_WRB initial_JJ license_NN fees_NNS are_VBP not_RB for_IN a_DT dened_JJ period_NN ,_, revenues_NNS are_VBP deferred_VBN and_CC recognized_VBN over_IN the_DT period_NN to_TO the_DT expiration_NN of_IN the_DT relevant_JJ patent_NN to_TO which_WDT the_DT license_NN relates_VBZ ._.
During_IN the_DT term_NN of_IN certain_JJ research_NN and_CC development_NN agreements_NNS and_CC licensing_NN agreements_NNS ,_, the_DT Company_NN receives_VBZ non-refundable_JJ milestones_NNS as_IN certain_JJ technical_JJ targets_NNS are_VBP achieved_VBN ._.
Revenues_NNS are_VBP recognized_VBN on_IN achievement_NN of_IN milestones_NNS ._.
The_DT Company_NN also_RB receives_VBZ non-refundable_JJ clinical_JJ milestones_NNS when_WRB certain_JJ targets_NNS are_VBP achieved_VBN during_IN the_DT clinical_JJ phases_NNS of_IN development_NN ,_, such_JJ as_IN the_DT submission_NN of_IN clinical_JJ data_NNS to_TO a_DT regulatory_JJ authority_NN ._.
These_DT clinical_JJ milestones_NNS are_VBP recognized_VBN when_WRB received_VBN ._.
Revenue_NN from_IN contract_NN research_NN and_CC development_NN agreements_NNS is_VBZ recognized_VBN as_IN the_DT services_NNS are_VBP performed_VBN ._.
iii_FW Royalty_NN income_NN Royalty_NN income_NN relating_VBG to_TO licensed_JJ technology_NN is_VBZ recognized_VBN when_WRB the_DT licensee_NN sells_VBZ the_DT underlying_JJ product_NN ._.
The_DT Company_NN receives_VBZ sales_NNS information_NN from_IN the_DT licensee_NN on_IN a_DT monthly_JJ basis_NN ._.
For_IN any_DT period_NN that_IN the_DT information_NN is_VBZ not_RB available_JJ ,_, the_DT Company_NN estimates_VBZ sales_NNS amounts_NNS based_VBN on_IN the_DT historical_JJ product_NN information_NN ._.
Where_WRB applicable_JJ ,_, all_DT revenues_NNS are_VBP stated_VBN net_NN of_IN value_NN added_VBD tax_NN and_CC similar_JJ taxes_NNS ,_, and_CC trade_NN discounts_NNS ._.
No_DT revenue_NN is_VBZ recognized_VBN for_IN consideration_NN ,_, the_DT value_NN or_CC receipt_NN of_IN which_WDT is_VBZ dependent_JJ on_IN future_JJ events_NNS ,_, future_JJ performance_NN ,_, or_CC refund_NN obligations_NNS ._.
d_LS Research_NNP and_CC development_NN Research_NN and_CC development_NN expenditures_NNS include_VBP funded_VBN and_CC unfunded_JJ expenditures_NNS and_CC are_VBP charged_VBN to_TO operations_NNS in_IN the_DT period_NN in_IN which_WDT the_DT expense_NN is_VBZ incurred_VBN ._.
e_LS Leased_VBN assets_NNS The_DT costs_NNS of_IN operating_VBG leases_NNS are_VBP charged_VBN to_TO operations_NNS on_IN a_DT straight-line_JJ basis_NN over_IN the_DT lease_NN term_NN ,_, even_RB if_IN rental_JJ payments_NNS are_VBP not_RB made_VBN on_IN such_PDT a_DT basis_NN ._.
Assets_NNS acquired_VBN under_IN capital_NN leases_NNS are_VBP included_VBN in_IN the_DT balance_NN sheet_NN as_IN tangible_JJ xed_JJ assets_NNS and_CC are_VBP depreciated_VBN over_IN the_DT shorter_JJR of_IN the_DT period_NN of_IN the_DT lease_NN or_CC their_PRP$ useful_JJ lives_NNS ._.
The_DT capital_NN elements_NNS of_IN future_JJ lease_NN payments_NNS are_VBP recorded_VBN as_IN liabilities_NNS ,_, while_IN the_DT interest_NN element_NN is_VBZ charged_VBN to_TO operations_NNS over_IN the_DT period_NN of_IN the_DT lease_NN to_TO produce_VB a_DT level_NN yield_NN on_IN the_DT balance_NN of_IN the_DT capital_NN lease_NN obligation_NN ._.
f_LS Finance_NNP costs_NNS of_IN debt_NN Finance_NNP costs_NNS of_IN debt_NN are_VBP recorded_VBN as_IN a_DT deferred_JJ asset_NN and_CC then_RB amortized_VBD to_TO the_DT statement_NN of_IN operations_NNS over_IN the_DT term_NN of_IN the_DT debt_NN ,_, using_VBG the_DT effective_JJ interest_NN rate_NN method_NN ._.
Deferred_JJ nancing_NN costs_NNS relating_VBG to_TO debt_NN extinguishments_NNS are_VBP written_VBN off_RP and_CC reected_VBD in_IN interest_NN expense_NN in_IN the_DT consolidated_JJ statement_NN of_IN operations_NNS ._.
g_NN Income_NN taxes_NNS The_DT Company_NN provides_VBZ for_IN income_NN taxes_NNS in_IN accordance_NN with_IN Statement_NN of_IN Financial_NNP Accounting_NNP Standards_NNPS SFAS_NNP No._NN ._.
109_CD ,_, Accounting_NNP for_IN Income_NNP Taxes_NNS SFAS_NNP No._NN ._.
Deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS are_VBP provided_VBN for_IN differences_NNS between_IN the_DT carrying_VBG amounts_NNS of_IN assets_NNS and_CC liabilities_NNS in_IN the_DT consolidated_JJ financial_JJ statements_NNS and_CC the_DT tax_NN bases_NNS of_IN assets_NNS and_CC liabilities_NNS that_WDT will_MD result_VB in_IN future_JJ taxable_JJ or_CC deductible_JJ amounts_NNS ._.
The_DT deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS are_VBP measured_VBN using_VBG the_DT enacted_VBN tax_NN laws_NNS and_CC rates_NNS applicable_JJ to_TO the_DT periods_NNS in_IN which_WDT the_DT differences_NNS are_VBP expected_VBN to_TO affect_VB taxable_JJ income_NN ._.
Income_NNP tax_NN expense_NN is_VBZ computed_VBN as_IN the_DT tax_NN payable_JJ or_CC refundable_JJ for_IN the_DT period_NN ,_, plus_CC or_CC minus_CC the_DT change_NN during_IN the_DT period_NN in_IN deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS ._.
Deferred_JJ tax_NN assets_NNS are_VBP reduced_VBN by_IN a_DT valuation_NN allowance_NN when_WRB ,_, in_IN the_DT opinion_NN of_IN management_NN ,_, it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB that_IN some_DT portion_NN or_CC all_DT of_IN the_DT deferred_JJ tax_NN assets_NNS will_MD not_RB be_VB realized_VBN ._.
h_NN Earnings_NNS per_IN share_NN Earnings_NNS per_IN share_NN EPS_NNP is_VBZ computed_VBN in_IN accordance_NN with_IN SFAS_NNP No._NN ._.
128_CD ,_, Earnings_NNS per_IN Share_NN SFAS_NNP No._NN ._.
Basic_JJ EPS_NNP is_VBZ computed_VBN by_IN dividing_VBG consolidated_JJ net_JJ income_NN available_JJ to_TO ordinary_JJ shareholders_NNS by_IN the_DT weighted_JJ average_JJ number_NN of_IN ordinary_JJ shares_NNS outstanding_JJ during_IN the_DT period_NN ._.
Diluted_JJ EPS_NNP is_VBZ computed_VBN by_IN dividing_VBG consolidated_JJ net_JJ income_NN available_JJ to_TO ordinary_JJ shareholders_NNS by_IN the_DT weighted_JJ average_JJ number_NN of_IN shares_NNS outstanding_JJ during_IN the_DT period_NN ,_, adjusted_VBN for_IN potentially_RB dilutive_JJ shares_NNS that_WDT might_MD be_VB issued_VBN upon_IN exercise_NN of_IN ordinary_JJ stock_NN options_NNS ._.
Such_JJ potentially_RB dilutive_JJ shares_NNS are_VBP excluded_VBN when_WRB the_DT effect_NN would_MD be_VB to_TO increase_VB earnings_NNS per_IN share_NN or_CC reduce_VB a_DT loss_NN per_IN share_NN ._.
56_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 2_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS continued_VBD i_FW Advertising_NN expense_NN The_DT Company_NN expenses_NNS the_DT cost_NN of_IN advertising_NN as_IN incurred_VBN ._.
Advertising_NN costs_NNS amounted_VBD to_TO $_$ 40.7_CD million_CD ,_, $_$ 45.6_CD million_CD and_CC $_$ 21.8_CD million_CD for_IN the_DT years_NNS ended_VBN December_NNP 31_CD ,_, 2003_CD ,_, 2002_CD and_CC 2001_CD respectively_RB ._.
j_NNP Foreign_NNP currency_NN Monetary_NNP assets_NNS and_CC liabilities_NNS in_IN foreign_JJ currencies_NNS are_VBP translated_VBN into_IN the_DT relevant_JJ functional_JJ currency_NN at_IN the_DT rate_NN of_IN exchange_NN ruling_NN at_IN the_DT balance_NN sheet_NN date_NN ._.
Transactions_NNS in_IN foreign_JJ currencies_NNS are_VBP translated_VBN into_IN the_DT relevant_JJ functional_JJ currency_NN at_IN the_DT rate_NN of_IN exchange_NN ruling_NN at_IN the_DT date_NN of_IN the_DT transaction_NN ._.
Transaction_NN gains_NNS and_CC losses_NNS are_VBP recognized_VBN in_IN arriving_VBG at_IN operating_VBG net_JJ income_NN ._.
The_DT results_NNS of_IN overseas_JJ operations_NNS ,_, whose_WP$ functional_JJ currency_NN is_VBZ not_RB US_NNP dollars_NNS ,_, are_VBP translated_VBN at_IN the_DT average_JJ rates_NNS of_IN exchange_NN during_IN the_DT period_NN and_CC their_PRP$ balance_NN sheets_NNS at_IN the_DT rates_NNS ruling_VBG at_IN the_DT balance_NN sheet_NN date_NN ._.
The_DT cumulative_JJ effect_NN of_IN exchange_NN rate_NN movements_NNS is_VBZ included_VBN in_IN a_DT separate_JJ component_NN of_IN other_JJ comprehensive_JJ income_NN ._.
Foreign_JJ currency_NN exchange_NN transaction_NN gains_NNS and_CC losses_NNS on_IN an_DT after-tax_JJ basis_NN included_VBD in_IN consolidated_JJ net_JJ income_NN in_IN the_DT years_NNS ended_VBN December_NNP 31_CD ,_, 2003_CD ,_, 2002_CD ,_, and_CC 2001_CD ,_, pursuant_JJ to_TO SFAS_NNP No._NN ._.
52_CD ,_, Foreign_NNP Currency_NNP Translation_NN ,_, amounted_VBD to_TO a_DT $_$ 6.7_CD million_CD loss_NN ,_, $_$ 0.3_CD million_CD loss_NN and_CC $_$ 0.5_CD million_CD loss_NN ,_, respectively_RB ._.
k_NN Employee_NN stock_NN plans_VBZ The_DT Company_NN accounts_NNS for_IN its_PRP$ stock_NN options_NNS using_VBG the_DT intrinsic-value_JJ method_NN prescribed_VBN in_IN Accounting_NNP Principles_NNP Board_NNP Opinion_NNP No._NN ._.
25_CD ,_, Accounting_NNP for_IN Stock_NNP Issued_NNP to_TO Employees_NNS APB_NNP No._NN ._.
Accordingly_RB ,_, compensation_NN cost_NN of_IN stock_NN options_NNS is_VBZ measured_VBN as_IN the_DT excess_NN ,_, if_IN any_DT ,_, of_IN the_DT quoted_VBN market_NN price_NN of_IN Shires_NNP stock_NN at_IN the_DT measurement_NN date_NN over_IN the_DT option_NN exercise_NN price_NN and_CC is_VBZ charged_VBN to_TO operations_NNS over_IN the_DT vesting_JJ period_NN ._.
For_IN plans_NNS where_WRB the_DT measurement_NN date_NN occurs_VBZ after_IN the_DT grant_NN date_NN ,_, referred_VBD to_TO as_IN variable_JJ plans_NNS ,_, compensation_NN cost_NN is_VBZ re-measured_JJ on_IN the_DT basis_NN of_IN the_DT current_JJ market_NN value_NN of_IN Shire_NNP stock_NN at_IN the_DT end_NN of_IN each_DT reporting_NN period_NN ._.
Shire_NNP recognizes_VBZ compensation_NN expense_NN for_IN variable_JJ plans_NNS with_IN performance_NN conditions_NNS if_IN achievement_NN of_IN those_DT conditions_NNS becomes_VBZ probable_JJ ._.
123_CD ,_, Accounting_NNP for_IN Stock_NNP Based_VBD on_IN Compensation_NNP SFAS_NNP No._NN ._.
123_CD ,_, the_DT Company_NN has_VBZ included_VBN in_IN these_DT financial_JJ statements_NNS the_DT required_VBN pro_FW forma_FW disclosures_NNS as_IN if_IN the_DT fair-value_JJ method_NN of_IN accounting_NN had_VBD been_VBN applied_VBN ._.
As_IN of_IN December_NNP 31_CD ,_, 2003_CD ,_, the_DT Company_NN had_VBD seven_CD stock-based_JJ employee_NN compensation_NN plans_NNS ,_, which_WDT are_VBP described_VBN more_RBR fully_RB in_IN Note_NN 27_CD to_TO the_DT consolidated_JJ financial_JJ statements_NNS ._.
The_DT following_VBG table_NN illustrates_VBZ the_DT effect_NN on_IN net_JJ income_NN and_CC earnings_NNS per_IN share_NN if_IN the_DT Company_NN had_VBD applied_VBN the_DT fair_JJ value_NN recognition_NN provisions_NNS of_IN SFAS_NNP No._NN ._.
2003 2002 2001_CD Year_NN ended_VBD December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Net_JJ income_NN ,_, as_IN reported_VBN 276,051_CD 250,569_CD 38,759_CD Add_VB :_: Stock-based_JJ employee_NN compensation_NN credit_NN charge_NN included_VBD in_IN reported_VBN net_JJ income_NN ,_, net_NN of_IN related_JJ tax_NN effects_NNS 24_CD 166_CD 2,278_CD Deduct_NNP :_: Total_JJ stock-based_JJ employee_NN compensation_NN expense_NN determined_VBN under_IN fair_JJ value_NN based_VBN method_NN for_IN all_DT awards_NNS 31,956_CD 24,084_CD 32,268_CD Pro_FW forma_FW net_JJ income_NN 244,071_CD 226,319_CD 8,769_CD 2003 2002 2001_CD Year_NN ended_VBD December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Earnings_NNS per_IN share_NN As_IN reported_VBN basic_JJ 55.3_CD 50.0_CD 7.9_CD As_IN reported_VBN diluted_VBN 48.9_CD 49.0_CD 7.7_CD Pro_FW forma_FW basic_JJ 54.1_CD 45.2_CD 1.8_CD Pro_FW forma_FW diluted_VBN 48.1_CD 44.4_CD 1.7_CD l_NN Cash_NN and_CC cash_NN equivalents_NNS Cash_NN and_CC cash_NN equivalents_NNS are_VBP dened_VBN as_IN short-term_JJ highly_RB liquid_JJ investments_NNS with_IN original_JJ maturities_NNS of_IN ninety_CD days_NNS or_CC less_JJR ._.
m_FW Marketable_JJ securities_NNS Marketable_JJ securities_NNS consist_VBP of_IN commercial_JJ paper_NN and_CC institutional_JJ and_CC managed_VBD cash_NN funds_NNS ._.
In_IN accordance_NN with_IN SFAS_NNP No._NN ._.
115_CD Accounting_NN for_IN Certain_NNP Investments_NNP in_IN Debt_NNP and_CC Equity_NNP Securities_NNPS ,_, and_CC based_VBN on_IN the_DT Companys_NNP intentions_NNS regarding_VBG these_DT instruments_NNS ,_, the_DT Company_NN has_VBZ classied_VBN all_DT marketable_JJ securities_NNS as_IN held-to-maturity_NN and_CC has_VBZ accounted_VBN for_IN these_DT investments_NNS at_IN amortized_JJ cost_NN ._.
Institutional_JJ and_CC managed_VBD cash_NN funds_NNS are_VBP short-term_JJ money_NN market_NN instruments_NNS ,_, including_VBG bank_NN and_CC building_NN society_NN term_NN deposits_NNS from_IN a_DT variety_NN of_IN companies_NNS with_IN strong_JJ credit_NN ratings_NNS ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 57_CD In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 2_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS continued_VBD n_JJ Inventories_NNS Inventories_NNS ,_, consisting_VBG primarily_RB of_IN nished_JJ goods_NNS ,_, are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN including_VBG manufacturing_NN overheads_NNS ,_, where_WRB appropriate_JJ or_CC net_JJ realizable_JJ value_NN ._.
Net_JJ realizable_JJ value_NN is_VBZ based_VBN on_IN estimated_VBN normal_JJ selling_NN price_NN less_RBR further_JJ costs_NNS expected_VBN to_TO be_VB incurred_VBN to_TO completion_NN and_CC disposal_NN ._.
o_NNP Investments_NNP The_NNP Company_NNP has_VBZ certain_JJ investments_NNS in_IN equity_NN securities_NNS ._.
Investments_NNP are_VBP accounted_VBN for_IN using_VBG the_DT equity_NN method_NN of_IN accounting_NN if_IN the_DT investment_NN gives_VBZ the_DT Company_NN the_DT ability_NN to_TO exercise_VB significant_JJ inuence_NN ,_, but_CC not_RB control_VB over_RP ,_, the_DT investee_NN ._.
significant_JJ inuence_NN is_VBZ generally_RB deemed_VBN to_TO exist_VB if_IN the_DT Company_NN has_VBZ an_DT ownership_NN interest_NN in_IN the_DT voting_NN stock_NN of_IN the_DT investee_NN between_IN 20_CD %_NN and_CC 50_CD %_NN ,_, although_IN other_JJ factors_NNS ,_, such_JJ as_IN representation_NN on_IN the_DT investees_NNS Board_NNP of_IN Directors_NNS and_CC the_DT impact_NN of_IN commercial_JJ arrangements_NNS ,_, are_VBP considered_VBN in_IN determining_VBG whether_IN the_DT equity_NN method_NN of_IN accounting_NN is_VBZ appropriate_JJ ._.
Under_IN the_DT equity_NN method_NN of_IN accounting_NN ,_, the_DT Company_NN records_NNS its_PRP$ investments_NNS in_IN equity-method_JJ investees_NNS in_IN the_DT consolidated_JJ balance_NN sheet_NN as_IN Investments_NNP Equity_NNP method_NN investments_NNS and_CC its_PRP$ share_NN of_IN the_DT investees_NNS earnings_NNS or_CC losses_NNS together_RB with_IN other-than_JJ temporary_JJ impairments_NNS in_IN value_NN as_IN Equity_NN in_IN losses_NNS earnings_NNS of_IN equity_NN method_NN investees_NNS in_IN the_DT consolidated_JJ statement_NN of_IN operations_NNS ._.
All_DT other_JJ equity_NN investments_NNS ,_, which_WDT consist_VBP of_IN investments_NNS for_IN which_WDT the_DT Company_NN does_VBZ not_RB have_VB the_DT ability_NN to_TO exercise_VB significant_JJ inuence_NN ,_, are_VBP accounted_VBN for_IN under_IN the_DT cost_NN method_NN or_CC at_IN fair_JJ value_NN ._.
Investments_NNP in_IN private_JJ companies_NNS are_VBP carried_VBN at_IN cost_NN ,_, less_JJR provisions_NNS for_IN other_JJ than_IN temporary_JJ impairment_NN in_IN value_NN ._.
For_IN public_JJ companies_NNS that_WDT have_VBP readily_RB determinable_JJ fair_JJ values_NNS ,_, the_DT Company_NN classies_VBZ its_PRP$ equity_NN investments_NNS as_IN available-for-sale_JJ and_CC ,_, accordingly_RB ,_, records_NNS these_DT investments_NNS at_IN their_PRP$ fair_JJ values_NNS with_IN unrealized_JJ gains_NNS and_CC losses_NNS included_VBD in_IN the_DT consolidated_JJ statements_NNS of_IN comprehensive_JJ income_NN ,_, net_NN of_IN any_DT related_JJ tax_NN effect_NN ._.
Realized_VBN gains_NNS and_CC losses_NNS and_CC declines_NNS in_IN value_NN judged_VBN to_TO be_VB other-than-temporary_JJ on_IN available-for-sale_JJ securities_NNS are_VBP included_VBN in_IN other_JJ expense_NN ,_, net_JJ see_VBP note_NN 23_CD ._.
The_DT cost_NN of_IN securities_NNS sold_VBN is_VBZ based_VBN on_IN the_DT specic_JJ identication_NN method_NN ._.
Interest_NN and_CC dividends_NNS on_IN securities_NNS classied_VBD as_IN available-for-sale_NN are_VBP included_VBN as_IN interest_NN income_NN ._.
p_NN Goodwill_NNP and_CC other_JJ intangible_JJ assets_NNS i_FW Goodwill_NNP Goodwill_NNP represents_VBZ the_DT excess_NN of_IN the_DT fair_JJ value_NN of_IN the_DT consideration_NN given_VBN over_IN the_DT fair_JJ value_NN of_IN the_DT identiable_JJ assets_NNS and_CC liabilities_NNS acquired_VBN ._.
Periods_NNS ending_VBG on_IN or_CC before_IN December_NNP 31_CD ,_, 2001_CD For_IN periods_NNS ending_VBG on_IN or_CC before_IN December_NNP 31_CD ,_, 2001_CD ,_, goodwill_NN recognized_VBN in_IN respect_NN of_IN each_DT significant_JJ business_NN combination_NN was_VBD amortized_VBN over_IN a_DT period_NN of_IN 5_CD to_TO 30_CD years_NNS weighted_JJ average_NN :_: 19_CD years_NNS on_IN a_DT straight_JJ line_NN basis_NN depending_VBG on_IN the_DT nature_NN of_IN the_DT goodwill_NN ,_, and_CC was_VBD evaluated_VBN for_IN impairment_NN when_WRB events_NNS or_CC changes_NNS in_IN circumstance_NN indicated_VBD ,_, in_IN managements_NNS judgment_NN ,_, that_IN the_DT carrying_VBG value_NN of_IN such_JJ assets_NNS may_MD not_RB be_VB recoverable_JJ ._.
Impairments_NNS of_IN goodwill_NN were_VBD recognized_VBN if_IN expected_VBN undiscounted_JJ cash_NN ows_NNS were_VBD not_RB sufficient_JJ to_TO recover_VB the_DT goodwill_NN ._.
If_IN a_DT material_NN impairment_NN was_VBD identied_VBN ,_, goodwill_NN was_VBD written_VBN down_RP to_TO its_PRP$ estimated_VBN fair_JJ value_NN ._.
Fair_NNP value_NN was_VBD determined_VBN based_VBN on_IN the_DT present_JJ value_NN of_IN expected_JJ net_JJ cash_NN ows_VBZ to_TO be_VB generated_VBN by_IN the_DT business_NN ,_, discounted_VBN using_VBG a_DT rate_NN commensurate_JJ with_IN the_DT risks_NNS involved_VBN ._.
Periods_NNS commencing_VBG January_NNP 1_CD ,_, 2002_CD Effective_NNP January_NNP 1_CD ,_, 2002_CD ,_, the_DT Company_NN adopted_VBN SFAS_NNP No._NN ._.
142_CD ,_, Goodwill_NNP and_CC Other_JJ Intangible_NNP Assets_NNPS SFAS_NNP No._NN ._.
142_CD ,_, which_WDT applies_VBZ to_TO all_DT goodwill_NN and_CC other_JJ intangible_JJ assets_NNS ,_, recognized_VBN in_IN the_DT balance_NN sheets_NNS at_IN that_DT date_NN ,_, regardless_RB of_IN when_WRB the_DT assets_NNS were_VBD initially_RB recognized_VBN ._.
This_DT statement_NN requires_VBZ that_IN goodwill_NN and_CC other_JJ intangibles_NNS with_IN indefinite_JJ lives_NNS no_RB longer_RB be_VB amortized_VBN to_TO operations_NNS ,_, but_CC instead_RB be_VB reviewed_VBN for_IN impairment_NN ,_, at_IN least_JJS annually_RB ._.
The_DT Company_NN has_VBZ no_DT intangible_JJ assets_NNS with_IN indefinite_JJ useful_JJ lives_NNS ._.
The_DT Company_NN annually_RB examines_VBZ the_DT carrying_VBG value_NN of_IN goodwill_NN to_TO determine_VB whether_IN there_EX are_VBP any_DT impairment_NN losses_NNS and_CC has_VBZ determined_VBN that_IN for_IN the_DT years_NNS ended_VBN December_NNP 31_CD ,_, 2002_CD and_CC 2003_CD ,_, there_EX are_VBP no_DT such_JJ losses_NNS ._.
ii_FW Other_JJ intangible_JJ assets_NNS Other_JJ intangible_JJ assets_NNS ,_, which_WDT comprise_VBP intellectual_JJ property_NN including_VBG trade_NN marks_NNS for_IN products_NNS with_IN a_DT dened_JJ revenue_NN stream_NN namely_RB commercial_JJ products_NNS or_CC rights_NNS to_TO products_NNS awaiting_VBG final_JJ regulatory_JJ approval_NN ,_, are_VBP recorded_VBN at_IN cost_NN and_CC amortized_VBN over_IN the_DT estimated_VBN useful_JJ life_NN of_IN the_DT related_JJ product_NN ,_, which_WDT ranges_VBZ from_IN 5_CD to_TO 40_CD years_NNS weighted_VBN average_JJ 23_CD years_NNS ._.
Intellectual_NNP property_NN with_IN no_DT dened_JJ revenue_NN stream_NN ,_, where_WRB the_DT related_JJ product_NN has_VBZ not_RB yet_RB completed_VBN the_DT necessary_JJ approval_NN process_NN ,_, is_VBZ written_VBN off_RP to_TO operations_NNS on_IN acquisition_NN ._.
58_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 2_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS continued_VBD The_DT following_JJ factors_NNS are_VBP considered_VBN in_IN estimating_VBG useful_JJ lives_NNS ._.
Where_WRB an_DT intangible_JJ asset_NN is_VBZ a_DT composite_NN of_IN a_DT number_NN of_IN factors_NNS ,_, the_DT period_NN of_IN amortization_NN is_VBZ determined_VBN from_IN considering_VBG these_DT factors_NNS together_RB :_: expected_VBN use_NN of_IN the_DT asset_NN :_: regulatory_JJ ,_, legal_JJ or_CC contractual_JJ provisions_NNS ,_, including_VBG the_DT regulatory_JJ approval_NN and_CC review_NN process_NN ,_, patent_NN issues_NNS and_CC actions_NNS by_IN government_NN agencies_NNS :_: the_DT effects_NNS of_IN obsolescence_NN ,_, changes_NNS in_IN demand_NN ,_, competing_VBG products_NNS and_CC other_JJ economic_JJ factors_NNS ,_, including_VBG the_DT stability_NN of_IN the_DT market_NN ,_, known_VBN technological_JJ advances_NNS ,_, development_NN of_IN competing_VBG drugs_NNS that_WDT are_VBP more_RBR effective_JJ clinically_RB or_CC economically_RB :_: and_CC actions_NNS of_IN competitors_NNS ,_, suppliers_NNS ,_, regulatory_JJ agencies_NNS or_CC others_NNS that_WDT may_MD eliminate_VB current_JJ competitive_JJ advantages_NNS ._.
q_NN Property_NN ,_, plant_NN and_CC equipment_NN Property_NN ,_, plant_NN and_CC equipment_NN is_VBZ shown_VBN at_IN cost_NN ,_, less_JJR accumulated_VBN depreciation_NN and_CC any_DT impairment_NN ._.
Cost_NN of_IN significant_JJ assets_NNS includes_VBZ capitalized_JJ interest_NN incurred_VBN during_IN the_DT construction_NN period_NN ._.
Depreciation_NN is_VBZ provided_VBN on_IN a_DT straight-line_JJ basis_NN at_IN rates_NNS calculated_VBN to_TO writeoff_VB the_DT cost_NN less_JJR estimated_VBN residual_JJ value_NN of_IN each_DT asset_NN over_IN its_PRP$ estimated_VBN useful_JJ life_NN as_IN follows_VBZ :_: Buildings_NNS 20_CD to_TO 50_CD years_NNS Ofce_NNP furniture_NN ,_, ttings_NNS and_CC equipment_NN 4_CD to_TO 10_CD years_NNS Warehouse_NNP ,_, laboratory_NN and_CC manufacturing_NN equipment_NN 4_CD to_TO 10_CD years_NNS The_DT cost_NN of_IN land_NN is_VBZ not_RB depreciated_VBN ._.
Expenditures_NNS for_IN maintenance_NN and_CC repairs_NNS are_VBP charged_VBN to_TO operations_NNS as_IN incurred_VBN ._.
The_DT costs_NNS of_IN major_JJ renewals_NNS and_CC improvements_NNS are_VBP capitalized_VBN ._.
At_IN the_DT time_NN property_NN ,_, plant_NN and_CC equipment_NN is_VBZ retired_VBN or_CC otherwise_RB disposed_JJ of_IN ,_, the_DT cost_NN and_CC accumulated_VBN depreciation_NN are_VBP eliminated_VBN from_IN the_DT asset_NN and_CC accumulated_VBN depreciation_NN accounts_NNS ._.
The_DT profit_NN or_CC loss_NN on_IN such_JJ disposition_NN is_VBZ reected_VBN in_IN operating_VBG income_NN ._.
r_NN Valuation_NN and_CC impairment_NN of_IN long-lived_JJ assets_NNS other_JJ than_IN goodwill_NN and_CC investments_NNS The_DT Company_NN evaluates_VBZ the_DT carrying_VBG value_NN of_IN long-lived_JJ assets_NNS other_JJ than_IN goodwill_NN and_CC investments_NNS for_IN impairment_NN whenever_WRB events_NNS or_CC changes_NNS in_IN circumstances_NNS indicate_VBP that_IN the_DT carrying_VBG amounts_NNS of_IN the_DT assets_NNS may_MD not_RB be_VB recoverable_JJ ._.
When_WRB such_PDT a_DT determination_NN is_VBZ made_VBN ,_, managements_NNS estimate_NN of_IN undiscounted_JJ cash_NN ows_VBZ to_TO be_VB generated_VBN by_IN the_DT assets_NNS is_VBZ compared_VBN to_TO the_DT carrying_VBG value_NN of_IN the_DT assets_NNS to_TO determine_VB whether_IN an_DT impairment_NN has_VBZ occurred_VBN ._.
If_IN an_DT impairment_NN is_VBZ indicated_VBN ,_, the_DT amount_NN of_IN the_DT impairment_NN recognized_VBN in_IN the_DT consolidated_JJ financial_JJ statements_NNS is_VBZ determined_VBN by_IN estimating_VBG the_DT fair_JJ value_NN of_IN the_DT assets_NNS and_CC recording_VBG a_DT loss_NN for_IN the_DT amount_NN that_IN the_DT carrying_VBG value_NN exceeds_VBZ the_DT estimated_VBN fair_JJ value_NN ._.
This_DT fair_JJ value_NN is_VBZ usually_RB estimated_VBN based_VBN on_IN estimated_VBN discounted_JJ cash_NN ows_NNS ._.
s_PRP Assets_NNPS held_VBD for_IN sale_NN An_DT asset_NN is_VBZ classied_VBN as_IN held_VBN for_IN sale_NN when_WRB ,_, amongst_IN other_JJ things_NNS ,_, the_DT Company_NN has_VBZ committed_VBN to_TO a_DT plan_NN of_IN disposition_NN ,_, the_DT asset_NN is_VBZ available_JJ for_IN immediate_JJ sale_NN ,_, and_CC the_DT plan_NN is_VBZ not_RB expected_VBN to_TO change_VB signicantly_RB ._.
t_NN Rebates_VBZ Rebates_NNS primarily_RB consist_VBP of_IN statutory_JJ rebates_NNS to_TO state_NN Medicaid_NNP agencies_NNS and_CC contractual_JJ rebates_NNS with_IN health-maintenance_NN organizations_NNS HMOs_NNS ._.
Provision_NNP for_IN rebates_NNS are_VBP recorded_VBN as_IN reductions_NNS to_TO revenue_NN in_IN the_DT same_JJ period_NN as_IN the_DT related_JJ sales_NNS with_IN estimates_NNS of_IN future_JJ utilization_NN derived_VBN from_IN historical_JJ trends_NNS ._.
u_NNP Common_NNP stock_NN The_DT authorized_VBN common_JJ stock_NN of_IN the_DT Company_NN as_IN of_IN December_NNP 31_CD ,_, 2003_CD was_VBD 799,999,965_CD ordinary_JJ shares_NNS and_CC 17,500,000_CD special_JJ ordinary_JJ voting_NN shares_NNS ._.
The_DT special_JJ ordinary_JJ voting_NN shares_NNS are_VBP entitled_VBN to_TO dividend_NN and_CC other_JJ rights_NNS that_WDT are_VBP economically_RB equivalent_JJ to_TO those_DT of_IN the_DT ordinary_JJ shares_NNS ._.
During_IN the_DT second_JJ quarter_NN of_IN 2003_CD ,_, the_DT Company_NN initiated_VBD a_DT planned_VBN re_NN purchase_NN of_IN its_PRP$ common_JJ stock_NN ._.
During_IN that_DT period_NN ,_, the_DT Company_NN repurchased_VBD 7,592,778_CD of_IN its_PRP$ ordinary_JJ shares_NNS at_IN an_DT average_JJ price_NN of_IN $_$ 6.78_CD per_IN share_NN ._.
v_FW Concentration_NNP of_IN risk_NN Revenues_NNS are_VBP mainly_RB derived_VBN from_IN agreements_NNS with_IN major_JJ pharmaceutical_JJ companies_NNS and_CC relationships_NNS with_IN pharmaceutical_JJ wholesale_JJ distributors_NNS and_CC retail_JJ pharmacy_NN chains_NNS ._.
significant_JJ customers_NNS are_VBP disclosed_VBN in_IN note_NN 21_CD ._.
Such_JJ clients_NNS have_VBP significant_JJ cash_NN resources_NNS and_CC therefore_RB any_DT credit_NN risk_NN associated_VBN with_IN these_DT transactions_NNS is_VBZ considered_VBN minimal_JJ ._.
Excess_JJ cash_NN is_VBZ invested_VBN in_IN bank_NN and_CC building_NN society_NN term_NN deposits_NNS and_CC commercial_JJ paper_NN from_IN a_DT variety_NN of_IN companies_NNS with_IN strong_JJ credit_NN ratings_NNS ._.
These_DT investments_NNS typically_RB bear_VBP minimal_JJ credit_NN risk_NN ._.
A_DT significant_JJ proportion_NN of_IN revenue_NN is_VBZ derived_VBN from_IN ADDERALL_NNP XR_NNP and_CC 3TC_NNP ._.
During_IN 2003_CD ,_, revenues_NNS from_IN these_DT products_NNS were_VBD $_$ 474.5_CD million_CD and_CC $_$ 144.6_CD million_CD respectively_RB ,_, representing_VBG 38_CD %_NN and_CC 12_CD %_NN of_IN total_JJ revenues_NNS respectively_RB ._.
As_IN a_DT result_NN ,_, factors_NNS affecting_VBG the_DT sale_NN or_CC production_NN of_IN ADDERALL_NNP XR_NNP or_CC 3TC_NNP would_MD have_VB a_DT material_NN adverse_JJ effect_NN on_IN the_DT Companys_NNPS financial_JJ condition_NN and_CC results_NNS of_IN operation_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 59_CD In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 2_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS continued_VBD w_JJ Reclassications_NNP Certain_NNP amounts_VBZ reported_VBN in_IN previous_JJ years_NNS have_VBP been_VBN reclassied_VBN to_TO conform_VB to_TO the_DT 2003_CD presentation_NN ._.
x_LS New_NNP accounting_NN pronouncements_NNS i_FW Adopted_VBN in_IN the_DT current_JJ year_NN In_IN April_NNP 2002_CD ,_, the_DT Financial_NNP Accounting_NNP Standards_NNP Board_NNP FASB_NNP issued_VBD SFAS_NNP No._NN ._.
145_CD ,_, Rescission_NNP of_IN FASB_NNP Statements_NNP No._NN ._.
4_CD ,_, 44_CD and_CC 64_CD ,_, Amendment_NNP of_IN FASB_NNP Statement_NNP No._NN ._.
13_CD and_CC Technical_NNP Corrections_NNPS SFAS_NNP No_NNP 145_CD ._.
The_DT principal_JJ change_NN reected_VBD in_IN this_DT pronouncement_NN is_VBZ that_IN gains_NNS or_CC losses_NNS from_IN extinguishment_NN of_IN debt_NN which_WDT were_VBD classied_VBN as_IN extraordinary_JJ items_NNS by_IN SFAS_NNP No._NN ._.
4_CD are_VBP no_RB longer_RB classied_VBN as_IN such_JJ ._.
The_DT Company_NN adopted_VBN SFAS_NNP No._NN ._.
When_WRB adopted_VBN ,_, prior_RB extraordinary_JJ items_NNS relating_VBG to_TO the_DT extinguishment_NN of_IN debt_NN were_VBD reclassied_VBN ._.
This_DT resulted_VBD in_IN extraordinary_JJ items_NNS of_IN $_$ 2.6_CD million_CD $_$ 4.1_CD million_CD before_IN taxes_NNS and_CC $_$ 1.5_CD million_CD of_IN income_NN taxes_NNS in_IN 2001_CD being_VBG reclassied_VBN to_TO interest_NN expense_NN and_CC income_NN taxes_NNS ,_, respectively_RB ._.
ii_FW To_TO be_VB adopted_VBN in_IN future_NN periods_NNS In_IN December_NNP 2003_CD ,_, the_DT FASB_NNP issued_VBD a_DT revision_NN to_TO Interpretation_NNP No._NN ._.
46_CD Consolidation_NN of_IN Variable_JJ Interest_NN Entities_NNS ,_, an_DT interpretation_NN of_IN ARB_NNP No._NN ._.
FIN_NNP 46R_NNP claries_VBZ the_DT application_NN of_IN Accounting_NNP Research_NNP Bulletin_NNP No._NN ._.
51_CD Consolidated_NNP Financial_NNP Statements_NNP to_TO certain_JJ entities_NNS in_IN which_WDT equity_NN investors_NNS do_VBP not_RB have_VB the_DT characteristics_NNS of_IN a_DT controlling_VBG financial_JJ interest_NN or_CC do_VB not_RB have_VB sufficient_JJ equity_NN at_IN risk_NN for_IN the_DT entity_NN to_TO finance_VB its_PRP$ activities_NNS without_IN additional_JJ subordinated_JJ financial_JJ support_NN ._.
FIN_NNP 46R_NNP requires_VBZ the_DT consolidation_NN of_IN these_DT entities_NNS ,_, known_VBN as_IN variable_JJ interest_NN entities_NNS ,_, by_IN the_DT primary_JJ beneciary_NN of_IN the_DT entity_NN ._.
The_DT primary_JJ beneciary_NN is_VBZ the_DT entity_NN ,_, if_IN any_DT ,_, that_WDT will_MD absorb_VB a_DT majority_NN of_IN the_DT entitys_NNS expected_VBN losses_NNS or_CC receive_VB a_DT majority_NN of_IN the_DT entitys_NNS expected_VBN residual_JJ returns_NNS ,_, or_CC both_DT ._.
Among_IN other_JJ changes_NNS ,_, FIN_NNP 46R_CD a_DT claried_VBN some_DT requirements_NNS of_IN the_DT original_JJ FIN_NNP 46_CD which_WDT had_VBD been_VBN issued_VBN in_IN January_NNP 2003_CD ,_, b_NN eased_VBD some_DT implementation_NN problems_NNS and_CC c_NN added_VBD new_JJ exceptions_NNS ._.
FIN_NNP 46R_NNP deferred_VBD the_DT effective_JJ date_NN of_IN the_DT Interpretation_NN for_IN public_JJ companies_NNS to_TO the_DT end_NN of_IN the_DT first_JJ reporting_NN period_NN after_IN March_NNP 15_CD ,_, 2004_CD except_IN that_IN all_DT public_JJ companies_NNS must_MD ,_, at_IN a_DT minimum_NN ,_, apply_VB the_DT provisions_NNS of_IN the_DT Interpretation_NN to_TO all_DT entities_NNS that_WDT were_VBD previously_RB considered_VBN special_JJ purpose_NN entities_NNS under_IN the_DT FASB_NNP literature_NN prior_RB to_TO the_DT issuance_NN of_IN FIN_NNP 46R_CD by_IN the_DT end_NN of_IN the_DT first_JJ reporting_NN period_NN ending_VBG after_IN December_NNP 15_CD ,_, 2003_CD ._.
The_DT Company_NN does_VBZ not_RB anticipate_VB that_IN the_DT adoption_NN of_IN FIN_NNP 46_CD will_MD have_VB a_DT material_NN impact_NN on_IN its_PRP$ financial_JJ position_NN ,_, cash_NN ows_NNS or_CC results_NNS of_IN operations_NNS ._.
y_RB Statutory_JJ accounts_NNS The_DT consolidated_JJ financial_JJ statements_NNS as_IN of_IN December_NNP 31_CD ,_, 2003_CD and_CC 2002_CD and_CC for_IN each_DT of_IN the_DT three_CD years_NNS in_IN the_DT period_NN ended_VBD December_NNP 31_CD ,_, 2003_CD do_VBP not_RB comprise_VB statutory_JJ accounts_NNS within_IN the_DT meaning_NN of_IN Section_NN 240_CD of_IN the_DT UK_NNP Companies_NNP Act_NNP 1985_CD ._.
Statutory_JJ accounts_NNS prepared_VBN in_IN accordance_NN with_IN generally_RB accepted_VBN accounting_NN principles_NNS in_IN the_DT United_NNP Kingdom_NNP for_IN the_DT years_NNS ended_VBN December_NNP 31_CD ,_, 2002_CD and_CC 2001_CD ,_, have_VBP been_VBN delivered_VBN to_TO the_DT Registrar_NNP of_IN Companies_NNS for_IN England_NNP and_CC Wales_NNP ._.
The_DT auditors_NNS report_VBP on_IN those_DT accounts_NNS was_VBD unqualied_JJ ._.
3_NNP Business_NNP combinations_NNS and_CC reorganizations_NNS Year_NN ended_VBD December_NNP 31_CD ,_, 2003_CD a_DT Closure_NN of_IN Lead_JJ Optimization_NNP On_IN July_NNP 31_CD ,_, 2003_CD ,_, Shire_NNP announced_VBD its_PRP$ decision_NN to_TO close_VB Lead_JJ Optimization_NN as_IN a_DT result_NN of_IN a_DT strategic_JJ review_NN ._.
The_DT closure_NN resulted_VBD in_IN :_: the_DT severance_NN of_IN approximately_RB 135_CD Lead_JJ Optimization_NN employees_NNS ._.
As_IN of_IN December_NNP 2003_CD ,_, 130_CD had_VBD left_VBN the_DT Company_NN ,_, and_CC the_DT remaining_VBG employees_NNS left_VBN by_IN January_NNP 31_CD ,_, 2004_CD ._.
Severance_NN payments_NNS are_VBP being_VBG made_VBN to_TO the_DT former_JJ employees_NNS over_IN a_DT fifteen-month_JJ period_NN ,_, as_IN required_VBN by_IN local_JJ regulations_NNS :_: a_DT $_$ 6.0_CD million_CD write-off_NN of_IN associated_VBN tangible_JJ xed_JJ assets_NNS ._.
These_DT assets_NNS ,_, primarily_RB laboratory_NN equipment_NN ,_, were_VBD used_VBN by_IN Lead_JJ Optimization_NN for_IN research_NN and_CC development_NN and_CC have_VBP no_DT alternative_NN use_NN :_: and_CC the_DT cancellation_NN ,_, to_TO the_DT extent_NN possible_JJ ,_, of_IN contracts_NNS directly_RB relating_VBG to_TO Lead_JJ Optimization_NN ._.
60_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 3_CD Business_NN combinations_NNS and_CC reorganizations_NNS continued_VBD The_DT costs_NNS have_VBP been_VBN reected_VBN in_IN the_DT statement_NN of_IN operations_NNS and_CC within_IN the_DT reporting_NN segments_NNS as_IN follows_VBZ :_: Income_NNP statement_NN classication_NN Allocation_NNP between_IN segments_NNS R&D_NNP SG&A_NNP R&D_NNP International_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Employee_NN severance_NN 6,425_CD 6,425_CD Write-off_NN of_IN tangible_JJ xed_JJ assets_NNS 6,026_CD 6,026_CD Other_JJ costs_NNS 800_CD 800_CD 7,225_CD 6,026_CD 7,225_CD 6,026_CD As_IN noted_VBN above_IN ,_, certain_JJ of_IN the_DT costs_NNS associated_VBN with_IN the_DT closure_NN will_MD be_VB incurred_VBN in_IN subsequent_JJ periods_NNS ._.
The_DT following_VBG provides_VBZ a_DT roll-forward_NN of_IN the_DT liability_NN that_WDT has_VBZ been_VBN recorded_VBN as_IN of_IN December_NNP 31_CD ,_, 2003_CD ._.
Costs_NNS recorded_VBD Utilization_NN in_IN year_NN to_TO in_IN year_NN to_TO Opening_NNP December_NNP 31_CD ,_, December_NNP 31_CD ,_, Closing_NN liablity_NN 2003_CD 2003_CD liability_NN $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Employee_NN severance_NN 6,425_CD 2,973_CD 3,452_CD Write-down_NN of_IN tangible_JJ xed_JJ assets_NNS 6,026_CD 6,026_CD Other_JJ costs_NNS 800 475 325_CD 13,251_CD 9,474_CD 3,777_CD b_NN Assets_NNS held_VBN for_IN sale_NN Subsequent_JJ to_TO the_DT closure_NN of_IN Lead_JJ Optimization_NNP ,_, the_DT decision_NN to_TO dispose_VB of_IN the_DT Biologics_NNPS business_NN and_CC the_DT announced_VBN US_NNP site_NN reorganization_NN all_DT discussed_VBN above_IN ,_, the_DT Company_NN began_VBD an_DT assessment_NN of_IN property_NN needs_NNS in_IN Canada_NNP and_CC the_DT United_NNP States_NNPS ._.
As_IN a_DT result_NN of_IN this_DT initial_JJ process_NN ,_, the_DT Company_NN decided_VBD to_TO dispose_VB of_IN its_PRP$ building_NN in_IN Laval_NNP ,_, Canada_NNP and_CC will_MD relocate_VB the_DT employees_NNS based_VBN in_IN Laval_NNP to_TO another_DT site_NN or_CC enter_VB into_IN a_DT lease_NN agreement_NN with_IN an_DT ultimate_JJ buyer_NN ._.
The_DT Company_NN also_RB decided_VBD to_TO sell_VB its_PRP$ building_NN in_IN Buffalo_NNP Grove_NNP ._.
As_IN of_IN December_NNP 31_CD ,_, 2003_CD ,_, the_DT Company_NN had_VBD obtained_VBN valuations_NNS of_IN the_DT properties_NNS and_CC entered_VBD into_IN sale_NN negotiations_NNS with_IN third_JJ parties_NNS on_IN the_DT Laval_NNP property_NN and_CC is_VBZ actively_RB seeking_VBG buyers_NNS for_IN its_PRP$ Buffalo_NNP Grove_NNP facility_NN ._.
Based_VBN on_IN these_DT negotiations_NNS ,_, the_DT valuations_NNS obtained_VBN ,_, the_DT limitations_NNS on_IN use_NN of_IN the_DT building_NN in_IN its_PRP$ current_JJ state_NN and_CC the_DT overall_JJ real_JJ estate_NN market_NN ,_, the_DT Company_NN has_VBZ recorded_VBN an_DT impairment_NN charge_NN of_IN $_$ 10.7_CD million_CD ,_, which_WDT is_VBZ included_VBN in_IN selling_NN ,_, general_JJ and_CC administrative_JJ expenses_NNS in_IN the_DT consolidated_JJ statement_NN of_IN operations_NNS :_: in_IN addition_NN ,_, the_DT Company_NN has_VBZ reclassied_VBN to_TO prepaid_JJ expenses_NNS and_CC other_JJ current_JJ assets_NNS the_DT assets_NNS held_VBN for_IN sale_NN in_IN the_DT consolidated_JJ balance_NN sheets_NNS ._.
Year_NN ended_VBD December_NNP 31_CD ,_, 2002_CD a_DT SUMI_NNP acquisition_NN On_IN September_NNP 27_CD ,_, 2002_CD ,_, the_DT Company_NN completed_VBD its_PRP$ acquisition_NN of_IN SUMI_NNP from_IN Niro_NNP Inc._NNP for_IN cash_NN consideration_NN of_IN $_$ 17.3_CD million_CD ,_, including_VBG $_$ 0.3_CD million_CD costs_NNS of_IN acquisition_NN ._.
This_DT transaction_NN provided_VBD the_DT Company_NN with_IN an_DT in-house_JJ facility_NN in_IN which_WDT to_TO manufacture_VB several_JJ key_JJ US_NNP products_NNS ._.
The_DT acquisition_NN was_VBD accounted_VBN for_IN using_VBG the_DT purchase_NN method_NN and_CC goodwill_NN of_IN $_$ 10.2_CD million_CD was_VBD recorded_VBN ._.
The_DT results_NNS of_IN operations_NNS of_IN SUMI_NNP have_VBP been_VBN included_VBN in_IN the_DT consolidated_JJ results_NNS of_IN the_DT Company_NN since_IN the_DT date_NN of_IN acquisition_NN ._.
The_DT purchase_NN price_NN of_IN $_$ 17.3_CD million_CD was_VBD allocated_VBN as_IN follows_VBZ :_: Fair_NNP value_NN $_$ 000_CD Total_JJ current_JJ assets_NNS 3,188_CD Property_NN ,_, plant_NN and_CC equipment_NN ,_, net_JJ 11,620_CD Current_JJ installments_NNS of_IN long-term_JJ debt_NN 216_CD Accounts_NNPS payable_JJ 1,367_CD Long-term_JJ debt_NN ,_, excluding_VBG current_JJ installments_NNS 6,050_CD Net_JJ assets_NNS acquired_VBN 7,175_CD Goodwill_NNP 10,175_CD 17,350_CD Represented_VBN by_IN :_: Purchase_NN consideration_NN 17,000_CD Acquisition_NNP fees_NNS 350_CD 17,350_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 61_CD In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 3_CD Business_NN combinations_NNS and_CC reorganizations_NNS continued_VBD The_DT following_JJ unaudited_JJ consolidated_JJ pro_FW forma_FW results_NNS of_IN operations_NNS for_IN the_DT years_NNS ended_VBN December_NNP 31_CD ,_, 2002_CD and_CC 2001_CD give_VBP effect_NN to_TO the_DT acquisition_NN of_IN SUMI_NNP as_IN if_IN it_PRP was_VBD completed_VBN at_IN the_DT beginning_NN of_IN each_DT period_NN ._.
These_DT proforma_NN results_NNS reect_VBP incremental_JJ nancing_NN costs_NNS resulting_VBG from_IN acquisition_NN and_CC the_DT amortization_NN of_IN acquired_VBN intangible_JJ assets_NNS :_: 2002_CD 2001_CD Year_NN ended_VBD December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD Revenues_NNS 1,042,748_CD 861,660_CD Net_JJ income_NN 248,983_CD 38,824_CD Earnings_NNS per_IN share_NN -_: basic_JJ 49.7_CD 7.9_CD Earnings_NNS per_IN share_NN -_: diluted_VBN 48.7_CD 7.7_CD This_DT unaudited_JJ pro_FW forma_FW financial_JJ information_NN has_VBZ been_VBN prepared_VBN for_IN comparative_JJ purposes_NNS only_RB and_CC does_VBZ not_RB purport_VB to_TO represent_VB the_DT results_NNS of_IN operations_NNS which_WDT would_MD actually_RB have_VB occurred_VBN had_VBD the_DT companies_NNS operated_VBD as_IN one_CD during_IN the_DT period_NN ,_, nor_CC to_TO predict_VB the_DT Companys_NNPS results_NNS of_IN future_JJ operations_NNS ._.
b_NN Divestment_NNP of_IN OTC_NNP products_NNS division_NN On_IN December_NNP 27_CD ,_, 2002_CD ,_, the_DT Company_NN completed_VBD its_PRP$ divestment_NN of_IN a_DT group_NN of_IN non-strategic_JJ US_NNP products_NNS ,_, known_VBN collectively_RB as_IN the_DT Over-The-Counter_NNP OTC_NNP products_NNS ._.
The_DT Company_NN received_VBD sale_NN proceeds_NNS of_IN $_$ 71.0_CD million_CD and_CC recorded_VBD a_DT gain_NN on_IN disposal_NN of_IN $_$ 2.1_CD million_CD ._.
Further_JJ details_NNS of_IN this_DT discontinued_VBN operation_NN are_VBP provided_VBN in_IN note_NN 4_CD below_IN ._.
4_CD Discontinued_VBN operations_NNS In_IN December_NNP 1999_CD the_DT Company_NN acquired_VBD a_DT group_NN of_IN products_NNS ,_, collectively_RB referred_VBD to_TO as_IN the_DT OTC_NNP portfolio_NN ,_, through_IN its_PRP$ merger_NN with_IN Roberts_NNP Pharmaceutical_NNP Corporation_NNP Roberts_NNP ._.
The_DT OTC_NNP portfolio_NN consisted_VBD of_IN non-prescription_JJ laxatives_NNS and_CC dietary_JJ supplements_NNS sold_VBN by_IN the_DT Companys_NNPS US_NNP operating_VBG segment_NN ._.
As_IN a_DT pharmaceuticals_NNS company_NN that_WDT focuses_VBZ on_IN prescription_NN only_RB products_NNS ,_, this_DT part_NN of_IN the_DT business_NN was_VBD not_RB considered_VBN to_TO be_VB a_DT core_NN part_NN of_IN the_DT Companys_NNP long-term_JJ strategy_NN and_CC hence_RB the_DT decision_NN was_VBD made_VBN to_TO divest_VB the_DT OTC_NNP portfolio_NN ._.
On_IN December_NNP 27_CD ,_, 2002_CD ,_, the_DT Company_NN completed_VBD its_PRP$ divestment_NN of_IN the_DT OTC_NNP business_NN ._.
The_DT historical_JJ consolidated_JJ financial_JJ statements_NNS have_VBP been_VBN restated_VBN to_TO reect_VB the_DT OTC_NNP business_NN as_IN a_DT discontinued_VBN operation_NN for_IN all_DT periods_NNS presented_VBN ._.
Operating_VBG results_NNS of_IN the_DT discontinued_VBN operations_NNS are_VBP summarized_VBN below_IN ._.
The_DT amounts_NNS include_VBP income_NN tax_NN provisions_NNS based_VBN on_IN the_DT stand_NN alone_RB results_NNS of_IN the_DT OTC_NNP business_NN ._.
There_EX have_VBP been_VBN no_DT allocations_NNS of_IN general_JJ and_CC administrative_JJ corporate_JJ costs_NNS or_CC interest_NN expense_NN related_VBN to_TO corporate_JJ credit_NN facilities_NNS to_TO the_DT discontinued_VBN operation_NN ._.
As_IN the_DT OTC_NNP business_NN functioned_VBD within_IN Shire_NNP US_NNP ,_, which_WDT itself_PRP essentially_RB functions_NNS as_IN an_DT independent_JJ entity_NN ,_, no_DT corporate_JJ costs_NNS were_VBD eliminated_VBN upon_IN discontinuance_NN of_IN the_DT operation_NN ._.
Within_IN Shire_NNP US_NNP ,_, the_DT OTC_NNP business_NN had_VBD few_JJ dedicated_VBN resources_NNS ._.
All_DT of_IN the_DT products_NNS were_VBD manufactured_VBN and_CC packaged_VBN by_IN third_JJ party_NN contract_NN manufacturers_NNS ._.
The_DT products_NNS were_VBD distributed_VBN through_IN a_DT shared_VBN warehouse_NN facility_NN and_CC sold_VBN through_IN a_DT small_JJ sales_NNS team_NN ._.
2002_CD 2001_CD Year_NN ended_VBD December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD Product_NN sales_NNS 24,010_CD 24,613_CD Cost_NN of_IN product_NN sales_NNS 5,764_CD 6,279_CD Gross_NNP profit_NN 18,246_CD 18,334_CD Operating_NN expenses_NNS :_: Selling_VBG ,_, general_JJ and_CC administrative_JJ 8,550_CD 7,623_CD Operating_NN income_NN 9,696_CD 10,711_CD Income_NN taxes_NNS 3,588_CD 3,963_CD Income_NN from_IN discontinued_VBN operations_NNS 6,108_CD 6,748_CD Gain_NN on_IN sale_NN net_NN of_IN tax_NN 2,083_CD 8,191_CD 6,748_CD 62_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 4_CD Discontinued_VBN operations_NNS continued_VBD The_DT assets_NNS and_CC liabilities_NNS of_IN the_DT discontinued_VBN operation_NN are_VBP summarized_VBN below_IN ._.
December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2002_CD 2001_CD $_$ 000_CD $_$ 000_CD Current_JJ assets_NNS :_: Inventories_NNS 1,779_CD Long_JJ term_NN assets_NNS :_: Goodwill_NNP and_CC other_JJ intangible_JJ assets_NNS ,_, net_JJ 65,348_CD Deferred_JJ tax_NN liability_NN 7,400_CD Total_JJ long_JJ term_NN assets_NNS 57,948_CD Current_JJ liabilities_NNS :_: Other_JJ current_JJ liabilities_NNS 12,784_CD Total_JJ current_JJ liabilities_NNS 12,784_CD Net_JJ liabilities_NNS assets_NNS 12,784_CD 59,727_CD Included_VBN in_IN the_DT 2002_CD other_JJ current_JJ liabilities_NNS are_VBP amounts_NNS for_IN ongoing_JJ liabilities_NNS that_WDT were_VBD not_RB transferred_VBN to_TO the_DT purchaser_NN ._.
There_EX are_VBP no_DT remaining_VBG liabilities_NNS as_IN of_IN December_NNP 31_CD ,_, 2003_CD ._.
5_CD Marketable_JJ securities_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2003_CD 2002_CD $_$ 000_CD $_$ 000_CD Commercial_JJ paper_NN 120,872_CD 87,843_CD Institutional_JJ and_CC managed_VBD cash_NN funds_NNS 183,257_CD 228,283_CD 304,129_CD 316,126_CD December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2003_CD 2002_CD Maturity_NN prole_NN of_IN commercial_JJ paper_NN $_$ 000_CD $_$ 000_CD Less_RBR than_IN one_CD month_NN 27,854_CD 7,297_CD 1-3_JJ months_NNS 84,763_CD 12,981_CD 3-6_CD months_NNS 8,255_CD 67,565_CD 120,872_CD 87,843_CD December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2003_CD 2002_CD Maturity_NN prole_NN of_IN institutional_JJ and_CC managed_VBD cash_NN funds_NNS $_$ 000_CD $_$ 000_CD Less_RBR than_IN one_CD month_NN 51,550_CD 63,600_CD 1-3_JJ months_NNS 19,861_CD 20,373_CD 3-6_CD months_NNS 26,791_CD 45,090_CD 6-12_CD months_NNS 36,195_CD 25,192_CD More_JJR than_IN one_CD year_NN 48,860_CD 74,028_CD 183,257_CD 228,283_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 63_CD In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 6_CD Accounts_NNPS receivable_NN ,_, net_JJ December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2003_CD 2002_CD $_$ 000_CD $_$ 000_CD Trade_NNP receivables_NN ,_, net_JJ 208,893_CD 130,210_CD Research_NNP and_CC development_NN contracts_NNS 5,151_CD 5,184_CD Other_JJ receivables_NN 1,646_CD 3,003_CD 215,690_CD 138,397_CD Included_VBN within_IN research_NN and_CC development_NN contracts_NNS receivable_NN are_VBP amounts_NNS due_JJ in_IN respect_NN of_IN an_DT agreement_NN with_IN the_DT Canadian_JJ government_NN ,_, Technology_NNP Partnerships_NNS Canada_NNP TPC_NNP ,_, under_IN which_WDT a_DT contribution_NN is_VBZ made_VBN towards_IN certain_JJ eligible_JJ research_NN and_CC development_NN costs_NNS incurred_VBN by_IN Shires_NNP Canadian_NNP subsidiary_NN ,_, Shire_NNP BioChem_NNP Inc._NNP ._.
Trade_NNP receivables_NNS are_VBP stated_VBN net_NN of_IN a_DT provision_NN for_IN doubtful_JJ accounts_NNS and_CC discounts_NNS of_IN $_$ 7.9_CD million_CD December_NNP 31_CD ,_, 2002_CD :_: $_$ 4.6_CD million_CD ._.
The_DT movement_NN in_IN the_DT provision_NN for_IN doubtful_JJ accounts_NNS and_CC discounts_NNS is_VBZ as_IN follows_VBZ :_: 2003 2002 2001_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD As_IN of_IN January_NNP 1_CD ,_, 4,585_CD 5,724_CD 2,709_CD Charged_VBN to_TO income_NN 42,841_CD 35,021_CD 27,239_CD Utilization_NN 39,573_CD 36,160_CD 24,224_CD As_IN of_IN December_NNP 31_CD ,_, 7,853_CD 4,585_CD 5,724_CD 7_CD Inventories_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2003_CD 2002_CD $_$ 000_CD $_$ 000_CD Finished_VBN goods_NNS 28,356_CD 27,672_CD Work-in-process_JJ 10,104_CD 13,716_CD Raw_NNP materials_NNS 6,798_CD 7,828_CD 45,258_CD 49,216_CD 8_CD Prepaid_NN expenses_NNS and_CC other_JJ current_JJ assets_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2003_CD 2002_CD $_$ 000_CD $_$ 000_CD Prepaid_NN expenses_NNS 19,747_CD 14,558_CD Assets_NNS held_VBN for_IN resale_NN 12,470_CD Deferred_JJ nancing_NN costs_NNS 1,004_CD 1,208_CD Value_NNP added_VBD taxes_NNS receivable_JJ 3,819_CD 2,730_CD Other_JJ current_JJ assets_NNS 10,977_CD 12,294_CD 48,017_CD 30,790_CD Deferred_JJ nancing_NN costs_NNS relate_VBP to_TO the_DT $_$ 370_CD million_CD convertible_JJ loan_NN note_NN see_VBP note_NN 15_CD ._.
These_DT costs_NNS are_VBP being_VBG amortized_VBN over_IN 10_CD years_NNS using_VBG the_DT effective_JJ interest_NN rate_NN method_NN ._.
64_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 9_CD Investments_NNPS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2003_CD 2002_CD $_$ 000_CD $_$ 000_CD Investments_NNPS in_IN private_JJ companies_NNS 46,068_CD 47,255_CD Investments_NNP in_IN public_JJ companies_NNS 22,057_CD 14,129_CD Equity_NN method_NN investments_NNS 5,028_CD 10,578_CD 73,153_CD 71,962_CD a_DT Investments_NNP in_IN private_JJ companies_NNS Investments_NNP in_IN private_JJ companies_NNS comprise_VBP investments_NNS in_IN a_DT number_NN of_IN pharmaceutical_JJ and_CC biotechnology_NN companies_NNS ._.
The_DT investments_NNS in_IN the_DT following_JJ private_JJ companies_NNS require_VBP Shire_NNP to_TO make_VB additional_JJ future_JJ investments_NNS :_: i_FW GeneChem_NNP funds_NNS Between_IN 1997_CD and_CC 2000_CD ,_, the_DT Company_NN made_VBD investments_NNS in_IN two_CD venture_NN capital_NN funds_NNS ._.
The_DT fund_NN managers_NNS distribute_VBP income_NN to_TO the_DT partners_NNS of_IN the_DT funds_NNS in_IN respect_NN of_IN dividends_NNS or_CC realized_VBN gains_NNS made_VBN on_IN sale_NN of_IN investments_NNS ._.
As_IN part_NN of_IN its_PRP$ initial_JJ investment_NN ,_, the_DT Company_NN was_VBD required_VBN to_TO make_VB additional_JJ future_JJ investments_NNS ._.
As_IN of_IN December_NNP 31_CD ,_, 2003_CD ,_, the_DT Company_NN is_VBZ committed_VBN to_TO making_VBG an_DT additional_JJ investment_NN of_IN $_$ 4.1_CD million_CD CAN$_NNP 5.3_CD million_CD ._.
ii_FW EGS_NNP Healthcare_NNP fund_NN In_IN November_NNP 2000_CD ,_, the_DT Company_NN entered_VBD into_IN an_DT agreement_NN to_TO invest_VB up_RP to_TO $_$ 10.0_CD million_CD in_IN various_JJ EGS_NNP healthcare_NN funds_NNS ._.
As_IN of_IN December_NNP 31_CD ,_, 2003_CD ,_, the_DT Company_NN has_VBZ invested_VBN $_$ 6.1_CD million_CD in_IN EGS_NNP healthcare_NN funds_NNS and_CC the_DT Company_NN is_VBZ committed_VBN to_TO invest_VB a_DT further_JJ $_$ 3.9_CD million_CD into_IN these_DT funds_NNS ._.
b_NN Investments_NNP in_IN public_JJ companies_NNS During_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2003_CD ,_, there_EX were_VBD no_DT new_JJ investments_NNS made_VBN in_IN public_JJ companies_NNS ._.
In_IN July_NNP 2002_CD ,_, the_DT Companys_NNPS $_$ 11.1_CD million_CD preference_NN share_NN investment_NN in_IN Immunogen_NNP Inc._NNP was_VBD converted_VBN in_IN to_TO a_DT common_JJ stock_NN holding_NN ._.
During_IN the_DT year_NN ending_VBG December_NNP 31_CD ,_, 2002_CD ,_, the_DT Company_NN wrote_VBD down_RP the_DT cost_NN of_IN investments_NNS in_IN public_JJ companies_NNS by_IN $_$ 4.5_CD million_CD due_JJ to_TO other_JJ than_IN temporary_JJ impairments_NNS ._.
This_DT expense_NN is_VBZ included_VBN within_IN non-operating_JJ other_JJ expense_NN income_NN ,_, net_JJ see_VBP note_NN 23_CD ._.
c_NN Equity_NN method_NN investments_NNS The_DT Company_NN has_VBZ accounted_VBN for_IN its_PRP$ commercialization_NN partnership_NN with_IN GSK_NNP through_IN which_WDT the_DT products_NNS 3TC_NNP and_CC ZEFFIX_NNP are_VBP marketed_VBN in_IN Canada_NNP using_VBG the_DT equity_NN method_NN of_IN accounting_NN ._.
The_DT Companys_NNP 50_CD %_NN share_NN of_IN the_DT partnership_NN is_VBZ included_VBN within_IN Equity_NN in_IN earnings_NNS of_IN equity_NN method_NN investees_NNS and_CC the_DT related_JJ equity_NN investment_NN of_IN $_$ 5.0_CD million_CD December_NNP 31_CD ,_, 2002_CD :_: $_$ 2.9_CD million_CD is_VBZ included_VBN above_IN ._.
On_IN December_NNP 31_CD ,_, 2003_CD ,_, the_DT Company_NN sold_VBD its_PRP$ investment_NN in_IN Qualia_NNP Computing_NNP Inc._NNP an_DT equity_NN method_NN investee_NN ,_, to_TO iCAD_NNP Inc._NNP ._.
The_DT Company_NN received_VBD sale_NN proceeds_NNS of_IN $_$ 5.5_CD million_CD consisting_VBG of_IN cash_NN and_CC a_DT receivable_NN ._.
There_EX was_VBD no_DT gain_NN or_CC loss_NN recognized_VBN on_IN this_DT transaction_NN ._.
During_IN 2003_CD the_DT Company_NN had_VBD applied_VBN the_DT equity_NN method_NN of_IN accounting_NN as_IN the_DT Company_NN owned_VBN ,_, but_CC did_VBD not_RB exercise_VB control_NN over_IN its_PRP$ 50_CD %_NN share_NN of_IN the_DT joint_JJ venture_NN ._.
As_IN a_DT result_NN ,_, the_DT Companys_NNP investment_NN was_VBD valued_VBN at_IN cost_NN ,_, adjusted_VBN for_IN its_PRP$ share_NN of_IN the_DT earnings_NNS or_CC losses_NNS of_IN the_DT joint_JJ venture_NN ._.
The_DT Companys_NNP share_NN of_IN the_DT partnership_NN was_VBD included_VBN within_IN Equity_NN in_IN earnings_NNS of_IN equity_NN method_NN investees_NNS in_IN the_DT consolidated_JJ statement_NN of_IN operations_NNS and_CC the_DT related_JJ equity_NN investment_NN was_VBD included_VBN in_IN equity_NN method_NN investments_NNS in_IN the_DT consolidated_JJ balance_NN sheet_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 65_CD In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBD 10_CD Property_NN ,_, plant_NN and_CC equipment_NN ,_, net_JJ December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2003_CD 2002_CD $_$ 000_CD $_$ 000_CD Land_NNP and_CC buildings_NNS 107,466_CD 111,164_CD Ofce_NNP furniture_NN ,_, ttings_NNS and_CC equipment_NN 48,847_CD 31,210_CD Warehouse_NNP ,_, laboratory_NN and_CC manufacturing_NN equipment_NN 80,978_CD 46,706_CD 237,291_CD 189,080_CD Less_RBR :_: Accumulated_VBN depreciation_NN 76,066_CD 53,846_CD 161,225_CD 135,234_CD Depreciation_NN expense_NN for_IN the_DT years_NNS ended_VBN December_NNP 31_CD ,_, 2003_CD ,_, 2002_CD and_CC 2001_CD was_VBD $_$ 32.8_CD million_CD ,_, $_$ 12.9_CD million_CD and_CC $_$ 14.4_CD million_CD respectively_RB ._.
Included_VBN within_IN the_DT charge_NN for_IN 2003_CD is_VBZ a_DT $_$ 6.0_CD million_CD write-down_NN of_IN equipment_NN from_IN Lead_JJ Optimization_NN ._.
11_CD Goodwill_NNP and_CC other_JJ intangible_JJ assets_NNS ,_, net_JJ December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2003_CD 2002_CD $_$ 000_CD $_$ 000_CD Goodwill_NNP arising_VBG on_IN businesses_NNS acquired_VBN 281,072_CD 254,207_CD Less_RBR :_: accumulated_VBN amortization_NN 55,212_CD 50,440_CD 225,860_CD 203,767_CD Intellectual_NNP property_NN rights_NNS acquired_VBD 469,137_CD 397,807_CD Less_RBR :_: accumulated_VBN amortization_NN 161,255_CD 96,723_CD 307,882_CD 301,084_CD Total_JJ 533,742_CD 504,851_CD The_DT increase_NN decrease_NN in_IN the_DT net_JJ book_NN value_NN of_IN goodwill_NN and_CC other_JJ intangible_JJ assets_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2003_CD is_VBZ shown_VBN in_IN the_DT table_NN below_IN :_: Other_JJ intangible_JJ Goodwill_NNP assets_NNS $_$ 000_CD $_$ 000_CD As_IN of_IN January_NNP 1_CD ,_, 2003_CD 203,767_CD 301,084_CD Acquisitions_NNPS 48,275_CD Amortization_NN charged_VBN 26,400_CD Asset_NNP impairments_NNS 27,489_CD Foreign_JJ currency_NN translation_NN 22,093_CD 12,412_CD As_IN of_IN December_NNP 31_CD ,_, 2003_CD 225,860_CD 307,882_CD The_DT acquisition_NN of_IN other_JJ intangible_JJ assets_NNS primarily_RB related_VBN to_TO METHYPATCH_NNP ,_, VANIQA_NNP and_CC five_CD products_NNS ,_, purchased_VBN in_IN Canada_NNP from_IN DRAXIS_NNP Health_NNP Inc._NNP ._.
Throughout_IN the_DT year_NN the_DT Company_NN continuously_RB assesses_VBZ the_DT carrying_VBG value_NN of_IN its_PRP$ other_JJ intangible_JJ assets_NNS ._.
This_DT involves_VBZ consideration_NN of_IN ,_, among_IN other_JJ things_NNS ,_, the_DT direction_NN of_IN the_DT business_NN and_CC the_DT marketability_NN of_IN the_DT underlying_VBG products_NNS ._.
The_DT Company_NN recorded_VBN asset_NN impairments_NNS of_IN $_$ 12.1_CD million_CD 2002_CD :_: $_$ 18.8_CD million_CD and_CC wrote_VBD down_RP $_$ 15.4_CD million_CD 2002_CD :_: $_$ nil_CD of_IN assets_NNS during_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2003_CD ._.
The_DT asset_NN impairments_NNS of_IN $_$ 12.1_CD million_CD resulted_VBD from_IN a_DT decline_NN in_IN product_NN prices_NNS ,_, which_WDT decreased_VBD the_DT estimated_JJ future_JJ cash_NN ows_NNS and_CC the_DT $_$ 15.4_CD million_CD resulted_VBD from_IN a_DT decision_NN not_RB to_TO renew_VB product_NN licenses_NNS that_WDT were_VBD not_RB core_NN to_TO the_DT business_NN ._.
The_DT impairments_NNS and_CC write-downs_NNS totalling_VBG $_$ 27.5_CD million_CD have_VBP been_VBN reected_VBN in_IN selling_NN ,_, general_JJ and_CC administrative_JJ expenses_NNS in_IN the_DT consolidated_JJ statement_NN of_IN operations_NNS $_$ 11.7_CD million_CD 2002_CD :_: $_$ 10.8_CD million_CD in_IN the_DT US_NNP segment_NN and_CC $_$ 15.8_CD million_CD 2002_CD :_: $_$ 8.0_CD million_CD in_IN the_DT International_NNP segment_NN ._.
During_IN 2002_CD the_DT Company_NN reviewed_VBD its_PRP$ existing_JJ product_NN base_NN ._.
On_IN completion_NN of_IN this_DT review_NN ,_, management_NN decided_VBD to_TO cease_VB supporting_VBG certain_JJ products_NNS that_WDT were_VBD not_RB considered_VBN to_TO be_VB core_NN to_TO the_DT business_NN and_CC to_TO redirect_VB investment_NN toward_IN other_JJ more_RBR profitable_JJ products_NNS ._.
Intangible_JJ assets_NNS associated_VBN with_IN these_DT products_NNS ,_, namely_RB product_NN rights_NNS and_CC licenses_NNS ,_, were_VBD written_VBN down_RP to_TO their_PRP$ fair_JJ value_NN based_VBN on_IN discounted_JJ cash_NN ow_NN analyses_NNS ._.
This_DT resulted_VBD in_IN the_DT recognition_NN of_IN an_DT impairment_NN loss_NN of_IN $_$ 18.8_CD million_CD $_$ 10.8_CD million_CD in_IN the_DT US_NNP segment_NN and_CC $_$ 8.0_CD million_CD in_IN the_DT international_JJ segment_NN ,_, which_WDT has_VBZ been_VBN reected_VBN in_IN selling_NN ,_, general_JJ and_CC administrative_JJ expenses_NNS in_IN the_DT consolidated_JJ statement_NN of_IN operations_NNS ._.
Amortization_NN charged_VBD for_IN the_DT three_CD years_NNS ended_VBN December_NNP 31_CD ,_, 2003_CD ,_, 2002_CD and_CC 2001_CD was_VBD $_$ 26.4_CD million_CD ,_, $_$ 23.5_CD million_CD and_CC $_$ 31.4_CD million_CD ,_, respectively_RB ._.
Goodwill_NN was_VBD no_RB longer_RB amortized_VBN with_IN effect_NN from_IN January_NNP 1_CD ,_, 2002_CD following_VBG the_DT adoption_NN of_IN SFAS_NNP No._NN ._.
66_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 11_CD Goodwill_NNP and_CC other_JJ intangible_JJ assets_NNS ,_, net_JJ continued_VBD Adoption_NNP of_IN SFAS_NNP No._NN ._.
142_CD As_IN described_VBN in_IN note_NN 2_CD ,_, the_DT Company_NN adopted_VBN SFAS_NNP No._NNP A_NNP transitional_JJ assessment_NN of_IN goodwill_NN impairment_NN as_IN of_IN January_NNP 1_CD ,_, 2002_CD was_VBD completed_VBN by_IN June_NNP 30_CD ,_, 2002_CD ._.
Management_NN concluded_VBD that_IN the_DT fair_JJ value_NN of_IN the_DT Companys_NNP individual_JJ reporting_VBG units_NNS exceeded_VBD the_DT carrying_VBG value_NN of_IN the_DT net_JJ assets_NNS including_VBG goodwill_NN ,_, and_CC hence_RB this_DT process_NN did_VBD not_RB result_VB in_IN any_DT impairment_NN being_VBG recorded_VBN on_IN adoption_NN of_IN SFAS_NNP No._NN ._.
A_DT reconciliation_NN table_NN is_VBZ provided_VBN below_IN to_TO exclude_VB the_DT effect_NN of_IN goodwill_NN amortization_NN in_IN accordance_NN with_IN the_DT transitional_JJ disclosures_NNS relating_VBG to_TO SFAS_NNP No._NN ._.
Results_NNS for_IN the_DT years_NNS ended_VBN December_NNP 31_CD ,_, 2003_CD and_CC 2002_CD have_VBP been_VBN prepared_VBN in_IN accordance_NN with_IN SFAS_NNP No._NN ._.
2001_CD Year_NN ended_VBD December_NNP 31_CD ,_, $_$ 000_CD Income_NN from_IN continuing_VBG operations_NNS as_IN reported_VBN 34,615_CD Add_VB back_RB of_IN goodwill_NN amortization_NN charge_NN 10,763_CD Adjusted_JJ income_NN from_IN continuing_VBG operations_NNS 45,378_CD Net_JJ income_NN as_IN reported_VBN 38,759_CD Add_VB back_RB of_IN goodwill_NN amortization_NN charge_NN 10,763_CD Adjusted_VBN net_JJ income_NN for_IN basic_JJ earnings_NNS per_IN share_NN 49,522_CD Interest_NN charged_VBN on_IN convertible_JJ debt_NN ,_, net_NN of_IN tax_NN Adjusted_VBN net_JJ income_NN for_IN diluted_JJ earnings_NNS per_IN share_NN 49,522_CD 2001_CD Year_NN ended_VBD December_NNP 31_CD ,_, $_$ 000_CD Basic_JJ earnings_NNS per_IN share_NN in_IN $_$ :_: Basic_JJ earnings_NNS per_IN share_NN ,_, as_IN reported_VBN 7.9_CD Add_VB back_RB goodwill_NN amortization_NN charge_NN 2.2_CD Adjusted_VBN basic_JJ earnings_NNS per_IN share_NN 10.1_CD Diluted_NNP earnings_NNS per_IN share_NN in_IN $_$ :_: Diluted_JJ earnings_NNS per_IN share_NN as_IN reported_VBN 7.7_CD Add_VB back_RB goodwill_NN amortization_NN charge_NN 2.1_CD Interest_NN charged_VBN on_IN convertible_JJ debt_NN ,_, net_NN of_IN tax_NN Adjusted_VBN diluted_JJ earnings_NNS per_IN share_NN 9.8_CD No._NN ._.
of_IN shares_NNS Weighted_VBN average_JJ number_NN of_IN shares_NNS :_: Basic_JJ 492,594,226_CD Diluted_NNP 504,875,587_CD There_EX is_VBZ no_DT tax_NN effect_NN related_VBN to_TO the_DT goodwill_NN amortization_NN disclosed_VBN above_IN ._.
The_DT useful_JJ economic_JJ lives_NNS of_IN all_DT intangible_JJ assets_NNS that_WDT continue_VBP to_TO be_VB amortized_VBN under_IN SFAS_NNP No._NN ._.
Management_NNP estimates_VBZ that_IN the_DT annual_JJ amortization_NN charges_NNS in_IN respect_NN of_IN intangible_JJ xed_JJ assets_NNS held_VBN at_IN December_NNP 31_CD ,_, 2003_CD will_MD be_VB approximately_RB $_$ 43_CD million_CD for_IN each_DT of_IN the_DT five_CD years_NNS to_TO December_NNP 31_CD ,_, 2008_CD ._.
Estimated_VBN amortization_NN expense_NN can_MD be_VB affected_VBN by_IN various_JJ factors_NNS including_VBG future_JJ acquisitions_NNS ,_, disposals_NNS of_IN product_NN rights_NNS and_CC the_DT technological_JJ advancement_NN and_CC regulatory_JJ approval_NN of_IN competitor_NN products_NNS ._.
The_DT net_JJ book_NN value_NN of_IN goodwill_NN by_IN operating_VBG segment_NN is_VBZ as_IN follows_VBZ :_: US_NNP International_NNP Biologics_NNPS Corporate_NNP R&D_NNP Total_NNP December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000 2003 193_CD ,023_CD 32,837_CD 225,860_CD 2002_CD 174,617_CD 29,150_CD 203,767_CD There_EX were_VBD no_DT changes_NNS in_IN allocation_NN of_IN goodwill_NN in_IN either_CC period_NN and_CC all_PDT the_DT movements_NNS are_VBP due_JJ to_TO foreign_JJ exchange_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 67_CD In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 12_CD Other_JJ non-current_JJ assets_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2003_CD 2002_CD $_$ 000_CD $_$ 000_CD Deferred_VBN nancing_NN costs_NNS 6,441_CD 7,915_CD SERP_NNP investment_NN 12,042_CD 12,070_CD Other_JJ assets_NNS 4,470_CD 3,279_CD 22,953_CD 23,264_CD The_DT deferred_VBN nancing_NN costs_NNS are_VBP in_IN respect_NN of_IN the_DT $_$ 370_CD million_CD convertible_JJ loan_NN note_NN ._.
These_DT costs_NNS are_VBP being_VBG amortized_VBN over_IN 10_CD years_NNS ._.
The_DT current_JJ element_NN of_IN these_DT costs_NNS is_VBZ included_VBN within_IN prepaid_JJ expenses_NNS and_CC other_JJ current_JJ assets_NNS note_VBP 8_CD ._.
Further_JJ details_NNS of_IN the_DT Supplemental_NNP Executive_NNP Retirement_NNP Plan_NNP SERP_NNP investment_NN are_VBP provided_VBN in_IN note_NN 24_CD ._.
The_DT amount_NN shown_VBN above_IN is_VBZ the_DT cash_NN surrender_NN value_NN of_IN life_NN insurance_NN policies_NNS which_WDT is_VBZ backed_VBN by_IN marketable_JJ securities_NNS ._.
A_DT liability_NN of_IN $_$ 8.9_CD million_CD is_VBZ included_VBN within_IN notes_NNS 14_CD and_CC 16_CD 2002_CD :_: $_$ 8.4_CD million_CD ._.
13_CD Accounts_NNPS payable_JJ and_CC accrued_VBN expenses_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2003_CD 2002_CD $_$ 000_CD $_$ 000_CD Trade_NNP accounts_NNS payable_JJ 21,301_CD 46,912_CD Accrued_VBN rebates_NNS and_CC charge-backs_NNS 59,397_CD 45,919_CD Accrued_VBN bonuses_NNS 18,920_CD 13,622_CD Research_NNP and_CC development_NN accruals_NNS 27,676_CD 26,298_CD Marketing_NNP accrual_NN 16,045_CD 21,269_CD Deferred_JJ revenue_NN 4,132_CD Other_JJ accrued_VBN expenses_NNS 68,023_CD 30,087_CD 215,494_CD 184,107_CD 14_CD Other_JJ current_JJ liabilities_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2003_CD 2002_CD $_$ 000_CD $_$ 000_CD Income_NN taxes_NNS payable_JJ 19,102_CD 5,440_CD Interest_NN on_IN long-term_JJ debt_NN 2,653_CD 2,893_CD Social_NNP security_NN liabilities_NNS 2,216_CD 1,934_CD Value_NNP added_VBD taxes_NNS 1,503_CD 1,957_CD SERP_NNP 2,781_CD 1,233_CD Other_JJ accrued_VBN liabilities_NNS 8,872_CD 3,268_CD 37,127_CD 16,725_CD 68_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 15_CD Long-term_JJ debt_NN December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2003_CD 2002_CD $_$ 000_CD $_$ 000_CD Total_JJ obligations_NNS 377,835_CD 408,190_CD Current_JJ maturities_NNS of_IN long-term_JJ obligations_NNS 1,054_CD 888_CD Total_JJ long-term_JJ debt_NN 376,781_CD 407,302_CD An_DT analysis_NN of_IN total_JJ obligations_NNS by_IN loan_NN type_NN is_VBZ presented_VBN below_IN :_: December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2003_CD 2002_CD $_$ 000_CD $_$ 000_CD Convertible_JJ notes_NNS due_JJ 2011_CD 370,225_CD 400,000_CD Canadian_JJ provincial_JJ and_CC federal_JJ government_NN loan_NN 1,532_CD 1,880_CD Capital_NN leases_NNS 6,078_CD 6,310_CD 377,835_CD 408,190_CD Principal_NN payments_NNS in_IN each_DT of_IN the_DT next_JJ five_CD years_NNS and_CC thereafter_RB on_IN total_JJ obligations_NNS outstanding_JJ as_IN of_IN December_NNP 31_CD ,_, 2003_CD amount_NN to_TO :_: December_NNP 31_CD ,_, 2003_CD $_$ 000_CD 2004_CD 1,054_CD 2005_CD 1,014_CD 2006 254 2007 272_CD 2008_CD 294_CD Thereafter_RB 374,947_CD 377,835_CD i_FW Convertible_JJ notes_NNS due_JJ 2011_CD The_DT $_$ 370_CD million_CD of_IN guaranteed_VBN convertible_JJ notes_NNS due_JJ 2011_CD ,_, were_VBD issued_VBN in_IN August_NNP 2001_CD by_IN Shire_NNP Finance_NNP Limited_NNP the_DT Issuer_NNP ,_, a_DT wholly_RB owned_VBN finance_NN subsidiary_NN of_IN Shire_NNP ._.
The_DT convertible_JJ notes_NNS are_VBP guaranteed_VBN by_IN Shire_NNP and_CC are_VBP convertible_JJ into_IN redeemable_JJ preference_NN shares_NNS of_IN the_DT Issuer_NN which_WDT upon_IN issuance_NN will_MD be_VB immediately_RB exchanged_VBN for_IN either_DT i_FW Shire_FW ordinary_JJ shares_NNS ,_, ii_FW Shire_FW ADSs_FW or_CC iii_FW at_IN the_DT Issuers_NNPS option_NN ,_, a_DT cash_NN amount_NN based_VBN upon_IN the_DT London_NNP Stock_NNP Exchange_NNP volume-weighted_JJ average_NN prices_NNS of_IN ordinary_JJ shares_NNS on_IN the_DT fourth_JJ through_IN eighth_JJ business_NN days_NNS following_VBG conversion_NN ._.
At_IN the_DT choice_NN of_IN investors_NNS ,_, each_DT $_$ 1,000_CD of_IN nominal_JJ value_NN notes_NNS can_MD be_VB converted_VBN into_IN 49.62_CD Shire_NNP ordinary_JJ shares_NNS subject_JJ to_TO adjustment_NN or_CC 16.54_CD Shire_NNP ADSs_NNP subject_NN to_TO adjustment_NN at_IN any_DT time_NN up_RP to_TO August_NNP 21_CD ,_, 2011_CD ._.
Alternatively_RB ,_, investors_NNS can_MD choose_VB to_TO receive_VB repayment_NN of_IN the_DT nominal_JJ principal_NN in_IN cash_NN either_CC at_IN the_DT maturity_NN date_NN of_IN August_NNP 21_CD ,_, 2011_CD or_CC by_IN exercising_VBG a_DT put_NN option_NN on_IN any_DT of_IN the_DT three_CD put_VBD dates_NNS being_VBG August_NNP 21_CD ,_, 2004_CD ,_, August_NNP 21_CD ,_, 2006_CD and_CC August_NNP 21_CD ,_, 2008_CD ._.
On_IN or_CC after_IN August_NNP 21_CD ,_, 2004_CD ,_, the_DT Company_NN may_MD redeem_VB ,_, for_IN cash_NN ,_, all_DT or_CC part_NN of_IN the_DT notes_NNS providing_VBG the_DT ordinary_JJ share_NN price_NN has_VBZ exceeded_VBN $_$ 26.20_CD British_JJ pound_NN equivalent_NN at_IN the_DT time_NN for_IN 20_CD of_IN the_DT 30_CD consecutive_JJ dealing_VBG days_NNS in_IN the_DT period_NN prior_RB to_TO redemption_NN ._.
The_DT decision_NN as_IN to_TO whether_IN a_DT note_NN holder_NN should_MD exercise_VB a_DT put_NN option_NN will_MD depend_VB on_IN a_DT number_NN of_IN factors_NNS ,_, particularly_RB the_DT price_NN of_IN Shire_NNP shares_NNS at_IN the_DT put_JJ date_NN and_CC the_DT likelihood_NN of_IN the_DT Companys_NNP share_NN price_NN exceeding_VBG the_DT conversion_NN threshold_NN price_NN ._.
The_DT conversion_NN threshold_NN price_NN is_VBZ equivalent_JJ to_TO $_$ 20.15_CD or_CC 12.52_CD at_IN the_DT closing_NN exchange_NN rate_NN for_IN 2003_CD for_IN Shire_NNP ordinary_JJ shares_NNS and_CC $_$ 60.46_CD for_IN Shire_NNP ADSs_NNP ._.
If_IN the_DT price_NN of_IN Shire_NNP ordinary_JJ shares_NNS at_IN the_DT first_JJ put_JJ date_NN of_IN August_NNP 21_CD ,_, 2004_CD remains_VBZ at_IN a_DT level_NN similar_JJ to_TO the_DT 2003_CD year-end_JJ price_NN of_IN 5.42_CD $_$ 29.06_CD for_IN Shire_NNP ADSs_NNP ,_, it_PRP is_VBZ quite_RB possible_JJ that_IN note_NN holders_NNS will_MD choose_VB to_TO exercise_VB their_PRP$ put_JJ options_NNS ._.
The_DT Company_NN currently_RB has_VBZ adequate_JJ resources_NNS from_IN which_WDT it_PRP could_MD satisfy_VB repayment_NN of_IN the_DT entire_JJ convertible_JJ debt_NN principal_NN of_IN $_$ 370.2_CD million_CD ._.
During_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2003_CD ,_, the_DT Company_NN repurchased_VBD $_$ 29.8_CD million_CD of_IN the_DT convertible_JJ notes_NNS due_JJ 2011_CD ,_, recording_VBG a_DT gain_NN of_IN $_$ 0.5_CD million_CD which_WDT is_VBZ reected_VBN in_IN other_JJ expense_NN ,_, net_NN on_IN the_DT consolidated_JJ statement_NN of_IN operations_NNS ._.
The_DT interest_NN expense_NN recorded_VBN in_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2003_CD was_VBD $_$ 7.5_CD million_CD 2002_CD :_: $_$ 8.0_CD million_CD ,_, 2001_CD :_: $_$ 2.9_CD million_CD ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 69_CD In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 15_CD Long-term_JJ debt_NN continued_VBD ii_FW Canadian_JJ federal_JJ and_CC provincial_JJ government_NN loan_NN The_DT Company_NN has_VBZ a_DT Canadian_JJ federal_JJ and_CC provincial_JJ government_NN loan_NN outstanding_JJ of_IN $_$ 1.5_CD million_CD CAN$_NNP 2.0_CD million_CD ._.
This_DT facility_NN is_VBZ noninterest_JJ bearing_NN and_CC is_VBZ repayable_JJ in_IN annual_JJ installments_NNS of_IN $_$ 0.8_CD million_CD CAN$_NNP 1.0_CD million_CD ._.
iii_FW Capital_NNP leases_VBZ December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2003_CD 2002_CD Obligations_NNS under_IN capital_NN leases_NNS $_$ 000_CD $_$ 000_CD Current_JJ 282_CD 261_CD Non-current_JJ 5,796_CD 6,049_CD 6,078_CD 6,310_CD The_DT following_NN is_VBZ an_DT analysis_NN of_IN the_DT leased_VBN property_NN under_IN capital_NN leases_NNS by_IN major_JJ asset_NN classes_NNS :_: December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2003_CD 2002_CD $_$ 000_CD $_$ 000_CD Land_NNP and_CC buildings_NNS 6,645_CD 6,259_CD Ofce_NNP furniture_NN ,_, ttings_NNS and_CC equipment_NN 172_CD 160_CD 6,817_CD 6,419_CD Less_RBR :_: accumulated_VBN depreciation_NN 888_CD 126_CD 5,929_CD 6,293_CD The_DT following_NN is_VBZ a_DT schedule_NN by_IN years_NNS of_IN future_JJ minimum_NN lease_NN payments_NNS under_IN capital_NN leases_NNS :_: December_NNP 31_CD ,_, 2003_CD $_$ 000 2004 282 2005_CD 254 2006 254 2007_CD 272 2008 294_CD Thereafter_RB 4,722_CD 6,078_CD 16_CD Other_JJ non-current_JJ liabilities_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2003_CD 2002_CD $_$ 000_CD $_$ 000_CD SERP_NNP note_NN 24_CD 6,102_CD 7,131_CD Long-term_JJ bonuses_NNS 3,117_CD Deferred_JJ revenue_NN 13,430_CD Other_JJ accrued_VBN liabilities_NNS 1,149_CD 6,520_CD 23,798_CD 13,651_CD The_DT deferred_JJ revenue_NN relates_VBZ to_TO amounts_NNS received_VBN from_IN the_DT out-licensing_NN of_IN AGRYLIN_NNP and_CC FOSRENOL_NNP in_IN Japan_NNP ._.
70_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 17_CD Financial_NNP instruments_NNS The_DT estimated_VBN fair_JJ value_NN of_IN the_DT Companys_NNPS financial_JJ instruments_NNS at_IN December_NNP 31_CD ,_, is_VBZ summarized_VBN below_IN ._.
Certain_JJ estimates_NNS and_CC judgments_NNS were_VBD required_VBN to_TO develop_VB the_DT fair_JJ value_NN amounts_NNS ._.
The_DT fair_JJ value_NN amounts_NNS shown_VBN below_IN are_VBP not_RB necessarily_RB indicative_JJ of_IN the_DT amounts_NNS that_IN the_DT Company_NN would_MD realize_VB upon_IN disposition_NN nor_CC do_VBP they_PRP indicate_VBP the_DT Companys_NNPS intent_NN or_CC ability_NN to_TO dispose_VB of_IN the_DT financial_JJ instrument_NN ._.
The_DT following_VBG methods_NNS and_CC assumptions_NNS were_VBD used_VBN to_TO estimate_VB the_DT fair_JJ value_NN of_IN each_DT material_NN class_NN of_IN financial_JJ instrument_NN :_: Marketable_JJ securities_NNS commercial_JJ paper_NN and_CC institutional_JJ and_CC managed_VBD cash_NN funds_NNS the_DT carrying_NN value_NN approximates_VBZ fair_JJ value_NN because_IN of_IN the_DT short-term_JJ nature_NN of_IN these_DT instruments_NNS ._.
Investments_NNP the_DT carrying_VBG value_NN of_IN non-current_JJ investments_NNS with_IN readily_RB determinable_JJ market_NN values_NNS equals_VBZ the_DT fair_JJ value_NN as_IN such_JJ instruments_NNS are_VBP marked_VBN to_TO market_NN ._.
Long-term_JJ debt_NN the_DT fair_JJ value_NN of_IN long-term_JJ debt_NN is_VBZ estimated_VBN based_VBN on_IN the_DT discounted_JJ future_JJ cash_NN ows_NNS using_VBG currently_RB available_JJ interest_NN rates_NNS or_CC ,_, where_WRB the_DT debt_NN instrument_NN is_VBZ traded_VBN ,_, by_IN reference_NN to_TO the_DT market_NN price_NN ._.
The_DT carrying_VBG amounts_NNS and_CC corresponding_JJ fair_JJ values_NNS of_IN financial_JJ instruments_NNS ,_, were_VBD as_IN follows_VBZ as_IN of_IN December_NNP 31_CD ,_, 2003_CD and_CC 2002_CD :_: Carrying_VBG Amount_NNP Fair_NNP Value_NNP $_$ 000_CD $_$ 000_CD December_NNP 31_CD ,_, 2003_CD Financial_JJ assets_NNS :_: Commercial_JJ paper_NN 120,872_CD 120,872_CD Institutional_JJ and_CC managed_VBD cash_NN funds_NNS 183,257_CD 183,257_CD Investments_NNP 22,057_CD 22,057_CD Financial_NNP liabilities_NNS :_: Long-term_JJ debt_NN 376,781_CD 378,769_CD December_NNP 31_CD ,_, 2002_CD Financial_JJ assets_NNS :_: Commercial_JJ paper_NN 87,843_CD 87,843_CD Institutional_JJ and_CC managed_VBD cash_NN funds_NNS 228,283_CD 228,283_CD Investments_NNP 14,129_CD 14,129_CD Financial_NNP liabilities_NNS :_: Long-term_JJ debt_NN 408,190_CD 376,883_CD The_DT carrying_VBG amounts_NNS of_IN cash_NN and_CC cash_NN equivalents_NNS ,_, accounts_NNS receivable_JJ ,_, accounts_NNS payable_JJ and_CC accrued_VBN liabilities_NNS approximate_JJ fair_JJ value_NN because_IN of_IN the_DT short-term_JJ maturity_NN of_IN these_DT instruments_NNS ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 71_CD In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 18_CD Commitments_NNS and_CC contingencies_NNS a_DT Leases_NNP The_NNP Company_NNP leases_VBZ facilities_NNS ,_, motor_NN vehicles_NNS and_CC certain_JJ equipment_NN under_IN operating_VBG leases_NNS expiring_VBG through_IN 2012_CD ._.
Expense_NN related_VBN to_TO operating_VBG leases_NNS is_VBZ recognized_VBN on_IN a_DT straight-line_JJ basis_NN over_IN the_DT life_NN of_IN the_DT lease_NN ._.
In_IN addition_NN ,_, the_DT Company_NN has_VBZ a_DT building_NN lease_NN ,_, which_WDT is_VBZ accounted_VBN for_IN as_IN a_DT capital_NN lease_NN ,_, which_WDT expires_VBZ in_IN 2019_CD ._.
Future_JJ minimum_NN lease_NN payments_NNS presented_VBD below_IN include_VBP principal_JJ lease_NN payments_NNS and_CC other_JJ xed_VBN executory_NN fees_NNS under_IN lease_NN arrangements_NNS as_IN of_IN December_NNP 31_CD ,_, 2003_CD :_: Operating_NNP Capital_NNP leases_VBZ lease_NN $_$ 000_CD $_$ 000_CD 2004_CD 12,719_CD 282_CD 2005_CD 7,854_CD 254_CD 2006_CD 5,234_CD 254_CD 2007_CD 3,646_CD 272_CD 2008_CD 2,794_CD 294_CD Thereafter_RB 11,819_CD 4,722_CD 44,066_CD 6,078_CD Less_RBR :_: amount_NN representing_VBG xed_JJ executory_NN costs_NNS ,_, including_VBG interest_NN ,_, included_VBD in_IN future_JJ minimum_NN lease_NN payments_NNS Total_JJ capital_NN lease_NN obligation_NN 6,078_CD Less_RBR :_: current_JJ portion_NN of_IN capital_NN lease_NN obligation_NN 282_CD Non-current_JJ portion_NN of_IN capital_NN lease_NN obligation_NN 5,796_CD Lease_NNP and_CC rental_JJ expense_NN included_VBD in_IN selling_NN ,_, general_JJ and_CC administrative_JJ expenses_NNS in_IN the_DT accompanying_VBG statements_NNS of_IN operations_NNS amounted_VBD to_TO $_$ 12.2_CD million_CD ,_, $_$ 6.7_CD million_CD and_CC $_$ 6.1_CD million_CD for_IN the_DT scal_JJ years_NNS ended_VBN December_NNP 31_CD ,_, 2003_CD ,_, 2002_CD and_CC 2001_CD ,_, respectively_RB ._.
Shire_NNP has_VBZ guaranteed_VBN a_DT building_NN lease_NN and_CC has_VBZ $_$ 6.8_CD million_CD of_IN restricted_VBN cash_NN held_VBN as_IN collateral_NN for_IN this_DT lease_NN ._.
b_NN Letters_NNS of_IN credit_NN As_IN of_IN December_NNP 31_CD ,_, 2003_CD the_DT Company_NN had_VBD an_DT irrevocable_JJ standby_JJ letter_NN of_IN credit_NN with_IN Fifth_NNP Third_NNP Bank_NNP to_TO Allrst_NNP Bank_NNP in_IN the_DT amount_NN of_IN $_$ 10.0_CD million_CD relating_VBG to_TO the_DT bonds_NNS that_WDT nanced_VBD the_DT construction_NN of_IN its_PRP$ US_NNP manufacturing_NN facility_NN ._.
As_IN of_IN December_NNP 31_CD ,_, 2003_CD the_DT Company_NN had_VBD an_DT irrevocable_JJ standby_JJ letter_NN of_IN credit_NN with_IN Barclays_NNP Bank_NNP plc_NN to_TO Zurich_NNP International_NNP UK_NNP Limited_NNP in_IN the_DT amount_NN of_IN $_$ 15.0_CD million_CD providing_VBG security_NN on_IN the_DT recoverability_NN of_IN insurance_NN claims_NNS ._.
An_DT irrevocable_JJ standby_JJ letter_NN of_IN credit_NN of_IN $_$ 19.0_CD million_CD CAN$_NNP 24.5_CD million_CD that_DT represented_VBD the_DT Company_NN 's_POS obligations_NNS with_IN respect_NN to_TO the_DT establishment_NN of_IN pandemic_JJ readiness_NN as_IN of_IN December_NNP 31_CD ,_, 2003_CD ._.
c_NN Commitments_NNS i_FW The_DT Company_NN has_VBZ undertaken_VBN to_TO subscribe_VB to_TO interests_NNS in_IN companies_NNS and_CC partnerships_NNS for_IN amounts_NNS totaling_VBG $_$ 44.8_CD million_CD December_NNP 31_CD ,_, 2002_CD :_: $_$ 38.1_CD million_CD ._.
As_IN of_IN December_NNP 31_CD ,_, 2003_CD an_DT amount_NN of_IN $_$ 36.8_CD million_CD December_NNP 31_CD ,_, 2002_CD :_: $_$ 26.4_CD million_CD has_VBZ been_VBN subscribed_VBN ,_, leaving_VBG an_DT outstanding_JJ commitment_NN of_IN $_$ 8.0_CD million_CD December_NNP 31_CD ,_, 2002_CD :_: $_$ 11.7_CD million_CD ._.
ii_FW Government_NN of_IN Canada_NNP In_IN 2001_CD ,_, the_DT Company_NN signed_VBD a_DT ten-year_JJ non-cancellable_JJ contract_NN with_IN the_DT Government_NN of_IN Canada_NNP GOC_NNP to_TO assure_VB a_DT state_NN of_IN readiness_NN in_IN the_DT case_NN of_IN an_DT inuenza_NN pandemic_JJ worldwide_NN epidemic_NN and_CC to_TO provide_VB inuenza_NN vaccine_NN for_IN all_DT Canadian_JJ citizens_NNS in_IN such_JJ an_DT event_NN hereinafter_NN referred_VBD to_TO as_IN the_DT Pandemic_NNP contract_NN ._.
The_DT Company_NN is_VBZ committed_VBN to_TO provide_VB 32_CD million_CD doses_NNS of_IN single-strain_JJ monovalent_JJ inuenza_NN vaccine_NN within_IN a_DT production_NN period_NN of_IN 16_CD weeks_NNS ._.
The_DT Company_NN has_VBZ therefore_RB begun_VBN a_DT process_NN of_IN expanding_VBG its_PRP$ production_NN capacity_NN in_IN order_NN to_TO meet_VB this_DT objective_NN within_IN a_DT five-year_JJ period_NN ending_VBG January_NNP 2006_CD ._.
The_DT Company_NN is_VBZ committed_VBN to_TO approximately_RB $_$ 13.9_CD million_CD CAN$_NNP 18.0_CD million_CD of_IN capital_NN expenditure_NN for_IN the_DT purpose_NN of_IN achieving_VBG the_DT level_NN of_IN pandemic_JJ readiness_NN required_VBN in_IN the_DT Pandemic_NNP contract_NN ._.
The_DT Government_NN has_VBZ agreed_VBN to_TO reimburse_VB the_DT Company_NN $_$ 10.4_CD million_CD CAN$_NNP 13.5_CD million_CD ._.
At_IN the_DT end_NN of_IN the_DT contract_NN ,_, the_DT Company_NN is_VBZ committed_VBN to_TO buy_VB back_RP any_DT unused_JJ and_CC unexpired_JJ materials_NNS and_CC capital_NN assets_NNS reimbursed_VBN by_IN the_DT GOC_NNP at_IN net_JJ book_NN value_NN that_WDT can_MD be_VB used_VBN for_IN production_NN of_IN trivalent_JJ vaccine_NN or_CC other_JJ products_NNS ._.
72_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 18_CD Commitments_NNS and_CC contingencies_NNS continued_VBD As_IN a_DT condition_NN of_IN the_DT Pandemic_NNP contract_NN ,_, Shire_NNP Biochem_NNP ,_, a_DT wholly_RB owned_VBN subsidiary_NN ,_, entered_VBD into_IN an_DT irrevocable_JJ standby_JJ letter_NN of_IN credit_NN of_IN $_$ 19.0_CD million_CD CAN$_NNP 24.5_CD million_CD ._.
The_DT standby_JJ letter_NN of_IN credit_NN is_VBZ collateralized_VBN by_IN an_DT equivalent_JJ amount_NN of_IN cash_NN ._.
In_IN addition_NN ,_, under_IN another_DT GOC_NNP contract_NN ,_, the_DT Company_NN is_VBZ required_VBN to_TO supply_VB the_DT GOC_NNP with_IN a_DT substantial_JJ proportion_NN of_IN its_PRP$ annual_JJ inuenza_NN vaccine_NN requirements_NNS over_IN a_DT ten-year_JJ period_NN ending_VBG March_NNP 2011_CD ._.
iii_FW Vaccine_NN production_NN facility_NN The_DT Company_NN is_VBZ also_RB committed_VBN to_TO the_DT expansion_NN of_IN its_PRP$ vaccine_NN production_NN facility_NN located_VBN in_IN Quebec_NNP City_NNP ._.
A_DT new_JJ building_NN will_MD be_VB located_VBN alongside_IN the_DT existing_VBG vaccine_NN production_NN facility_NN in_IN the_DT Quebec_NNP Metro_NNP High_NNP Tech_NNP Park_NNP for_IN an_DT estimated_VBN $_$ 37.8_CD million_CD CAN$_NNP 48.8_CD million_CD ._.
It_PRP is_VBZ expected_VBN that_IN this_DT facility_NN will_MD be_VB operational_JJ in_IN 2006_CD ._.
iv_NN TPC_NNP research_NN facility_NN In_IN March_NNP 2000_CD ,_, the_DT Company_NN entered_VBD into_IN a_DT funding_NN agreement_NN with_IN TPC_NNP ,_, a_DT Canadian_JJ governmental_JJ agency_NN ,_, hereinafter_NN referred_VBD to_TO as_IN the_DT TPC_NNP agreement_NN relating_VBG to_TO the_DT research_NN and_CC development_NN of_IN recombinant_JJ protein_NN vaccines_NNS ._.
The_DT TPC_NNP agreed_VBD to_TO a_DT total_JJ contribution_NN not_RB to_TO exceed_VB $_$ 61.9_CD million_CD CAN$_NNP 80.0_CD million_CD ._.
Such_JJ contribution_NN is_VBZ repayable_JJ to_TO the_DT TPC_NNP in_IN the_DT form_NN of_IN royalties_NNS on_IN the_DT net_JJ sales_NNS value_NN gross_JJ invoiced_JJ amounts_NNS less_RBR discounts_NNS ,_, taxes_NNS and_CC delivery_NN costs_NNS if_IN the_DT products_NNS become_VBP commercialized_VBN ._.
The_DT Company_NN is_VBZ obligated_VBN to_TO pay_VB such_JJ royalties_NNS in_IN the_DT period_NN to_TO December_NNP 31_CD ,_, 2016_CD ._.
No_DT amounts_NNS have_VBP been_VBN accrued_VBN with_IN respect_NN to_TO this_DT obligation_NN as_IN the_DT conditions_NNS for_IN repayment_NN have_VBP not_RB yet_RB been_VBN met_VBN ._.
As_IN a_DT condition_NN of_IN the_DT TPC_NNP agreement_NN ,_, the_DT Company_NN has_VBZ an_DT obligation_NN to_TO build_VB a_DT vaccine_NN research_NN facility_NN in_IN Canada_NNP ._.
The_DT construction_NN of_IN the_DT vaccine_NN research_NN center_NN in_IN Laval_NNP ,_, Canada_NNP will_MD represent_VB an_DT investment_NN of_IN approximately_RB $_$ 27.5_CD million_CD CAN$_NNP 35.6_CD million_CD and_CC should_MD be_VB completed_VBN in_IN December_NNP 2004_CD ._.
The_DT TPC_NNP agreement_NN requires_VBZ the_DT Company_NN to_TO comply_VB with_IN certain_JJ conditions_NNS as_IN outlined_VBN in_IN the_DT agreement_NN ._.
Any_DT violation_NN of_IN such_JJ conditions_NNS allows_VBZ the_DT TPC_NNP to_TO declare_VB the_DT Company_NN in_IN default_NN and_CC may_MD result_VB in_IN repayment_NN of_IN all_DT previous_JJ funding_NN ._.
v_NN METHYPATCH_NNP In_IN connection_NN with_IN the_DT Companys_NNP purchase_NN of_IN METHYPATCH_NNP in_IN 2003_CD ,_, the_DT Company_NN is_VBZ committed_VBN to_TO pay_VB an_DT additional_JJ $_$ 50_CD million_CD upon_IN regulatory_JJ approval_NN of_IN the_DT product_NN ._.
In_IN addition_NN the_DT Company_NN has_VBZ an_DT obligation_NN to_TO make_VB further_JJ milestone_NN payments_NNS ,_, which_WDT are_VBP linked_VBN to_TO the_DT future_JJ sales_NNS performance_NN of_IN the_DT product_NN ._.
These_DT payments_NNS could_MD total_VB $_$ 75_CD million_CD ._.
vi_FW DRAXIS_NNP In_IN connection_NN with_IN the_DT Companys_NNP purchase_NN of_IN a_DT range_NN of_IN products_NNS from_IN DRAXIS_NNP Health_NNP Inc._NNP in_IN 2003_CD ,_, the_DT Company_NN has_VBZ an_DT obligation_NN to_TO make_VB certain_JJ milestone_NN payments_NNS if_IN no_DT generic_JJ events_NNS occur_VBP for_IN certain_JJ products_NNS purchased_VBN ._.
The_DT milestone_NN payments_NNS could_MD reach_VB an_DT amount_NN up_RP to_TO $_$ 3.1_CD million_CD CAN$_NNP 4_CD million_CD if_IN no_DT generic_JJ events_NNS have_VBP occurred_VBN for_IN those_DT products_NNS by_IN January_NNP 22_CD ,_, 2007_CD ._.
d_LS Legal_NNP proceedings_NNS i_FW General_NNP The_NNP Company_NNP accounts_VBZ for_IN litigation_NN losses_NNS in_IN accordance_NN with_IN SFAS_NNP No._NN ._.
5_CD ,_, Accounting_NNP for_IN Contingencies_NNPS SFAS_NNP No._NN ._.
5_CD ,_, loss_NN contingency_NN provisions_NNS are_VBP recorded_VBN for_IN probable_JJ losses_NNS when_WRB management_NN is_VBZ able_JJ to_TO reasonably_RB estimate_VB the_DT loss_NN ._.
Where_WRB the_DT estimated_JJ loss_NN lies_VBZ within_IN in_IN a_DT range_NN and_CC no_DT particular_JJ amount_NN within_IN that_DT range_NN is_VBZ a_DT better_JJR estimate_NN than_IN any_DT other_JJ amount_NN ,_, the_DT minimum_NN amount_NN is_VBZ recorded_VBN ._.
In_IN other_JJ cases_NNS management_NN 's_POS best_JJS estimate_NN of_IN the_DT loss_NN is_VBZ recorded_VBN ._.
These_DT estimates_NNS are_VBP developed_VBN substantially_RB before_IN the_DT ultimate_JJ loss_NN is_VBZ known_VBN and_CC the_DT estimates_NNS are_VBP rened_VBN each_DT accounting_NN period_NN in_IN light_NN of_IN additional_JJ information_NN being_VBG known_VBN ._.
In_IN instances_NNS where_WRB the_DT Company_NN is_VBZ unable_JJ to_TO develop_VB a_DT best_JJS estimate_NN of_IN loss_NN ,_, no_DT litigation_NN loss_NN is_VBZ recorded_VBN at_IN that_DT time_NN ._.
As_IN information_NN becomes_VBZ known_VBN a_DT loss_NN provision_NN is_VBZ set_VBN up_RP when_WRB a_DT best_JJS estimate_NN can_MD be_VB made_VBN ._.
The_DT best_JJS estimates_NNS are_VBP reviewed_VBN quarterly_JJ and_CC the_DT estimates_NNS are_VBP changed_VBN when_WRB expectations_NNS are_VBP revised_VBN ._.
Any_DT outcome_NN upon_IN settlement_NN that_IN deviates_VBZ from_IN the_DT Companys_NNPS best_JJS estimate_NN may_MD result_VB in_IN an_DT additional_JJ expense_NN in_IN a_DT future_JJ accounting_NN period_NN ._.
During_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2003_CD a_DT legal_JJ accrual_NN of_IN $_$ 2.0_CD million_CD was_VBD released_VBN ,_, to_TO the_DT consolidated_JJ statement_NN of_IN operations_NNS ,_, because_IN of_IN the_DT outcome_NN of_IN previously_RB pending_VBG litigation_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 73_CD In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 18_CD Commitments_NNS and_CC contingencies_NNS continued_VBD ii_FW Phentermine_NNP Shire_NNP US_NNP Inc._NNP ._.
SUS_NNP ,_, a_DT wholly-owned_JJ subsidiary_NN of_IN Shire_NNP ,_, is_VBZ a_DT defendant_NN in_IN 429_CD lawsuits_NNS still_RB pending_VBG in_IN both_DT US_NNP federal_JJ and_CC state_NN courts_NNS which_WDT seek_VBP damages_NNS for_IN ,_, among_IN other_JJ things_NNS ,_, personal_JJ injury_NN arising_VBG from_IN phentermine_NN products_NNS supplied_VBD for_IN the_DT treatment_NN of_IN obesity_NN by_IN SUS_NNP and_CC several_JJ other_JJ pharmaceutical_JJ companies_NNS ._.
Accordingly_RB ,_, SUS_NNP intends_VBZ to_TO defend_VB vigorously_RB any_DT and_CC all_DT claims_NNS made_VBN against_IN the_DT Company_NN in_IN respect_NN of_IN phentermine_NN ._.
Legal_JJ expenses_NNS to_TO date_NN have_VBP been_VBN paid_VBN by_IN Eon_NNP ,_, the_DT supplier_NN to_TO SUS_NNP ,_, or_CC Eons_NNS insurance_NN carriers_NNS ,_, but_CC such_JJ insurance_NN is_VBZ now_RB exhausted_VBN ._.
Eon_NNP has_VBZ agreed_VBN to_TO defend_VB and_CC indemnify_VB SUS_NNP in_IN this_DT litigation_NN pursuant_JJ to_TO an_DT agreement_NN dated_VBN November_NNP 30_CD ,_, 2000_CD between_IN Eon_NNP and_CC SUS_NNP ._.
iii_FW ADDERALL_NNP XR_NNP Shires_NNP extended_VBD release_NN once_RB daily_JJ version_NN of_IN ADDERALL_NNP ,_, ADDERALL_NNP XR_NNP is_VBZ covered_VBN by_IN US_NNP patent_NN No._NN ._.
In_IN January_NNP 2003_CD the_DT Company_NN was_VBD notied_VBN that_IN Barr_NNP Laboratories_NNPS ,_, Inc._NNP ._.
Barr_NNP had_VBD submitted_VBN an_DT Abbreviated_NNP New_NNP Drug_NNP Application_NNP ANDA_NNP under_IN the_DT Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB a_DT generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT Companys_NNPS 819_CD Patent_NN ._.
The_DT notication_NN alleged_VBD that_IN the_DT 819_CD Patent_NN is_VBZ not_RB infringed_VBN by_IN Barrs_NNP extended_VBD release_NN mixed_JJ amphetamine_NN salt_NN product_NN ,_, which_WDT is_VBZ the_DT subject_NN of_IN Barrs_NNP ANDA_NNP ._.
On_IN February_NNP 24_CD ,_, 2003_CD Shire_NNP Laboratories_NNPS Inc._NNP ._.
Shire_NNP Laboratories_NNPS led_VBD suit_NN against_IN Barr_NNP in_IN the_DT United_NNP States_NNPS District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP alleging_VBG that_IN Barrs_NNP ANDA_NNP infringes_VBZ the_DT 819_CD Patent_NN ._.
The_DT Company_NN is_VBZ seeking_VBG a_DT ruling_NN that_WDT Barrs_VBZ ANDA_NNP infringes_VBZ the_DT 819_CD Patent_NN and_CC should_MD not_RB be_VB approved_VBN before_IN the_DT expiration_NN date_NN of_IN the_DT 819_CD Patent_NN ._.
The_DT Company_NN is_VBZ also_RB seeking_VBG an_DT injunction_NN to_TO prevent_VB Barr_NNP from_IN commercializing_VBG its_PRP$ ANDA_NNP product_NN before_IN the_DT expiration_NN of_IN the_DT 819_CD Patent_NN ,_, damages_NNS in_IN the_DT event_NN that_IN Barr_NNP should_MD engage_VB in_IN such_JJ commercialization_NN ,_, as_RB well_RB its_PRP$ attorneys_NNS fees_NNS and_CC costs_NNS ._.
Barr_NNP is_VBZ also_RB seeking_VBG its_PRP$ attorneys_NNS fees_NNS ,_, costs_NNS and_CC expenses_NNS ._.
On_IN August_NNP 12_CD ,_, 2003_CD ,_, Shire_NNP Laboratories_NNP was_VBD issued_VBN a_DT new_JJ US_NNP patent_NN No._NN ._.
The_DT Company_NN is_VBZ seeking_VBG a_DT ruling_NN that_WDT Barrs_VBZ ANDA_NNP infringes_VBZ the_DT 300_CD Patent_NN and_CC should_MD not_RB be_VB approved_VBN before_IN the_DT expiration_NN date_NN of_IN the_DT 300_CD Patent_NN ._.
The_DT Company_NN is_VBZ also_RB seeking_VBG an_DT injunction_NN to_TO prevent_VB Barr_NNP from_IN commercializing_VBG its_PRP$ ANDA_NNP product_NN before_IN the_DT expiration_NN of_IN the_DT 300_CD Patent_NN ,_, damages_NNS in_IN the_DT event_NN that_IN Barr_NNP should_MD engage_VB in_IN such_JJ commercialization_NN ,_, as_RB well_RB its_PRP$ attorneys_NNS fees_NNS and_CC costs_NNS ._.
By_IN way_NN of_IN a_DT counterclaim_NN Barr_NNP is_VBZ seeking_VBG a_DT declaration_NN that_IN the_DT 300_CD Patent_NN is_VBZ invalid_JJ and_CC Barr_NNP has_VBZ also_RB asked_VBN for_IN its_PRP$ attorneys_NNS fees_NNS ,_, costs_NNS and_CC expenses_NNS ._.
Barr_NNP may_MD not_RB launch_VB a_DT generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP before_IN it_PRP receives_VBZ final_JJ approval_NN of_IN its_PRP$ ANDA_NNP from_IN the_DT FDA_NNP ._.
The_DT lawsuits_NNS triggered_VBD stays_NNS of_IN FDA_NNP approval_NN of_IN up_RB to_TO 30_CD months_NNS from_IN the_DT Companys_NNP receipt_NN of_IN Barrs_NNP notices_NNS to_TO allow_VB the_DT court_NN to_TO resolve_VB the_DT suits_NNS ._.
Even_RB if_IN Barr_NNP receives_VBZ a_DT tentative_JJ approval_NN from_IN the_DT FDA_NNP ,_, it_PRP can_MD not_RB lawfully_RB launch_VB its_PRP$ generic_JJ version_NN before_IN the_DT earlier_JJR of_IN the_DT expiration_NN of_IN the_DT latest_JJS stay_NN February_NNP 2006_CD or_CC a_DT district_NN court_NN decision_NN in_IN its_PRP$ favor_NN ._.
In_IN the_DT event_NN that_IN the_DT Company_NN does_VBZ not_RB prevail_VB ,_, then_RB Barr_NNP could_MD be_VB in_IN a_DT position_NN to_TO market_VB its_PRP$ extended_JJ release_NN mixed_JJ amphetamine_NN salt_NN product_NN upon_IN FDA_NNP final_JJ approval_NN of_IN its_PRP$ ANDA_NNP following_VBG the_DT expiry_NN of_IN the_DT existing_VBG Hatch-Waxman_NNP exclusivity_NN in_IN October_NNP 2004_CD ._.
In_IN November_NNP 2003_CD ,_, Shire_NNP was_VBD notied_VBN that_IN Impax_NNP Laboratories_NNPS Impax_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN dates_NNS of_IN the_DT 819_CD and_CC 300_CD Patents_NNP and_CC alleging_VBG that_IN the_DT 819_CD and_CC 300_CD Patents_NNP are_VBP not_RB infringed_VBN by_IN Impaxs_NNP extended_VBD release_NN mixed_JJ amphetamine_NN salt_NN product_NN ,_, the_DT subject_NN of_IN Impaxs_NNP ANDA_NNP ._.
The_DT Company_NN is_VBZ seeking_VBG a_DT ruling_NN that_WDT Impaxs_VBZ ANDA_NNP infringes_VBZ the_DT 819_CD and_CC 300_CD Patents_NNP and_CC should_MD not_RB be_VB approved_VBN before_IN the_DT expiration_NN dates_NNS of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ._.
The_DT Company_NN is_VBZ also_RB seeking_VBG an_DT injunction_NN to_TO prevent_VB Impax_NNP from_IN commercializing_VBG its_PRP$ ANDA_NNP product_NN before_IN the_DT expiration_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ,_, damages_NNS in_IN the_DT event_NN that_WDT Impax_NNP should_MD engage_VB in_IN such_JJ commercialization_NN ,_, as_RB well_RB its_PRP$ attorneys_NNS fees_NNS and_CC costs_NNS ._.
Impaxs_NNP afrmative_JJ defenses_NNS include_VBP non-infringement_JJ and_CC invalidity_NN of_IN both_DT the_DT 819_CD and_CC 300_CD Patents_NNP ._.
Impax_NNP is_VBZ also_RB requesting_VBG that_IN costs_NNS be_VB assessed_VBN against_IN the_DT Company_NN ._.
74_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 18_CD Commitments_NNS and_CC contingencies_NNS continued_VBD Impax_NNP may_MD not_RB launch_VB a_DT generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP before_IN it_PRP receives_VBZ final_JJ approval_NN of_IN its_PRP$ ANDA_NNP from_IN the_DT FDA_NNP ._.
The_DT lawsuit_NN triggered_VBD a_DT stay_NN of_IN FDA_NNP approval_NN of_IN up_RB to_TO 30_CD months_NNS from_IN the_DT Companys_NNP receipt_NN of_IN Impaxs_NNP notice_NN to_TO allow_VB the_DT court_NN to_TO resolve_VB the_DT suit_NN ._.
Even_RB if_IN Impax_NNP receives_VBZ a_DT tentative_JJ approval_NN from_IN the_DT FDA_NNP ,_, it_PRP can_MD not_RB lawfully_RB launch_VB its_PRP$ generic_JJ version_NN before_IN the_DT earlier_JJR of_IN the_DT expiration_NN of_IN the_DT stay_NN May_NNP 2006_CD or_CC a_DT district_NN court_NN decision_NN in_IN its_PRP$ favor_NN ._.
In_IN the_DT event_NN that_IN the_DT Company_NN does_VBZ not_RB prevail_VB ,_, then_RB Impax_NNP could_MD be_VB in_IN a_DT position_NN to_TO market_VB its_PRP$ extended_JJ release_NN mixed_JJ amphetamine_NN salt_NN product_NN upon_IN FDA_NNP final_JJ approval_NN of_IN its_PRP$ ANDA_NNP following_VBG the_DT expiry_NN of_IN the_DT existing_VBG Hatch-Waxman_NNP exclusivity_NN in_IN October_NNP 2004_CD and_CC upon_IN expiry_NN of_IN any_DT exclusivity_NN that_IN Barr_NNP may_MD hold_VB ._.
iv_NN CARBATROL_NNP In_IN August_NNP 2003_CD ,_, the_DT Company_NN was_VBD notied_VBN that_IN Nostrum_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
Nostrum_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT HatchWaxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ version_NN of_IN the_DT 300_CD mg_NN strength_NN of_IN CARBATROL_NNP prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT Companys_NNPS US_NNP patents_NNS for_IN CARBATROL_NNP ,_, US_NNP patent_NN No._NN ._.
This_DT dosage_JJ strength_NN represents_VBZ about_IN half_NN of_IN Shires_NNP current_JJ sales_NNS in_IN epilepsy_NN ._.
On_IN September_NNP 18_CD ,_, 2003_CD Shire_NNP Laboratories_NNPS served_VBD suit_NN against_IN Nostrum_NNP in_IN the_DT United_NNP States_NNPS District_NNP Court_NNP for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP for_IN infringement_NN of_IN these_DT two_CD patents_NNS ._.
The_DT Company_NN is_VBZ seeking_VBG a_DT ruling_NN that_WDT Nostrums_VBZ ANDA_NNP infringes_VBZ the_DT 013_CD and_CC 570_CD Patents_NNP and_CC should_MD not_RB be_VB approved_VBN before_IN the_DT expiration_NN date_NN of_IN the_DT 013_CD and_CC 570_CD Patents_NNP ._.
The_DT Company_NN is_VBZ also_RB seeking_VBG an_DT injunction_NN to_TO prevent_VB Nostrum_NNP from_IN commercializing_VBG its_PRP$ ANDA_NNP product_NN before_IN the_DT expiration_NN of_IN the_DT 013_CD and_CC 570_CD Patents_NNP ,_, damages_NNS in_IN the_DT event_NN that_WDT Nostrum_NNP should_MD engage_VB in_IN such_JJ commercialization_NN ,_, as_RB well_RB its_PRP$ attorneys_NNS fees_NNS and_CC costs_NNS ._.
On_IN January_NNP 23_CD ,_, 2004_CD the_DT Company_NN amended_VBD the_DT Complaint_NNP to_TO delete_VB the_DT allegations_NNS with_IN respect_NN to_TO the_DT 013_CD Patent_NN ._.
Even_RB if_IN Nostrum_NNP receives_VBZ tentative_JJ approval_NN from_IN the_DT FDA_NNP for_IN its_PRP$ ANDA_NNP ,_, it_PRP can_MD not_RB lawfully_RB launch_VB its_PRP$ generic_JJ version_NN before_IN the_DT earlier_JJR of_IN the_DT expiration_NN of_IN the_DT stay_NN February_NNP 2006_CD or_CC a_DT district_NN court_NN decision_NN in_IN its_PRP$ favor_NN ._.
In_IN the_DT event_NN that_IN the_DT Company_NN does_VBZ not_RB prevail_VB ,_, then_RB Nostrum_NNP could_MD be_VB in_IN a_DT position_NN to_TO market_VB its_PRP$ 300_CD mg_NN extended_VBN release_NN carbamazepine_NN product_NN upon_IN FDA_NNP final_JJ approval_NN of_IN its_PRP$ ANDA_NNP ._.
19_CD Related_VBN parties_NNS a_DT Professional_JJ fees_NNS The_DT Company_NN incurred_VBN professional_JJ fees_NNS with_IN Stikeman_NNP Elliott_NNP ,_, a_DT law_NN rm_NN in_IN which_WDT the_DT Hon_NNP James_NNP Grant_NNP ,_, a_DT director_NN of_IN the_DT Company_NN ,_, is_VBZ a_DT partner_NN ,_, totaling_VBG $_$ 0.8_CD million_CD for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2003_CD $_$ 1.2_CD million_CD for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2002_CD and_CC $_$ 1.9_CD million_CD for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2001_CD ._.
$_$ 0.5_CD million_CD was_VBD due_JJ to_TO the_DT law_NN rms_VBZ in_IN which_WDT the_DT Hon_NNP James_NNP Grant_NNP is_VBZ a_DT partner_NN as_IN of_IN December_NNP 31_CD ,_, 2003_CD 2002_CD $_$ nil_JJ ._.
b_NN Immunosystems_NNPS BioChem_NNP Immunosystems_NNPS Inc._NNP ._.
Immunosystems_NNS ,_, formally_RB a_DT wholly_RB owned_VBN subsidiary_NN of_IN BioChem_NNP ,_, was_VBD sold_VBN in_IN February_NNP 2000_CD to_TO a_DT third_JJ party_NN ._.
Dr_NNP Bellini_NNP ,_, the_DT former_JJ chief_NN executive_NN officer_NN of_IN BioChem_NNP ,_, continued_VBD as_IN a_DT Director_NNP of_IN Immunosystems_NNPS ._.
In_IN December_NNP 2001_CD ,_, the_DT Company_NN acquired_VBD a_DT 19.9_CD %_NN equity_NN interest_NN in_IN Immunosystems_NNPS in_IN consideration_NN for_IN the_DT release_NN of_IN a_DT debt_NN owing_NN to_TO the_DT Company_NN from_IN Immunosystems_NNPS ._.
This_DT debt_NN existed_VBD prior_RB to_TO the_DT Companys_NNPS merger_NN with_IN BioChem_NNP ._.
As_IN part_NN of_IN the_DT same_JJ transaction_NN ,_, the_DT Company_NN was_VBD released_VBN from_IN a_DT pre-existing_JJ BioChem_NNP guarantee_NN over_IN other_JJ Immunosystems_NNPS liabilities_NNS ._.
c_NN Mr_NNP Spitznagel_NNP Mr_NNP Spitznagel_NNP ,_, a_DT former_JJ Director_NNP of_IN the_DT Company_NN ,_, who_WP resigned_VBD during_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2001_CD ,_, entered_VBD into_IN a_DT consultancy_NN agreement_NN with_IN the_DT Company_NN in_IN December_NNP 1999_CD ,_, which_WDT provided_VBD that_DT :_: If_IN he_PRP had_VBD good_JJ reason_NN ,_, as_IN dened_VBN in_IN his_PRP$ service_NN agreement_NN with_IN Roberts_NNP ,_, to_TO terminate_VB his_PRP$ employment_NN with_IN Roberts_NNP under_IN his_PRP$ service_NN agreement_NN ,_, the_DT Company_NN would_MD cause_VB Roberts_NNP to_TO provide_VB him_PRP with_IN the_DT payments_NNS and_CC benets_NNS he_PRP would_MD be_VB entitled_VBN to_TO upon_IN a_DT good_JJ reason_NN termination_NN :_: Mr_NNP Spitznagel_NNP would_MD provide_VB consulting_VBG services_NNS to_TO the_DT Company_NN for_IN at_IN least_JJS 42_CD months_NNS following_VBG the_DT acquisition_NN of_IN Roberts_NNP ,_, unless_IN nd_NN Mr_NNP Spitznagel_NNP terminated_VBD the_DT consultancy_NN agreement_NN prior_RB to_TO the_DT end_NN of_IN the_DT 42_CD month_NN upon_IN 30_CD days_NNS notice_NN :_: and_CC The_DT Company_NN would_MD pay_VB Mr_NNP Spitznagel_NNP at_IN a_DT rate_NN of_IN $_$ 400,000_CD per_IN annum_NN for_IN his_PRP$ consulting_NN services_NNS ,_, $_$ 150,000_CD per_IN annum_NN as_IN an_DT ofce_NN allowance_NN ,_, $_$ 250,000_CD per_IN annum_NN to_TO comply_VB with_IN certain_JJ restrictive_JJ covenants_NNS contained_VBD therein_RB and_CC $_$ 150,000_CD per_IN annum_NN for_IN tax_NN ,_, financial_JJ and_CC estate_NN planning_NN advice_NN ,_, life_NN insurance_NN and_CC health_NN insurance_NN ._.
During_IN 2003_CD the_DT final_JJ payment_NN was_VBD made_VBN to_TO Mr_NNP Spitznagel_NNP of_IN $_$ 0.5_CD million_CD ._.
The_DT consultancy_NN agreement_NN has_VBZ now_RB been_VBN terminated_VBN and_CC no_DT further_JJ payments_NNS will_MD be_VB made_VBN ._.
At_IN December_NNP 31_CD ,_, 2002_CD Mr_NNP Spitznagel_NNP was_VBD owed_VBN $_$ 0.5_CD million_CD 2001_CD :_: $_$ 1.4_CD million_CD ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 75_CD In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 20_CD Earnings_NNS per_IN share_NN The_DT following_VBG table_NN reconciles_NNS income_NN from_IN continuing_VBG operations_NNS and_CC the_DT weighted_JJ average_JJ ordinary_JJ shares_NNS outstanding_JJ for_IN basic_JJ and_CC diluted_JJ EPS_NNP for_IN the_DT periods_NNS presented_VBN :_: 2003 2002 2001_CD Year_NN ended_VBD December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Income_NN from_IN continuing_VBG operations_NNS 276,051_CD 242,378_CD 32,011_CD Income_NN from_IN discontinued_VBN operations_NNS ,_, net_NN of_IN tax_NN 8,191_CD 6,748_CD Numerator_NN for_IN basic_JJ earnings_NNS per_IN share_NN 276,051_CD 250,569_CD 38,759_CD Interest_NN charged_VBN on_IN convertible_JJ debt_NN ,_, net_NN of_IN tax_NN 5,218_CD 5,585_CD Numerator_NN for_IN diluted_JJ earnings_NNS per_IN share_NN 281,269_CD 256,154_CD 38,759_CD No._NN ._.
of_IN shares_NNS of_IN shares_NNS of_IN shares_NNS Weighted_VBN average_JJ number_NN of_IN shares_NNS outstanding_JJ Basic_NNP 498,212,826_CD 500,687,594_CD 492,594,226_CD Effect_NN of_IN dilutive_JJ shares_NNS :_: Share_NN options_NNS 1,859,076_CD 1,883,475_CD 11,362,332_CD Convertible_JJ debt_NN 18,895,493_CD 19,847,177_CD Warrants_NNS 919,029_CD 20,754,569_CD 21,730,652_CD 12,281,361_CD Diluted_NNP 518,967,395_CD 522,418,246_CD 504,875,587_CD Basic_JJ earnings_NNS per_IN share_NN :_: Income_NN from_IN continuing_VBG operations_NNS 55.4_CD 48.4_CD 6.5_CD Income_NN from_IN discontinued_VBN operations_NNS ,_, net_NN of_IN tax_NN 1.6_CD 1.4_CD 55.4_CD 50.0_CD 7.9_CD Diluted_VBN earnings_NNS per_IN share_NN :_: Income_NN from_IN continuing_VBG operations_NNS 54.2_CD 47.4_CD 6.4_CD Income_NN from_IN discontinued_VBN operations_NNS ,_, net_NN of_IN tax_NN 1.6_CD 1.3_CD 54.2_CD 49.0_CD 7.7_CD The_DT computation_NN of_IN weighted_JJ average_JJ number_NN of_IN shares_NNS for_IN diluted_VBN EPS_NNP for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2001_CD does_VBZ not_RB include_VB convertible_JJ debt_NN because_IN ,_, after_IN eliminating_VBG interest_NN charged_VBN to_TO operations_NNS from_IN the_DT numerator_NN ,_, the_DT inclusion_NN would_MD be_VB anti-dilutive_JJ ._.
The_DT warrants_NNS are_VBP issuable_JJ in_IN respect_NN of_IN a_DT research_NN and_CC development_NN agreement_NN ._.
A_DT charge_NN of_IN $_$ 4.5_CD million_CD has_VBZ been_VBN reected_VBN in_IN research_NN and_CC development_NN in_IN the_DT consolidated_JJ statement_NN of_IN operations_NNS in_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2001_CD ._.
The_DT warrants_NNS and_CC share_NN options_NNS not_RB included_VBD within_IN the_DT calculation_NN of_IN the_DT diluted_VBN weighted_JJ average_JJ number_NN of_IN shares_NNS ,_, because_IN the_DT exercise_NN prices_NNS exceeded_VBD the_DT Companys_NNPS average_JJ share_NN price_NN during_IN the_DT calculation_NN period_NN ,_, are_VBP shown_VBN below_IN :_: 2003 2002 2001_CD No._NN ._.
Year_NN ended_VBD December_NNP 31_CD ,_, of_IN shares_NNS of_IN shares_NNS of_IN shares_NNS Share_NN options_NNS 17,006,093_CD 17,492,575_CD 10,384,600_CD Warrants_NNS 1,346,407_CD 1,346,407_CD 18,352,500_CD 18,838,982_CD 10,384,600_CD 76_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 21_CD Segment_NN reporting_VBG The_DT Company_NN has_VBZ disclosed_VBN segment_NN information_NN for_IN the_DT individual_JJ reporting_NN segments_NNS of_IN the_DT business_NN ,_, based_VBN on_IN the_DT way_NN in_IN which_WDT the_DT business_NN is_VBZ managed_VBN and_CC controlled_VBN ._.
The_DT Companys_NNPS principal_JJ reporting_NN segments_NNS are_VBP by_IN operational_JJ function_NN ,_, each_DT being_VBG managed_VBN and_CC monitored_VBN separately_RB and_CC serving_VBG different_JJ markets_NNS ._.
The_DT Company_NN evaluates_VBZ performance_NN based_VBN on_IN operating_VBG income_NN ._.
The_DT Company_NN does_VBZ not_RB have_VB inter-segment_JJ transactions_NNS ._.
The_DT US_NNP segment_NN represents_VBZ our_PRP$ commercial_JJ operations_NNS in_IN the_DT United_NNP States_NNPS and_CC the_DT International_NNP segment_NN represents_VBZ the_DT commercial_JJ operations_NNS in_IN the_DT Rest_VB of_IN the_DT World_NNP ._.
The_DT Biologics_NNPS segment_NN represents_VBZ the_DT vaccine_NN operations_NNS in_IN Canada_NNP and_CC the_DT research_NN and_CC development_NN center_NN in_IN the_DT United_NNP States_NNPS ._.
The_DT R&D_NNP segment_NN represents_VBZ all_DT direct_JJ research_NN and_CC development_NN costs_NNS incurred_VBN by_IN the_DT Company_NN throughout_IN the_DT world_NN ._.
Corporate_JJ represents_VBZ the_DT royalty_NN business_NN that_WDT is_VBZ managed_VBN at_IN the_DT corporate_JJ ofce_NN and_CC certain_JJ costs_NNS that_WDT are_VBP managed_VBN at_IN the_DT corporate_JJ ofce_NN and_CC not_RB allocated_VBN to_TO the_DT other_JJ segments_NNS ._.
Depreciation_NN from_IN manufacturing_VBG plants_NNS is_VBZ included_VBN within_IN cost_NN of_IN product_NN sales_NNS ._.
Depreciation_NN and_CC amortization_NN relating_VBG to_TO R&D_NNP assets_NNS are_VBP included_VBN within_IN US_NNP and_CC International_NNP segments_NNS ._.
2_CD Total_JJ assets_NNS and_CC long_JJ lived_VBD assets_NNS in_IN the_DT Biologics_NNPS segment_NN relate_VBP to_TO the_DT research_NN and_CC development_NN center_NN in_IN the_DT US_NNP ._.
Depreciation_NN from_IN manufacturing_VBG plants_NNS is_VBZ included_VBN within_IN cost_NN of_IN sales_NNS ._.
2_CD The_DT total_JJ assets_NNS and_CC long_JJ lived_VBD assets_NNS relating_VBG to_TO the_DT Biologics_NNPS segment_NN are_VBP managed_VBN within_IN the_DT International_NNP segment_NN ._.
78_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 21_CD Segment_NN reporting_NN continued_VBD Material_NNP customers_NNS In_IN the_DT periods_NNS set_VBN out_RP below_IN ,_, certain_JJ customers_NNS accounted_VBD for_IN greater_JJR than_IN 10_CD %_NN of_IN the_DT Companys_NNPS total_VBP revenues_NNS :_: 2003 2003 2002 2002_CD 2001_CD 2001_CD Year_NN ended_VBD December_NNP 31_CD ,_, $_$ 000_CD %_NN revenue_NN $_$ 000_CD %_NN revenue_NN $_$ 000_CD %_NN revenue_NN Customer_NN A_DT 274,771_CD 22_CD %_NN 231,270_CD 22_CD %_NN 176,941_CD 21_CD %_NN Customer_NN B_NNP 269,364_CD 22_CD %_NN 197,184_CD 19_CD %_NN 123,350_CD 14_CD %_NN Customer_NN C_NNP 175,856_CD 14_CD %_NN 160,210_CD 15_CD %_NN 136,927_CD 16_CD %_NN Customer_NN D_NNP 158,689_CD 13_CD %_NN 149,613_CD 14_CD %_NN Amounts_NNS outstanding_JJ as_IN of_IN December_NNP 31_CD ,_, in_IN respect_NN of_IN these_DT material_NN customers_NNS were_VBD as_IN follows_VBZ :_: 2003_CD 2002_CD December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD Customer_NN A_DT 23,793_CD 4,354_CD Customer_NN B_NNP 25,676_CD 9,189_CD Customer_NN C_NNP 45,712_CD 45,227_CD Customer_NN D_NNP 8,212_CD 9,738_CD 22_CD Other_JJ charges_NNS 2001_CD Year_NN ended_VBD December_NNP 31_CD ,_, $_$ 000_CD BioChem_NNP merger_NN :_: Restructuring_NN charges_NNS 8,809_CD Asset_NNP impairments_NNS 20,890_CD Merger_NNP transaction_NN expenses_NNS 83,470_CD Loss_NN on_IN disposition_NN of_IN facility_NN 8,100_CD 121,269_CD Year_NN ended_VBD December_NNP 31_CD ,_, 2001_CD a_DT BioChem_NNP merger_NN i_FW Restructuring_NN charges_NNS Upon_IN consummation_NN of_IN the_DT merger_NN with_IN BioChem_NNP ,_, the_DT Company_NN formalized_VBD a_DT plan_NN to_TO restructure_VB the_DT combined_VBN organization_NN by_IN a_DT closing_VBG a_DT duplicate_VB manufacturing_VBG facility_NN and_CC b_NN eliminating_VBG certain_JJ duplicate_VBP positions_NNS throughout_IN the_DT combined_VBN organization_NN ._.
This_DT plan_NN resulted_VBD in_IN the_DT decision_NN to_TO terminate_VB 57_CD employees_NNS and_CC to_TO dispose_VB of_IN Shires_NNP existing_VBG manufacturing_NN facility_NN ._.
All_DT of_IN the_DT planned_VBN terminations_NNS were_VBD completed_VBN by_IN December_NNP 31_CD ,_, 2001_CD ,_, at_IN a_DT cost_NN of_IN $_$ 8.8_CD million_CD ._.
The_DT Company_NN paid_VBD $_$ 8.0_CD million_CD of_IN this_DT during_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2001_CD and_CC the_DT remaining_VBG $_$ 0.8_CD million_CD over_IN the_DT following_JJ year_NN ._.
ii_FW Asset_NNP impairments_VBZ Asset_NNP impairments_NNS consist_VBP of_IN the_DT write-off_NN of_IN approximately_RB $_$ 6.3_CD million_CD of_IN patents_NNS ,_, $_$ 6.8_CD million_CD of_IN licenses_NNS and_CC $_$ 7.8_CD million_CD of_IN distribution_NN rights_NNS ,_, which_WDT were_VBD held_VBN by_IN BioChem_NNP at_IN the_DT time_NN of_IN the_DT merger_NN ._.
Upon_IN consummation_NN of_IN the_DT BioChem_NNP merger_NN ,_, the_DT Company_NN reviewed_VBD the_DT carrying_VBG value_NN of_IN all_DT intangible_JJ assets_NNS of_IN the_DT combined_VBN organization_NN in_IN an_DT attempt_NN to_TO identify_VB any_DT intangible_JJ assets_NNS that_WDT were_VBD duplicative_JJ ,_, inconsistent_JJ with_IN the_DT strategic_JJ direction_NN of_IN the_DT Company_NN ,_, or_CC where_WRB management_NN did_VBD not_RB perceive_VB any_DT ongoing_JJ value_NN that_WDT would_MD be_VB derived_VBN from_IN these_DT assets_NNS ._.
This_DT review_NN resulted_VBD in_IN the_DT write-off_NN of_IN certain_JJ patents_NNS and_CC licenses_NNS that_WDT were_VBD related_VBN to_TO products_NNS and_CC know-how_NN that_WDT would_MD not_RB be_VB utilized_VBN by_IN the_DT combined_VBN organization_NN and_CC that_DT had_VBD no_DT residual_JJ sales_NNS value_NN ._.
In_IN addition_NN ,_, it_PRP resulted_VBD in_IN the_DT write-off_NN of_IN distribution_NN rights_NNS related_VBN to_TO a_DT specic_JJ product_NN for_IN which_WDT BioChem_NNP management_NN was_VBD pursuing_VBG sales_NNS in_IN the_DT United_NNP States_NNPS ._.
The_DT combined_VBN organization_NN did_VBD not_RB intend_VB to_TO sell_VB this_DT product_NN in_IN the_DT United_NNP States_NNPS :_: additionally_RB ,_, the_DT distribution_NN rights_NNS had_VBD no_DT residual_JJ sales_NNS value_NN ._.
iii_FW Merger_NNP transaction_NN expenses_NNS The_DT merger_NN transaction_NN expenses_NNS represent_VBP direct_JJ costs_NNS incurred_VBN by_IN the_DT Company_NN in_IN connection_NN with_IN the_DT merger_NN with_IN BioChem_NNP ._.
These_DT costs_NNS include_VBP bank_NN and_CC other_JJ advisory_JJ fees_NNS ,_, taxes_NNS associated_VBN with_IN the_DT transaction_NN and_CC other_JJ direct_JJ incremental_JJ costs_NNS associated_VBN with_IN the_DT merger_NN ._.
iv_NN Loss_NN on_IN disposition_NN of_IN facility_NN As_IN described_VBN above_IN ,_, the_DT Company_NN made_VBD the_DT decision_NN to_TO close_VB its_PRP$ existing_VBG manufacturing_NN facility_NN in_IN Toronto_NNP and_CC to_TO dispose_VB of_IN the_DT facility_NN ._.
The_DT Company_NN incurred_VBD a_DT loss_NN of_IN $_$ 8.1_CD million_CD upon_IN the_DT disposition_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 79_CD In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 23_CD Other_JJ expense_NN ,_, net_JJ 2003 2002 2001_CD Year_NN ended_VBD December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD SERP_NNP valuation_NN adjustment_NN 175_CD 2,301_CD 2,018_CD Write-down_NN of_IN long-term_JJ investments_NNS due_JJ to_TO impairment_NN 15,540_CD 8,680_CD 55,748_CD GeneChem_NNP funds_NNS income_NN 3,755_CD 3,333_CD 3,995_CD Foreign_JJ exchange_NN 6,716_CD 344_CD 487_CD Other_JJ 787_CD 270_CD 1,325_CD 17,539_CD 8,262_CD 52,933_CD December_NNP 31_CD ,_, 2003_CD The_DT Company_NN recorded_VBD an_DT impairment_NN of_IN $_$ 8.5_CD million_CD against_IN its_PRP$ investments_NNS in_IN the_DT GeneChem_NNP funds_NNS during_IN the_DT year_NN due_JJ to_TO an_DT other_JJ than_IN temporary_JJ impairment_NN in_IN the_DT investment_NN portfolio_NN ._.
In_IN addition_NN ,_, the_DT Company_NN recorded_VBD an_DT impairment_NN of_IN $_$ 4.5_CD million_CD due_JJ to_TO a_DT decrease_NN in_IN the_DT market_NN value_NN of_IN its_PRP$ investment_NN in_IN private_JJ companies_NNS ._.
The_DT assessment_NN of_IN market_NN value_NN was_VBD based_VBN on_IN the_DT projected_VBN value_NN of_IN an_DT anticipated_JJ share_NN offering_NN in_IN early_JJ 2004_CD by_IN the_DT Company_NN at_IN a_DT value_NN less_JJR than_IN the_DT current_JJ price_NN per_IN share_NN recorded_VBN by_IN the_DT Company_NN ._.
The_DT impairments_NNS were_VBD recorded_VBN in_IN the_DT International_NNP segment_NN ._.
December_NNP 31_CD ,_, 2002_CD The_DT Company_NN recorded_VBD an_DT impairment_NN of_IN $_$ 5.5_CD million_CD against_IN its_PRP$ investments_NNS in_IN the_DT GeneChem_NNP funds_NNS during_IN 2002_CD due_JJ to_TO an_DT other_JJ than_IN temporary_JJ impairment_NN in_IN the_DT investment_NN portfolio_NN ._.
In_IN addition_NN ,_, the_DT Company_NN recorded_VBD an_DT impairment_NN of_IN $_$ 3.2_CD million_CD due_JJ to_TO a_DT decrease_NN in_IN the_DT market_NN value_NN of_IN its_PRP$ investment_NN in_IN private_JJ companies_NNS ,_, based_VBN on_IN changes_NNS in_IN estimates_NNS in_IN value_NN from_IN the_DT prior_JJ year_NN ._.
December_NNP 31_CD ,_, 2001_CD Following_VBG the_DT merger_NN with_IN BioChem_NNP in_IN 2001_CD ,_, management_NN of_IN the_DT combined_VBN organization_NN determined_VBN that_IN it_PRP should_MD review_VB the_DT carrying_VBG value_NN of_IN all_DT cost_NN method_NN investments_NNS held_VBN by_IN the_DT combined_VBN organization_NN ,_, considering_VBG ,_, amongst_IN other_JJ things_NNS ,_, a_DT the_DT combined_VBN organizations_NNS strategic_JJ direction_NN and_CC re-prioritization_NN of_IN investments_NNS ,_, b_NN the_DT Companys_NNPS knowledge_NN of_IN certain_JJ developments_NNS in_IN 2001_CD with_IN regards_VBZ to_TO the_DT US_NNP Food_NNP and_CC Drug_NNP Administrations_NNP approval_NN process_NN of_IN certain_JJ products_NNS ,_, and_CC c_NN a_DT strategic_JJ re-evaluation_NN of_IN the_DT risks_NNS that_IN the_DT combined_VBN organization_NN was_VBD willing_JJ to_TO retain_VB ,_, relating_VBG to_TO certain_JJ ventures_NNS and_CC guarantees_NNS ._.
As_IN a_DT result_NN of_IN this_DT review_NN ,_, the_DT Company_NN determined_VBD that_IN it_PRP was_VBD necessary_JJ to_TO record_VB impairment_NN charges_NNS totaling_VBG $_$ 55.7_CD million_CD related_VBN to_TO certain_JJ of_IN these_DT investments_NNS ._.
The_DT impairment_NN consisted_VBD of_IN the_DT write-off_NN of_IN an_DT investment_NN in_IN Qualia_NNP ,_, of_IN $_$ 18.7_CD million_CD ,_, the_DT write-off_NN of_IN the_DT investment_NN in_IN a_DT Biovector_NNP of_IN $_$ 6.2_CD million_CD and_CC a_DT write-down_NN of_IN the_DT net_JJ assets_NNS of_IN Immunosystems_NNS by_IN $_$ 30.8_CD million_CD ._.
a_DT Qualia_NNP BioChem_NNP held_VBD a_DT 14.1_CD %_NN equity_NN interest_NN in_IN common_JJ stock_NN and_CC an_DT investment_NN in_IN preferred_JJ shares_NNS of_IN Qualia_NNP ,_, which_WDT ,_, at_IN the_DT time_NN of_IN the_DT merger_NN ,_, owned_VBN ,_, amongst_IN other_JJ development_NN projects_NNS ,_, the_DT rights_NNS to_TO a_DT product_NN that_WDT was_VBD approved_VBN for_IN sale_NN in_IN Europe_NNP and_CC Canada_NNP ._.
This_DT product_NN was_VBD in_IN development_NN for_IN a_DT planned_VBN submission_NN to_TO the_DT FDA_NNP for_IN approval_NN to_TO sell_VB in_IN the_DT United_NNP States_NNPS ._.
The_DT Company_NN reviewed_VBD the_DT status_NN of_IN the_DT product_NN and_CC the_DT estimated_VBN timing_NN of_IN submission_NN to_TO the_DT FDA_NNP ,_, its_PRP$ estimate_NN of_IN the_DT future_JJ cash_NN ows_NNS from_IN royalties_NNS which_WDT would_MD be_VB received_VBN upon_IN sale_NN of_IN the_DT product_NN without_IN such_JJ registration_NN and_CC Qualias_NNPS access_NN to_TO additional_JJ funding_NN ._.
Based_VBN on_IN the_DT assessment_NN of_IN these_DT factors_NNS ,_, the_DT Company_NN determined_VBD that_IN the_DT investment_NN should_MD be_VB written_VBN off_RP as_IN 1_CD approval_NN by_IN the_DT FDA_NNP ,_, originally_RB expected_VBN in_IN June_NNP 2001_CD ,_, had_VBD not_RB occurred_VBN ,_, creating_VBG doubt_NN relative_JJ to_TO the_DT timing_NN of_IN an_DT eventual_JJ approval_NN of_IN the_DT product_NN by_IN the_DT FDA_NNP ,_, 2_CD Shire_NNP management_NN believed_VBD that_IN without_IN registration_NN with_IN the_DT FDA_NNP the_DT projected_VBN royalties_NNS generated_VBD from_IN the_DT sale_NN of_IN this_DT product_NN could_MD not_RB generate_VB cash_NN ows_NNS sufficient_JJ to_TO recover_VB the_DT investment_NN and_CC 3_CD Shire_NNP anticipated_VBD the_DT efforts_NNS necessary_JJ to_TO obtain_VB approval_NN from_IN the_DT FDA_NNP as_IN significant_JJ ._.
BioChem_NNP management_NN assessed_VBD the_DT carrying_VBG value_NN of_IN the_DT Qualia_NNP investment_NN at_IN the_DT end_NN of_IN 2000_CD ._.
Based_VBN on_IN the_DT projected_VBN operating_NN results_NNS at_IN that_DT time_NN ,_, the_DT initial_JJ sales_NNS of_IN the_DT product_NN in_IN Canada_NNP and_CC Europe_NNP ,_, and_CC ,_, most_RBS importantly_RB ,_, their_PRP$ expectation_NN of_IN FDA_NNP approval_NN by_IN June_NNP 2001_CD ,_, BioChem_NNP management_NN concluded_VBD that_IN an_DT other_JJ than_IN temporary_JJ impairment_NN did_VBD not_RB exist_VB ._.
In_IN February_NNP 2002_CD ,_, FDA_NNP approval_NN was_VBD received_VBN to_TO sell_VB the_DT product_NN into_IN the_DT United_NNP States_NNPS ._.
Subsequent_JJ to_TO the_DT approval_NN ,_, structural_JJ changes_NNS were_VBD made_VBN to_TO the_DT Companys_NNPS holding_VBG in_IN Qualia_NNP and_CC the_DT Companys_NNPS distribution_NN rights_NNS for_IN the_DT product_NN ,_, which_WDT resulted_VBD in_IN the_DT Company_NN owning_VBG a_DT 50_CD %_NN interest_NN in_IN a_DT combined_VBN structure_NN and_CC releasing_VBG the_DT Company_NN from_IN any_DT future_JJ funding_NN obligations_NNS ._.
Qualia_NNP has_VBZ continued_VBN to_TO incur_VB operating_NN losses_NNS since_IN the_DT approval_NN of_IN the_DT product_NN by_IN the_DT FDA_NNP ,_, and_CC the_DT Company_NN has_VBZ recorded_VBN its_PRP$ portion_NN of_IN those_DT losses_NNS ._.
b_NN Biovector_NNP In_IN late_JJ 2000_CD ,_, BioChem_NNP management_NN noted_VBD that_IN Biovector_NNP Therapeutics_NNP S._NNP A._NNP Biovector_NNP ,_, a_DT privately_RB held_VBN French_JJ company_NN in_IN which_WDT it_PRP held_VBD a_DT 9.6_CD %_NN interest_NN ,_, had_VBD begun_VBN to_TO experience_VB financial_JJ and_CC operational_JJ difficulties_NNS ._.
At_IN that_DT time_NN ,_, management_NN considered_VBN whether_IN there_EX was_VBD an_DT other_JJ than_IN temporary_JJ impairment_NN and_CC determined_VBD there_EX was_VBD not_RB ,_, based_VBN on_IN its_PRP$ estimate_NN of_IN the_DT future_JJ operations_NNS ,_, the_DT historical_JJ financial_JJ information_NN available_JJ and_CC publicly_RB available_JJ information_NN ._.
However_RB ,_, in_IN April_NNP 2001_CD ,_, Biovector_NNP formally_RB informed_VBD its_PRP$ investors_NNS that_IN it_PRP was_VBD experiencing_VBG financial_JJ difficulties_NNS ,_, principally_RB because_IN of_IN an_DT inability_NN to_TO attract_VB additional_JJ research_NN and_CC development_NN collaboration_NN partners_NNS and_CC an_DT inability_NN to_TO identify_VB additional_JJ sources_NNS of_IN nancing_NN ._.
Following_VBG the_DT merger_NN with_IN BioChem_NNP ,_, the_DT Company_NN made_VBD a_DT decision_NN not_RB to_TO invest_VB further_JJ money_NN in_IN this_DT entity_NN and_CC to_TO take_VB steps_NNS to_TO cancel_VB any_DT contracts_NNS therewith_RB ._.
Based_VBN on_IN this_DT decision_NN and_CC the_DT financial_JJ difficulties_NNS being_VBG experienced_VBN by_IN Biovector_NNP ,_, the_DT Company_NN determined_VBD that_IN it_PRP was_VBD appropriate_JJ to_TO write-off_NN this_DT investment_NN ._.
In_IN February_NNP 2002_CD ,_, Biovector_NNP went_VBD into_IN liquidation_NN ._.
80_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 23_CD Other_JJ expense_NN ,_, net_JJ continued_VBD c_NN Immunosystems_NNS In_IN January_NNP 1999_CD ,_, BioChem_NNP adopted_VBD a_DT formal_JJ plan_NN to_TO dispose_VB of_IN its_PRP$ diagnostic_JJ operations_NNS and_CC at_IN that_DT time_NN recorded_VBD an_DT impairment_NN of_IN $_$ 8.8_CD million_CD to_TO reect_VB the_DT net_JJ assets_NNS at_IN the_DT estimated_VBN realizable_JJ value_NN ._.
In_IN March_NNP 2000_CD ,_, BioChem_NNP made_VBD the_DT decision_NN to_TO divest_VB of_IN certain_JJ of_IN its_PRP$ diagnostics_NNS operations_NNS Immunosystems_NNPS to_TO a_DT management-led_JJ group_NN ._.
It_PRP did_VBD so_RB in_IN exchange_NN for_IN a_DT debenture_NN of_IN $_$ 35.8_CD million_CD and_CC an_DT agreement_NN that_WDT BioChem_NNP would_MD act_VB as_IN a_DT guarantor_NN of_IN certain_JJ long-term_JJ debt_NN of_IN Immunosystems_NNPS ,_, in_IN the_DT amount_NN of_IN 37.3_CD million_CD Italian_JJ Lira_NN $_$ 18.1_CD million_CD as_IN of_IN December_NNP 31_CD ,_, 2000_CD ._.
As_IN the_DT risk_NN and_CC rewards_NNS of_IN ownership_NN had_VBD not_RB transferred_VBN to_TO the_DT management_NN group_NN ,_, BioChem_NNP continued_VBD to_TO carry_VB the_DT assets_NNS on_IN its_PRP$ balance_NN sheet_NN ._.
The_DT assets_NNS ,_, classied_VBN as_IN net_JJ assets_NNS of_IN a_DT business_NN transferred_VBN under_IN contractual_JJ arrangements_NNS ,_, had_VBD a_DT carrying_VBG value_NN of_IN $_$ 35.8_CD million_CD the_DT same_JJ value_NN of_IN the_DT debenture_NN at_IN the_DT time_NN of_IN the_DT merger_NN between_IN Shire_NNP and_CC BioChem_NNP ._.
On_IN consummation_NN of_IN the_DT merger_NN ,_, Shire_NNP management_NN was_VBD concerned_VBN as_IN to_TO the_DT recoverability_NN of_IN the_DT debenture_NN the_DT repayment_NN terms_NNS of_IN which_WDT were_VBD contingent_JJ on_IN the_DT future_JJ cash_NN ows_NNS of_IN the_DT underlying_VBG Immunosystems_NNS business_NN ._.
Additionally_RB ,_, they_PRP were_VBD also_RB concerned_VBN that_IN they_PRP would_MD be_VB required_VBN ,_, at_IN some_DT stage_NN ,_, to_TO make_VB a_DT cash_NN payment_NN pursuant_JJ to_TO the_DT third-party_JJ guarantee_NN ._.
While_IN the_DT liability_NN related_VBN to_TO the_DT third-party_JJ guarantee_NN was_VBD in_IN substance_NN already_RB recognized_VBN by_IN Shire_NNP i._FW e._FW it_PRP formed_VBD part_NN of_IN the_DT carrying_VBG value_NN of_IN the_DT net_JJ assets_NNS of_IN $_$ 35.8_CD million_CD ,_, the_DT Company_NN was_VBD concerned_VBN over_IN a_DT potential_JJ cash_NN outow_NN of_IN $_$ 18.1_CD million_CD ,_, combined_VBN with_IN the_DT legal_JJ fees_NNS necessary_JJ to_TO pursue_VB collection_NN on_IN the_DT debenture_NN ._.
This_DT concern_NN was_VBD substantial_JJ ,_, resulting_VBG in_IN Shire_NNP managements_NNS revisiting_VBG all_DT agreements_NNS with_IN the_DT management-led_JJ group_NN which_WDT bought_VBD the_DT Immunosystems_NNPS operations_NNS ._.
As_IN a_DT result_NN of_IN these_DT negotiations_NNS ,_, the_DT following_NN was_VBD agreed_VBN :_: The_DT debenture_NN was_VBD eliminated_VBN in_IN full_JJ :_: Shares_NNP representing_VBG a_DT 19.9_CD %_NN interest_NN in_IN Immunosystems_NNPS were_VBD legally_RB transferred_VBN back_RB to_TO the_DT Company_NN :_: and_CC Shire_NNP was_VBD released_VBN from_IN the_DT guarantee_NN of_IN the_DT third-party_JJ debt_NN ._.
Based_VBN on_IN these_DT negotiations_NNS ,_, the_DT Company_NN recorded_VBD an_DT impairment_NN of_IN $_$ 28.7_CD million_CD ,_, i._FW e._FW 80.1_CD %_NN of_IN the_DT carrying_VBG value_NN of_IN the_DT assets_NNS classied_VBD as_IN Net_JJ assets_NNS of_IN a_DT business_NN transferred_VBN under_IN contractual_JJ arrangement_NN ._.
The_DT remaining_VBG balance_NN of_IN $_$ 7.1_CD million_CD was_VBD reclassied_VBN to_TO cost_VB investments_NNS ._.
The_DT Company_NN subsequently_RB recorded_VBD an_DT impairment_NN of_IN $_$ 2.1_CD million_CD against_IN the_DT carrying_VBG value_NN of_IN the_DT retained_VBN interest_NN of_IN 19.9_CD %_NN based_VBN on_IN its_PRP$ estimate_NN of_IN the_DT fair_JJ value_NN thereof_RB ._.
24_CD Retirement_NNP benets_VBZ a_DT Personal_JJ dened_JJ contribution_NN pension_NN plans_VBZ The_DT Company_NN makes_VBZ contributions_NNS to_TO dened_JJ contribution_NN retirement_NN plans_NNS that_WDT together_RB cover_VBP substantially_RB all_DT employees_NNS ._.
For_IN the_DT dened_VBN contribution_NN retirement_NN plans_NNS ,_, the_DT level_NN of_IN the_DT Companys_NNP contribution_NN is_VBZ xed_VBN at_IN a_DT set_VBN percentage_NN of_IN employees_NNS pay_VBP ._.
Company_NN contributions_NNS to_TO personal_JJ dened_VBN contribution_NN pension_NN plans_NNS totaled_VBD $_$ 16.1_CD million_CD ,_, $_$ 6.8_CD million_CD and_CC $_$ 4.9_CD million_CD for_IN the_DT years_NNS ended_VBN December_NNP 31_CD ,_, 2003_CD ,_, 2002_CD and_CC 2001_CD ,_, respectively_RB ,_, and_CC were_VBD charged_VBN to_TO operations_NNS as_IN they_PRP became_VBD payable_JJ ._.
b_NN Dened_VBN benefit_NN pension_NN plan_NN Roberts_NNP ,_, a_DT company_NN with_IN whom_WP the_DT Company_NN merged_VBD in_IN December_NNP 1999_CD ,_, operated_VBD a_DT dened_VBN SERP_NNP for_IN certain_JJ US_NNP employees_NNS ,_, which_WDT was_VBD established_VBN in_IN 1998_CD ._.
This_DT plan_NN was_VBD available_JJ to_TO former_JJ employees_NNS of_IN Roberts_NNP who_WP met_VBD certain_JJ age_NN and_CC service_NN requirements_NNS ._.
As_IN part_NN of_IN the_DT restructuring_NN of_IN the_DT Company_NN following_VBG the_DT Roberts_NNP merger_NN ,_, the_DT SERP_NNP was_VBD closed_VBN to_TO new_JJ members_NNS and_CC contributions_NNS ceased_VBD being_VBG paid_VBN into_IN the_DT plan_NN for_IN existing_VBG members_NNS ._.
As_IN part_NN of_IN this_DT arrangement_NN ,_, the_DT Company_NN paid_VBD a_DT lump_NN sum_NN contribution_NN into_IN the_DT plan_NN of_IN $_$ 18.0_CD million_CD ,_, the_DT result_NN of_IN which_WDT is_VBZ that_IN the_DT Company_NN has_VBZ no_DT future_JJ contributions_NNS under_IN the_DT plan_NN ._.
In_IN accordance_NN with_IN EITF_NNP 97-14_CD ,_, the_DT asset_NN and_CC liability_NN of_IN $_$ 12.0_CD million_CD and_CC $_$ 8.9_CD million_CD ,_, respectively_RB ,_, are_VBP shown_VBN on_IN the_DT balance_NN sheet_NN within_IN the_DT categories_NNS Other_JJ non-current_JJ assets_NNS and_CC Other_JJ non-current_JJ liabilities_NNS ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 81_CD In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 25_CD Income_NN taxes_NNS The_DT components_NNS of_IN income_NN before_IN income_NN taxes_NNS and_CC equity_NN in_IN net_JJ loss_NN income_NN of_IN associates_NNS for_IN the_DT years_NNS ended_VBN December_NNP 31_CD are_VBP as_IN follows_VBZ :_: 2003 2002 2001_CD Year_NN ended_VBD December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD UK_NNP 76,267_CD 50,520_CD 101,756_CD US_NNP 285,221_CD 218,139_CD 190,068_CD Other_JJ jurisdictions_NNS 175,507_CD 161,441_CD 9,495_CD Income_NN from_IN continuing_VBG operations_NNS before_IN income_NN taxes_NNS and_CC equity_NN in_IN net_JJ losses_NNS income_NN of_IN associates_NNS and_CC discontinued_VBN operations_NNS 384,461_CD 329,060_CD 97,807_CD Income_NN before_IN income_NN taxes_NNS attributable_JJ to_TO discontinued_VBN operations_NNS 9,696_CD 6,748_CD Total_JJ income_NN before_IN income_NN taxes_NNS and_CC equity_NN in_IN net_JJ losses_NNS income_NN of_IN associates_NNS 384,461_CD 338,756_CD 104,555_CD The_DT provision_NN for_IN income_NN taxes_NNS by_IN location_NN of_IN the_DT taxing_VBG jurisdiction_NN for_IN the_DT years_NNS ended_VBN December_NNP 31_CD ,_, consisted_VBN of_IN the_DT following_NN :_: 2003 2002 2001_CD Year_NN ended_VBD December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Current_JJ income_NN taxes_NNS :_: UK_NNP corporation_NN tax_NN US_NNP federal_JJ tax_NN 101,174_CD 67,686_CD 40,818_CD US_NNP state_NN and_CC local_JJ taxes_NNS 4,313_CD 9,561_CD 8,988_CD Other_JJ jurisdictions_NNS 18,792_CD 19,864_CD 16,746_CD Total_JJ current_JJ taxes_NNS 124,279_CD 97,111_CD 66,552_CD Deferred_JJ taxes_NNS UK_NNP corporation_NN tax_NN 9,696_CD US_NNP federal_JJ tax_NN 3,647_CD 1,136_CD 20,586_CD US_NNP state_NN and_CC local_JJ taxes_NNS 180_CD 34_CD 618_CD Other_JJ jurisdictions_NNS 30,449_CD 9,931_CD 19,975_CD Total_JJ deferred_JJ taxes_NNS 16,926_CD 8,761_CD 1,229_CD Total_JJ income_NN taxes_NNS attributable_JJ to_TO continuing_VBG operations_NNS 107,353_CD 88,350_CD 67,781_CD Total_JJ incomes_NNS taxes_NNS attributable_JJ to_TO discontinued_VBN operations_NNS 4,812_CD 3,963_CD Total_JJ income_NN taxes_NNS 107,353_CD 93,162_CD 71,744_CD The_DT reconciliation_NN of_IN income_NN from_IN continuing_VBG operations_NNS before_IN income_NN taxes_NNS and_CC equity_NN in_IN net_JJ losses_NNS income_NN of_IN associates_NNS and_CC discontinued_VBN operations_NNS to_TO the_DT provision_NN for_IN income_NN taxes_NNS is_VBZ shown_VBN in_IN the_DT table_NN below_IN :_: 2003 2002 2001_CD Year_NN ended_VBD December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Income_NN from_IN continuing_VBG operations_NNS before_IN income_NN taxes_NNS and_CC equity_NN in_IN net_JJ losses_NNS income_NN of_IN associates_NNS and_CC discontinued_VBN operations_NNS 384,461_CD 329,060_CD 97,807_CD Corporation_NNP tax_NN rate_NN 30_CD %_NN 30_CD %_NN 30_CD %_NN Income_NN tax_NN expense_NN at_IN corporation_NN tax_NN rate_NN 115,338_CD 98,718_CD 29,342_CD Adjustments_NNS to_TO derive_VB effective_JJ rate_NN :_: Non-deductible_JJ items_NNS :_: Goodwill_NNP amortization_NN 3,309_CD Permanent_NNP differences_NNS 4,404_CD 4,280_CD 32,268_CD Other_JJ items_NNS :_: Change_NNP in_IN valuation_NN allowance_NN 28,663_CD 13,948_CD 27,395_CD Difference_NN in_IN taxation_NN rates_NNS 45,580_CD 36,450_CD 27,662_CD Prior_RB year_NN adjustment_NN 8,544_CD 2,317_CD 2,958_CD Other_JJ 4,016_CD 5,537_CD 6,087_CD Provision_NNP for_IN income_NN taxes_NNS on_IN continuing_VBG operations_NNS 107,353_CD 88,350_CD 67,781_CD Provision_NNP for_IN income_NN taxes_NNS on_IN discontinued_VBN operations_NNS 4,812_CD 3,963_CD Provision_NNP for_IN income_NN taxes_NNS 107,353_CD 93,162_CD 71,744_CD 82_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 25_CD Income_NN taxes_NNS continued_VBD The_DT significant_JJ components_NNS of_IN deferred_JJ income_NN tax_NN assets_NNS and_CC liabilities_NNS and_CC their_PRP$ balance_NN sheet_NN classications_NNS ,_, as_IN of_IN December_NNP 31_CD ,_, are_VBP as_IN follows_VBZ :_: December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2003_CD 2002_CD $_$ 000_CD $_$ 000_CD Deferred_VBN tax_NN assets_NNS :_: Accrued_VBN expenses_NNS not_RB currently_RB deductible_JJ 3,340_CD 7,847_CD Losses_NNS carried_VBD forward_RB 248,239_CD 188,937_CD Provisions_NNS 11,299_CD 5,347_CD Other_JJ 1,876_CD 6,517_CD Gross_NNP deferred_VBN tax_NN assets_NNS 264,754_CD 208,648_CD Less_RBR :_: valuation_NN allowance_NN 168,176_CD 139,513_CD 96,578_CD 69,135_CD Excess_NNPS of_IN tax_NN value_NN over_IN book_NN value_NN of_IN assets_NNS 33,446_CD 28,070_CD Net_JJ deferred_JJ tax_NN assets_NNS 63,132_CD 41,065_CD Balance_NN sheet_NN classications_NNS :_: Deferred_JJ tax_NN assets_NNS -_: current_JJ 64,532_CD 34,849_CD Deferred_JJ tax_NN liabilities_NNS assets_NNS -_: non-current_JJ 1,400_CD 6,216_CD 63,132_CD 41,065_CD The_DT approximate_JJ net_JJ operating_NN loss_NN carry-forwards_NNS as_IN of_IN December_NNP 31_CD ,_, are_VBP as_IN follows_VBZ :_: December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2003_CD 2002_CD $_$ 000_CD $_$ 000_CD Approximate_JJ net_JJ operating_NN loss_NN carry-forwards_NNS against_IN future_JJ US_NNP federal_JJ tax_NN liabilities_NNS 23,468_CD 33,386_CD Approximate_JJ net_JJ operating_NN loss_NN carry-forwards_NNS against_IN future_JJ US_NNP state_NN tax_NN 130,755_CD 132,480_CD Approximate_JJ net_JJ operating_NN loss_NN carry-forwards_NNS against_IN future_JJ foreign_JJ tax_NN liabilities_NNS 800,509_CD 507,276_CD Total_JJ 954,732_CD 673,142_CD The_DT tax_NN losses_NNS shown_VBN above_IN have_VBP the_DT following_VBG expiration_NN dates_NNS :_: December_NNP 31_CD ,_, 2003_CD $_$ 000 2004 2005 2006_CD 646_CD 2007_CD 40,854_CD 2008_CD 65,478_CD 2009_CD 28,320_CD 2010_CD Available_JJ indefinitely_RB 819,434_CD 954,732_CD As_IN of_IN December_NNP 31_CD ,_, 2003_CD ,_, the_DT Company_NN had_VBD a_DT valuation_NN allowance_NN of_IN $_$ 168.2_CD million_CD to_TO reduce_VB its_PRP$ deferred_JJ tax_NN assets_NNS to_TO estimated_VBN realizable_JJ value_NN ._.
The_DT valuation_NN allowance_NN relates_VBZ to_TO the_DT deferred_VBN tax_NN assets_NNS arising_VBG from_IN overseas_JJ tax_NN operating_NN loss_NN carry-forwards_NNS and_CC capital_NN loss_NN carry-forwards_NNS ,_, which_WDT have_VBP no_DT expiration_NN date_NN ._.
The_DT utilization_NN of_IN operating_VBG loss_NN carry_VBP forwards_RB is_VBZ ,_, however_RB ,_, restricted_VBN to_TO the_DT taxable_JJ income_NN of_IN the_DT subsidiary_NN generating_VBG the_DT losses_NNS ._.
In_IN addition_NN ,_, capital_NN loss_NN carry-forwards_NNS can_MD only_RB be_VB offset_VBN against_IN capital_NN gains_NNS ._.
As_IN of_IN December_NNP 31_CD ,_, 2003_CD ,_, based_VBN upon_IN the_DT level_NN of_IN historical_JJ taxable_JJ income_NN and_CC projections_NNS for_IN future_JJ taxable_JJ income_NN over_IN the_DT periods_NNS in_IN which_WDT the_DT temporary_JJ differences_NNS are_VBP anticipated_VBN to_TO reverse_VB ,_, and_CC reasonable_JJ and_CC feasible_JJ tax-planning_JJ strategies_NNS ,_, management_NN believes_VBZ it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB that_IN the_DT Company_NN will_MD realize_VB the_DT benets_NNS of_IN these_DT deductible_JJ differences_NNS ,_, net_NN of_IN the_DT valuation_NN allowances_NNS ._.
However_RB ,_, the_DT amount_NN of_IN the_DT deferred_JJ tax_NN asset_NN considered_VBN realizable_JJ could_MD be_VB adjusted_VBN in_IN the_DT future_NN if_IN estimates_NNS of_IN taxable_JJ income_NN are_VBP revised_VBN ._.
The_DT Company_NN recognizes_VBZ a_DT deferred_JJ tax_NN liability_NN related_VBN to_TO the_DT undistributed_JJ earnings_NNS of_IN subsidiaries_NNS when_WRB the_DT Company_NN expects_VBZ that_IN it_PRP will_MD recover_VB those_DT undistributed_JJ earnings_NNS in_IN a_DT taxable_JJ manner_NN ,_, such_JJ as_IN through_IN receipt_NN of_IN dividends_NNS or_CC sale_NN of_IN the_DT investments_NNS ._.
The_DT Company_NN does_VBZ not_RB ,_, however_RB ,_, provide_VB for_IN income_NN taxes_NNS on_IN the_DT unremitted_JJ earnings_NNS of_IN certain_JJ other_JJ subsidiaries_NNS located_VBN outside_IN the_DT UK_NNP ,_, where_WRB ,_, in_IN management_NN 's_POS opinion_NN ,_, such_JJ earnings_NNS have_VBP been_VBN indefinitely_RB reinvested_VBN in_IN these_DT operations_NNS ,_, will_MD be_VB remitted_VBN in_IN a_DT tax_NN free_JJ liquidation_NN ,_, or_CC will_MD be_VB remitted_VBN as_IN dividends_NNS with_IN taxes_NNS substantially_RB offset_VBN by_IN foreign_JJ tax_NN credits_NNS ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 83_CD In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 26_CD Equity_NN in_IN losses_NNS earnings_NNS of_IN equity_NN method_NN investees_VBZ 2003 2002 2001_CD Year_NN ended_VBD December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD GSK_NNP 3,495_CD 2,592_CD 1,985_CD CADx_NNP Qualia_NNP 4,552_CD 924_CD 1,057_CD 1,668_CD 1,985_CD The_DT Company_NN has_VBZ accounted_VBN for_IN its_PRP$ commercialization_NN partnership_NN with_IN GSK_NNP through_IN which_WDT the_DT products_NNS 3TC_NNP and_CC ZEFFIX_NNP are_VBP marketed_VBN in_IN Canada_NNP using_VBG the_DT equity_NN method_NN of_IN accounting_NN ._.
The_DT Company_NN owns_VBZ ,_, but_CC does_VBZ not_RB exercise_VB control_NN over_IN ,_, a_DT 50_CD %_NN share_NN of_IN the_DT partnership_NN ._.
On_IN December_NNP 31_CD ,_, 2003_CD ,_, the_DT Company_NN sold_VBD its_PRP$ investment_NN in_IN Qualia_NNP Computing_NNP Inc._NNP to_TO iCAD_NNP Inc._NNP ._.
During_IN 2003_CD the_DT Company_NN had_VBD applied_VBN the_DT equity_NN method_NN of_IN accounting_NN as_IN the_DT Company_NN owned_VBN ,_, but_CC did_VBD not_RB exercise_VB control_NN over_IN its_PRP$ 50_CD %_NN share_NN of_IN the_DT joint_JJ venture_NN ._.
27_CD Stock_NNP incentive_NN plans_VBZ The_DT Company_NN has_VBZ adopted_VBN the_DT disclosure_NN only_RB provisions_NNS of_IN SFAS_NNP No._NN ._.
25_CD and_CC related_VBN interpretations_NNS in_IN accounting_NN for_IN its_PRP$ plans_NNS ._.
In_IN the_DT years_NNS ended_VBN December_NNP 31_CD ,_, 2003_CD ,_, 2002_CD and_CC 2001_CD the_DT Company_NN recognized_VBD a_DT credit_NN charge_NN under_IN APB_NNP No._NN ._.
25_CD of_IN $_$ 0.02_CD million_CD ,_, $_$ 0.2_CD million_CD and_CC $_$ 2.3_CD million_CD ,_, respectively_RB ._.
The_DT fair_JJ value_NN of_IN stock_NN options_NNS used_VBN to_TO compute_VB pro_FW forma_FW net_JJ income_NN and_CC per_IN share_NN disclosures_NNS is_VBZ the_DT estimated_VBN present_JJ value_NN at_IN grant_NN date_NN using_VBG the_DT Black-Scholes_NNP option-pricing_NN model_NN with_IN the_DT following_VBG weighted_JJ average_JJ assumptions_NNS :_: 2003 2002 2001_CD Year_NN ended_VBD December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Risk-free_JJ interest_NN rate_NN 1.89_CD -_: 3.40_CD %_NN 1.90_CD -_: 5.33_CD %_NN 3.43_CD -_: 5.22_CD %_NN Expected_VBN dividend_NN yield_NN 0_CD %_NN 0_CD %_NN 0_CD %_NN Expected_VBN life_NN 5_CD years_NNS 5_CD years_NNS 5_CD years_NNS Expected_VBN volatility_NN 60.0_CD %_NN 55.2_CD %_NN 59.5_CD %_NN Directors_NNS and_CC employees_NNS have_VBP been_VBN granted_VBN options_NNS over_IN ordinary_JJ shares_NNS under_IN the_DT following_VBG eight_CD stock_NN option_NN plans_NNS :_: i_FW Shire_FW Pharmaceuticals_NNP Executive_NNP Share_NNP Option_NN Scheme_NN -_: Parts_NNS A_DT and_CC B_NNP Executive_NNP Scheme_NNP Options_NNPS granted_VBN under_IN the_DT Executive_NNP Scheme_NNP are_VBP subject_JJ to_TO performance_NN criteria_NNS and_CC can_MD not_RB be_VB exercised_VBN in_IN full_JJ ,_, unless_IN Shires_NNP share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN at_IN least_JJS 20.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ._.
If_IN Shires_NNP share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN 14.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ,_, 60_CD %_NN of_IN the_DT options_NNS may_MD be_VB exercised_VBN ._.
On_IN February_NNP 28_CD ,_, 2000_CD ,_, the_DT Remuneration_NNP Committee_NNP of_IN the_DT Board_NNP exercised_VBD its_PRP$ powers_NNS to_TO amend_VB the_DT terms_NNS of_IN the_DT Executive_NNP Share_NNP Option_NN Scheme_NN so_RB as_IN to_TO include_VB a_DT cliff_NN vesting_VBG provision_NN ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS will_MD be_VB granted_VBN under_IN the_DT Executive_NNP Scheme_NNP ._.
ii_FW Shire_FW Pharmaceuticals_NNPS Group_NNP plc_NN 2000_CD Executive_NNP Share_NNP Option_NN Scheme_NNP 2000_CD Executive_NNP Scheme_NNP Options_NNPS granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP vest_NN six_CD weeks_NNS prior_RB to_TO the_DT expiry_NN date_NN ._.
If_IN it_PRP increases_VBZ by_IN at_IN least_JJS 14.5_CD %_NN per_IN annum_NN over_IN the_DT same_JJ three_CD year_NN period_NN ,_, the_DT option_NN may_MD be_VB exercised_VBN up_RP to_TO 60_CD %_NN of_IN the_DT shares_NNS covered_VBN by_IN the_DT option_NN ._.
Given_VBN Shires_NNPS development_NN ,_, it_PRP was_VBD considered_VBN appropriate_JJ that_IN an_DT earnings_NNS per_IN share_NN EPS_NNP based_VBN measure_NN should_MD be_VB adopted_VBN in_IN place_NN of_IN share_NN price_NN growth_NN targets_NNS ._.
Therefore_RB ,_, the_DT performance_NN criteria_NNS was_VBD amended_VBN so_RB that_IN an_DT option_NN would_MD only_RB become_VB exercisable_JJ in_IN full_JJ if_IN Shires_NNP fully_RB diluted_VBD EPS_NNP growth_NN over_IN a_DT three_CD year_NN period_NN from_IN the_DT date_NN of_IN award_NN exceeds_VBZ the_DT UK_NNP Retail_NNP Prices_NNS Index_NNP RPI_NNP on_IN average_NN a_DT year_NN for_IN the_DT following_VBG tranches_NNS of_IN grants_NNS :_: Options_NNS with_IN a_DT grant_NN value_NN of_IN up_RB to_TO 100_CD %_NN of_IN salary_NN RPI_NNP plus_CC 3_CD %_NN per_IN annum_NN directors_NNS ,_, RPI_NNP plus_CC 5_CD %_NN Between_IN 101_CD %_NN and_CC 200_CD %_NN of_IN salary_NN RPI_NNP plus_CC 5_CD %_NN per_IN annum_NN Between_IN 201_CD %_NN and_CC 300_CD %_NN of_IN salary_NN RPI_NNP plus_CC 7_CD %_NN per_IN annum_NN Over_IN 301_CD %_NN of_IN salary_NN RPI_NNP plus_CC 9_CD %_NN per_IN annum_NN 84_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 27_CD Stock_NNP incentive_NN plans_NNS continued_VBD The_DT new_JJ EPS_NNP performance_NN criteria_NNS apply_VBP to_TO options_NNS granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP from_IN August_NNP 2002_CD ._.
The_DT retest_NN will_MD be_VB applied_VBN only_RB where_WRB Shires_NNP EPS_NNP growth_NN has_VBZ fallen_VBN short_JJ of_IN the_DT minimum_JJ annual_JJ average_JJ percentage_NN increase_NN over_IN the_DT three_CD year_NN period_NN from_IN grant_NN ._.
iii_FW Shire_FW Pharmaceuticals_NNPS Sharesave_NNP Scheme_NNP Sharesave_NNP Scheme_NNP Options_NNPS granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP are_VBP granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 80_CD %_NN of_IN the_DT mid-market_JJ price_NN on_IN the_DT day_NN before_IN invitations_NNS are_VBP issued_VBN to_TO employees_NNS ._.
iv_NN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Employee_NNP Stock_NNP Purchase_NNP Plan_NNP Stock_NNP Purchase_NNP Plan_NNP Under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP ,_, options_NNS are_VBP granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 85_CD %_NN of_IN the_DT fair_JJ market_NN value_NN of_IN a_DT share_NN on_IN the_DT enrolment_NN date_NN the_DT first_JJ day_NN of_IN the_DT offering_NN period_NN or_CC the_DT exercise_NN date_NN the_DT last_JJ day_NN of_IN the_DT offering_NN period_NN ,_, whichever_WDT is_VBZ the_DT lower_JJR ._.
v_NN Pharmavene_NNP 1991_CD Stock_NNP Option_NN Plan_NN SLI_NNP Plan_NNP Options_NNPS issued_VBN under_IN the_DT SLI_NNP Plan_NNP were_VBD originally_RB granted_VBN over_IN shares_NNS in_IN SLI_NNP ,_, formerly_RB Pharmavene_NNP Inc._NNP a_DT company_NN acquired_VBN by_IN the_DT Company_NN on_IN March_NNP 23_CD ,_, 1997_CD ._.
Exercise_NN of_IN these_DT options_NNS results_NNS in_IN the_DT option_NN holder_NN receiving_VBG ordinary_JJ shares_NNS in_IN Shire_NNP ._.
As_IN a_DT result_NN of_IN the_DT acquisition_NN of_IN SLI_NNP ,_, and_CC in_IN accordance_NN with_IN the_DT terms_NNS of_IN the_DT original_JJ share_NN option_NN plan_NN ,_, all_DT options_NNS granted_VBN under_IN that_DT plan_NN became_VBD immediately_RB capable_JJ of_IN exercise_NN ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS will_MD be_VB granted_VBN under_IN the_DT SLI_NNP Plan_NNP ._.
vi_FW Roberts_NNP Stock_NNP Option_NN Plans_NNS Roberts_NNP Plans_NNP Options_NNPS issued_VBN under_IN the_DT Roberts_NNP Plans_NNS were_VBD originally_RB granted_VBN over_IN shares_NNS in_IN Roberts_NNP ,_, a_DT company_NN acquired_VBN by_IN the_DT Company_NN on_IN December_NNP 23_CD ,_, 1999_CD ._.
As_IN a_DT result_NN of_IN the_DT acquisition_NN of_IN Roberts_NNP ,_, and_CC in_IN accordance_NN with_IN the_DT terms_NNS of_IN the_DT original_JJ Roberts_NNP plans_NNS ,_, all_DT options_NNS granted_VBN under_IN the_DT Roberts_NNP Plans_NNP became_VBD immediately_RB capable_JJ of_IN exercise_NN ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS will_MD be_VB granted_VBN under_IN the_DT Roberts_NNP Plans_NNP ._.
vii_FW BioChem_NNP Stock_NNP Option_NN Plan_NN BioChem_NNP Plan_NNP Following_VBG the_DT acquisition_NN of_IN BioChem_NNP Pharma_NNP ,_, Inc._NNP on_IN May_NNP 11_CD ,_, 2001_CD ,_, the_DT BioChem_NNP Stock_NNP Option_NN Plan_NN was_VBD amended_VBN such_JJ that_IN options_NNS over_IN BioChems_NNPS common_JJ stock_NN became_VBD options_NNS over_IN ordinary_JJ shares_NNS of_IN Shire_NNP ._.
All_DT BioChem_NNP options_NNS ,_, which_WDT were_VBD not_RB already_RB exercisable_JJ ,_, vested_JJ and_CC became_VBD exercisable_JJ as_IN a_DT result_NN of_IN the_DT acquisition_NN ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS will_MD be_VB granted_VBN under_IN the_DT BioChem_NNP Stock_NNP Option_NN Plan_NN ._.
In_IN a_DT period_NN of_IN ten_CD years_NNS ,_, not_RB more_JJR than_IN 10_CD %_NN of_IN the_DT issued_VBN share_NN capital_NN of_IN Shire_NNP may_MD be_VB placed_VBN under_IN option_NN under_IN any_DT employee_NN share_NN scheme_NN ._.
In_IN addition_NN ,_, the_DT following_VBG terms_NNS apply_VB to_TO options_NNS that_WDT may_MD be_VB granted_VBN under_IN the_DT various_JJ plans_NNS :_: 2000_CD Executive_NNP Scheme_NNP :_: the_DT maximum_JJ number_NN of_IN shares_NNS over_IN which_WDT incentive_NN options_NNS may_MD be_VB granted_VBN under_IN Part_NN 3_CD of_IN the_DT scheme_NN is_VBZ 25,000,000_CD ._.
Stock_NNP Purchase_NNP Plan_NNP :_: up_RP to_TO 2,000,000_CD ordinary_JJ shares_NNS ._.
Options_NNS outstanding_JJ at_IN December_NNP 31_CD ,_, 2003_CD under_IN the_DT various_JJ plans_NNS are_VBP as_IN follows_VBZ :_: Scheme_NNP Number_NNP of_IN options_NNS Expiry_JJ period_NN from_IN date_NN of_IN issue_NN Vesting_JJ period_NN Executive_NNP Scheme_NNP 3,698,397_CD 10_CD years_NNS 3_CD years_NNS ,_, subject_JJ to_TO performance_NN criteria_NNS 2000_CD Executive_NNP Scheme_NNP 16,123,388_CD 10_CD years_NNS 3_CD years_NNS ,_, subject_JJ to_TO performance_NN criteria_NNS Sharesave_NNP Scheme_NNP 272,411_CD 6_CD months_NNS after_IN vesting_VBG 3_CD or_CC 5_CD years_NNS Stock_NNP Purchase_NNP Plan_NNP 838,906_CD On_IN vesting_VBG date_NN 27_CD months_NNS SLI_NNP Plan_NNP 11,287_CD 10_CD years_NNS Immediate_NNP on_IN acquisition_NN by_IN Shire_NNP Roberts_NNP Plans_NNP 138,338_CD 6_CD years_NNS Immediate_NNP on_IN acquisition_NN by_IN Shire_NNP BioChem_NNP Plan_NNP 4,912,816_CD 10_CD years_NNS Immediate_NNP on_IN acquisition_NN by_IN Shire_NNP Total_NNP 25,995,543_CD A_DT summary_NN of_IN the_DT status_NN of_IN the_DT Companys_NNP stock_NN option_NN plans_NNS as_IN of_IN December_NNP 31_CD ,_, 2003_CD ,_, 2002_CD and_CC 2001_CD and_CC of_IN the_DT related_JJ transactions_NNS during_IN the_DT periods_NNS then_RB ended_VBD is_VBZ presented_VBN below_IN :_: Weighted_JJ average_JJ exercise_NN price_NN Year_NN ended_VBD December_NNP 31_CD ,_, 2003_CD $_$ Number_CD of_IN shares_NNS Outstanding_JJ as_IN of_IN beginning_NN of_IN period_NN 11.55_CD 20,051,297_CD Granted_VBN 6.30_CD 9,407,852_CD Exercised_VBN 5.12_CD 1,039,439_CD Forfeited_NNP 11.28_CD 2,424,167_CD Outstanding_JJ as_IN of_IN end_NN of_IN period_NN 10.92_CD 25,995,543_CD Exercisable_JJ as_IN of_IN end_NN of_IN period_NN 12.79_CD 8,989,450_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 85_CD In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 27_CD Stock_NNP incentive_NN plans_NNS continued_VBD 8,819,199_CD options_NNS were_VBD granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP ._.
These_DT options_NNS were_VBD issued_VBN with_IN exercise_NN prices_NNS equivalent_JJ to_TO the_DT market_NN value_NN on_IN the_DT date_NN of_IN grant_NN ._.
182,639_CD options_NNS were_VBD granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP at_IN a_DT price_NN of_IN 3.86_CD approximately_RB $_$ 6.91_CD ._.
These_DT options_NNS were_VBD granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 80_CD %_NN of_IN the_DT mid-market_JJ price_NN on_IN the_DT day_NN before_IN invitations_NNS were_VBD issued_VBN to_TO employees_NNS ._.
406,014_CD options_NNS were_VBD granted_VBN under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP at_IN a_DT price_NN of_IN 4.09_CD approximately_RB $_$ 7.32_CD ._.
These_DT options_NNS were_VBD granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 85_CD %_NN of_IN the_DT mid-market_JJ price_NN on_IN the_DT day_NN before_IN invitations_NNS were_VBD issued_VBN to_TO employees_NNS ._.
The_DT average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN in_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2003_CD is_VBZ $_$ 6.39_CD ._.
Weighted_JJ average_JJ exercise_NN price_NN Year_NN ended_VBD December_NNP 31_CD ,_, 2002_CD $_$ Number_CD of_IN shares_NNS Outstanding_JJ as_IN of_IN beginning_NN of_IN period_NN 10.80_CD 16,249,844_CD Granted_VBN 8.49_CD 6,179,894_CD Exercised_VBN 3.52_CD 1,940,546_CD Forfeited_NNP 11.07_CD 437,895_CD Outstanding_JJ as_IN of_IN end_NN of_IN period_NN 11.55_CD 20,051,297_CD Exercisable_JJ as_IN of_IN end_NN of_IN period_NN 9.24_CD 8,491,051_CD 4,539,529_CD options_NNS were_VBD granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP ._.
186,052_CD options_NNS were_VBD granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP at_IN a_DT price_NN of_IN 5.02_CD approximately_RB $_$ 8.08_CD ._.
18,342_CD and_CC 1,435,971_CD options_NNS were_VBD granted_VBN under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP at_IN a_DT price_NN of_IN 3.19_CD and_CC 5.44_CD approximately_RB $_$ 5.14_CD and_CC $_$ 8.76_CD ,_, respectively_RB ._.
The_DT average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN in_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2002_CD is_VBZ $_$ 8.91_CD ._.
Weighted_JJ average_JJ exercise_NN price_NN Year_NN ended_VBD December_NNP 31_CD ,_, 2001_CD $_$ Number_CD of_IN shares_NNS Outstanding_JJ as_IN of_IN beginning_NN of_IN period_NN 7.83_CD 24,790,322_CD Granted_VBN 17.24_CD 4,405,089_CD Exercised_VBN 6.29_CD 11,443,831_CD Forfeited_NNP 13.86_CD 1,501,736_CD Outstanding_JJ as_IN of_IN end_NN of_IN period_NN 10.80_CD 16,249,844_CD Exercisable_JJ as_IN of_IN end_NN of_IN period_NN 7.50_CD 9,054,150_CD All_DT options_NNS granted_VBN under_IN the_DT Executive_NNP Scheme_NNP ,_, 2000_CD Executive_NNP Scheme_NNP and_CC BioChem_NNP Plan_NNP were_VBD issued_VBN with_IN exercise_NN prices_NNS equivalent_JJ to_TO the_DT market_NN value_NN on_IN the_DT date_NN of_IN grant_NN ._.
81,888_CD options_NNS were_VBD granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP at_IN a_DT price_NN of_IN 8.41_CD approximately_RB $_$ 12.24_CD ._.
301,656_CD ,_, 120,819_CD and_CC 6,551_CD options_NNS were_VBD granted_VBN under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP at_IN a_DT price_NN of_IN 8.06_CD ,_, 9.10_CD and_CC 9.74_CD approximately_RB $_$ 11.73_CD ,_, $_$ 13.24_CD and_CC $_$ 14.18_CD ,_, respectively_RB ._.
The_DT average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN in_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2001_CD is_VBZ $_$ 17.51_CD ._.
86_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 27_CD Stock_NNP incentive_NN plans_NNS continued_VBD Options_NNS outstanding_JJ as_IN of_IN December_NNP 31_CD ,_, 2003_CD have_VBP the_DT following_VBG characteristics_NNS :_: Weighted_JJ average_JJ Weighted_JJ average_JJ Weighted_JJ average_JJ exercise_NN price_NN of_IN No._NN ._.
of_IN options_NNS exercise_NN price_NN of_IN No._NN ._.
The_DT 2002_CD results_NNS for_IN all_DT quarterly_JJ periods_NNS presented_VBN have_VBP been_VBN restated_VBN to_TO reect_VB the_DT OTC_NNP divestment_NN which_WDT has_VBZ been_VBN accounted_VBN for_IN as_IN a_DT discontinued_VBN operation_NN ._.
142_CD with_IN effect_NN from_IN January_NNP 1_CD ,_, 2002_CD ,_, the_DT amortization_NN expense_NN shown_VBN for_IN 2003_CD and_CC 2002_CD in_IN the_DT selected_VBN consolidated_JJ financial_JJ data_NNS presented_VBN below_IN is_VBZ not_RB on_IN a_DT consistent_JJ basis_NN of_IN accounting_NN with_IN earlier_JJR periods_NNS ._.
The_DT impact_NN of_IN this_DT is_VBZ shown_VBN in_IN note_NN 11_CD of_IN the_DT Companys_NNP consolidated_JJ financial_JJ statements_NNS included_VBD herein_NN ._.
2003 2002 2001 2000_CD 1999_CD December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Balance_NNP Sheet_NNP :_: Total_JJ current_JJ assets_NNS 1,787,707_CD 1,467,096_CD 1,140,555_CD 695,853_CD 520,023_CD Total_JJ assets_NNS 2,578,780_CD 2,208,623_CD 1,910,731_CD 1,548,495_CD 1,351,791_CD Total_JJ current_JJ liabilities_NNS 253,675_CD 214,504_CD 231,616_CD 227,850_CD 233,818_CD Total_JJ liabilities_NNS 655,654_CD 635,457_CD 647,742_CD 374,109_CD 471,905_CD Total_JJ shareholders_NNS equity_NN 1,923,126_CD 1,573,166_CD 1,262,989_CD 1,174,386_CD 879,886_CD 88_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Summary_NNP financial_JJ statement_NN For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD General_NNP Directors_NNS The_DT summary_NN financial_JJ statement_NN does_VBZ not_RB contain_VB sufficient_JJ The_DT Directors_NNS who_WP served_VBD during_IN the_DT year_NN were_VBD as_IN follows_VBZ :_: information_NN to_TO allow_VB for_IN a_DT full_JJ understanding_NN of_IN the_DT results_NNS and_CC state_NN of_IN affairs_NNS of_IN the_DT Company_NN or_CC Group_NNP ._.
The_DT summary_NN financial_JJ Dr_NNP James_NNP Cavanaugh_NNP ,_, Chairman_NNP and_CC non-executive_JJ Director_NNP statement_NN is_VBZ prepared_VBN under_IN UK_NNP GAAP_NNP ._.
For_IN further_JJ information_NN ,_, Chairman_NNP of_IN Nomination_NNP Committee_NNP the_DT full_JJ UK_NNP statutory_JJ accounts_NNS ,_, the_DT auditors_NNS report_VBP on_IN those_DT accounts_NNS and_CC the_DT Directors_NNS report_NN should_MD be_VB consulted_VBN ._.
Mr_NNP Matthew_NNP Emmens_NNP ,_, Chief_NNP Executive_NNP officer_NN Appointed_VBN 12_CD March_NNP 2003_CD In_IN accordance_NN with_IN Section_NN 239_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD shareholders_NNS have_VBP a_DT right_NN and_CC can_MD elect_VB to_TO obtain_VB the_DT full_JJ report_NN Mr_NNP Angus_NNP Russell_NNP ,_, Chief_NNP Financial_NNP officer_NN and_CC accounts_NNS free_JJ of_IN charges_NNS by_IN writing_VBG to_TO :_: Dr_NNP Wilson_NNP Totten_NNP ,_, Group_NNP R&D_NNP Director_NNP The_NNP Company_NNP Secretary_NNP Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Dr_NNP Barry_NNP Price_NNP ,_, Senior_NNP non-executive_JJ Director_NNP Hampshire_NNP International_NNP Business_NNP Park_NNP Chairman_NNP of_IN the_DT Remuneration_NNP Committee_NNP Chineham_NNP Basingstoke_NNP The_NNP Hon_NNP James_NNP Grant_NNP ,_, non-executive_JJ Director_NNP Hampshire_NNP RG24_NNP 8EP_NNP Mr_NNP Ronald_NNP Nordmann_NNP ,_, non-executive_JJ Director_NNP Chairman_NNP of_IN the_DT Audit_NNP Committee_NNP The_NNP full_JJ UK_NNP statutory_JJ annual_JJ accounts_NNS are_VBP signed_VBN on_IN behalf_NN of_IN the_DT Board_NNP by_IN AC_NNP Russell_NNP ,_, Chief_NNP Financial_NNP officer_NN ._.
Mr_NNP Robin_NNP Buchanan_NNP ,_, non-executive_JJ Director_NNP Appointed_VBN 30_CD July_NNP 2003_CD The_DT Companys_NNPS auditors_NNS have_VBP given_VBN an_DT unqualied_JJ report_NN on_IN the_DT statutory_JJ accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD ._.
Mr_NNP Rolf_NNP Stahel_NNP ,_, Former_NNP Chief_NNP Executive_NNP The_NNP report_NN did_VBD not_RB contain_VB any_DT statement_NN under_IN Section_NN 237_CD 2_CD Resigned_VBN 19_CD March_NNP 2003_CD or_CC 3_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
Mr_NNP Grard_NNP Veilleux_NNP ,_, non-executive_JJ Director_NNP Results_NNS and_CC dividends_NNS Resigned_VBN 10_CD May_NNP 2003_CD The_DT loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN of_IN the_DT Group_NNP was_VBD 298.3_CD million_CD 2002_CD :_: 526.8_CD million_CD ._.
The_DT net_JJ assets_NNS of_IN the_DT Group_NNP Dr_NNP Francesco_NNP Bellini_NNP ,_, non-executive_JJ Director_NNP as_IN at_IN 31_CD December_NNP 2003_CD were_VBD 2,308.5_CD million_CD 2002_CD :_: 2,747.7_CD Resigned_VBN 10_CD May_NNP 2003_CD million_CD ._.
The_DT Directors_NNS do_VBP not_RB recommend_VB the_DT payment_NN of_IN a_DT dividend_NN ._.
Business_NNP review_NN A_DT review_NN of_IN the_DT Groups_NNS business_NN and_CC important_JJ events_NNS during_IN the_DT year_NN and_CC likely_JJ future_NN developments_NNS is_VBZ set_VBN out_RP in_IN the_DT Chairmans_NNPS statement_NN ,_, the_DT Chief_NNP Executive_NNP Ofcers_NNP review_NN ,_, the_DT financial_JJ review_NN and_CC the_DT Directors_NNS remuneration_NN report_NN in_IN the_DT full_JJ UK_NNP statutory_JJ annual_JJ accounts_NNS ,_, which_WDT are_VBP similar_JJ to_TO the_DT statements_NNS contained_VBN in_IN the_DT annual_JJ review_NN at_IN the_DT front_NN of_IN this_DT document_NN which_WDT form_VBP part_NN of_IN this_DT summary_NN financial_JJ statement_NN ._.
Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Summary_NNP financial_JJ statement_NN 89_CD For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD Independent_NNP Auditors_NNS Statement_NN to_TO the_DT Members_NNS Basis_NN of_IN opinion_NN of_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN :_: We_PRP conduct_VBP our_PRP$ work_NN in_IN accordance_NN with_IN bulletin_NN 1999_CD 6_CD We_PRP have_VBP examined_VBN the_DT summary_NN financial_JJ statement_NN which_WDT The_DT Auditors_NNS Statement_NN of_IN Summary_NNP Financial_NNP Statement_NNP comprises_VBZ the_DT summary_NN Directors_NNS report_NN ,_, consolidated_JJ profit_NN and_CC issued_VBN by_IN the_DT United_NNP Kingdom_NNP Auditing_NNP Practices_NNPS Board_NNP ._.
loss_NN account_NN ,_, consolidated_JJ balance_NN sheet_NN ,_, consolidated_JJ cash_NN ow_NN statement_NN ,_, the_DT consolidated_JJ statement_NN of_IN total_JJ recognized_VBN gains_NNS Opinion_NNP and_CC losses_NNS and_CC notes_NNS 1_CD to_TO 3_CD of_IN the_DT summary_NN financial_JJ statement_NN ._.
In_IN our_PRP$ opinion_NN ,_, the_DT summary_NN financial_JJ statement_NN is_VBZ consistent_JJ with_IN the_DT full_JJ annual_JJ accounts_NNS ,_, the_DT Directors_NNS report_NN and_CC the_DT Directors_NNS This_DT statement_NN is_VBZ made_VBN solely_RB to_TO the_DT Companys_NNPS members_NNS ,_, remuneration_NN report_NN of_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN for_IN the_DT as_IN a_DT body_NN ,_, in_IN accordance_NN with_IN section_NN 251_CD of_IN the_DT Companies_NNS year_NN ended_VBD 31_CD December_NNP 2003_CD and_CC complies_VBZ with_IN the_DT applicable_JJ Act_NNP 1985_CD ._.
Our_PRP$ work_NN has_VBZ been_VBN undertaken_VBN so_RB that_IN we_PRP might_MD state_VB requirements_NNS of_IN Section_NN 251_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD and_CC the_DT to_TO the_DT Companys_NNPS members_NNS those_DT matters_NNS we_PRP are_VBP required_VBN to_TO regulations_NNS made_VBN thereunder_RB ._.
state_NN to_TO them_PRP in_IN an_DT auditors_NNS report_NN and_CC for_IN no_DT other_JJ purpose_NN ._.
To_TO the_DT fullest_JJS extent_NN permitted_VBN by_IN law_NN ,_, we_PRP do_VBP not_RB accept_VB or_CC assume_VB responsibility_NN to_TO anyone_NN other_JJ than_IN the_DT Company_NN and_CC the_DT Companys_NNPS members_NNS as_IN a_DT body_NN ,_, for_IN our_PRP$ audit_NN work_NN ,_, for_IN this_DT report_NN ,_, or_CC for_IN the_DT opinions_NNS we_PRP have_VBP formed_VBN ._.
Respective_JJ responsibilities_NNS of_IN Directors_NNS and_CC auditors_NNS The_DT Directors_NNS are_VBP responsible_JJ for_IN preparing_VBG the_DT Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN in_IN accordance_NN with_IN applicable_JJ United_NNP Kingdom_NNP law_NN and_CC accounting_NN standards_NNS ._.
Our_PRP$ responsibility_NN is_VBZ to_TO report_VB to_TO you_PRP our_PRP$ opinion_NN on_IN the_DT consistency_NN of_IN the_DT summary_NN financial_JJ statement_NN with_IN the_DT full_JJ annual_JJ accounts_NNS ,_, the_DT Directors_NNS report_NN and_CC the_DT Directors_NNS remuneration_NN report_NN ,_, and_CC its_PRP$ compliance_NN with_IN the_DT relevant_JJ requirements_NNS of_IN Section_NN 251_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD and_CC the_DT regulations_NNS made_VBD thereunder_RB ._.
We_PRP also_RB read_VBD the_DT other_JJ information_NN contained_VBN in_IN the_DT Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN as_IN described_VBN in_IN the_DT contents_NNS section_NN ,_, and_CC Deloitte_NNP &_CC Touche_NNP LLP_NNP consider_VBP the_DT implications_NNS for_IN our_PRP$ report_NN if_IN we_PRP become_VBP aware_JJ Chartered_NNP Accountants_NNPS and_CC Registered_NNP Auditors_NNS of_IN any_DT apparent_JJ misstatements_NNS or_CC material_NN inconsistencies_NNS with_IN Reading_VBG the_DT summary_NN financial_JJ statement_NN ._.
12_CD March_NNP 2004_CD 90_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Summary_NNP financial_JJ statement_NN For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD Consolidated_NNP profit_NN and_CC loss_NN account_NN 2003 2002 000 000_CD Turnover_NN :_: Group_NNP and_CC share_NN of_IN joint_JJ venture_NN 764,662_CD 697,314_CD Less_RBR :_: share_NN of_IN joint_JJ ventures_NNS turnover_NN 3,594_CD 762_CD Continuing_VBG operations_NNS 761,068_CD 696,552_CD Discontinued_VBN operations_NNS 15,975_CD Group_NNP turnover_NN 761,068_CD 712,527_CD Cost_NN of_IN sales_NNS 102,384_CD 95,042_CD Gross_NNP profit_NN 658,684_CD 617,485_CD Net_JJ operating_NN expenses_NNS 2003_CD :_: including_VBG 426,362,000_CD exceptional_JJ goodwill_NN impairment_NN ,_, 2002_CD :_: 613,983,000_CD 958,619_CD 1,150,630_CD Other_JJ operating_NN income_NN 698_CD Operating_NN loss_NN 299,237_CD 533,145_CD Continuing_VBG operations_NNS Group_NNP 299,237_CD 541,603_CD Discontinued_VBN operations_NNS 8,458_CD 299,237_CD 533,145_CD Share_NN of_IN joint_JJ ventures_NNS operating_VBG loss_NN 2,806_CD 559_CD Finance_NNP charges_NNS ,_, net_JJ 3,702_CD 6,931_CD Loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 298,341_CD 526,773_CD Tax_NNP on_IN loss_NN on_IN ordinary_JJ activities_NNS 65,014_CD 61,626_CD Retained_VBN loss_NN for_IN the_DT year_NN transferred_VBN from_IN reserves_NNS 363,355_CD 588,399_CD Loss_NN per_IN share_NN Basic_JJ 72.9_CD p_NN 117.5_CD p_NN Diluted_NNP 72.9_CD p_NN 117.5_CD p_NN Consolidated_NNP statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS Year_NN ended_VBD Year_NN ended_VBD 31_CD December_NNP ,_, 31_CD December_NNP ,_, 2003 2002 000 000_CD Loss_NN for_IN the_DT year_NN 363,355_CD 588,399_CD Translation_NN of_IN the_DT financial_JJ statements_NNS of_IN overseas_JJ subsidiaries_NNS 47,157_CD 62,739_CD Total_JJ recognized_VBN gains_NNS and_CC losses_NNS relating_VBG to_TO the_DT year_NN 410,512_CD 651,138_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Summary_NNP financial_JJ statement_NN 91_CD Consolidated_NNP balance_NN sheet_NN 31_CD December_NNP 31_CD December_NNP 2003 2002 000 000_CD Fixed_JJ assets_NNS Intangible_JJ assets_NNS intellectual_JJ property_NN 171,548_CD 183,404_CD Intangible_JJ assets_NNS goodwill_NN 1,365,583_CD 1,900,896_CD Tangible_JJ assets_NNS 97,054_CD 84,001_CD Fixed_VBN asset_NN investments_NNS 33,269_CD 37,345_CD Investment_NN in_IN joint_JJ ventures_NNS share_NN of_IN gross_JJ assets_NNS 5,082_CD share_NN of_IN gross_JJ liabilities_NNS 342_CD 1,667,454_CD 2,210,386_CD Current_JJ assets_NNS Stocks_NNS 25,282_CD 30,571_CD Debtors_NNS due_JJ within_IN one_CD year_NN excluding_VBG deferred_JJ tax_NN 141,046_CD 106,125_CD due_JJ within_IN one_CD year_NN deferred_VBN tax_NN 36,049_CD 21,646_CD due_JJ after_IN more_JJR than_IN one_CD year_NN excluding_VBG deferred_JJ tax_NN 9,224_CD 9,535_CD due_JJ after_IN more_JJR than_IN one_CD year_NN deferred_VBN tax_NN 3,861_CD Current_JJ asset_NN investments_NNS 169,895_CD 196,364_CD Cash_NN at_IN bank_NN and_CC in_IN hand_NN 621,670_CD 558,432_CD 1,003,166_CD 926,534_CD Creditors_NNPS :_: Amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN 141,722_CD 131,885_CD Net_JJ current_JJ assets_NNS 861,444_CD 794,649_CD Total_JJ assets_NNS less_RBR current_JJ liabilities_NNS 2,528,898_CD 3,005,035_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ after_IN more_JJR than_IN one_CD year_NN Convertible_JJ debt_NN 202,659_CD 243,547_CD Deferred_JJ tax_NN 782_CD Other_JJ creditors_NNS 16,957_CD 13,782_CD 220,398_CD 257,329_CD Net_JJ assets_NNS 2,308,500_CD 2,747,706_CD Capital_NN and_CC reserves_NNS Called-up_JJ share_NN capital_NN 23,895_CD 24,217_CD Share_NN premium_NN 3,218,695_CD 3,214,512_CD Exchangeable_JJ shares_NNS 190,425_CD 191,552_CD Capital_NN reserve_NN 3,135_CD 2,755_CD Other_JJ reserves_NNS 24,247_CD 24,247_CD profit_NN and_CC loss_NN account_NN 1,151,897_CD 709,577_CD Equity_NNP shareholders_NNS funds_NNS 2,308,500_CD 2,747,706_CD 92_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Summary_NNP financial_JJ statement_NN For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD Consolidated_NNP cash_NN ow_NN statement_NN 2003 2002 000 000_CD Net_JJ cash_NN inow_NN from_IN operating_VBG activities_NNS 280,275_CD 302,321_CD Returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN :_: Interest_NN and_CC other_JJ income_NN received_VBD 13,165_CD 15,434_CD Interest_NN paid_VBN 9,404_CD 8,458_CD Interest_NN element_NN of_IN finance_NN lease_NN rentals_NNS 59_CD 45_CD Net_JJ cash_NN inow_NN from_IN returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN 3,702_CD 6,931_CD Taxation_NNP :_: Overseas_NNP corporation_NN tax_NN paid_VBN 66,874_CD 73,145_CD Capital_NN expenditure_NN and_CC financial_JJ investments_NNS :_: Purchase_NN of_IN long-term_JJ investment_NN 3,447_CD 2,957_CD Purchase_NN of_IN intangible_JJ xed_JJ assets_NNS 30,238_CD 15,470_CD Purchase_NN of_IN tangible_JJ xed_JJ assets_NNS 31,400_CD 15,014_CD Proceeds_NNS from_IN sale_NN of_IN a_DT business_NN 559_CD 44,103_CD Proceeds_NNS from_IN sale_NN of_IN tangible_JJ xed_JJ assets_NNS 1,060_CD 542_CD Net_JJ cash_NN inow_NN for_IN capital_NN expenditure_NN and_CC financial_JJ investments_NNS 63,466_CD 11,204_CD Acquisitions_NNPS and_CC disposals_NNS :_: Purchase_NN of_IN subsidiary_NN undertaking_NN 11,647_CD Expenses_NNS of_IN acquisitions_NNS 235_CD Net_JJ cash_NN acquired_VBN with_IN subsidiary_NN undertakings_NNS 33_CD Net_JJ cash_NN outow_NN from_IN acquisitions_NNS 11,849_CD Cash_NN inow_NN before_IN management_NN of_IN liquid_JJ resources_NNS and_CC nancing_VBG 153,637_CD 235,462_CD Management_NN of_IN liquid_JJ resources_NNS :_: Increase_VB in_IN cash_NN placed_VBN on_IN short-term_JJ deposit_NN 17,848_CD 254,561_CD Financing_NN :_: Exercise_NN of_IN share_NN options_NNS 3,114_CD 3,985_CD Repurchase_NN of_IN ordinary_JJ share_NN capital_NN 31,808_CD Capital_NNP element_NN of_IN finance_NN leases_NNS 160_CD 74_CD Net_JJ decrease_NN in_IN debt_NN during_IN the_DT year_NN 18,053_CD 832_CD Net_JJ cash_NN outow_NN inow_NN from_IN nancing_VBG 46,907_CD 3,079_CD Increase_VBP in_IN cash_NN in_IN the_DT year_NN 124,578_CD 493,102_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT summary_NN financial_JJ statement_NN 93_CD For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 1_CD Basis_NN of_IN preparation_NN The_DT summary_NN financial_JJ statement_NN has_VBZ been_VBN prepared_VBN in_IN accordance_NN with_IN the_DT accounting_NN policies_NNS set_VBN out_RP in_IN the_DT full_JJ UK_NNP statutory_JJ annual_JJ accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD ._.
2_CD Directors_NNS remuneration_JJ Aggregate_NNP Directors_NNS remuneration_VBP The_DT total_JJ amounts_NNS for_IN Directors_NNS remuneration_NN and_CC other_JJ benets_NNS were_VBD as_IN follows_VBZ :_: 2003 2002 000 000_CD Emoluments_NNP 2,256_CD 2,300_CD Money_NN purchase_NN pension_NN contributions_NNS 4,676_CD 383_CD Gains_NNS on_IN exercise_NN of_IN share_NN options_NNS 114_CD 2,962_CD Amounts_NNS receivable_JJ under_IN long-term_JJ incentive_NN schemes_NNS 276_CD Compensation_NNP for_IN loss_NN of_IN ofce_NN 1,335_CD 8,657_CD 5,645_CD Directors_NNS emoluments_VBZ Cash_NNP Non-cash_JJ benets_NNS benets_VBZ Total_JJ Total_JJ Salary_NNP Bonuses_NNS Fees_NNS in_IN kind_NN in_IN kind_NN 2003 2002 000 000_CD 000 000 000 000_CD 000_CD Executive_NNP Mr_NNP Matthew_NNP Emmens_NNP ii_FW i_FW 446_FW 235_CD 14_CD 4_CD 699_CD Mr_NNP Angus_NNP Russell_NNP 320_CD 162_CD 10_CD 7_CD 499_CD 444_CD Dr_NNP Wilson_NNP Totten_NNP 340_CD 163_CD 11 17 531 481_CD Mr_NNP Rolf_NNP Stahel_NNP iii_FW 154_CD 124_CD 33_CD 311_CD 1,144_CD 1,260_CD 684_CD 35_CD 61_CD 2,040_CD 2,069_CD Non-executive_JJ Dr_NNP James_NNP Cavanaugh_NNP 54_CD 54_CD 45_CD Dr_NNP Barry_NNP Price_NNP 43_CD 43_CD 37_CD The_DT Hon_NNP James_NNP Grant_NNP 35_CD 35_CD 30_CD Mr_NNP Ronald_NNP Nordmann_NNP 45_CD 45_CD 34_CD Mr_NNP Robin_NNP Buchanan_NNP iv_VBD 16_CD 16_CD Dr_NNP Francesco_NNP Bellini_NNP v_NNP 11_CD 11_CD 30_CD Mr_NNP Grard_NNP Veilleux_NNP v_VBD 12_CD 12_CD 32_CD The_DT late_JJ Dr_NNP Bernard_NNP Canavan_NNP 23 216 216 231_CD Total_JJ 1,260_CD 684_CD 216_CD 35_CD 61_CD 2,256_CD 2,300_CD i_FW Paid_FW in_IN US$_$ ,_, Mr_NNP Emmens_NNP annual_JJ salary_NN in_IN 2003_CD was_VBD $_$ 935,018_CD ii_FW Appointed_VBN 12_CD March_NNP 2003_CD iii_FW Stepped_VBN down_RP on_IN 19_CD March_NNP 2003_CD iv_NN Appointed_VBN 30_CD July_NNP 2003_CD v_NN Stepped_VBD down_RP on_IN 10_CD May_NNP 2003_CD 3_CD Loss_NN per_IN share_NN Loss_NN per_IN share_NN has_VBZ been_VBN calculated_VBN by_IN dividing_VBG the_DT loss_NN on_IN ordinary_JJ activities_NNS after_IN taxation_NN for_IN each_DT period_NN by_IN the_DT weighted_JJ average_JJ number_NN of_IN shares_NNS in_IN issue_NN during_IN those_DT periods_NNS ._.
Total_JJ for_IN basic_JJ and_CC diluted_JJ EPS_NNP 498,212,826_CD 500,687,594_CD 94_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Shire_NNP head_NN ofce_NN and_CC main_JJ operating_NN locations_NNS Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Shire_NNP US_NNP ,_, Inc._NNP ._.
Chief_NNP Executive_NNP officer_NN :_: Matthew_NNP Emmens_NNP EVP_NNP and_CC General_NNP Manager_NNP ,_, North_NNP America_NNP :_: Hampshire_NNP International_NNP Business_NNP Park_NNP Greg_NNP Flexter_NNP Chineham_NNP ,_, Basingstoke_NNP One_CD Riverfront_NNP Place_NNP Hampshire_NNP RG24_NNP 8EP_NNP ,_, UK_NNP Newport_NNP ,_, KY_NNP 41071_CD ,_, USA_NNP Tel_NNP 44_CD 0_CD 1256 894 000_CD Tel_NNP 1_CD 800 828 2088_CD Fax_NNP 44_CD 0_CD 1256 894 708_CD Tel_NNP 1_CD 859 669 8000_CD Fax_NN 1_CD 859 669 8414_CD Shire_NNP Pharmaceuticals_NNP Limited_NNP Managing_VBG Director_NNP :_: John_NNP Freeman_NNP Shire_NNP US_NNP Manufacturing_NNP ,_, Inc._NNP ._.
Hampshire_NNP International_NNP Business_NNP Park_NNP EVP_NNP Global_NNP Supply_NNP Chain_NNP &_CC Quality_NNP :_: John_NNP Lee_NNP Chineham_NNP ,_, Basingstoke_NNP 11200_CD Gundry_NNP Lane_NNP Hampshire_NNP RG24_NNP 8EP_NNP ,_, UK_NNP Owings_NNP Mills_NNP ,_, MD_NNP 21117_CD ,_, USA_NNP Tel_NNP 44_CD 0_CD 1256 894 000_CD Tel_NNP 1_CD 410 413 1000_CD Fax_NNP 44_CD 0_CD 1256 894 708_CD Fax_NN 1_CD 410 413 2000_CD Shire_NNP Pharmaceuticals_NNP Ireland_NNP Limited_NNP Shire_NNP Laboratories_NNPS ,_, Inc._NNP ._.
Director_NNP and_CC General_NNP Manager_NNP :_: Brian_NNP Martin_NNP President_NNP and_CC Chief_NNP Executive_NNP officer_NN :_: 2nd_VB Floor_NNP ,_, Building_NNP 1A_NNP Jack_NNP Khattar_NNP Citylink_NNP Business_NNP Park_NNP 1550_CD East_NNP Gude_NNP Drive_NNP Old_NNP Naas_NNP Road_NNP Rockville_NNP ,_, MD_NNP 20850_CD ,_, USA_NNP Dublin_NNP 12_CD ,_, Ireland_NNP Tel_NNP 1_CD 301 838 2500_CD Tel_NNP 353_CD 1_CD 429_CD 7700_CD Fax_NN 1_CD 301 838 2501_CD Fax_NNP 353_CD 1_CD 429_CD 7701_CD Shire_NNP Pharmaceutical_NNP Development_NNP ,_, Inc._NNP ._.
Shire_NNP Pharmaceutical_NNP Contracts_NNPS Limited_NNP Senior_NNP Vice_NNP President_NNP :_: Simon_NNP Tulloch_NNP Singapore_NNP representative_NN ofce_NN 1801_CD Research_NNP Blvd._NNP ._.
40_CD ,_, Bajo_NNP Izda_NNP ,_, 28008_CD Madrid_NNP ,_, Spain_NNP Tel_NNP 34 915 500691_CD Fax_NNP 34 915 493 695_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Shareholder_NN information_NN 95_CD Registered_NNP ofce_NN address_NN US_NNP Shareholders_NNP Hampshire_NNP International_NNP Business_NNP Park_NNP i_FW ADSs_NNP Chineham_NNP ,_, Basingstoke_NNP The_NNP Companys_NNP American_NNP Depository_NNP Shares_NNP Hampshire_NNP ,_, RG24_NNP 8EP_NNP ,_, UK_NNP ADSs_NNP ,_, each_DT representing_VBG three_CD ordinary_JJ shares_NNS Registered_NNP in_IN England_NNP are_VBP listed_VBN on_IN the_DT Nasdaq_NNP national_JJ market_NN under_IN No._NN ._.
The_DT Company_NN les_FW reports_NNS and_CC other_JJ documents_NNS with_IN the_DT Securities_NNPS and_CC Investor_NNP relations_NNS Exchange_NNP Commission_NNP SEC_NNP which_WDT are_VBP available_JJ Cla_NNP Rosenfeld_NNP for_IN inspection_NN and_CC copying_NN at_IN the_DT SEC_NNP 's_POS public_JJ Tel_NNP 44_CD 0_CD 1256 892160_CD reference_NN facilities_NNS or_CC can_MD be_VB obtained_VBN by_IN writing_VBG Fax_NNP 44_CD 0_CD 1256 894712_CD to_TO the_DT Company_NNP Secretary_NNP ._.
com_NN ii_FW ADR_NNP Depositary_NNP Morgan_NNP Guaranty_NNP Trust_NNP Company_NN of_IN New_NNP York_NNP Registrars_NNPS and_CC transfer_VB ofce_NN is_VBZ the_DT depositary_NN for_IN Shire_NNP Pharmaceuticals_NNP All_NNP administrative_JJ enquiries_NNS relating_VBG to_TO Group_NNP plc_NN ADSs_NNS ._.
All_DT enquiries_NNS concerning_VBG ADS_NNPS shareholdings_NNS should_MD be_VB addressed_VBN to_TO Lloyds_NNP records_NNS ,_, certicates_NNS or_CC transfer_NN of_IN ordinary_JJ shares_NNS TSB_NNP Registrars_NNPS ,_, clearly_RB stating_VBG the_DT registered_VBN into_IN ADSs_NNS should_MD be_VB addressed_VBN to_TO :_: shareholder_NN 's_POS name_NN and_CC address_NN ._.
Morgan_NNP Guaranty_NNP Trust_NNP Company_NN of_IN New_NNP York_NNP Lloyds_NNP TSB_NNP Registrars_NNPS PO_NNP Box_NNP 8205_CD ,_, Boston_NNP The_NNP Causeway_NNP ,_, Worthing_NNP MA_NNP 02266-8205_CD ,_, USA_NNP West_NNP Sussex_NNP ,_, BN99_NNP 6DA_NNP ,_, UK_NNP Tel_NNP 1_CD 781 575 4328_CD Fax_NN 1_CD 781 575 4088_CD 96_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NNP Trade_NNP marks_VBZ Cautionary_JJ statements_NNS Shire_NNP trade_NN marks_NNS Cautionary_JJ statements_NNS ADDERALL_NNP XR_NNP mixed_JJ amphetamine_NN salts_VBZ Statements_NNP included_VBD herein_NN that_WDT are_VBP not_RB historical_JJ ADDERALL_NNP mixed_JJ amphetamine_NN salts_NNS facts_NNS ,_, are_VBP forward-looking_JJ statements_NNS ._.
Such_JJ AGRYLIN_NNP anagrelide_NN hydrochloride_NN forward-looking_JJ statements_NNS involve_VBP a_DT number_NN AMATINE_NNP midodrine_NN hydrochloride_NN of_IN risks_NNS and_CC uncertainties_NNS and_CC are_VBP subject_JJ to_TO BIPOTROL_NNP carbamazepine_NN change_NN at_IN any_DT time_NN ._.
In_IN the_DT event_NN such_JJ risks_NNS or_CC CALCICHEW_NNP calcium_NN carbonate_NN uncertainties_NNS materialize_VBP ,_, Shires_NNP results_NNS could_MD CALCICHEW_NNP D3_CD FORTE_NNP calcium_NN carbonate_NN be_VB materially_RB affected_VBN ._.
The_DT risks_NNS and_CC uncertainties_NNS CARBATROL_NNP carbamazepine_NN include_VBP ,_, but_CC are_VBP not_RB limited_VBN to_TO ,_, risks_NNS associated_VBN COLAZIDE_NNP balsalazide_NN with_IN the_DT inherent_JJ uncertainty_NN of_IN pharmaceutical_JJ EMUTROL_NNP research_NN ,_, product_NN development_NN ,_, manufacturing_VBG ENSOTROL_NNP and_CC commercialization_NN ,_, the_DT impact_NN of_IN competitive_JJ FLUVIRAL_NNP S_NNP F_NN split-virion_NN inuenza_NN vaccine_NN products_NNS ,_, including_VBG ,_, but_CC not_RB limited_VBN to_TO ,_, the_DT impact_NN FOSRENOL_NNP lanthanum_NN carbonate_NN on_IN Shires_NNP attention_NN deficit_NN hyperactivity_NN disorder_NN METHYPATCH_NNP methylphenidate_NN ADHD_NNP franchise_NN ,_, patents_NNS ,_, including_VBG but_CC not_RB MICROTROL_NNP limited_VBD to_TO ,_, legal_JJ challenges_NNS relating_VBG to_TO Shires_NNP MICROTROL_NNP DR_NNP ADHD_NNP franchise_NN ,_, government_NN regulation_NN and_CC MICROTROL_NNP PR_NNP approval_NN ,_, including_VBG but_CC not_RB limited_VBN to_TO the_DT expected_VBN MICROTROL_NNP XR_NNP product_NN approval_NN dates_NNS of_IN lanthanum_NN carbonate_NN MIDON_NNP midodrine_NN hydrochloride_NN FOSRENOL_NNP ,_, METHYPATCH_NNP ,_, XAGRID_NNP OPTISCREEN_NNP and_CC the_DT adult_NN indication_NN for_IN ADDERALL_NNP XR_NNP ,_, PROAMATINE_NNP midodrine_NN hydrochloride_NN the_DT implementation_NN of_IN the_DT planned_VBN reorganization_NN PROSCREEN_NNP and_CC other_JJ risks_NNS and_CC uncertainties_NNS detailed_VBN from_IN RAPITROL_NNP time_NN to_TO time_NN in_IN Shires_NNP regulatory_JJ lings_NNS ._.
SOLARAZE_NNP diclofenac_JJ sodium_NN 3_CD %_NN SOLUTROL_NNP The_NNP statements_NNS of_IN the_DT medical_JJ practitioners_NNS TROXATYL_NNP troxacitabine_NN appearing_VBG on_IN pages_NNS 11_CD ,_, 13_CD ,_, 14_CD ,_, 17_CD and_CC 19_CD of_IN this_DT VANIQA_NNP document_NN have_VBP been_VBN made_VBN by_IN and_CC represent_VB the_DT XAGRID_NNP anagrelide_NN hydrochloride_NN views_NNS of_IN the_DT named_VBN individuals_NNS ._.
These_DT statements_NNS are_VBP not_RB ,_, and_CC should_MD not_RB be_VB interpreted_VBN to_TO be_VB ,_, Third-party_JJ trade_NN marks_NNS statements_NNS by_IN Shire_NNP ._.
3TC_CD lamivudine_JJ trade_NN mark_NN of_IN GSK_NNP ADEPT_NNP 4_CD %_NN icodextrin_NN solution_NN trade_NN mark_NN of_IN ML_NNP Laboratories_NNP plc_NN COMBIVIR_NNP trade_NN mark_NN of_IN GSK_NNP EPIVIR_NNP trade_NN mark_NN of_IN GSK_NNP EPIVIR-HBV_NNP trade_NN mark_NN of_IN GSK_NNP PENTASA_NNP mesalamine_NN trade_NN mark_NN of_IN Ferring_NNP AS_NNP REMINYL_NNP galantamine_NN hydrobromide_NN trade_NN mark_NN of_IN Johnson_NNP &_CC Johnson_NNP TRIZIVIR_NNP trade_NN mark_NN of_IN GSK_NNP ZEFFIX_NNP lamivudine_NN trade_NN mark_NN of_IN GSK_NNP Designed_VBN and_CC produced_VBN by_IN Bostock_NNP and_CC Pollitt_NNP Limited_NNP Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN UK_NNP Head_NNP Ofce_NNP Hampshire_NNP International_NNP Business_NNP Park_NNP Chineham_NNP ,_, Basingstoke_NNP Hampshire_NNP RG24_NNP 8EP_NNP T_NNP :_: 44_CD 0_CD 1256 894 000_CD F_NN :_: 44_CD 0_CD 1256 894 708_CD www_NN ._.
